0001213900-23-020746.txt : 20230317 0001213900-23-020746.hdr.sgml : 20230317 20230317061842 ACCESSION NUMBER: 0001213900-23-020746 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20220831 FILED AS OF DATE: 20230317 DATE AS OF CHANGE: 20230317 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Better For You Wellness, Inc. CENTRAL INDEX KEY: 0001852707 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] IRS NUMBER: 000000000 STATE OF INCORPORATION: NV FISCAL YEAR END: 0228 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-56262 FILM NUMBER: 23740636 BUSINESS ADDRESS: STREET 1: 1349 EAST BROAD STREET CITY: COLUMBUS STATE: OH ZIP: 43205 BUSINESS PHONE: 6143689898 MAIL ADDRESS: STREET 1: 1349 EAST BROAD STREET CITY: COLUMBUS STATE: OH ZIP: 43205 FORMER COMPANY: FORMER CONFORMED NAME: Fast Track Solutions, Inc. DATE OF NAME CHANGE: 20210322 10-Q/A 1 f10q0822a1_betterforyou.htm AMENDMENT NO. 1 TO FORM 10-Q

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q/A

(Amendment No. 1)

(Mark One)

 

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: August 31, 2022

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                to               

 

Commission File Number: 000-56262

 

BETTER FOR YOU WELLNESS, INC.
(Exact name of registrant as specified in its charter)

 

nevada   87-2903933
  (State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

c/o Ian James

1349 East Broad Street

Columbus, OH 43205

(Address of Principal Executive Offices) (Zip Code)

 

(614) 368-9898
(Registrant’s Telephone Number, Including Area Code)

 

N/A
(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   None   None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒   No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐   Accelerated filer ☐  
Non-accelerated Filer ☒   Smaller reporting company   
    Emerging growth company   

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of March 17, 2023 there were 404,014,987 shares of Common Stock and 700,000 shares of Series A Preferred Stock issued and outstanding.

 

 

 

 

 

 

EXPLANATORY NOTE

 

Better For You Wellness, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment No. 1”) to amend its Quarterly Report on Form 10-Q for the quarterly period ended August 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on October 21, 2022 (the “Original Form 10-Q”).

 

Background of Restatement

 

This Amendment No. 1 is being filed for the sole purpose of restating certain of the financial statements included in the Original Form 10-Q (the “Restatement”) due to the Company discovering that it made the following errors in the Original Form 10-Q: (i) not translating correctly the foreign currency balance for a mark-to-market contract; and (ii) not including certain debt issuance costs in the computation of the effective interest rate for a loan note. In the Original Form 10-Q filed October 21, 2022, the negative net loss was reported as $787,106 for the three months ended May 31, 2022, and $1,582,699 for the six months ended August 31, 2022. The Amended and Restated negative net loss is reported as $767,677 a difference of $19,429 in lower net loss for the three month period ended May 31, 2022, and $76,850 greater net loss for the six month period ended August 31, 2022.

 

On March 3, 2023, the Company filed a Current Report on Form 8-K disclosing that the financial statements included in the Original Form 10-Q should not be relied upon.   

 

In connection with the Restatement, management had concluded that the Company had a material weakness in its internal control over financial reporting as of May 31, 2022, as the Company’s internal control over financial reporting did not operate effectively, resulting in material errors in the financial statements included in the Original 10-Q. For a discussion of management’s considerations of the Company’s disclosure controls and procedures, internal control over financial reporting, and material weakness identified, refer to Controls and Procedures in Part I, Item 4.

 

Internal Control Considerations

 

In connection with the Restatement, management has concluded that the Company had a material weakness in its internal control over financial reporting as of August 31, 2022, as the Company’s review control over the accuracy of its financial statements did not operate effectively, resulting in material errors in the financial statements. For a discussion of management’s considerations of the Company’s disclosure controls and procedures, internal control over financial reporting, and material weakness identified, refer to Controls and Procedures in Part I, Item 4.

 

Items Amended in this Amendment No. 1

 

This Amendment No. 1 sets forth the Original Form 10-Q, as modified and superseded where necessary to reflect the Restatement and the related disclosure controls and procedures and internal control considerations. Accordingly, the following items included in the Original Form 10-Q have been amended:

 

Part I, Item 1, Financial Statements
   
Part I, Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations
   
Part I, Item 4, Controls and Procedures
   
Part II, Item 1A, Risk Factors

 

Additionally, in accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended, the Company is including with this Amendment No. 1 currently dated certifications from its Chief Executive Officer, Chief Financial Officer, and President.

 

Except as described above and in Note 9, Restatement, this Amendment No. 1 does not amend, update or change any other disclosures in the Original Form 10-Q. In addition, the information contained in this Amendment No. 1 does not reflect events occurring after the Original Form 10-Q and does not modify or update the disclosures therein, except to reflect the effects of the Restatement.

 

 

 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Amendment No. 1 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of historical fact, included in this Amendment No. 1 regarding development of our strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management are forward-looking statements. Forward-looking statements may include, but are not limited to, statements about:

 

any statements of the plans, strategies and objectives of management for future operations;
   
any statements concerning proposed new products, services or developments;
   
any statements regarding future economic conditions or performance;
   
our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;
   
our estimates regarding the sufficiency of our cash resources and our need for additional funding; and,
   
any statement that our business, financial condition and results of operations may be materially adversely affected by global health epidemics, including the recent COVID-19 pandemic.

 

The words “believe,” “anticipate,” “design,” “estimate,” “plan,” “predict,” “seek,” “expect,” “intend,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. We cannot guarantee that we actually will achieve the plans, intentions or expectations expressed in our forward-looking statements and you should not place undue reliance on these statements. There are a number of important factors that could cause our actual results to differ materially from those indicated or implied by forward-looking statements. These factors and the other cautionary statements made in this Amendment No. 1 should be read as being applicable to all related forward-looking statements whenever they appear herein. Except as required by law, we do not assume any obligation to update any forward-looking statement. We disclaim any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

 

 

 

 

INDEX

 

    Page
PART I - FINANCIAL INFORMATION  
   
ITEM 1 FINANCIAL STATEMENTS - UNAUDITED
  CONSOLIDATED Balance Sheets as of August 31, 2022 (UNAUDITED) and February 28, 2022 1
  CONSOLIDATED Statements of Operations for the Three and Six Months ended August 31, 2022 and 2021- UNAUDITED 2
  STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) for the Three and Six Months Ended August 31, 2022 and 2021 - UNAUDITED 3
  CONSOLIDATED Statement of Cash Flows for the Six Months Ended August 31, 2022 - UNAUDITED 4
  Notes to Financial Statements - UNAUDITED 5
     
ITEM 2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS 19
ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 32
ITEM 4 CONTROLS AND PROCEDURES 32
 
PART II - OTHER INFORMATION  
 
ITEM 1 LEGAL PROCEEDINGS 33
ITEM 1A RISK FACTORS 33
ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 33
ITEM 3 DEFAULTS UPON SENIOR SECURITIES 33
ITEM 4 MINE SAFETY DISCLOSURES 33
ITEM 5 OTHER INFORMATION 33
ITEM 6 EXHIBITS 34
   
SIGNATURES 35

 

i

 

 

PART I - FINANCIAL INFORMATION

 

BETTER FOR YOU WELLNESS, INC.

Condensed Consolidated Balance Sheet (unaudited)

As of August 31, 2022 and February 28, 2022

 

  

Consolidated

August 31,

   February 28, 
   2022   2022 
ASSETS        
Current Assets:        
Cash and cash equivalents  $2,130   $9,642 
Accounts Receivable   123    
-
 
Related Party Receivable   107,068    
-
 
Inventory   5,198    
-
 
Prepaids and other assets   78,072    
-
 
Total Current assets   192,591    9,642 
Equipment, net   1,935    
-
 
Goodwill   583,485    
-
 
TOTAL ASSETS  $778,011   $9,642 
           
LIABILITIES AND STOCKHOLDER EQUITY (DEFICIT)          
CURRENT LIABILITIES:          
Accounts Payable  $257,821   $375,408 
Deferred Compensation   190,320    
-
 
Clearbanc Debit Card   1,656    
-
 
Note Payable- RP   110,000    - 
Other Current Liabilities   14    
-
 
Total Current liabilities  $559,810   $375,408 
Long-Term Liabilities   
 
    
 
 
Notes Payable - PayPal Capital   2,216    
-
 
Notes Payable Shopify Capital   201    
-
 
Convertible notes payable, net accumulated interest   543,176    
-
 
TOTAL LIABILITIES  $1,105,403   $375,408 
           
STOCKHOLDERS’ EQUITY (DEFICIT):          
Preferred stock ( $.0001 par value, 200,000,000 shares authorized; 700,000 issued and outstanding as of August 31, 2022 and February 28, 2022)   70    70 
Common stock ($.0001 par value, 500,000,000 shares authorized, 385,198,451 and 370,747,042 issued and outstanding as of August 31, 2022 and February 28, 2022 respectively)   38,521    37,075 
Additional Paid in Capital   2,931,841    1,485,364 
Shares cancelable   
-
    (250,000)
Accumulated Deficit   (3,297,825)   (1,638,275)
Total Stockholders’ Equity (Deficit)   (327,392)   (365,766)
TOTAL LIABILITIES & EQUITY (DEFICIT)  $778,011   $9,642 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

1

 

 

BETTER FOR YOU WELLNESS, INC.

Condensed Consolidated Statement of Operations

(Unaudited)

For the three and six months ended August 31, 2022 and 2021

 

   For the Three Months
Ended August 31,
   For the Six Months
Ended August 31,
 
   2022   2021   2022   2021 
Revenue 
 
  
 
         
Merchandise Sales  $1,716   $
-
   $2,022   $
-
 
Cost of Good Sold   3,489    
-
    9,558    
-
 
Gross Profit  $(1,772)  $
-
   $(7,536)  $
-
 
Operating Expenses                    
Share based expense   301,663    7,000    985,713    77,000 
Selling, General and Administrative   446,262    7,005    643,257    9,057 
Total Operating Expenses   747,925    14,005    1,628,970    86,057 
                     
Operating Income/(Loss)   (749,697)   (14,005)   (1,636,506)   (86,057)
                     
Other Income (Expense)                    
Interest expense   (17,980)   
-
    (23,043)   
-
 
Other expense   
-
    
-
         
-
 
Total Other Income   (17,980)   
-
    (23,043)   
-
 
                     
Net income/(loss)  $(767,677)  $(14,005)  $(1,659,549)  $(86,057)
                     
Basic and Diluted net loss per common share
  $(0.00)  $(0.00)  $(0.00)  $(0.00)
                     
Weighted average number of common shares outstanding   372,031,446    360,000,680    372,031,446    250,434,405 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

2

 

 

BETTER FOR YOU WELLNESS, INC.

Consolidated and Condensed Statement of Changes in Stockholder (Deficit)

For the Three and Six Months Ended August 31, 2022 and 2021

(UNAUDITED)

 

   Common
Shares
   Par
Value
Common
Shares
   Series A
Preferred
Shares
   Par
Value
Series A
Preferred
Shares
   Additional Paid-in-
Capital
   Shares
Cancellable
    Accumulated
Deficit
   Total 
                                  
Balances, February 28, 2022   370,747,042   $37,075    700,000   $70   $1,485,364   $(250,000)   $(1,638,275)  $(365,766)
Common shares cancelled and returned to the Company   (7,048,873)   (705)   
-
    
-
    (249,295)   250,000     
-
    
-
 
Common shares issued for shares payable   325,000    33    
-
    
-
    (33)   
-
     
-
    
-
 
Common shares issued for services to Company   5,085,000    509    
-
    
-
    272,226    
-
     
-
    272,735 
Common shares issued for purchase of subsidiary   11,000,000    1,100    
-
    
-
    548,900    
-
     
-
    550,000 
Stock option expense   -    
-
    -    
-
    411,315    
-
     
-
    411,315 
Warrants Issued   -    
-
    -    
-
    78,072    
-
     
-
    78,072 
Warrants Issued        
 
         
 
    13,514    
 
     
 
    13,514 
Debt Forgiveness   -    
-
    -    
-
    49,686    
-
     
-
    49,686 
Net loss   -    -    -    
-
    
-
    -     (891,872)   (891,872)
Balances, May 31, 2022   380,108,169   $38,012    700,000   $70   $2,609,749   $
-
    $(2,530,147)  $117,684 
Common shares issued for services to the Company   5,060,000    506    
-
    
-
    250,192    
-
     
-
    250,698 
Common shares issued for cash received   30,282    3    
-
    
-
    3,747    
-
     
-
    3,750 
Stock option expense   -    
-
    -    
-
    274,025    
-
     
-
    274,025 
Fair value of warrants issued   -    
-
    -    
-
    17,188    
-
     
-
    17,188 
Forfeiture of stock compensation   -    
-
    -    
-
    (223,060)   
-
     
-
    (223,060)
Net loss   -    -    -    
-
    
-
    
-
     (767,677)   (767,677)
Balance August 31,2022   385,198,451   $38,521    700,000   $70   $2,931,841   $
-
    $(3,297,824)  $(327,392)

 

   Common
Shares
   Par
Value
Common
Shares
   Series A
Preferred
Shares
   Par
Value
Series A
Preferred
Shares
   Additional
Paid-in-
Capital
    Accumulated
Deficit
   Total 
                                     
Balances, February 28, 2021   -   $
-
    
-
   $
-
   $1,185    $(4,935)  $(3,750)
Common shares issued after reorganization   359,996,332    36,000    -    
-
    (36,000)    
-
    
-
 
Preferred shares issued after reorganization   -    
-
    700,000    70    69,930     -    70,000 
Expenses paid on behalf of the Company and contributed to capital -   -    -    
-
    3,951    -     3,951    
-
 
Net loss   -    -    -    -    
-
     (72,051)   (72,051)
Balance, May 31, 2021  $359,996,332   $36,000    700,000   $70   $39,607    $(76,986)  $(1,850)
Common shares issued for services   50,000    5    -    
-
    6,995     -    7,000 
                                     
Expenses paid on behalf of the Company and contributed to capital   -   -    -    
-
    2,990    -     2,990    
 
 
Net loss   -    -    -    -    
-
     (14,005)   (14,005)
Balances, August 31, 2021  $360,046,332   $36,005    700,000   $70   $49,052    $(90,992)  $(5,865)

 

The accompanying notes are an integral part of these unaudited financial statements.

 

3

 

 

BETTER FOR YOU WELLNESS, INC.

Condensed Consolidated Statements of Cash Flows (Unaudited)

For the six months ended August 31, 2022 and 2021

 

   Six Months   Six Months 
   August 31,   August 31, 
   2022   2021 
CASH FLOWS FROM OPERATING ACTIVITIES        
Net (loss)  $(1,659,549)  $(86,057)
Adjustments to reconcile Net Loss to net cash provided by (used in) operating activities:          
Share based expenses   985,713    77,000 
Amortized debt discount and debt issuance costs   49,475    
-
 
Depreciation   388    
-
 
Changes in current assets and liabilities:          
Inventory   7,899    
-
 
Accounts Receivable   (123)   - 
Related Party Receivable   (107,068)   - 
Accounts Payable   (117,587)   1,750 
Deferred Compensation   190,320    
-
 
Other Liabilities   (7,496)   - 
Accrued Interest   23,043    - 
Net cash provided by (used in) Operating Activities   (634,985)   (7,307)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Fixed Asset   (2,323)   
-
 
Total Cash Flow from Investing Activities   (2,323)   
-
 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Payment of debt issuance costs   (56,640)   
-
 
Proceeds from Convertible loan, net of original issue discount   558,000    
-
 
Proceed from related party note payable   75,000    365 
Common Share Issuance   3,750    
-
 
Expenses contributed to capital   49,686    6,942 
Net cash provided by financing activities   629,796    7,307 
           
Net Change in Cash  $(7,512)  $
-
 
           
Cash at beginning of period:  $9,642   $
-
 
Cash at end of period:  $2,130   $
-
 
           
NON-CASH FINANCING TRANSACTIONS:          
Discount on notes payable for warrants  $30,702   $- 
Warrants issued and extended for common stock issuance costs  $78,072   $- 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

4

 

 

Better For You Wellness, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

 

Note 1 - Organization and Description of Business

 

Better For You Wellness, Inc. (“we,” “us,” “our”, the “Company” or the “Registrant”) was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.

 

On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230 and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Our former director, Jeffrey DeNunzio, was the sole director/officer of each constituent corporation in the Reorganization.

 

Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.

 

Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021, at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.

 

Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until the new ticker symbol “FTRK” for the Company was released into the OTC MarketPlace on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.

 

The Company believes that the Reorganization, deemed effective on May 5, 2021, was not a transaction of the type described in subparagraph (a) of Rule 145 under the Securities Act of 1933 and the consummation of the Reorganization will not be deemed to involve an “offer”, “offer to sell”, “offer for sale” or “sale” within the meaning of Section 2(3) of the Securities Act of 1933. The Reorganization was consummated without the vote or consent of the Company’s stockholders. In addition, the provisions of NRS 92A.180 did not provide a stockholder of the Company with appraisal rights in connection with the Reorganization. The Company believes that in the absence of any right of any of the Company’s stockholders to vote with respect to the Reorganization or to insist that their shares be purchased for fair value, the Reorganization could not be deemed to involve an “offer” “offer to sell”; or “sale” within the meaning of Section 2(3) of the Securities Act of 1933.”

 

On May 5, 2021, after the completion of the Holding Company Reorganization, we canceled all of the stock we held in Sauer Energy, Inc., resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.

 

Given that the former business plan and objectives of Sauer Energy, Inc. and the business plan and objectives of Fast Track Solutions, Inc. substantially differed from one another, we conducted the corporate separation with Sauer Energy, Inc. immediately after the effective time of the Reorganization in order to avoid any shareholder confusion. The former business plan of Sauer Energy, Inc. (the development and marketing of wind powered electric generators) under the leadership of its former directors, did not, in any way, represent the blank check business plan of Fast Track Solutions, Inc. at that time, and thus it is the belief of the Company that the corporate separation ameliorated shareholder confusion about our identity and/or corporate objectives. It is our belief that Sauer Energy was a shell company at the time of the Reorganization.

 

5

 

 

The corporate actions taken by the Company, including, but not limited to, the corporate structuring of the transactions, was deemed, in the discretion of our sole director, to be for the benefit of the corporation and its shareholders. Former shareholders of Sauer Energy, Inc. were then the shareholders of Fast Track Solutions, Inc. and had the opportunity to benefit from a business combination with another company. The Company intended to serve as a vehicle to affect an asset acquisition, merger, exchange of capital stock or other business combination with a domestic or foreign business at that time

 

After the reorganization and through July 18, 2021, CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody, was our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock.

 

On July 19, 2021, Better For You Wellness, Inc., FKA “Fast Track Solutions, Inc.”, a Nevada Corporation (the “Company”), entered into a Share Purchase Agreement (the “Agreement”) by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021 (“Closing Date”), CRS sold 700,000 shares of the Company’s Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of the Company; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000) (the “Purchase Price”). The consummation of the transactions contemplated by the Agreement resulted in a change in control of the Company, with GOHV, Ian James, and Stephen Letourneau, becoming the Company’s largest controlling stockholders having approximately 89.62% combined voting control over the Company.

 

On August 19, 2021, the Company filed an 8-K with the SEC to disclose an amendment to the Company’s Articles of Incorporation that the Company filed on August 18, 2021, with the Nevada Secretary of State to change its name to Better For You Wellness, Inc. Within the aforementioned 8-K, the Company disclosed that, at the time, it was pending a FINRA corporate action to affect the name change on the OTC to Better For You Wellness, Inc., and also a ticker symbol change. FINRA announced, on their September 29, 2021 daily list, that the market effective date of our name change, and ticker symbol change, will be September 30, 2021. On September 30, 2021, we will begin trading under the symbol BFYW. The new CUSIP number associated with our common stock, as of the market effective date of September 30, 2021, is 08771B105.

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided. This transaction did not result in MRKTS Group Inc. owning 5% or more of any class of securities of the issuer.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau. The aforementioned transaction(s) did not result in any individual shareholder owning 5% or more of any class of securities of the issuer. The aforementioned transaction was carried out as it was deemed by GOHV to be in the best interests of its members.

 

On February 3. 2022, the Company was approved by OTC Markets to up-list its common stock from the OTC Pink Sheets to the OTCQB® Venture Market (the “OTCQB”). The Company began trading of its common shares on the OTCQB as of the market open on February 3, 2022, under its same symbol, “BFYW.”

 

The Company’s current business plan is to explore and evaluate various opportunities in the plant-based food and beverage and consumer packaged goods sectors, including but not limited to, mergers, acquisitions, or business combination transactions, after which the Company would cease to be a “shell” or “blank check” company. The Company’s principal business objective for the next 12 months and beyond will be to achieve long-term growth potential through a combination with a business rather than immediate, short-term earnings.

 

6

 

 

On November 15, 2021, the Company’s wholly owned subsidiary, Glow Market, LLC was formed in the State of Ohio. Subsequently, Glow Market, LLC launched its first brand, Better Suds, an online retailer of specialty all-natural, cruelty-free, gluten-free and chemical-free soaps. Better Suds commenced operations in December 2021.

 

On April 29, 2022 the Company entered into a Membership Interest Purchase Agreement (the “MIPA”) with Amanda Cayemitte and Yapo M’be (referred to together as the “Sellers”) to acquire the right, title and interest in, including all of the outstanding membership interests (referred to together as the “MM Interests”) of Mango Moi, LLC (“Mango Moi”). Mango Moi is a hair and skincare business located in Chicago, Illinois. Pursuant to the MIPA, in exchange for the MM Interests, the Company agreed to pay the Sellers a purchase price consisting of shares of the Company’s common stock, par value $0.0001 per share which consists of 11,000,000 shares of common stock (the “Company Common Stock”), with a fair market value of approximately $550,000, with 5,720,000 shares of Company Common Stock issued to Amanda Cayemitte and 5,280,000 shares of Company Common Stock issued to Yapo M’be (referred to together herein as the “Purchase Price”). Additionally, pursuant to the terms of the MIPA, the Company agreed to enter into an Employment Agreement with Mango Moi founder Amanda Cayemitte (the “Employment Agreement”), and a Consulting Agreement with Yapo M’be (the “Consulting Agreement”), respectively, as disclosed by the Company on its Current Report on Form 8-K filed with the SEC on May 2, 2022.

 

The MIPA closed (the “Closing”) on May 26, 2022, on which date the Company paid the Sellers the Purchase Price by issuing the Company Common Stock to the Sellers and the Sellers transferred the MM Interests to the Company, and on which date Mango Moi became a wholly owned subsidiary of the Company. At the Closing the Company entered into the Employment Agreement with Amanda Cayemitte and the Consulting Agreement with Yapo M’be.

 

The Company intends to optimize Mango Moi’s product formulae and packaging, as well as secure new manufacturing relationships to scale production capacity. Additionally, the Company plans to expand Mango Moi’s product offerings to include additional products and product bundles. Furthermore, the Company intends to grow sales through direct-to-consumer marketing efforts, subscription box sales, and pursuing wholesale sales relationships.

 

The Company’s main office is located at 1349 East Broad Street, Columbus OH 43205.

 

The Company has elected February 28th as its year end.

 

Note 2 - Summary of Significant Accounting Policies

 

Principles of Consolidation

 

The accompanying interim unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements on Form 10-K have been condensed or omitted. The condensed consolidated balance sheet as of February 28, 2022 has been derived from the audited consolidated financial statements as of that date, but does not include all disclosures required for audited annual financial statements. For further information, please refer to and read these interim condensed Consolidated Financial Statements in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended February 28, 2022 filed with the SEC.

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Glow Markets, LLC and Mango Moi, LLC. All significant intercompany accounts and transactions have been eliminated.

 

Basis of Presentation

 

This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.

 

Use of Estimates

 

There were no material changes in the Company’s significant accounting policies for the three and six months ended August 31, 2022 as compared to the year ended February 28, 2022. See Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022, as filed with the SEC, for additional information regarding the Company’s significant accounting policies and use of estimates.

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.

 

7

 

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at August 31, 2022 and February 28, 2022 were $2,130 and $9,642 respectively.

 

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets (primarily three to five years).

 

Revenue Recognition

 

The Company has prepared its unaudited condensed consolidated financial statements in accordance with GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.

 

The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

 

Revenue for products is recognized when the products are delivered to the customer and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of August 31, 2022 and February 28, 2022, the Company had no deferred revenues.

 

Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at August 31, 2022.

 

Basic Earnings (Loss) Per Share

 

The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, Earnings per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company did not have any dilutive instruments for the three and six months ended August 31, 2022, and 2021, respectively. Thus, anti-dilution issues are not applicable.

 

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

 

ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

8

 

 

- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of August 31, 2022 and February 28, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.

 

Related Parties

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

Share-Based Compensation

 

ASC 718, “Compensation – Stock Compensation”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity–Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

 

Except as specified for the Independent Directors’ compensation, the Company had no stock-based compensation plans as of August 31, 2022 and February 28, 2022.

 

Recently Issued Accounting Pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13 “Credit Losses - Measurement of Credit Losses on Financial Instruments.” ASU No. 2016-13 significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables, by replacing today’s “incurred loss” approach with an “expected loss” model under which allowances will be recognized based on expected rather than incurred losses. ASU No. 2016-13 will become effective for us in the first quarter of 2023. We are evaluating the impact that the adoption of this update will have on our financial statements; however, it is not expected to be material.

 

Reclassification of Prior Year Presentation

 

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

 

Note 3 - Going Concern

 

The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

 

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.

 

The Company has not established enough sources of revenue to cover its operating costs. Management plans to fund operating expenses with related party capital contributions. There is no assurance that management’s plan will be successful. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

 

Note 4 - Business Combinations

 

On April 29, 2022, we entered into an asset purchase agreement to acquire substantially all of the assets of Mango Moi. The acquisition was accounted for in accordance with GAAP and was made to expand our market share in the personal care category and due to synergies of product lines and services between the Companies. The acquisition closed May 26, 2022.

 

9

 

 

The purchase price has been preliminarily allocated to assets acquired and liabilities assumed based on the estimated fair value of such assets and liabilities at the date of acquisitions as follows:

 

Assets acquired:    
Cash  $913 
Inventory   12,995 
Total Assets Acquired   13,908 
Liabilities assumed:     
Clearbanc Debit Card   2,365 
Notes Payable - PayPal Capital   2,454 
Notes Payable Shopify Capital   53 7 
 Sales Tax Payable   138 
Total Liabilities Assumed   5,494 
      
Total identifiable net assets   8,414 
      
Purchase price   592,000 
      
Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date  $583,586 

 

The purchase price of $592,000 was paid in stock and discharge of liability in cash as a combination. Goodwill in the amount of $583,586 was recognized in the acquisition of Mango Moi LLC and is attributable to the cash flows of the business derived from our potential to outperform the market due to its existing relationship and other synergies created within the Company.

 

As the Company finalizes the fair value of assets acquired and liabilities assumed, additional purchase price adjustments may be recorded. The finalization of the purchase accounting assessment may result in changes in the valuation of assets acquired and liabilities assumed and may have an impact on the Company’s results of operations and financial position.

 

The following unaudited pro forma information presents a summary of the condensed consolidated results of operations for the Company as if the acquisition of Mango Moi had occurred on March 1, 2021.

 

   For the Three months ended 
   (unaudited)   (unaudited) 
   August 31,
2022
   August 31,
2021
 
Total revenues  $1,716   $15,991 
           
Net (loss) income  $(767,677)  $(31,364)
           
Loss per share  $
-
   $
-
 

 

   For the Six months ended 
   (unaudited)   (unaudited) 
   August 31,
2022
   August 31,
2021
 
Total revenues  $2,022   $35,447 
           
Net (loss) income  $(1,659,594)  $(112,841)
           
Loss per share  $
-
   $
-
 

 

The unaudited pro forma consolidated results are based on our historical financial statements and those of Mango Moi and do not necessarily indicate the results of operations that would have resulted had the acquisition actually been completed at the beginning of the applicable period presented. The pro forma financial information assumes that the companies were combined as of March 1, 2021.

 

The following tables present the amounts of revenue and earnings of Mango Moi since the acquisition date included in the condensed consolidated income statement for the reporting period.

 

10

 

 

   (unaudited)   (unaudited) 
   For the
three months ended
August 31,
   For the
six months ended
August 31,
 
   2022   2021 
Mango Moi:        
Total revenues  $1,716   $8,690 
Net income  $(819)  $(9,100)

 

Note 5 - Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at August 31, 2022.

 

Note 6 - Commitments and Contingencies

 

The Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of August 31, 2022 other than the following:

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

Also on September 17, 2021, our Board of Directors unanimously agreed to approve to enter into and consummate another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.

 

On April 18, 2022, Better For You Wellness, Inc., a Nevada corporation (the “Company”), entered into a Standby Equity Commitment Agreement, dated April 11, 2022 (the “SECA”) with MacRab LLC, a Florida limited liability company (the “Investor”). The SECA provides the Company with an option to sell up to $5,000,000 worth of the Company’s common stock, par value $0.0001 (the “Common Stock”), to the Investor, in increments, over the period ending twenty-four (24) months after the date the Registration Statement (as defined below) is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. The purchase price per share, for each respective put under the SECA, is equal to 90% of the average of the two (2) lowest volume weighted average prices of the Common Stock during the six (6) trading days following the clearing date associated with the respective put under the SECA. Additionally, we issued a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock (the “Warrant”) to Investor as a commitment fee in connection with the execution of the SECA.

 

On May 26, 2022 the Company acquired Mango Moi, LLC as a wholly-owned subsidiary (See Note 1). As part of the purchase agreement, the Company entered into an employment agreement and a consulting agreement as follows:

 

Employment Agreement

 

Pursuant to the Employment Agreement, which is to be effective as of 45 days from the signing of the MIPA, the Company agreed to employ Amanda Cayemitte as the Chief Visionary Officer of Mango Moi to provide duties including normalizing the Company’s strategic-planning processes, forging new working relationships and synergies across the organization, and establishing greater transparency and accountability for those people carrying out the Company’s strategy. As compensation under the Employment Agreement, the Company agreed to pay Amanda Cayemitte an annual salary of $65,000 payable semi-monthly on the first day and the fifteenth day of the month and subject to applicable federal, state, and local withholding.

 

The Employment Agreement can be terminated any time by either party by giving 30 days written notice to the other party. If the Employment Agreement is terminated, Amanda Cayemitte will be entitled to receive compensation for:

 

one month upon completion of one full calendar year of employment with the Company;

 

two months upon completion of two full calendar years of employment with the Company, and

 

three months upon competition of two full calendar years of employment with the Company.

 

However, if Amanda Cayemitte breaches any terms of the Employment Agreement, the Company may terminate the Employment Agreement without any notice and with compensation being paid to Amanda Cayemitte only through the date of such termination.

 

11

 

 

Consulting Agreement

 

Pursuant to the Consulting Agreement, the Company engaged Yapo M’be as a consultant to provide manufacturing services for Mango Moi, to begin on May 2, 2022. As compensation under the Consulting Agreement, the Company agreed to pay Yapo M’be at the rate of $30.00 per hour, not to exceed $1,500 per month. The Consulting Agreement can be terminated by either party upon the failure of the other to perform under the Consulting Agreement by giving ten days written notice to the non-performing party. The Consulting Agreement can also be terminated by the Company by giving ten days written notice to Yapo M’be in the event that there is a reduction of the program budget.

 

Ian James Employment Agreement

 

On July 21, 2022 the Company’s Compensation Committee approved a formal Employment Agreement with Ian James, the Company’s Chief Executive Officer and the Company entered into the Agreement with Mr. James as of July 21, 2022. As compensation under the Employment Agreement, beginning March 1, 2022, Employee will earn a Base Salary in the amount of $199,196 per annum, $16,599.67 per month, less statutory and other required deductions, for all work and services Ian James performs for the Company. The Company calculates Annual Base Salary on a January 1 through December 31 basis (i.e., a calendar year). Base Salary payments shall be subject to applicable federal, state, and local withholding. Under the Agreement, the Employee and Company mutually agree that until the Company is cash flow positive, the Company shall pay Employee a mutually agreeable amount each month toward the Employee’s Base Salary, and the balance of Base Salary unpaid, shall be accrued and recorded as an obligation of the Company. It shall become payable to the Employee when the Company is cash flow positive or at a time mutually agreed by the Company and Employee.

 

The Employee shall also be eligible to earn an additional payment (BONUS) of $68,328. The parties consider the Bonus Pay as “at-risk” and therefore not guaranteed. Bonus Pay could include a cash bonus, commission, and other at-risk pay categories. BONUS shall be determined at the sole discretion of the Company. The Employee’s Bonus shall be based on Employee’s annual performance reviews and overall company performance, subject to the terms and conditions of applicable incentive plans and policies.

 

Should this Contract be terminated, payments under Section 2 shall cease; provided, however, that Employee shall be entitled to Base Salary and accrued Base Salary for periods or partial periods that occurred before the date of termination and for which the Employee has not yet been paid and for any commission earned per the Company’s customary procedures, if applicable.

 

After completion of 90-days of Employment, Employee shall be entitled to a pro-rated 15 days paid time per year for utilization by Employee for personal business, illness, care of another person, or vacation. Personal Leave shall be calculated from the effective date of this Contract as of the date first above written through December 31st.

 

Employee shall be permitted to carry over into the following year of employment a maximum of five days of Personal Leave; however, as of December 31, Employee shall forfeit unused Personal Leave benefits above five days. Further, Employee shall not be permitted to carry over or accumulate more than ten days of Personal Leave from one year to the next.

 

Stephen Letourneau Employment Agreement

 

On July 21, 2022 the Company’s Compensation Committee approved a formal Employment Agreement with Stephen Letourneau, the Company’s Chief Branding Officer and the Company entered into the Agreement with Mr. Letourneau as of July 21, 2022. As compensation under the Employment Agreement, beginning March 1, 2022, Employee will earn a Base Salary in the amount of $152,787 per annum, $12,732.25 per month, less statutory and other required deductions, for all work and services Ian James performs for the Company. The Company calculates Annual Base Salary on a January 1 through December 31 basis (i.e., a calendar year). Base Salary payments shall be subject to applicable federal, state, and local withholding. Under the Agreement, the Employee and Company mutually agree that until the Company is cash flow positive, the Company shall pay Employee a mutually agreeable amount each month toward the Employee’s Base Salary, and the balance of Base Salary unpaid, shall be accrued and recorded as an obligation of the Company. It shall become payable to the Employee when the Company is cash flow positive or at a time mutually agreed by the Company and Employee.

 

12

 

 

The Employee shall also be eligible to earn an additional payment (Bonus) of $70,632. The parties consider the Bonus Pay as “at-risk” and therefore not guaranteed. Bonus Pay could include a cash bonus, commission, and other at-risk pay categories. Bonus shall be determined at the sole discretion of the Company. The Employee’s Bonus shall be based on Employee’s annual performance reviews and overall company performance, subject to the terms and conditions of applicable incentive plans and policies.

 

Should this Contract be terminated, payments under Section 2 shall cease; provided, however, that Employee shall be entitled to Base Salary and accrued Base Salary for periods or partial periods that occurred before the date of termination and for which the Employee has not yet been paid and for any commission earned per the Company’s customary procedures, if applicable.

 

After completion of 90-days of Employment, Employee shall be entitled to a pro-rated 15 days paid time per year for utilization by Employee for personal business, illness, care of another person, or vacation. Personal Leave shall be calculated from the effective date of this Contract as of the date first above written through December 31st.

 

Employee shall be permitted to carry over into the following year of employment a maximum of five days of Personal Leave; however, as of December 31, Employee shall forfeit unused Personal Leave benefits above five days. Further, Employee shall not be permitted to carry over or accumulate more than ten days of Personal Leave from one year to the next.

 

Jacob Ellman Employment Agreement

 

Pursuant to the Company’s Compensation Committee approval of July 21, 2022, The Company entered a formal Employment Agreement with Jacob Ellman, the Company’s Chief Business Development Officer and the Company entered into the Agreement with Mr. Ellman as of October 14, 2022. As compensation under the Employment Agreement, beginning March 1, 2022, Employee will earn a Base Salary in the amount of $128,656 per annum, $10,721.33 per month, less statutory and other required deductions, for all work and services Ian James performs for the Company. The Company calculates Annual Base Salary on a January 1 through December 31 basis (i.e., a calendar year). Base Salary payments shall be subject to applicable federal, state, and local withholding. Under the Agreement, the Employee and Company mutually agree that until the Company is cash flow positive, the Company shall pay Employee a mutually agreeable amount each month toward the Employee’s Base Salary, and the balance of Base Salary unpaid, shall be accrued and recorded as an obligation of the Company. It shall become payable to the Employee when the Company is cash flow positive or at a time mutually agreed by the Company and Employee.

 

The Employee shall also be eligible to earn an additional payment (Bonus) of $41,140. The parties consider the Bonus Pay as “at-risk” and therefore not guaranteed. Bonus Pay could include a cash bonus, commission, and other at-risk pay categories. Bonus shall be determined at the sole discretion of the Company. The Employee’s Bonus shall be based on Employee’s annual performance reviews and overall company performance, subject to the terms and conditions of applicable incentive plans and policies.

 

Should this Contract be terminated, payments under Section 2 shall cease; provided, however, that Employee shall be entitled to Base Salary and accrued Base Salary for periods or partial periods that occurred before the date of termination and for which the Employee has not yet been paid and for any commission earned per the Company’s customary procedures, if applicable.

 

After completion of 90-days of Employment, Employee shall be entitled to a pro-rated 15 days paid time per year for utilization by Employee for personal business, illness, care of another person, or vacation. Personal Leave shall be calculated from the effective date of this Contract as of the date first above written through December 31st.

 

Employee shall be permitted to carry over into the following year of employment a maximum of five days of Personal Leave; however, as of December 31, Employee shall forfeit unused Personal Leave benefits above five days. Further, Employee shall not be permitted to carry over or accumulate more than ten days of Personal Leave from one year to the next.

 

13

 

 

Note 7 - Convertible Note Payable

 

On June 7, 2022, the Company entered into a second Securities Purchase Agreement with Mast Hill Fund, L.P., a Delaware limited partnership (“Mast Hill”). The first Security Purchase Agreement with Mast Hill Fund, L.P. was entered On April 12, 2022. Pursuant to the June 7, 2022 Security Purchase Agreement, Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on June 7, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on June 7, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.

 

Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.

 

In connection with the Purchase Agreements, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Mast Hill, pursuant to which the Company is obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the Commitment Shares and the shares of the Company’s common stock that may be issued to Mast Hill pursuant to the conversion of the Note.

 

JH Darbie & Co., Inc. (“JH Darbie”) and the Company are parties to a Finder’s Fee Agreement, signed March 15, 2020 (“Finder’s Agreement”) pursuant to which JH Darbie would introduce the Issuer to third-party investors. Pursuant to the Finder’s Agreement, in relation to both the April 12, 2022 and the June 7, 2022 Securities Purchase Agreement with Mast Hill Fund, L.P., J.H. Darbie received approximately $22,320 for each Security Purchase Agreement. In addition, JH Darbie is to receive non-callable warrants of equal to 8% warrant coverage of the amount raised. The warrants shall entitle JH Darbie thereof to purchase common stock of the Company at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of the Issuer’s common stock on the date of the Transaction, whichever is lower (such price, the “Warrant Price”). The warrants shall be exercisable immediately after the date of issuance, shall have anti-dilutive price protection, participating registration rights, and shall expire 5 years after the date of issuance, in accordance with the Finder’s Agreement.

 

On July 11, 2022, Mast Hill Fund agreed to extend the timeframes in section 2(a) of the Registration Rights Agreement dated 4/12/22 to 180 calendar days to file the initial Registration Statement and 270 calendar days to have it declared effective. On October 11, 2022, Mast Hill Fund agreed to extend the timeframes in section 2(a) of the Registration Rights Agreement dated 4/12/22 until February 9, 2023, and to have the Registration Statement become effective on or before February 9, 2037.

 

Note 8 - Stock Purchase Warrant Liability

 

JH Darbie & Co., Inc. (“JH Darbie”) and the Company are parties to a Finder’s Fee Agreement, signed March 15, 2020 (“Finder’s Agreement”) pursuant to which JH Darbie would introduce the Issuer to third-party investors. Pursuant to the Finder’s Agreement, in relation to the April 12, 2022 and the June 7, 2022 Securities Purchase Agreement with Mast Hill Fund, L.P., two equal payments of fees of approximately $22,320 were paid to JH Darbie. In addition, JH Darbie is to receive non-callable warrants of equal to 8% warrant coverage of the amount raised. The warrants shall entitle JH Darbie thereof to purchase common stock of the Company at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of the Issuer’s common stock on the date of the Transaction, whichever is lower (such price, the “Warrant Price”). The warrants shall be exercisable immediately after the date of issuance, shall have anti-dilutive price protection, participating registration rights, and shall expire 5 years after the date of issuance, in accordance with the Finder’s Agreement.

 

14

 

 

Note 9 - Shareholder Equity

 

Preferred Stock

 

The authorized preferred stock of the Company consists of 200,000,000 shares with a par value of $0.0001. There were 700,000 shares issued and outstanding as of August 31, 2022 and February 28, 2022.

 

During the three months ended May 31, 2021, 700,000 shares of Series A Preferred Stock were issued to CRS Consulting, LLC (“CRS”), a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody. CRS is our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock. Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock. On July 19, 2021, these shares were purchased. As of November 30, 2021, our CEO, Ian James, and Director, Stephen Letourneau, each hold 350,000 shares of Series A Preferred Stock (See Note 1).

 

Common Stock

 

The authorized common stock of the Company consists of 500,000,000 shares with a par value of $0.0001. There were 385,198,451 and 370,747,042 shares of common stock issued and outstanding as of August 31, 2022 and February 28, 2022, respectively.

 

At the time of reorganization, former shareholders of Sauer Energy, Inc. became shareholders of Fast Track Solutions, Inc., representing 359,996,332 of the common shares outstanding.

 

On July 19, 2021, 250,000,000 shares of restricted Common Stock were purchased by Ohio Green Ventures, LLC from CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody (See Note 1).

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau (See Note 1).

 

On August 24, 2021, 50,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $7,000.

 

On October 11, 2021, 2,602,740 shares of Restricted Common Stock were issued to SRAX, Inc as compensation for marketing services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $468,493.

 

On October 11, 2021, 250,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $45,000.

 

On November 17, 2021, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $18,750.

 

15

 

 

On January 3, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $15,000.

 

On January 13, 2022, 549,097 shares of Restricted Common Stock were sold to five shareholders for proceeds totaling $68,000.

 

On April12, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled approximately $15,468.

 

On April 12, 2022, the Company entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., in which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on April 12, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.

 

Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.

 

On May 26, 2022, 11,000,000 share of Restricted Common Stock were issued to the two Sellers of Mango Moi, LLC (See Note 1). The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled approximately $550,000.

 

On July 12, 2022, 100,000 shares of Restricted Common Stock were issued to four Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $3,990.

 

On July 27, 2022 the Company filed its Pre-14-C notice and accompanying Information Statement and furnished this information to the holders of shares of common stock, par value $0.0001 per share, of Better For You Wellness, Inc., a Nevada corporation (the “Company”), pursuant to Section 78.320 of the Nevada General Corporation Law, Section 14 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Regulation 14C and Schedule 14C thereunder, in connection with the approval of the following actions taken by the Company’s Board of Directors (the “Board”) and by written consent of the holders of a majority of the voting power of the issued and outstanding capital stock of the Company, to amend our certificate of incorporation, as amended (the “Certificate”), to increase the number of authorized shares of common stock from 500,000,000 to 1,000,000,000 (the “Authorized Share Increase” or “Corporate Action”).

 

During the period ended August 31, 2022, a total of 30,282 shares of Restricted Common Stock were sold to two shareholders for proceeds totaling approximately $3,75.13.

 

On October 12, 2022, the Board of Directors authorized the issuance of 2,686,667 Common Shares to Mast Hill for consideration of the extension of the 4/12/2022 Registration Rights Agreement.

 

Shares Cancellable

 

On July 11, 2022, the Company entered into a Common Share Option Cancellation and Forfeiture Agreement with former Director Dr. Nicola Finley (the “Option Cancellation and Forfeiture Agreement”). Under the Option Cancellation and Forfeiture Agreement, Dr. Nicola Finley forfeited, and the Company canceled Dr. Nicola Finley’s option to purchase 4,000,000 common shares of the Company that was granted to the optionee pursuant to the Director Agreement dated as of August 29, 2021. Upon such forfeiture and cancellation, Dr. Nicola Finley has no further rights to exercise the option to purchase 4,000,000 common shares of the Company. The cancellation and forfeiture set forth in the Option Cancellation and Forfeiture Agreement shall not affect the restricted common shares granted by the Company to Dr. Nicola Finley pursuant to the Director Agreement dated as of August 29, 2021. As a payment in lieu of whatever benefits, if any, to which Dr. Nicola Finley may have been entitled to under the option to purchase 4,000,000 common shares of the Company, the Company shall pay Dr. Nicola Finley $1.00.

 

Stock Options

 

During the fiscal year ended February 28, 2022, the Company granted options exercisable for up to 20,000,000 shares of Common Stock of which 8,500,000 fully vested on August 31, 2021. The remaining 11,500,000 shares vest over the next 2 years. During the three months ended August 31, 2023, 2,000,000 shares were forfeited. The options have the exercise price of $.25 per share. These options expire 5 years after issue. The aggregate intrinsic value of these outstanding options as of August 31, 2022, was $0

 

The Company fair valued the options on the grant dates at $2,127,565 using a Black-Scholes option pricing model with the following assumptions: stock price of $.15 and $.11 per share (based on the quoted trading price on the dates of the grants). The Company is amortizing the expense over the vesting terms of each. The total stock option expense for the period ended August 31, 2022 was approximately $297,414. The total unamortized stock option expense at August 31, 2022 was approximately $1,854,208.

 

16

 

 

Additional Paid-In Capital

 

During the quarterly period ended August 31, 2022, a total of $2,931,841 posted as additional paid-in capital.

 

This includes Common Shares issued for services for the Company including $250,192 for Mast Hill, cash received for shares sold $3,747, $274,025 of share option vestment/expense for the Board of Directors, $17,188 in Warrants issued related to JH Darbie for finder agreement and debt treatment of Mast hill, and negative $223,060 in forfeiture of stock options by former Director Dr. Nicola Finley.

 

Related-Party Transactions

 

Loan to Company

 

During the six-month period ended August 31, 2022, Green Ohio Ventures, LLC, paid expenses on behalf of the Company totaling approximately $82,788 and during the same period, Green Ohio Ventures was reimbursed $176,544, which included the $82,788 expense paid from this period. During the same period of August 31, 2022, Green Ohio Ventures, LLC, loaned the Company $7,000. During the same period, the following Company Officers and Directors made the following financial contributions to the Company:

 

Ian James, the Company’s Chief Executive Officer loaned the Company $18,000 during the period. Additionally, Mr. James paid expenses on behalf of the Company totaling approximately $26,057 and during the same period, Mr. James was reimbursed $19,775, leaving a balance of expense paid from prior reporting periods in the amount of $9,791, which was in addition to the $18,000 loan as referenced above.

 

Stephen Letourneau the Company’s Chief Branding Officer paid expenses on behalf of the Company totaling approximately $48,068, and during the same period, Mr. Letourneau was reimbursed $40,389 leaving a balance of $2,780 to be reimbursed.

 

Director David Deming paid expenses on behalf of the Company totaling approximately $50,000.

 

In addition, the Company acquired $35,000 of a loan to Mango Moi, LLC when it became a wholly-owned subsidiary of the Company. This loan was made to Mango Moi, LLC by a relative of Amanda Cayemitte (i.e., Mr. Gushy Joseph), one of the sellers of the subsidiary. On October 12, 2022, the Board of Directors authorized the issuance of 760,870 Common Shares @ $0.023 per share to retire $17,500 of the $35,000 Loan. The balance of $17,500 was agreed to be paid in the first quarter of the 2023 calendar year.

 

Additionally, during the six-month period ended August 31, 2022, Company Officers Deferred Compensation totaling $190,320. These payments are considered as loans to the Company, which are noninterest-bearing, unsecured, and payable on demand.

 

Note 10 - Impairment Expense

 

During the period ended August 31, 2022, the Company had no Impairment Expenses.

 

Note 11 - Subsequent Events

 

On September 20, 2022, the Company entered into a Manufacturing Agreement with Ironwood Clay Company (ICCI) to develop commercially scaled Personal Care Products for Mango Moi and other products in the Company’s portfolio. The Company agreed to pay a non-refundable deposit of $10,000 USD for up to 8 Product Formula. This includes three formulation revisions and samples per Product Formula (each iteration of sampling of up to 500gr./ml.). Additional revisions to the Formula(s) will be charges to the Client at a rate of $500 USD per revision.

 

Once the Company has approved the final Formula(s) and places a Purchase Order exceeding $10,000 USD, the non-refundable deposit will be applied to the total amount of the Purchase Order. Upon ordering at least Twenty-Five Thousand US Dollars ($25,000 USD) of each Product Formula, the exclusivity granted to ICCI herein in respect of such Product and Formula shall cease, the Company shall no longer be obligated to purchase Products from ICCI, and the Client shall be free to engage any other manufacturer for such purpose.

 

17

 

 

On September 22, 2022, the Company announced the cancelation of the Letter of Intent (LOI) to acquire Ironwood Clay Company (ICCI) because ICCI was unable to have its Clay Mining Operation adequately meet SEC reporting requirements related to the mining of a natural resource. Additionally, ICCI owners were unwilling to bifurcate the Mining Operation from the Personal Care Manufacturing.

 

On September 22, 2022, the Company announced the Letter of Intent (LOI) to acquire The Ideation Lab and its functional beverage division, The Jordre Well.

 

The Ideation Lab is a brand solutions incubator and accelerator focused on the plant-based wellness and hemp-infused industry. The Ideation Lab has been developing plant-based wellness brands since 2020, including Garrett and Emmett’s Pet Treats, a pet lifestyle brand, E.J. Well Co, a women’s wellness brand, and others.

 

The Jordre Well is a functional beverage company that is 49% owned by Coffee Holding Co., Inc. (NASDAQ: JVA), a leading integrated wholesale coffee roaster and dealer in the United States. Earlier this week, The Jordre Well announced its portfolio of products from Stephen James Curated Coffee Collection (“SJCCC”), the Company’s premium coffee brand, which is now being sold through Amazon.com and is in discussion with major national retailers. The e-commerce giant carries 8 of SJCCC’s premium coffee products and ships to more than 100 countries around the globe. Additionally, the deal contemplates Coffee Holding Company continuing its global purchase of coffee beans, manufacturing, distribution, and licensure of its Cafe Caribe and Harmony Bay to The Jordre Well for Hemp infusion.

 

On October 11, 2022, Mast Hill Fund agreed to extend the timeframes in section 2(a) of the Registration Rights Agreement dated 4/12/22 to 270 calendar days to file the initial Registration Statement and 360 calendar days to have it declared effective. This extension follows the July 11, 2022 extension in which Mast Hill Fund agreed to extend the timeframes in section 2(a) of the Registration Rights Agreement dated 4/12/22 to 180 calendar days to file the initial Registration Statement and 270 calendar days to have it declared effective. In consideration of the extension, on October 12, 2022, the Board of Directors authorized the issuance of 2,686,667 Common Shares to Mast Hill for consideration of the extension of the 4/12/2022 Registration Rights Agreement.

 

On October 12, 2022, the Board of Directors authorized the issuance of 760,870 Common Shares @ $0.023 per share to retire $17,500 of the $35,000 Loan. The balance of $17,500 was agreed to be paid in the first quarter of the 2023 calendar year.

 

On October 12, 2022, our Board of Directors approved to renew an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies.” In exchange for twelve months of access to the Sequire Platform, we paid SRAX $30,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

18

 

 

ITEM 2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements

 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.”

 

These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions.

 

Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

 

Company Overview

 

Business Overview

 

We are a sustainable brands and services company headquartered in Columbus, Ohio. We are evaluating opportunities targeting six goals-based wellness categories within the rapidly growing wellness industry to create a leading global wellness conglomerate.

 

Through our dual buy and build model, we evaluate the wellness industry in the following six goals-based categories:

 

Better Health
   
Better Fitness
   
Better Nutrition
   
Better Appearance
   
Better Sleep
   
Better Mindfulness

 

As an early-stage company, our Company generated $1,716 and a $0 in revenue for the three months ended August 31, 2022, and 2021 respectively. Our Company generated $2,022 and $0 in revenue for the six months ended August 31, 2022, and 2021 respectively. Our strategy is designed to offer wellness consumers a diverse synergistic portfolio of brands and products that will allow them to live a life of intention and improve their quality of life.

 

We believe wellness consumers purchase with intention and specifically seek out the brands and products that improve their quality of life. Furthermore, we believe wellness consumers pursue these six goals-based dimensions of wellness and are positioning the Company to capitalize on this demand. With skin being humans’ largest organ, we have initially prioritized skincare and haircare to help wellness consumers look and feel better with clean and natural products. We intend to expand into additional wellness categories with functional foods, beverages, supplements, and more.

 

Our management team brings deep expertise in heavily regulated industries, operating, brand identity, genetics, and services, and raising capital to the public market. We seek synergistic and complementary mergers and acquisition opportunities, implementing operational efficiencies to eliminate duplicative measures and centralize administrative operations to achieve more significant revenues and profitability. Additionally, we expect to leverage our network of retail relationships and acquire and manage brands and services cultivated in the beauty and wellness industry to secure sales in major retailers in the United States and globally.

 

19

 

 

Our management team monitors various trends and factors that follow, which could impact our operating performance.

 

As an early-stage company, the Company has relatively few transactions to date.

 

Trends and Other Factors Affecting Our Operating Performance

 

Our management team monitors various trends and factors that could impact our operating performance.

 

Revenue Strategy — Our revenue growth strategy follows a dual buy-and-build business model in which we acquire brands and related infrastructure and develop brands and related infrastructure in-house. In addition to scaling the Company’s wholly-owned subsidiary, Glow Market LLC, which currently owns and operates our Better Suds soap brand, we have executed multiple non-binding letters of intent to acquire companies within the skincare sector, including a vertically-integrated skincare manufacturer and multiple brands. The closing of these respective transactions depends on numerous factors, including but not limited to the satisfactory completion of due diligence, capital constraints, and more. Furthermore, any of these contemplated transactions would likely have a material impact on the Company’s operating performance. On May 26, 2022, our Company closed its first acquisition of the right, title and interest in, including all of the outstanding membership interests of Mango Moi, LLC, a hair and skincare business located in Chicago, Illinois.

 

Market Opportunity

 

We aim to become a major participant in the $1.5 trillion global wellness industry. We believe our innovative wellness-related offerings converge with wellness consumer trends and demands for “Better-For-You” brands and products that can satisfy all pricing points. We expect consumer trends towards the adoption of these healthier lifestyles to continue.

 

Competition 

 

We will compete with companies that operate in the plant-based and science-focused wellness market. Many of our competitors will have substantially greater financial resources, a broader market presence, longer-standing relationships with distributors, retailers, and suppliers, longer operating histories, more extensive production and distribution capabilities, robust brand recognition, and significant marketing resources, and more comprehensive product lines than us. We believe that principal competitive factors in this category include, among others, quality ingredients, wellness profile, cost, convenience, branding, and marketing.

 

Sales and Marketing Costs 

 

As we continue to grow our “BFYW” product portfolio, we expect to expand our sales and marketing team by adding dedicated personnel to service additional retail customers. Outside sales representatives and brokers may be added to expand our sales efforts. We further envision engaging, developing, and possibly acquiring a subscription box retail operation. Marketing expenditures are expected to begin primarily online and in product fees (as we engage retail store expansion), as well as other similar in-store marketing costs. These expenses will be categorized as net deductions to revenue under GAAP instead of marketing expenses. We plan to hire a national marketing firm to implement digital video and display campaigns, connected television, social media, and search engine marketing. As we expand and grow revenue, we will build a brand management team (to support Management, who oversees all “BFYW” marketing efforts) to focus on digital marketing, social media, and other marketing functions.

 

Operating Costs 

 

Our operating costs include raw materials, labor, related benefits, manufacturing overhead, marketing, sales, distribution, shipping, and other general and administrative expenses. We attempt to manage the impact of our operating costs through fixed hourly rate agreements with legal counsel and certain consultants.

 

Fluctuations in Costs 

 

Our costs are subject to fluctuations, particularly due to changes in commodity prices, transportation costs, and our productivity efforts. If we are unable to manage cost fluctuations through pricing actions, cost savings projects, sourcing decisions, and consistent productivity improvements, it may adversely impact our gross margin, operating margin, and net earnings. Sales can also be adversely impacted following pricing actions if there is a negative impact on the consumption of our products. We strive to implement, achieve, and sustain cost improvement plans, including supply chain optimization, general overhead, workforce optimization, and outsourcing projects as deemed appropriate.

 

Commodities

 

In the future, our profitability could depend on our ability to anticipate and react to raw material costs, among other things. Raw materials can be sourced from various parts of the globe, and the prices of raw goods are subject to many factors beyond our control. These factors include variables in world economic conditions, political events, tariffs, trade wars, or other events.

 

20

 

 

Acquisitions 

 

The Company follows a dual buy-and-build business model for growth through acquisitions and in-house development of brands. We have executed multiple non-binding letters of intent to acquire companies within the skincare sector including a vertically-integrated skincare manufacturer and multiple brands. The closing of these respective transactions depends on numerous factors including but not limited to the satisfactory completion of due diligence, capital constraints, and more. Furthermore, any of these contemplated transactions would likely have a material impact on the Company’s operating performance.

 

Strategic Advisory Committee

 

To assist in the expansion of the Company, management sought and received unanimous consent from the Board of Directors to create and seat a Strategic Advisory Committee composed of respected industry leaders who bring relevant experience, networks, and leadership to the Company’s various initiatives.

 

Discussion of Financial Statement

 

As an Early-Stage Company with few transactions, the Company’s expenditures were heavily Selling General, and Administrative (“SG&A”). The Company engaged Carter, Ledyard, & Milburn LLP and Anthony L.G., PLLC as legal counsel, to be consulted on a case-by-case basis as may be necessary for corporate legal services and securities counsel. Payroll expenses were the single largest category of cash expenditures for the quarter. Management expects legal costs to taper as a percentage of overall SG&A as the company grows. The Company’s SG&A further includes the cost of EDGAR and news release filing services, payroll of a single person, website development and publishing, professional services such as accounting, SRAX for regular updates of NOBO data for the shareholder lists for ongoing shareholder communications, Governmental filing fees including business licensing.

 

Systems and Controls

 

As an early-stage company, the Company has very few transactions to date. The Company’s Board of Directors comprises 6 members, 4 of which are non-executive independent directors. The Board of Directors’ reviews transactions, and the CEO signs off on transactions. The Company is developing revenue recognition processes and procedures for the business, including revenue streams, point of performance obligation discharged, etc., to comply with applicable State, Provincial, Federal, and International Laws and Regulations.

 

Critical Accounting Policies and Estimates

 

We prepare our consolidated financial statements in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Under Note 2 – Summary of Significant Accounting Policies, the consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.

 

The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. 

 

Revenue for products is recognized when the products are delivered to the customer, and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of August 31, 2022, the Company had no deferred revenues. 

 

21

 

 

Going Concern

 

The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

 

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.

 

The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

 

COVID-19

 

An outbreak of infectious respiratory illness caused by a novel coronavirus known as COVID-19 spread globally in 2020. This outbreak resulted in travel restrictions, closed international borders, enhanced health screenings at ports of entry and elsewhere, disruption of and delays in healthcare service preparation and delivery, prolonged quarantines, cancellations, supply chain disruptions, lower consumer demand, layoffs, defaults, and other significant economic impacts, as well as general concern and uncertainty.

 

The pandemic has not materially impacted our operations in 2021 or 2022 thus far. 

 

Financial Statements and Exhibits

 

The Company has been engaged in organizational efforts and obtaining initial financing. The Company was formed as a vehicle to pursue a business combination. The Company’s business purpose is to seek the acquisition of or merger with an existing company.

 

The Company is an “emerging growth company” (“EGC”) that is exempt from certain financial disclosure and governance requirements for up to five years as defined in the Jumpstart Our Business Startups Act (the JOBS Act), which eases restrictions on the sale of securities; and increases the number of shareholders a company must have before becoming subject to the U.S. Securities and Exchange Commissions (SEC’s) reporting and disclosure rules (See Emerging Growth Companies Section Below).

 

The Company has elected February 28th as its fiscal year-end.

 

22

 

 

Results of Operations

 

The following table sets forth selected items in our consolidated financial data in dollar amounts and as a percentage of revenue for the period represented:

 

   For the
 three months
   For the
 three months
   For the
six months
   For the
six months
 
   Ended
August 31,
2022
   Ended
August 31,
2021
   Ended
August 31,
2022
   Ended
August 31,
2021
 
                 
Revenues   1,716    0    2,022    0 
Cost of Goods   3,489    0    9,558    0 
Gross Profit and Gross Margin   (1,772)   0    (7,536)   0 
Operating Expenses   747,925    14,005    1,628,970    86,057 
Net (Loss) Income   (767,677)   (14,005)   (1,659,549)   (86,057)

 

Revenues  

 

The company generated $1,716 and $0 for the three months ended August 31, 2022, and 2021 respectively, a increase of $1,716. The increase was due to the Company having sales from its Mango Moi operation. The company generated $2,022 and $0 for the six months ended August 31, 2022, and 2021 respectively, an increase of $2,022. The increase was due to the Company having sales from its Mango Moi operation. The Company’s current business plan is to explore and evaluate various business opportunities in the plant-based food, beverage, and consumer packaged goods (“CPG”) sectors including but not limited to mergers, acquisitions, or business combination transactions.

 

Cost of Goods Sold

 

We recorded $3,489 and $0 for the Cost of Goods Sold for the three months ended August 31, 2022, and 2021 respectively, an increase of $3,489. We recorded $9,558 and $0 for the Cost of Goods Sold for the six months ended August 31, 2022, and 2021 respectively, an increase of $9,558.

 

Gross Profit and Gross Margin

 

We recorded a negative $1,772 and $0 in Gross Profit for the three months ended August 31, 2022, and 2021 respectively, a decrease of $1,772. In the six months ended August 31, 2022, and 2021 respectively, we recorded a negative $7,536 and $0 in Gross Profit. a decrease of $7,536. The decrease was due to declines in merchandise sales due to lack of inventory due to supply-chain issues with ingredients from the ivory coast and other regions required for Mango Moi products.

 

Operating Expenses

 

We recorded $747,925 and $14,005 in Operating Expenses for the three months ended August 31, 2022, and 2021 respectively. We recorded $1,628,970 and $86,057 in Operating Expenses for the six months ended August 31, 2022, and 2021 respectively.

 

We incurred $733,920 in higher Operating Expenses for the three months ended August 31, 2022, due to approximately $301,663 in share-based expenses and approximately $446,262 in general and administrative expenses. For the six months ended August 31, 2022, we incurred $1,542,913 in higher Operating Expenses due to approximately $985,713 in share-based expenses and approximately $643,257 in general and administrative expenses. The increase in general and administrative expenses was due to the stock option expense for Independent Directors, recognition of deferred compensation, and increased costs due to the acquisition of Mango Moi.

 

Income Taxes 

 

We file a consolidated federal income tax return with our subsidiaries. The provision for income taxes is computed by applying statutory rates to income before taxes.

 

Deferred income taxes are recognized for the tax consequences in future years of temporary differences between the financial reporting and tax bases of assets and liabilities as of each period-end based on enacted tax laws and statutory rates. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. A 100% valuation allowance has been established on deferred tax assets for the period ending August 31, 2022 and February 28, 2022, due to the uncertainty of our ability to realize future taxable income.

 

We account for uncertainty in income taxes in our financial statements as required under ASC 740, “Income Taxes.” The standard prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The standard also guides de-recognition, classification, interest, and penalties, accounting in interim periods, and disclosure and transition accounting. Management determined we took no material uncertain positions in our tax returns.

 

23

 

 

Net (Loss) Income 

 

We recorded a loss of $767,677 and $14,005 for the three months ended November 30, 2022, and 2021 respectively. We recorded a greater net loss during this period compared to the same quarter of the prior year due to an increased Operating Expenses during the period. We recorded a loss of $1,659,549 and $86,057 for the six months ended August 31, 2022, and 2021 respectively. We recorded a higher net loss for our second quarter ended August 31, 2022, compared to the previous quarter due to an increase in Operating Expenses.

 

Liquidity and Capital Resources 

 

Our cash balance was $2,130 and $0 as of August 31, 2022, and 2021 respectively. We received $507,984 and $0 from the sale of shares of Common Stock for the six months ended August 31, 2022, and 2021 respectively. We presently are largely reliant on capital contributions towards expenses from Mr. Ian James, the Company’s Chief Executive Officer, Chief Financial Officer, President, Treasurer, and Chairman of the Board of Directors. However, we raised a total of $250,492 in net proceeds from Mast Hill Fund, LLC in convertible debt in the three months ended August 31, 2022 and $3,750 from the sale of Common Shares.

 

Mr. Ian James has not guaranteed that he will continue to support our capital needs. Therefore, we may not be able to continue as a going concern. We may require further funding to implement our operations plan for the next twelve months. Being a start-up stage company, we have a very limited operating history. After a twelve-month period, we may need additional financing but currently do not have any arrangements for such financing.

 

If we need additional cash and cannot raise it, we will either have to suspend operations until our Company raises the necessary financing or cease operations entirely. 

 

Off Balance Sheet Arrangements

 

We have no off-balance sheet arrangements including special purpose entities.

 

Corporate History

 

Better For You Wellness, Inc. (we, us, our, the “Company” or the “Registrant”), was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.

 

On January 28, 2021, as a result of an Application for Custodianship granted by the Eighth Judicial District Court, Clark County, Nevada, styled as “In the matter of Sauer Energy, Inc., a Nevada corporation, Case Number: A-20-826848-P”, Jeffrey DeNunzio was appointed Custodian of Sauer Energy, Inc. (the “Predecessor”).

 

On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230, and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Jeffrey DeNunzio was the sole director/officer of each constituent corporation in the Reorganization.

 

Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor, and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.

 

Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021 at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.

 

24

 

 

Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until trading under the new ticker symbol “FTRK” for the Company began on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.

 

On May 5, 2021, after the completion of the Holding Company Reorganization, we canceled all of the stock we held in Sauer Energy, Inc. resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.

 

On July 19, 2021, Fast Track Solutions entered into a Share Purchase Agreement by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021, CRS sold 700,000 shares of the Fast Track Solutions’ Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of Fast Track Solutions; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000). The consummation of the transactions contemplated by this Share Purchase Agreement resulted in a change in control of Fast Track Solutions, with Ian James, Stephen Letourneau, and GOHV becoming the largest controlling stockholders.

 

Ian James and Stephen Letourneau retained a majority of the membership interests (collectively constituting approximately 84.12%) of GOVH.

 

On July 30, 2021, Mr. Jeffrey DeNunzio resigned as the Chief Executive Officer, Chief Financial Officer, President, Secretary, and Treasurer. In addition, Mr. DeNunzio resigned as Director on July 30, 2021. Mr. Ian James was appointed as the Chief Executive Officer, Chief Financial Officer, President, Secretary, Treasurer, and Chairman of the Board of Directors. Mr. Stephen Letourneau was appointed Director. The resignation of Mr. DeNunzio was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

On August 18, 2021, a Certificate of Amendment to change our name to “Better For You Wellness, Inc.” was filed with the Nevada Secretary of State.

 

On August 27, 2021, Montel Williams, Leslie G. Bumgarner, Joseph J. Watson, David H. Deming, and Dr. Nicola R. Finley, MD, were each appointed by our Board of Directors to serve as Independent Directors of the Company.

 

On September 17, 2021, we entered into a “Term Sheet” with Williamsburg Venture Holdings LLC, a Nevada limited liability company (“WVH”). WVH is a multi-strategy, private investment fund located in New York. The Term Sheet is a private placement with registration rights, allowing WVH to purchase up to $30,500,000 of our Common Stock. The term of the Term Sheet is for 36 months. Following the execution of the term sheet, the Company is to pay WVH $15,000 to cover associated expenses relating to, amongst other things, preparation of future securities agreements relating to the Term Sheet. Upon entering into definitive agreements with WVH for the purchase and sale of equity, WVH is to immediately purchase $250,000 of the Company’s restricted common stock from the Company at a 15% discount to the last closing price of our Common Stock as reported by the OTC Markets Group. According to the aforementioned term sheet, any future proceeds from the sale of shares are to go towards the Company to be used for working capital. According to the Term Sheet, WVH may not acquire, at any point, more than 4.99% of our outstanding shares of common stock.

 

25

 

 

On September 17, 2021, we entered into an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Under the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

On September 17, 2021, we entered into another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.

 

On September 17, 2021, Mr. David H. Deming was appointed Secretary of the Company’s Board of Directors.

 

On September 17, 2021, we engaged Carter Ledyard Milburn LLP as the Company’s legal counsel going forward, to be consulted on a case-by-case basis. Any future legal fees that may be incurred are to be billed hourly and may not be static. We believe legal counsel is important to the company’s growth going forward.

 

On September 30, 2021, we began trading under the symbol BFYW. The new CUSIP number associated with our common stock is 08771B105.

 

On October 1, 2021, our Board of Directors unanimously approved the establishment of an Audit Committee and appointed Montel Williams, David Deming, and Joseph Watson to the newly formed Audit Committee. Our Board of Directors also unanimously approved the establishment of a Compensation Committee and appointed Leslie Bumgarner, Montel Williams, and Joseph Watson to the newly formed Compensation Committee.

 

On November 18, 2021, Ms. Leslie Bumgarner advised the Company’s Board of Directors that she would resign as a director and Compensation Committee member of the Company effective upon December 31, 2021. The resignation of Ms. Bumgarner was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

On December 3, 2021, the Company executed an Amended and Corrected Equity Purchase Agreement (the “Equity Purchase Agreement”) with Williamsburg Venture Holdings LLC, a Nevada limited liability Company (“WVH”). The Equity Purchase Agreement provides that WVH shall purchase from the Company, upon the filing of a Current Report on Form 8-K regarding the Company ceasing to be a “shell” company and on the approval of an uplisting to the OTCQB or higher market, $250,000 of the Company’s common stock at a 15% discount to the last closing price of the Company’s Common Stock as reported by the OTC Markets Group. The Equity Purchase Agreement also provides that, upon the filing of a registration statement on Form S-1 covering all the shares sold to WVH under the Equity Purchase Agreement and related Amended and Corrected Registration Rights Agreement (the “Registration Rights Agreement”), WVH shall purchase an additional $250,000 of the Company’s Common Stock at a 15% discount to the last closing price of the Company’s Common Stock as reported by the OTC Markets Group.

 

On December 3, 2021, the Company also executed the Registration Rights Agreement with WVH. Under the terms and conditions of the Registration Rights Agreement, and to induce WVH to enter into the Equity Purchase Agreement, the Company has agreed to provide certain registration rights under the Securities Act. The Registration Rights agreement provides that the Company shall, on or before the one hundred and eightieth (180th) day after December 3, 2021, file with the SEC a prospectus supplement on effective Form S-1 covering the maximum number of Registrable Securities (as defined therein) as shall be permitted to be included thereon in accordance with applicable SEC rules, regulations and interpretations so as to permit the resale of such Registrable Securities by the WVH, including but not limited to under Rule 415 under the Securities Act at then prevailing market prices (and not fixed prices), as mutually determined by both the Company and the WVH (the “Initial Registration Statement”). The Initial Registration Statement shall register only registrable securities. The Company shall use its commercially reasonable efforts to have the Initial Registration Statement and any amendment thereto declared effective by the SEC at the earliest possible date (in any event, within ninety (90) calendar days after the filing date of the Initial Registration Statement). The Registration Rights Agreement also provides that the Company is obligated to file additional registration statements under certain circumstances.

 

26

 

 

On December 6, 2021, we announced that the Company had formed a wholly-owned subsidiary, Glow Market LLC, an Ohio Limited Liability Company, to build and operate digitally-native, mission-driven brands within the clean beauty sector in multiple consumer product categories. Glow Market, LLC, launched its first brand, Better Suds, an impact-driven brand that sells cruelty-free natural soap. Better Suds is committed to positively impacting the environment by removing 1 pound of plastic from the ocean for every soap sold through donations to Ocean Blue Project Inc., a 501(c)(3) organization that removes plastics from oceans and waterways. With the Company’s launch of Glow Market LLC, we ceased to be a shell company, as defined in Rule 12b-2 under the Exchange Act, and are no longer a blank-check company.

 

On December 9, 2021, we announced that the Company had submitted an application to the OTC Markets Group to up-list its common stock for trading on the OTC Markets Venture Market, or the OTCQB, and pending the completion of the application process and its acceptance by the OTC Markets Group, the Company expects that its common stock will begin trading on the OTCQB under the Company’s current ticker symbol “BFYW”.

 

On December 14, 2021, we appointed Christina Jefferson to the Board as an Independent Director, effective January 1, 2022, in order to replace Leslie Bumgarner whose resignation became effective December 31, 2021.

 

On December 15, 2021, we reported on a phased fundraising of up to $1,000,000 USD in a Private Placement of restricted Common Stock to investors who qualify as “accredited investors”.

 

On February 2, 2022, we received approval from OTC Markets Group to up-list our common stock for trading to the OTC Markets Venture Market, or the OTCQB, as of February 3, 2022 under the Company’s current ticker symbol “BFYW”.

 

On February 5, 2022, our Board of Directors unanimously approved the Establishment of a Strategic Advisory Committee tasked with providing acceleration, reach and guidance to further enhance the Company’s value proposition and portfolio. Our Board of Directors appointed six initial Committee Members by unanimous consent including: David King, Laurie Racine, Zhiping Zhang, Melisse Gelula, Christopher Brown, and Kate Hendrickson.

 

Also on February 5, 2022, by unanimous consent of the five non-executive independent members of our Board of Directors, David Deming was appointed Chairperson of the Company’s Audit Committee, and Christina Jefferson was appointed to the Company’s Compensation Committee filling the vacancy left by former director Leslie Bumgarner, and Joseph Watson was appointed as Chairperson of the Company’s Compensation Committee.

 

On February 11, 2022, we entered into a non-binding Letter of Intent with Amanda Cayemitte, Yapo M’Be, and Mango Moi, LLC setting forth the contemplated terms for a transaction in which the Company would acquire 100% ownership interest in Mango Moi, LLC and substantially all of the property and assets of Mango Moi including without limitation inventory, formulas, packaging, intellectual property, customer lists, websites, domain names, and social media accounts.

 

On March 15, 2022, we entered into a Finder’s Fee Agreement with JH Darbie & Co., Inc. Pursuant to which JH Darbie & Co., Inc. would introduce the Issuer to third-party investors.

 

On April 12, 2022, we entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., a Delaware limited partnership, pursuant to which Mast Hill Fund, L.P. purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 bearing an original issue discount of $31,000, interest of 12% per year and a maturity date of April 12, 2023. The promissory note is convertible into shares of our common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. We have the right to prepay the promissory note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. Pursuant to the Securities Purchase Agreement, we issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock as a condition to closing. In connection with the Securities Purchase Agreement, the Company entered into a Registration Rights Agreement with Mast Hill Fund, L.P. pursuant to which we are obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the commitment shares and the shares of our common stock that may be issued to Mast Hill Fund, L.P. pursuant to the conversion of the promissory note. Pursuant to the Finder’s Fee Agreement, we entered into on March 15, 2022, with JH Darbie & Co., Inc., fees of approximately $22,320.00 were paid to JH Darbie & Co., Inc. in addition to non-callable warrants expiring 5 years after the date of issuance equal to 8% warrant coverage of the amount raised, entitling JH Darbie & Co., Inc. thereof to purchase our common stock at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of our common stock on the date of the transaction, whichever is lower.

 

27

 

 

Also on April 12, 2022, we entered into an Agreement to Terminate Amended and Corrected Equity Purchase Agreement (the “Agreement to Terminate”) with WVH to terminate the aforementioned Equity Purchase Agreement, whereby WVH agreed to forfeit the 7,048,873 shares of our common stock that were previously issued to WVH as commitment shares pursuant to the Equity Purchase Agreement.

 

On April 15, 2022, we entered into a Placement Agent Agreement with JH Darbie & Co., Inc. pursuant to which JH Darbie would possibly participate as a sales agent in the private placement of a $5,000,000 Equity Line of Credit.

 

On April 18, 2022, we entered into a Standby Equity Commitment Agreement with MacRab LLC, a Florida limited liability company providing us with an option to sell up to $5,000,000 worth of our common stock, par value $0.0001, to MacRab LLC, in increments, over the period ending 24 months after the date that the Company’s registration statement is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. Additionally, we issued MacRab LLC a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock as a commitment fee in connection with the execution of the Standby Equity Commitment Agreement. We also entered into a Registration Rights Agreement with the Investor requiring the Company to file a registration statement providing for the registration of the common stock issuable to MacRab LLC under the Standby Equity Commitment Agreement and their common stock purchase warrant and the subsequent resale by MacRab LLC of such common stock. Pursuant to the Placement Agent Agreement entered into on April 15, 2022, with JH Darbie & Co., Inc., the Company will pay Darbie a fee equal to 3% of the gross proceeds raised from the sale of the securities, including all amounts placed in an escrow account or payable in the future and all amounts paid or payable upon exercise, conversion or exchange of such securities received or receivable directly by the Company. Such consideration paid in cash shall be paid directly to Darbie out of escrow, as and when such consideration is paid to the Company.

 

On April 29, 2022, we entered into a Membership Interest Purchase Agreement (the “MIPA”) with Amanda Cayemitte and Yapo M’be (the “Sellers”) to acquire the right, title, and interest in, including all of the outstanding membership interests of Mango Moi, LLC, for the consideration and on the terms set forth in the MIPA. Additionally, in accordance with the terms of the MIPA, we entered into an Employment Agreement with Mango Moi, LLC founder Amanda Cayemitte, and a Consulting Agreement with Yapo M’be, respectively.

 

On May 26, 2022 closed on the Membership Interest Purchase Agreement (the “MIPA”) and acquired Mango Moi, LLC with a purchase price of $597,726.57 worth of shares of the Company’s common stock, which consisted of 11,000,000 shares of common stock, with 5,720,000 shares of Company Common Stock issued to Amanda Cayemitte and 5,280,000 shares of Company Common Stock issued to Yapo M’be. In accordance with the terms of the MIPA, we entered into an Employment Agreement with Mango Moi, LLC founder Amanda Cayemitte, and a Consulting Agreement with Yapo M’be, respectively.

 

On June 7, 2022, we entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., a Delaware limited partnership, pursuant to which Mast Hill Fund, L.P. purchased a promissory note with a principal amount of $310,000 for a purchase price of $279,000 bearing an original issue discount of $31,000, the interest of 12% per year and a maturity date of June 7, 2023. The promissory note is convertible into shares of our common stock at a conversion price of $0.037 per share, subject to adjustment as provided therein. We have the right to prepay the promissory note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. Pursuant to the Securities Purchase Agreement, we issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock as a condition to closing. In connection with the Securities Purchase Agreement, the Company entered into a Registration Rights Agreement with Mast Hill Fund, L.P. pursuant to which we are obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the commitment shares and the shares of our common stock that may be issued to Mast Hill Fund, L.P. pursuant to the conversion of the promissory note. Pursuant to the Finder’s Fee Agreement, we entered into on March 15, 2022, with JH Darbie & Co., Inc., fees of approximately $22,320.00 were paid to JH Darbie & Co., Inc. in addition to non-callable warrants expiring 5 years after the date of issuance equal to 8% warrant coverage of the amount raised, entitling JH Darbie & Co., Inc. thereof to purchase our common stock at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of our common stock on the date of the transaction, whichever is lower.

 

28

 

 

On June 18, 2022, Dr. Nicola Finley advised the Company’s board of directors that she will resign as a board member of the Company and that her resignation is effective immediately. Dr Finley also notified the board of directors of her willingness to voluntarily relinquish the compensatory options referenced in her Director Agreement dated August 29, 2021. The resignation of Dr. Finley was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

On June 20, 2022, the Company’s board of directors unanimously approved the appointment of Melisse Gelula as a non-executive independent director of the Company, effective immediately.

 

On July 11, 2022, the Company entered into a Common Share Option Cancellation and Forfeiture Agreement with former Director Dr. Nicola Finley (the “Option Cancellation and Forfeiture Agreement”). Under the Option Cancellation and Forfeiture Agreement, Dr. Nicola Finley forfeited, and the Company canceled Dr. Nicola Finley’s option to purchase 4,000,000 common shares of the Company that was granted to the optionee pursuant to the Director Agreement dated August 29, 2021. Upon such forfeiture and cancellation, Dr. Nicola Finley has no further rights to exercise the option to purchase 4,000,000 common shares of the Company. The cancellation and forfeiture set forth in the Option Cancellation and Forfeiture Agreement shall not affect the restricted common shares granted by the Company to Dr. Nicola Finley pursuant to the Director Agreement dated August 29, 2021. As a payment in lieu of whatever benefits, if any, to which Dr. Nicola Finley may have been entitled under the option to purchase 4,000,000 common shares of the Company, the Company shall pay Dr. Nicola Finley $1.00.

 

On July 19, 2022, the Company’s Board of Directors approved and adopted a Code of Business Conduct and Ethics and Compliance Program designed to deter wrongdoing and to promote the types of conduct by directors, executives, and employees to uphold a strong sense of ethics and integrity.

 

On July 21, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Ian James, the Company’s Chief Executive Officer, and the Company entered into the Agreement with Mr. James as of July 21, 2022. As compensation under the Employment Agreement, beginning March 1, 2022, Mr. James will earn a Base Salary in the amount of $199,196 per annum and shall also be eligible to earn an additional payment (Bonus) of $68,328.

 

Also on July 21, 2022, the Company’s Compensation Committee approved a formal Employment Agreement with Stephen Letourneau, the Company’s Chief Branding Officer, and the Company entered into the Agreement with Mr. Letourneau as of July 21, 2022. As compensation under the Employment Agreement, beginning March 1, 2022, Mr. Letourneau will earn a Base Salary in the amount of $152,787 per annum and shall also be eligible to earn an additional payment (Bonus) of $70,632.

 

On August 15, 2022, Melisse Gelula advised the Company’s board of directors that she will resign as a board member of the Company and that her resignation is effective immediately. Melisse Gelula was not compensated by the Company for her services as a director since June 20, 2022. Melisse Gelula is to remain a member of the Company’s Strategic Advisory Committee as previously announced and filed on February 10, 2022.

 

The resignation of Melisse Gelula as a director was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

 

29

 

 

On August 31, 2022, BF Borgers CPA PC (“BF Borgers”) furnished a letter addressed to the Securities and Exchange Commission stating whether BF Borgers agrees with following statements:

 

The Audit Committee (the “Committee”) of the Company had conducted a competitive selection process to determine the Company’s independent registered public accounting firm for the fiscal year ending February 28, 2023. The Committee evaluated several public accounting firms in this process, including BF Borgers, the Company’s independent registered public accounting firm for the fiscal year ended February 28, 2022. As a result of this process, the Committee approved the appointment of GBQ Partners LLC (“GBQ”) as the Company’s independent registered public accounting firm for the fiscal year ending February 28, 2023. This action effectively dismissed BF Borgers as the Company’s independent registered public accounting firm as of August 31, 2022.

 

The reports of BF Borgers on the Company’s consolidated financial statements for the fiscal years ended February 28, 2022 and 2021 did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles. In connection with the audits of the Company’s consolidated financial statements for the fiscal years ended February 28, 2022 and 2021, and in the subsequent interim periods through August 31, 2022, there were no disagreements with BF Borgers on any matters of accounting principles or practices, financial statement disclosure or auditing scope and procedures which, if not resolved to the satisfaction of BF Borgers, would have caused BF Borgers to make reference to the matter in their reports. There were no reportable events (as that term is described in Item 304(a)(1)(v) of Regulation S-K) during the two fiscal years ended February 28, 2022 and 2021, or in the subsequent periods through August 31, 2022.

 

A copy of BF Borgers’ letter, dated August 31, 2022, is filed as Exhibit 16.1 to a Current Report on Form 8-K filed with the Securities and Exchange Commission on August 31, 2022.

 

During the two most recent fiscal years and in the subsequent interim periods through August 31, 2022, the Company has not consulted with GBQ with respect to the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that would have been rendered on the Company’s consolidated financial statements, or any other matters set forth in Item 304(a)(2)(i) or (ii) of Regulation S-K.

 

On September 20, 2022, the Company entered into a Manufacturing Agreement with Ironwood Clay Company (ICCI) to develop commercially scaled Personal Care Products for Mango Moi and other products in the Company’s portfolio. The Company agreed to pay a non-refundable deposit of $10,000 USD for up to 8 Product Formula. This includes three formulation revisions and samples per Product Formula (each iteration of sampling of up to 500gr./ml.). Additional revisions to the Formula(s) will be charged to the Client at a rate of $500 USD per revision.

 

Once the Company has approved the final Formula(s) and places a Purchase Order exceeding $10,000 USD, the non-refundable deposit will be applied to the total amount of the Purchase Order. Upon ordering at least Twenty Five Thousand US Dollars ($25,000 USD) of each Product Formula, the exclusivity granted to ICCI herein in respect of such Product and Formula shall cease, the Company shall no longer be obligated to purchase Products from ICCI, and the Client shall be free to engage any other manufacturer for such purpose.

 

On September 22, 2022, the Company announced the cancellation of the Letter of Intent (LOI) to acquire Ironwood Clay Company (ICCI) because ICCI was unable to have its Clay Mining Operation adequately meet SEC reporting requirements related to the mining of a natural resource. Additionally, ICCI owners were unwilling to bifurcate the Mining Operation from the Personal Care Manufacturing.

 

On September 22, 2022, the Company announced the Letter of Intent (LOI) to acquire The Ideation Lab and its functional beverage division, The Jordre Well.

 

The Ideation Lab is a brand incubator and accelerator focused on the plant-based wellness and the hemp-infused industry. The Ideation Lab has been developing plant-based wellness brands since 2020, including Garrett and Emmett’s Pet Treats, a pet lifestyle brand, E.J. Well Co, a women’s wellness brand, and others.

 

30

 

 

The Jordre Well is a functional beverage company that is 49% owned by Coffee Holding Co., Inc. (NASDAQ: JVA), a leading integrated wholesale coffee roaster and dealer in the United States. Earlier this week, The Jordre Well announced its portfolio of products from Stephen James Curated Coffee Collection (“SJCCC”), the Company’s premium coffee brand, which is now being sold through Amazon.com and is in discussion with major national retailers. The e-commerce giant carries 8 of SJCCC’s premium coffee products and ships to more than 100 countries around the globe. Additionally, the deal contemplates Coffee Holding Company continuing its global purchase of coffee beans, manufacturing, distribution, and licensure of its Cafe Caribe and Harmony Bay to The Jordre Well for Hemp infusion.

 

On October 11, 2022, Mast Hill Fund agreed to extend the timeframes in section 2(a) of the Registration Rights Agreement dated 4/12/22 to require the filing of the initial Registration Statement by February 6, 2023, and to have it declared effective by May 7, 2023.

 

On October 12, 2022, the Board of Directors authorized the issuance of 760,870 Common Shares to Gushy Joseph @ $0.023 per share to retire $17,500 of the $35,000 Loan related to Mango Moi. The Company agrees to pay the remaining balance of $17,500 in the first quarter of the 2023 calendar year, to fully retire the debt.

 

On October 12, 2022, the Company renewed its Agreement with SRAX to retain access to the platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $30,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

Pursuant to the Company’s Compensation Committee approval of July 21, 2022, the Company entered a formal Employment Agreement with Jacob Ellman, the Company’s Chief Business Development Officer and the Company entered into the Agreement with Mr. Ellman as of October 14, 2022. As compensation under the Employment Agreement, beginning March 1, 2022, Mr. Ellman will earn a Base Salary in the amount of $128,656 per annum and shall also be eligible to earn an additional payment (Bonus) of $41,140.

 

ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item.

 

ITEM 4 CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our fractional Chief Financial Officer to allow for timely decisions regarding required disclosure.

 

As of February 5, 2023, our management, with the participation of, and under the supervision of, our Chief Executive Officer and fractional Chief Financial Officer, evaluated the effectiveness of the design and the operation of our disclosure controls and procedures. Based upon that evaluation, management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were not effective as of August 31, 2022, due to the identification of a material weakness in the Company’s internal control over financial reporting as of August 31, 2022.

 

31

 

 

As disclosed in the Company’s Current Report on Form 8-K filed on March 3, 2023 with the SEC, on February 5, 2023, the Company’s management concluded that the following financial statements should be restated and should no longer be relied upon:

 

(i)The Company’s unaudited consolidated financial statements for the three months ended May 31, 2022 included in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on August 9, 2022 (the “Q1 2022 10-Q”); and

 

(ii)The Company’s unaudited consolidated financial statements for the three and six months ended August 31, 2022 included in the Company’s Quarterly Report on Form 10-Q, filed with the SEC on October 21, 2022 (the “Q2 2022 10-Q” and together with the Q1 2022 10-Q, the “Filings”).

 

The following errors impacted the Filings:

 

(i)Incorrect itemization of accounts payable to reflect certain itemized expenses;

 

(ii)Failure to include the rounding up of shares to reflect the correct total number of issued common stock;

 

(iii)Failure to include certain accrued expenses to the accounts payable section;

 

(iv)Incorrect calculation of closing dates regarding the reporting period for goods sold;

 

(v)Incorrect calculation of closing dates regarding the reporting period for costs of goods sold;

 

(vi)Incorrect statement of impaired expenses of $577,473 related to the acquisition of Mango Moi;

 

(vii)Incorrect calculation of stock option agreements with Mast Hill and members of the Company’s Board of Directors;

 

(viii)Incorrect calculation of selling, general and administrative operating expenses, which have been retranslated to comply with reporting standards under GAAP;

 

(ix)Incorrect itemization of stock warrant expenses, reflected in the reitemization of $36,366;

 

(x)Portions of the cash flow section of the financials did not meet GAAP standards;

 

(xi)Omission of unaccounted depreciation in the financial statements; and

 

(xii)Certain other incorrect calculations.

 

The Company has determined that the reporting effects of the above errors had a material impact to the Company’s unaudited consolidated financial statements of the Company for the three months ended May 31, 2022, as reported in the Q1 2022 10-Q, and for the three and six months ended August 31, 2022, as reported in the Q2 2022 10-Q. As a result, the unaudited consolidated financial statements for the three months ended May 31, 2022 and the unaudited consolidated financial statements for the three and six months ended August 31, 2022 will be restated, and the Company will file an amendment to each of the Q1 2022 10-Q and the Q2 2022 10-Q with the SEC.

 

Remediation of Material Weakness

 

We are in the process of implementing improvements and remedial measures in response to the material weakness, including the hiring of a fractional Chief Financial Officer with over 24 years of diverse professional experience in financial reporting and auditing under GAAP and IFRS, with expertise in PCAOB audits. Additionally, we entered into an agreement with Aprari Solutions for accounting and audit-related services. Established in 2018, Aprari Solutions is a leading audit and accounting firm in India with a team consisting of qualified CPAs, Chartered Accountants, CFAs, Ph.D. and MBAs from top institutions, and experienced professionals well-trained in GAAP and PCAOB audit standards and procedures. 

 

Changes in Internal Control over Financial Reporting  

 

Since February 5, 2023, and in connection with the evaluation required by Rule 13a-15 under the Exchange Act as of August 31, 2022, the Company has made changes to its internal control over financial reporting that materially affected or are reasonably likely to affect our internal control over financial reporting, including those changes set forth under “—Remediation of Material Weakness.” 

 

Limitations on the effectiveness of internal controls 

 

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls system, no matter how well designed and operated, can provide only reasonable assurance of achieving its desired objectives. In addition, the design of disclosure controls and procedures must reflect resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Our management does not expect the Company’s disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management overriding internal controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. 

 

32

 

 

PART II-OTHER INFORMATION

 

ITEM 1 LEGAL PROCEEDINGS

 

There are no legal proceedings against the Company and the Company is unaware of such proceedings contemplated against it.

 

ITEM 1A RISK FACTORS

 

As a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item.

 

ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3 DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4 MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5 OTHER INFORMATION

 

None.

 

33

 

 

ITEM 6 EXHIBITS

 

Exhibit No.   Description
     
31.1   Certification of the Company’s Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s report on Form 10-Q for the period ended August 31, 2022.(1)
31.2   Certification of the Company’s Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s report on Form 10-Q for the period ended August 31, 2022.(1)
32.1   Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.(1)
32.2   Certification of the Company’s Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.(1)
101.INS   Inline XBRL Instance Document.(2)
101.SCH   Inline XBRL Taxonomy Extension Schema Document.(2)
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.(2)
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.(2)
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.(2)
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.(2)
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

(1) Filed herewith.
(2) Users of this data are advised that, pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or Annual Report for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Exchange Act of 1934 and otherwise are not subject to liability.

 

34

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, there unto duly authorized.

 

Better For You Wellness, Inc.  
(Registrant)  
   
By: /s/ Ian James  
Name:    Ian James  
  Chairman and Chief Executive Officer  
  (Principal Executive Officer)  
     
Dated: March 17, 2023  

 

35

 

 

NONE 0.00 0.00 0.00 0.00 537 375.13 true --02-28 Q2 0001852707 0001852707 2022-03-01 2022-08-31 0001852707 2023-03-17 0001852707 2022-08-31 0001852707 2022-02-28 0001852707 2022-06-01 2022-08-31 0001852707 2021-06-01 2021-08-31 0001852707 2021-03-01 2021-08-31 0001852707 us-gaap:CommonStockMember 2022-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-02-28 0001852707 bfyw:SharesCancelableMember 2022-02-28 0001852707 us-gaap:RetainedEarningsMember 2022-02-28 0001852707 us-gaap:CommonStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-03-01 2022-05-31 0001852707 bfyw:SharesCancelableMember 2022-03-01 2022-05-31 0001852707 us-gaap:RetainedEarningsMember 2022-03-01 2022-05-31 0001852707 2022-03-01 2022-05-31 0001852707 us-gaap:CommonStockMember 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001852707 bfyw:SharesCancelableMember 2022-05-31 0001852707 us-gaap:RetainedEarningsMember 2022-05-31 0001852707 2022-05-31 0001852707 us-gaap:CommonStockMember 2022-06-01 2022-08-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-06-01 2022-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-06-01 2022-08-31 0001852707 bfyw:SharesCancelableMember 2022-06-01 2022-08-31 0001852707 us-gaap:RetainedEarningsMember 2022-06-01 2022-08-31 0001852707 us-gaap:CommonStockMember 2022-08-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-08-31 0001852707 bfyw:SharesCancelableMember 2022-08-31 0001852707 us-gaap:RetainedEarningsMember 2022-08-31 0001852707 us-gaap:CommonStockMember 2021-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-02-28 0001852707 us-gaap:RetainedEarningsMember 2021-02-28 0001852707 2021-02-28 0001852707 us-gaap:CommonStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-03-01 2021-05-31 0001852707 us-gaap:RetainedEarningsMember 2021-03-01 2021-05-31 0001852707 2021-03-01 2021-05-31 0001852707 us-gaap:CommonStockMember 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001852707 us-gaap:RetainedEarningsMember 2021-05-31 0001852707 2021-05-31 0001852707 us-gaap:CommonStockMember 2021-06-01 2021-08-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-06-01 2021-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-06-01 2021-08-31 0001852707 us-gaap:RetainedEarningsMember 2021-06-01 2021-08-31 0001852707 us-gaap:CommonStockMember 2021-08-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-08-31 0001852707 us-gaap:RetainedEarningsMember 2021-08-31 0001852707 2021-08-31 0001852707 bfyw:PredecessorsMember 2022-08-31 0001852707 bfyw:FastTrackSolutionsIncMember 2022-08-31 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-18 0001852707 us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-18 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-30 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:CommonStockMember 2021-07-01 2021-07-30 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember bfyw:CRSConsultingsLLCMember 2021-07-30 0001852707 bfyw:IanJamesMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:StephenLetourneauMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:GreenOhioVenturesLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:PurchasePriceMember 2021-07-01 2021-07-30 0001852707 bfyw:PurchasePriceMember 2021-07-30 0001852707 bfyw:MRKTSGroupIncMember 2021-08-01 2021-08-24 0001852707 bfyw:PurchasePriceMember bfyw:MRKTSGroupIncMember 2021-08-24 0001852707 bfyw:BetterForYouWellnessIncMember 2021-08-01 2021-08-25 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-08-25 0001852707 bfyw:MangoMoiLLCMember us-gaap:CommonStockMember 2022-04-29 0001852707 2022-04-29 0001852707 bfyw:AmandaCayemitteMember us-gaap:CommonStockMember 2022-04-29 0001852707 bfyw:YapoMbeMember us-gaap:CommonStockMember 2022-04-29 0001852707 bfyw:MangoMoiMember 2022-06-01 2022-08-31 0001852707 bfyw:MangoMoiMember 2021-06-01 2021-08-31 0001852707 bfyw:MangoMoiMember 2022-03-01 2022-08-31 0001852707 bfyw:MangoMoiMember 2021-03-01 2021-08-31 0001852707 bfyw:MangoMoiLLCMember 2022-06-01 2022-08-31 0001852707 bfyw:MangoMoiLLCMember 2022-03-01 2022-08-31 0001852707 bfyw:SRAXIncMember 2021-09-02 2021-09-17 0001852707 2022-04-18 0001852707 2022-04-01 2022-04-18 0001852707 bfyw:IanJamesEmploymentAgreementMember 2022-08-31 0001852707 bfyw:IanJamesEmploymentAgreementMember 2022-03-01 2022-08-31 0001852707 bfyw:StephenLetourneauEmploymentAgreementMember 2022-08-31 0001852707 bfyw:StephenLetourneauEmploymentAgreementMember 2022-03-01 2022-08-31 0001852707 bfyw:JacobEllmanEmploymentAgreementMember 2022-08-31 0001852707 bfyw:JacobEllmanEmploymentAgreementMember 2022-03-01 2022-08-31 0001852707 bfyw:MastHillFundLPMember 2022-06-01 2022-06-07 0001852707 bfyw:MastHillFundLPMember 2022-06-07 0001852707 2022-06-07 0001852707 2022-06-01 2022-06-07 0001852707 bfyw:MastHillFundLPMember 2022-03-01 2022-08-31 0001852707 bfyw:CRSConsultingLLCMember us-gaap:SeriesAPreferredStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember 2021-11-30 0001852707 bfyw:SauerEnergyIncMember 2022-08-31 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-07-01 2021-07-19 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-23 2021-08-25 0001852707 bfyw:CRSConsultingLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:SRAXIncMember 2021-10-01 2021-10-11 0001852707 bfyw:CRSConsultingLLCMember 2021-10-01 2021-10-11 0001852707 srt:BoardOfDirectorsChairmanMember 2021-11-01 2021-11-17 0001852707 srt:BoardOfDirectorsChairmanMember 2021-12-25 2022-01-03 0001852707 us-gaap:MajorityShareholderMember 2022-01-01 2022-01-13 0001852707 srt:BoardOfDirectorsChairmanMember 2022-04-01 2022-04-12 0001852707 srt:BoardOfDirectorsChairmanMember 2022-04-12 2022-04-12 0001852707 2022-04-12 0001852707 2022-04-12 2022-04-12 0001852707 bfyw:MangoMoiLLCMember 2022-05-01 2022-05-26 0001852707 srt:BoardOfDirectorsChairmanMember 2022-07-01 2022-07-12 0001852707 bfyw:NevadaCorporationMember 2022-07-27 0001852707 2022-07-27 0001852707 srt:MinimumMember 2022-07-27 0001852707 srt:MaximumMember 2022-07-27 0001852707 us-gaap:MajorityShareholderMember 2022-03-01 2022-08-31 0001852707 us-gaap:SubsequentEventMember 2022-10-12 0001852707 2022-07-11 2022-07-11 0001852707 2021-08-31 2021-08-31 0001852707 us-gaap:EmployeeStockOptionMember 2022-03-01 2022-08-31 0001852707 bfyw:MastHillFundLPMember 2022-03-01 2022-08-31 0001852707 bfyw:GreenOhioVenturesLLCMember 2022-03-01 2022-08-31 0001852707 bfyw:IanJamesMember 2022-03-01 2022-08-31 0001852707 bfyw:IanJamesMember 2022-03-01 2022-08-31 0001852707 bfyw:StephenLetourneauMember 2022-03-01 2022-08-31 0001852707 bfyw:StephenLetourneauMember 2022-03-01 2022-08-31 0001852707 srt:BoardOfDirectorsChairmanMember 2022-08-31 0001852707 srt:BoardOfDirectorsChairmanMember 2022-10-12 0001852707 us-gaap:CommonStockMember 2022-10-12 0001852707 2022-10-01 2022-10-12 0001852707 2022-10-12 0001852707 us-gaap:SubsequentEventMember 2022-09-20 0001852707 us-gaap:SubsequentEventMember 2022-09-01 2022-09-20 0001852707 srt:BoardOfDirectorsChairmanMember us-gaap:SubsequentEventMember 2022-10-11 0001852707 srt:BoardOfDirectorsChairmanMember us-gaap:SubsequentEventMember 2022-10-12 0001852707 srt:BoardOfDirectorsChairmanMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-12 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure
EX-31.1 2 f10q0822a1ex31-1_better.htm CERTIFICATION

Exhibit 31.1

 

CERTIFICATIONS

 

I, Ian James, certify that:

 

1.I have reviewed this amended Quarterly Report on Form 10-Q/A for the quarter ended August 31, 2022 of Better For You Wellness, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 17, 2023

 

/s/ Ian James  
Ian James  

Chairman of the Board and

Chief Executive Officer

 
(Principal Executive Officer)  

EX-31.2 3 f10q0822a1ex31-2_better.htm CERTIFICATION

 

Exhibit 31.2

 

CERTIFICATIONS

 

I, Pratibha Chaurasia, Fractional Chief Financial Officer, certify that:

 

  1. I have reviewed this amended Quarterly Report on Form 10-Q/A for the quarter ended August 31, 2022 of Better For You Wellness, Inc.;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 17, 2023

   
/s/ Pratibha Chaurasia  
Fractional Chief Financial Officer    
(Principal Financial and Accounting Officer)  

 

EX-32.1 4 f10q0822a1ex32-1_better.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the amended Quarterly Report of Better For You Wellness, Inc. (the “Company”) on Form 10-Q/A for the quarter ended August 31, 2022 as filed with the Securities and Exchange Commission (the “Report”), I, Ian James, Chief Executive Officer of the Company, certify that:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
  
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: March 17, 2023

 

/s/ Ian James  
Ian James  

Chairman of the Board and

Chief Executive Officer

 
(Principal Executive Officer)  

 

 

EX-32.2 5 f10q0822a1ex32-2_better.htm CERTIFICATION

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the amended Quarterly Report of Better For You Wellness, Inc. (the “Company”) on Form 10-Q/A for the quarter ended August 31, 2022 as filed with the Securities and Exchange Commission (the “Report”), I, Pratibha Chaurasia, Fractional Chief Financial Officer of the Company, certify that:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
  
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: March 17, 2023

 

/s/ Pratibha Chaurasia  
Fractional Chief Financial Officer    
(Principal Financial and Accounting Officer)  
   

 

 

EX-101.SCH 6 bfyw-20220831.xsd XBRL SCHEMA FILE 001 - Statement - Unaudited Condensed Consolidated Balance Sheet link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Unaudited Condensed Consolidated Balance Sheet (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Statement of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Statement of Operations (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Consolidated and Condensed Statement of Changes in Stockholder (Deficit) (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Organization and Description of Business link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Business Combinations link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Convertible Note Payable link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Stock Purchase Warrant Liability link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Shareholder Equity link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Impairment Expense link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Business Combinations (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Organization and Description of Business (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Business Combinations (Details) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Business Combinations (Details) - Schedule of fair value of such assets and liabilities link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Business Combinations (Details) - Schedule of unaudited condensed consolidated results of operations link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Business Combinations (Details) - Schedule of unaudited segment reporting information by segment link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Convertible Note Payable (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Stock Purchase Warrant Liability (Details) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Shareholder Equity (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 bfyw-20220831_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 bfyw-20220831_def.xml XBRL DEFINITION FILE EX-101.LAB 9 bfyw-20220831_lab.xml XBRL LABEL FILE EX-101.PRE 10 bfyw-20220831_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information - shares
6 Months Ended
Aug. 31, 2022
Mar. 17, 2023
Document Information Line Items    
Entity Registrant Name BETTER FOR YOU WELLNESS, INC.  
Trading Symbol None  
Document Type 10-Q/A  
Current Fiscal Year End Date --02-28  
Entity Common Stock, Shares Outstanding   404,014,987
Amendment Flag true  
Amendment Description Better For You Wellness, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment No. 1”) to amend its Quarterly Report on Form 10-Q for the quarterly period ended August 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on October 21, 2022 (the “Original Form 10-Q”).Background of RestatementThis Amendment No. 1 is being filed for the sole purpose of restating certain of the financial statements included in the Original Form 10-Q (the “Restatement”) due to the Company discovering that it made the following errors in the Original Form 10-Q: (i) not translating correctly the foreign currency balance for a mark-to-market contract; and (ii) not including certain debt issuance costs in the computation of the effective interest rate for a loan note. In the Original Form 10-Q filed October 21, 2022, the negative net loss was reported as $787,106 for the three months ended May 31, 2022, and $1,582,699 for the six months ended August 31, 2022. The Amended and Restated negative net loss is reported as $767,677 a difference of $19,429 in lower net loss for the three month period ended May 31, 2022, and $76,850 greater net loss for the six month period ended August 31, 2022.On March 3, 2023, the Company filed a Current Report on Form 8-K disclosing that the financial statements included in the Original Form 10-Q should not be relied upon.   In connection with the Restatement, management had concluded that the Company had a material weakness in its internal control over financial reporting as of May 31, 2022, as the Company’s internal control over financial reporting did not operate effectively, resulting in material errors in the financial statements included in the Original 10-Q. For a discussion of management’s considerations of the Company’s disclosure controls and procedures, internal control over financial reporting, and material weakness identified, refer to Controls and Procedures in Part I, Item 4.Internal Control ConsiderationsIn connection with the Restatement, management has concluded that the Company had a material weakness in its internal control over financial reporting as of August 31, 2022, as the Company’s review control over the accuracy of its financial statements did not operate effectively, resulting in material errors in the financial statements. For a discussion of management’s considerations of the Company’s disclosure controls and procedures, internal control over financial reporting, and material weakness identified, refer to Controls and Procedures in Part I, Item 4.Items Amended in this Amendment No. 1This Amendment No. 1 sets forth the Original Form 10-Q, as modified and superseded where necessary to reflect the Restatement and the related disclosure controls and procedures and internal control considerations. Accordingly, the following items included in the Original Form 10-Q have been amended: ●Part I, Item 1, Financial Statements     ●Part I, Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations     ●Part I, Item 4, Controls and Procedures     ●Part II, Item 1A, Risk Factors Additionally, in accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended, the Company is including with this Amendment No. 1 currently dated certifications from its Chief Executive Officer, Chief Financial Officer, and President.Except as described above and in Note 9, Restatement, this Amendment No. 1 does not amend, update or change any other disclosures in the Original Form 10-Q. In addition, the information contained in this Amendment No. 1 does not reflect events occurring after the Original Form 10-Q and does not modify or update the disclosures therein, except to reflect the effects of the Restatement.  
Entity Central Index Key 0001852707  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Document Period End Date Aug. 31, 2022  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Entity Small Business false  
Entity Emerging Growth Company true  
Entity Shell Company false  
Entity Ex Transition Period false  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 000-56262  
Entity Incorporation, State or Country Code NV  
Entity Tax Identification Number 87-2903933  
Entity Address, Address Line One 1349 East Broad Street  
Entity Address, City or Town Columbus  
Entity Address, State or Province OH  
Entity Address, Postal Zip Code 43205  
City Area Code (614)  
Local Phone Number 368-9898  
Title of 12(b) Security None  
Security Exchange Name NONE  
Entity Interactive Data Current Yes  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Unaudited Condensed Consolidated Balance Sheet - USD ($)
Aug. 31, 2022
Feb. 28, 2022
Current Assets:    
Cash and cash equivalents $ 2,130 $ 9,642
Accounts Receivable 123
Related Party Receivable 107,068
Inventory 5,198
Prepaids and other assets 78,072
Total Current assets 192,591 9,642
Equipment, net 1,935
Goodwill 583,485
TOTAL ASSETS 778,011 9,642
CURRENT LIABILITIES:    
Accounts Payable 257,821 375,408
Deferred Compensation 190,320
Clearbanc Debit Card 1,656
Note Payable- RP 110,000  
Other Current Liabilities 14
Total Current liabilities 559,810 375,408
Long-Term Liabilities
Notes Payable - PayPal Capital 2,216
Notes Payable Shopify Capital 201
Convertible notes payable, net accumulated interest 543,176
TOTAL LIABILITIES 1,105,403 375,408
STOCKHOLDERS’ EQUITY (DEFICIT):    
Preferred stock ( $.0001 par value, 200,000,000 shares authorized; 700,000 issued and outstanding as of August 31, 2022 and February 28, 2022) 70 70
Common stock ($.0001 par value, 500,000,000 shares authorized, 385,198,451 and 370,747,042 issued and outstanding as of August 31, 2022 and February 28, 2022 respectively) 38,521 37,075
Additional Paid in Capital 2,931,841 1,485,364
Shares cancelable (250,000)
Accumulated Deficit (3,297,825) (1,638,275)
Total Stockholders’ Equity (Deficit) (327,392) (365,766)
TOTAL LIABILITIES & EQUITY (DEFICIT) $ 778,011 $ 9,642
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Unaudited Condensed Consolidated Balance Sheet (Parentheticals) - $ / shares
Aug. 31, 2022
Feb. 28, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 200,000,000 200,000,000
Preferred stock, shares issued 700,000 700,000
Preferred stock, shares outstanding 700,000 700,000
Common stock, par value (in Dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 385,198,451 370,747,042
Common stock, shares outstanding 385,198,451 370,747,042
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Statement of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Aug. 31, 2022
Aug. 31, 2021
Aug. 31, 2022
Aug. 31, 2021
Income Statement [Abstract]        
Revenue    
Merchandise Sales 1,716 $ 2,022
Cost of Good Sold 3,489 9,558
Gross Profit (1,772) (7,536)
Operating Expenses        
Share based expense 301,663 7,000 985,713 77,000
Selling, General and Administrative 446,262 7,005 643,257 9,057
Total Operating Expenses 747,925 14,005 1,628,970 86,057
Operating Income/(Loss) (749,697) (14,005) (1,636,506) (86,057)
Other Income (Expense)        
Interest expense (17,980) (23,043)
Other expense  
Total Other Income (17,980) (23,043)
Net income/(loss) $ (767,677) $ (14,005) $ (1,659,549) $ (86,057)
Basic net loss per common share (in Dollars per share) $ 0 $ 0 $ 0 $ 0
Weighted average number of common shares outstanding (in Shares) 372,031,446 360,000,680 372,031,446 250,434,405
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Statement of Operations (Unaudited) (Parentheticals) - $ / shares
3 Months Ended 6 Months Ended
Aug. 31, 2022
Aug. 31, 2021
Aug. 31, 2022
Aug. 31, 2021
Income Statement [Abstract]        
Diluted net loss per common share $ 0.00 $ 0.00 $ 0.00 $ 0.00
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated and Condensed Statement of Changes in Stockholder (Deficit) (Unaudited) - USD ($)
Par Value Series A
Preferred Shares
Common Shares
Additional Paid-in Capital
Shares Cancellable
Accumulated Deficit
Total
Balance at Feb. 28, 2021 $ 1,185   $ (4,935) $ (3,750)
Balance (in Shares) at Feb. 28, 2021          
Common shares issued after reorganization $ 36,000 (36,000)  
Common shares issued after reorganization (in Shares)   359,996,332        
Preferred shares issued after reorganization $ 70 69,930     70,000
Preferred shares issued after reorganization (in Shares) 700,000          
Expenses paid on behalf of the Company and contributed to capital - $ 3,951       3,951
Expenses paid on behalf of the Company and contributed to capital - (in Shares)          
Net loss       (72,051) (72,051)
Balance at May. 31, 2021 $ 70 $ 36,000 39,607   (76,986) (1,850)
Balance (in Shares) at May. 31, 2021 700,000 359,996,332        
Common shares issued for services to the Company $ 5 6,995     7,000
Common shares issued for services to the Company (in Shares)   50,000        
Expenses paid on behalf of the Company and contributed to capital - $ 2,990       2,990
Expenses paid on behalf of the Company and contributed to capital - (in Shares)          
Net loss       (14,005) (14,005)
Balance at Aug. 31, 2021 $ 70 $ 36,005 49,052   (90,992) (5,865)
Balance (in Shares) at Aug. 31, 2021 700,000 360,046,332        
Balance at Feb. 28, 2022 $ 70 $ 37,075 1,485,364 $ (250,000) (1,638,275) (365,766)
Balance (in Shares) at Feb. 28, 2022 700,000 370,747,042        
Common shares cancelled and returned to the Company $ (705) (249,295) 250,000
Common shares cancelled and returned to the Company (in Shares) (7,048,873)        
Common shares issued for shares payable $ 33 (33)
Common shares issued for shares payable (in Shares) 325,000        
Common shares issued for services to the Company $ 509 272,226 272,735
Common shares issued for services to the Company (in Shares) 5,085,000        
Common shares issued for purchase of subsidiary $ 1,100 548,900 550,000
Common shares issued for purchase of subsidiary (in Shares) 11,000,000        
Stock option expense 411,315 411,315
Warrants Issued 78,072 78,072
Warrants Issued 13,514 13,514
Debt Forgiveness 49,686 49,686
Net loss     (891,872) (891,872)
Balance at May. 31, 2022 $ 70 $ 38,012 2,609,749 (2,530,147) 117,684
Balance (in Shares) at May. 31, 2022 700,000 380,108,169        
Balance at Feb. 28, 2022 $ 70 $ 37,075 1,485,364 (250,000) (1,638,275) (365,766)
Balance (in Shares) at Feb. 28, 2022 700,000 370,747,042        
Balance at Aug. 31, 2022 $ 70 $ 38,521 2,931,841 (3,297,824) (327,392)
Balance (in Shares) at Aug. 31, 2022 700,000 385,198,451        
Balance at May. 31, 2022 $ 70 $ 38,012 2,609,749 (2,530,147) 117,684
Balance (in Shares) at May. 31, 2022 700,000 380,108,169        
Common shares issued for services to the Company $ 506 250,192 250,698
Common shares issued for services to the Company (in Shares) 5,060,000        
Common shares issued for cash received $ 3 3,747 3,750
Common shares issued for cash received (in Shares) 30,282        
Fair value of warrants issued 17,188 17,188
Forfeiture of stock compensation (223,060) (223,060)
Stock option expense 274,025 274,025
Net loss   (767,677) (767,677)
Balance at Aug. 31, 2022 $ 70 $ 38,521 $ 2,931,841 $ (3,297,824) $ (327,392)
Balance (in Shares) at Aug. 31, 2022 700,000 385,198,451        
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)
6 Months Ended
Aug. 31, 2022
Aug. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES    
Net (loss) $ (1,659,549) $ (86,057)
Adjustments to reconcile Net Loss to net cash provided by (used in) operating activities:    
Share based expenses 985,713 77,000
Amortized debt discount and debt issuance costs 49,475
Depreciation 388
Changes in current assets and liabilities:    
Inventory 7,899
Accounts Receivable (123)  
Related Party Receivable (107,068)  
Accounts Payable (117,587) 1,750
Deferred Compensation 190,320
Other Liabilities (7,496)  
Accrued Interest 23,043  
Net cash provided by (used in) Operating Activities (634,985) (7,307)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Fixed Asset (2,323)
Total Cash Flow from Investing Activities (2,323)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Payment of debt issuance costs (56,640)
Proceeds from Convertible loan, net of original issue discount 558,000
Proceed from related party note payable 75,000 365
Common Share Issuance 3,750
Expenses contributed to capital 49,686 6,942
Net cash provided by financing activities 629,796 7,307
Net Change in Cash (7,512)
Cash at beginning of period 9,642
Cash at end of period 2,130
NON-CASH FINANCING TRANSACTIONS:    
Discount on notes payable for warrants 30,702  
Warrants issued and extended for common stock issuance costs $ 78,072  
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Organization and Description of Business
6 Months Ended
Aug. 31, 2022
Organization and Description of Business [Abstract]  
Organization and Description of Business

Note 1 - Organization and Description of Business

 

Better For You Wellness, Inc. (“we,” “us,” “our”, the “Company” or the “Registrant”) was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.

 

On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230 and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Our former director, Jeffrey DeNunzio, was the sole director/officer of each constituent corporation in the Reorganization.

 

Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.

 

Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021, at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.

 

Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until the new ticker symbol “FTRK” for the Company was released into the OTC MarketPlace on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.

 

The Company believes that the Reorganization, deemed effective on May 5, 2021, was not a transaction of the type described in subparagraph (a) of Rule 145 under the Securities Act of 1933 and the consummation of the Reorganization will not be deemed to involve an “offer”, “offer to sell”, “offer for sale” or “sale” within the meaning of Section 2(3) of the Securities Act of 1933. The Reorganization was consummated without the vote or consent of the Company’s stockholders. In addition, the provisions of NRS 92A.180 did not provide a stockholder of the Company with appraisal rights in connection with the Reorganization. The Company believes that in the absence of any right of any of the Company’s stockholders to vote with respect to the Reorganization or to insist that their shares be purchased for fair value, the Reorganization could not be deemed to involve an “offer” “offer to sell”; or “sale” within the meaning of Section 2(3) of the Securities Act of 1933.”

 

On May 5, 2021, after the completion of the Holding Company Reorganization, we canceled all of the stock we held in Sauer Energy, Inc., resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.

 

Given that the former business plan and objectives of Sauer Energy, Inc. and the business plan and objectives of Fast Track Solutions, Inc. substantially differed from one another, we conducted the corporate separation with Sauer Energy, Inc. immediately after the effective time of the Reorganization in order to avoid any shareholder confusion. The former business plan of Sauer Energy, Inc. (the development and marketing of wind powered electric generators) under the leadership of its former directors, did not, in any way, represent the blank check business plan of Fast Track Solutions, Inc. at that time, and thus it is the belief of the Company that the corporate separation ameliorated shareholder confusion about our identity and/or corporate objectives. It is our belief that Sauer Energy was a shell company at the time of the Reorganization.

 

The corporate actions taken by the Company, including, but not limited to, the corporate structuring of the transactions, was deemed, in the discretion of our sole director, to be for the benefit of the corporation and its shareholders. Former shareholders of Sauer Energy, Inc. were then the shareholders of Fast Track Solutions, Inc. and had the opportunity to benefit from a business combination with another company. The Company intended to serve as a vehicle to affect an asset acquisition, merger, exchange of capital stock or other business combination with a domestic or foreign business at that time

 

After the reorganization and through July 18, 2021, CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody, was our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock.

 

On July 19, 2021, Better For You Wellness, Inc., FKA “Fast Track Solutions, Inc.”, a Nevada Corporation (the “Company”), entered into a Share Purchase Agreement (the “Agreement”) by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021 (“Closing Date”), CRS sold 700,000 shares of the Company’s Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of the Company; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000) (the “Purchase Price”). The consummation of the transactions contemplated by the Agreement resulted in a change in control of the Company, with GOHV, Ian James, and Stephen Letourneau, becoming the Company’s largest controlling stockholders having approximately 89.62% combined voting control over the Company.

 

On August 19, 2021, the Company filed an 8-K with the SEC to disclose an amendment to the Company’s Articles of Incorporation that the Company filed on August 18, 2021, with the Nevada Secretary of State to change its name to Better For You Wellness, Inc. Within the aforementioned 8-K, the Company disclosed that, at the time, it was pending a FINRA corporate action to affect the name change on the OTC to Better For You Wellness, Inc., and also a ticker symbol change. FINRA announced, on their September 29, 2021 daily list, that the market effective date of our name change, and ticker symbol change, will be September 30, 2021. On September 30, 2021, we will begin trading under the symbol BFYW. The new CUSIP number associated with our common stock, as of the market effective date of September 30, 2021, is 08771B105.

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided. This transaction did not result in MRKTS Group Inc. owning 5% or more of any class of securities of the issuer.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau. The aforementioned transaction(s) did not result in any individual shareholder owning 5% or more of any class of securities of the issuer. The aforementioned transaction was carried out as it was deemed by GOHV to be in the best interests of its members.

 

On February 3. 2022, the Company was approved by OTC Markets to up-list its common stock from the OTC Pink Sheets to the OTCQB® Venture Market (the “OTCQB”). The Company began trading of its common shares on the OTCQB as of the market open on February 3, 2022, under its same symbol, “BFYW.”

 

The Company’s current business plan is to explore and evaluate various opportunities in the plant-based food and beverage and consumer packaged goods sectors, including but not limited to, mergers, acquisitions, or business combination transactions, after which the Company would cease to be a “shell” or “blank check” company. The Company’s principal business objective for the next 12 months and beyond will be to achieve long-term growth potential through a combination with a business rather than immediate, short-term earnings.

 

On November 15, 2021, the Company’s wholly owned subsidiary, Glow Market, LLC was formed in the State of Ohio. Subsequently, Glow Market, LLC launched its first brand, Better Suds, an online retailer of specialty all-natural, cruelty-free, gluten-free and chemical-free soaps. Better Suds commenced operations in December 2021.

 

On April 29, 2022 the Company entered into a Membership Interest Purchase Agreement (the “MIPA”) with Amanda Cayemitte and Yapo M’be (referred to together as the “Sellers”) to acquire the right, title and interest in, including all of the outstanding membership interests (referred to together as the “MM Interests”) of Mango Moi, LLC (“Mango Moi”). Mango Moi is a hair and skincare business located in Chicago, Illinois. Pursuant to the MIPA, in exchange for the MM Interests, the Company agreed to pay the Sellers a purchase price consisting of shares of the Company’s common stock, par value $0.0001 per share which consists of 11,000,000 shares of common stock (the “Company Common Stock”), with a fair market value of approximately $550,000, with 5,720,000 shares of Company Common Stock issued to Amanda Cayemitte and 5,280,000 shares of Company Common Stock issued to Yapo M’be (referred to together herein as the “Purchase Price”). Additionally, pursuant to the terms of the MIPA, the Company agreed to enter into an Employment Agreement with Mango Moi founder Amanda Cayemitte (the “Employment Agreement”), and a Consulting Agreement with Yapo M’be (the “Consulting Agreement”), respectively, as disclosed by the Company on its Current Report on Form 8-K filed with the SEC on May 2, 2022.

 

The MIPA closed (the “Closing”) on May 26, 2022, on which date the Company paid the Sellers the Purchase Price by issuing the Company Common Stock to the Sellers and the Sellers transferred the MM Interests to the Company, and on which date Mango Moi became a wholly owned subsidiary of the Company. At the Closing the Company entered into the Employment Agreement with Amanda Cayemitte and the Consulting Agreement with Yapo M’be.

 

The Company intends to optimize Mango Moi’s product formulae and packaging, as well as secure new manufacturing relationships to scale production capacity. Additionally, the Company plans to expand Mango Moi’s product offerings to include additional products and product bundles. Furthermore, the Company intends to grow sales through direct-to-consumer marketing efforts, subscription box sales, and pursuing wholesale sales relationships.

 

The Company’s main office is located at 1349 East Broad Street, Columbus OH 43205.

 

The Company has elected February 28th as its year end.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies
6 Months Ended
Aug. 31, 2022
Organization and Description of Business [Abstract]  
Summary of Significant Accounting Policies

Note 2 - Summary of Significant Accounting Policies

 

Principles of Consolidation

 

The accompanying interim unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements on Form 10-K have been condensed or omitted. The condensed consolidated balance sheet as of February 28, 2022 has been derived from the audited consolidated financial statements as of that date, but does not include all disclosures required for audited annual financial statements. For further information, please refer to and read these interim condensed Consolidated Financial Statements in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended February 28, 2022 filed with the SEC.

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Glow Markets, LLC and Mango Moi, LLC. All significant intercompany accounts and transactions have been eliminated.

 

Basis of Presentation

 

This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.

 

Use of Estimates

 

There were no material changes in the Company’s significant accounting policies for the three and six months ended August 31, 2022 as compared to the year ended February 28, 2022. See Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022, as filed with the SEC, for additional information regarding the Company’s significant accounting policies and use of estimates.

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at August 31, 2022 and February 28, 2022 were $2,130 and $9,642 respectively.

 

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets (primarily three to five years).

 

Revenue Recognition

 

The Company has prepared its unaudited condensed consolidated financial statements in accordance with GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.

 

The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

 

Revenue for products is recognized when the products are delivered to the customer and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of August 31, 2022 and February 28, 2022, the Company had no deferred revenues.

 

Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at August 31, 2022.

 

Basic Earnings (Loss) Per Share

 

The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, Earnings per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company did not have any dilutive instruments for the three and six months ended August 31, 2022, and 2021, respectively. Thus, anti-dilution issues are not applicable.

 

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

 

ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of August 31, 2022 and February 28, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.

 

Related Parties

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

Share-Based Compensation

 

ASC 718, “Compensation – Stock Compensation”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity–Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

 

Except as specified for the Independent Directors’ compensation, the Company had no stock-based compensation plans as of August 31, 2022 and February 28, 2022.

 

Recently Issued Accounting Pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13 “Credit Losses - Measurement of Credit Losses on Financial Instruments.” ASU No. 2016-13 significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables, by replacing today’s “incurred loss” approach with an “expected loss” model under which allowances will be recognized based on expected rather than incurred losses. ASU No. 2016-13 will become effective for us in the first quarter of 2023. We are evaluating the impact that the adoption of this update will have on our financial statements; however, it is not expected to be material.

 

Reclassification of Prior Year Presentation

 

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.4
Going Concern
6 Months Ended
Aug. 31, 2022
Going Concern [Abstract]  
Going Concern

Note 3 - Going Concern

 

The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.

 

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.

 

The Company has not established enough sources of revenue to cover its operating costs. Management plans to fund operating expenses with related party capital contributions. There is no assurance that management’s plan will be successful. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combinations
6 Months Ended
Aug. 31, 2022
Business Combinations [Abstract]  
Business Combinations

Note 4 - Business Combinations

 

On April 29, 2022, we entered into an asset purchase agreement to acquire substantially all of the assets of Mango Moi. The acquisition was accounted for in accordance with GAAP and was made to expand our market share in the personal care category and due to synergies of product lines and services between the Companies. The acquisition closed May 26, 2022.

 

The purchase price has been preliminarily allocated to assets acquired and liabilities assumed based on the estimated fair value of such assets and liabilities at the date of acquisitions as follows:

 

Assets acquired:    
Cash  $913 
Inventory   12,995 
Total Assets Acquired   13,908 
Liabilities assumed:     
Clearbanc Debit Card   2,365 
Notes Payable - PayPal Capital   2,454 
Notes Payable Shopify Capital   53 7 
 Sales Tax Payable   138 
Total Liabilities Assumed   5,494 
      
Total identifiable net assets   8,414 
      
Purchase price   592,000 
      
Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date  $583,586 

 

The purchase price of $592,000 was paid in stock and discharge of liability in cash as a combination. Goodwill in the amount of $583,586 was recognized in the acquisition of Mango Moi LLC and is attributable to the cash flows of the business derived from our potential to outperform the market due to its existing relationship and other synergies created within the Company.

 

As the Company finalizes the fair value of assets acquired and liabilities assumed, additional purchase price adjustments may be recorded. The finalization of the purchase accounting assessment may result in changes in the valuation of assets acquired and liabilities assumed and may have an impact on the Company’s results of operations and financial position.

 

The following unaudited pro forma information presents a summary of the condensed consolidated results of operations for the Company as if the acquisition of Mango Moi had occurred on March 1, 2021.

 

   For the Three months ended 
   (unaudited)   (unaudited) 
   August 31,
2022
   August 31,
2021
 
Total revenues  $1,716   $15,991 
           
Net (loss) income  $(767,677)  $(31,364)
           
Loss per share  $
-
   $
-
 

 

   For the Six months ended 
   (unaudited)   (unaudited) 
   August 31,
2022
   August 31,
2021
 
Total revenues  $2,022   $35,447 
           
Net (loss) income  $(1,659,594)  $(112,841)
           
Loss per share  $
-
   $
-
 

 

The unaudited pro forma consolidated results are based on our historical financial statements and those of Mango Moi and do not necessarily indicate the results of operations that would have resulted had the acquisition actually been completed at the beginning of the applicable period presented. The pro forma financial information assumes that the companies were combined as of March 1, 2021.

 

The following tables present the amounts of revenue and earnings of Mango Moi since the acquisition date included in the condensed consolidated income statement for the reporting period.

 

   (unaudited)   (unaudited) 
   For the
three months ended
August 31,
   For the
six months ended
August 31,
 
   2022   2021 
Mango Moi:        
Total revenues  $1,716   $8,690 
Net income  $(819)  $(9,100)
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Income Taxes
6 Months Ended
Aug. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes

Note 5 - Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at August 31, 2022.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies
6 Months Ended
Aug. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 6 - Commitments and Contingencies

 

The Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of August 31, 2022 other than the following:

 

On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

 

Also on September 17, 2021, our Board of Directors unanimously agreed to approve to enter into and consummate another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.

 

On April 18, 2022, Better For You Wellness, Inc., a Nevada corporation (the “Company”), entered into a Standby Equity Commitment Agreement, dated April 11, 2022 (the “SECA”) with MacRab LLC, a Florida limited liability company (the “Investor”). The SECA provides the Company with an option to sell up to $5,000,000 worth of the Company’s common stock, par value $0.0001 (the “Common Stock”), to the Investor, in increments, over the period ending twenty-four (24) months after the date the Registration Statement (as defined below) is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. The purchase price per share, for each respective put under the SECA, is equal to 90% of the average of the two (2) lowest volume weighted average prices of the Common Stock during the six (6) trading days following the clearing date associated with the respective put under the SECA. Additionally, we issued a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock (the “Warrant”) to Investor as a commitment fee in connection with the execution of the SECA.

 

On May 26, 2022 the Company acquired Mango Moi, LLC as a wholly-owned subsidiary (See Note 1). As part of the purchase agreement, the Company entered into an employment agreement and a consulting agreement as follows:

 

Employment Agreement

 

Pursuant to the Employment Agreement, which is to be effective as of 45 days from the signing of the MIPA, the Company agreed to employ Amanda Cayemitte as the Chief Visionary Officer of Mango Moi to provide duties including normalizing the Company’s strategic-planning processes, forging new working relationships and synergies across the organization, and establishing greater transparency and accountability for those people carrying out the Company’s strategy. As compensation under the Employment Agreement, the Company agreed to pay Amanda Cayemitte an annual salary of $65,000 payable semi-monthly on the first day and the fifteenth day of the month and subject to applicable federal, state, and local withholding.

 

The Employment Agreement can be terminated any time by either party by giving 30 days written notice to the other party. If the Employment Agreement is terminated, Amanda Cayemitte will be entitled to receive compensation for:

 

one month upon completion of one full calendar year of employment with the Company;

 

two months upon completion of two full calendar years of employment with the Company, and

 

three months upon competition of two full calendar years of employment with the Company.

 

However, if Amanda Cayemitte breaches any terms of the Employment Agreement, the Company may terminate the Employment Agreement without any notice and with compensation being paid to Amanda Cayemitte only through the date of such termination.

 

Consulting Agreement

 

Pursuant to the Consulting Agreement, the Company engaged Yapo M’be as a consultant to provide manufacturing services for Mango Moi, to begin on May 2, 2022. As compensation under the Consulting Agreement, the Company agreed to pay Yapo M’be at the rate of $30.00 per hour, not to exceed $1,500 per month. The Consulting Agreement can be terminated by either party upon the failure of the other to perform under the Consulting Agreement by giving ten days written notice to the non-performing party. The Consulting Agreement can also be terminated by the Company by giving ten days written notice to Yapo M’be in the event that there is a reduction of the program budget.

 

Ian James Employment Agreement

 

On July 21, 2022 the Company’s Compensation Committee approved a formal Employment Agreement with Ian James, the Company’s Chief Executive Officer and the Company entered into the Agreement with Mr. James as of July 21, 2022. As compensation under the Employment Agreement, beginning March 1, 2022, Employee will earn a Base Salary in the amount of $199,196 per annum, $16,599.67 per month, less statutory and other required deductions, for all work and services Ian James performs for the Company. The Company calculates Annual Base Salary on a January 1 through December 31 basis (i.e., a calendar year). Base Salary payments shall be subject to applicable federal, state, and local withholding. Under the Agreement, the Employee and Company mutually agree that until the Company is cash flow positive, the Company shall pay Employee a mutually agreeable amount each month toward the Employee’s Base Salary, and the balance of Base Salary unpaid, shall be accrued and recorded as an obligation of the Company. It shall become payable to the Employee when the Company is cash flow positive or at a time mutually agreed by the Company and Employee.

 

The Employee shall also be eligible to earn an additional payment (BONUS) of $68,328. The parties consider the Bonus Pay as “at-risk” and therefore not guaranteed. Bonus Pay could include a cash bonus, commission, and other at-risk pay categories. BONUS shall be determined at the sole discretion of the Company. The Employee’s Bonus shall be based on Employee’s annual performance reviews and overall company performance, subject to the terms and conditions of applicable incentive plans and policies.

 

Should this Contract be terminated, payments under Section 2 shall cease; provided, however, that Employee shall be entitled to Base Salary and accrued Base Salary for periods or partial periods that occurred before the date of termination and for which the Employee has not yet been paid and for any commission earned per the Company’s customary procedures, if applicable.

 

After completion of 90-days of Employment, Employee shall be entitled to a pro-rated 15 days paid time per year for utilization by Employee for personal business, illness, care of another person, or vacation. Personal Leave shall be calculated from the effective date of this Contract as of the date first above written through December 31st.

 

Employee shall be permitted to carry over into the following year of employment a maximum of five days of Personal Leave; however, as of December 31, Employee shall forfeit unused Personal Leave benefits above five days. Further, Employee shall not be permitted to carry over or accumulate more than ten days of Personal Leave from one year to the next.

 

Stephen Letourneau Employment Agreement

 

On July 21, 2022 the Company’s Compensation Committee approved a formal Employment Agreement with Stephen Letourneau, the Company’s Chief Branding Officer and the Company entered into the Agreement with Mr. Letourneau as of July 21, 2022. As compensation under the Employment Agreement, beginning March 1, 2022, Employee will earn a Base Salary in the amount of $152,787 per annum, $12,732.25 per month, less statutory and other required deductions, for all work and services Ian James performs for the Company. The Company calculates Annual Base Salary on a January 1 through December 31 basis (i.e., a calendar year). Base Salary payments shall be subject to applicable federal, state, and local withholding. Under the Agreement, the Employee and Company mutually agree that until the Company is cash flow positive, the Company shall pay Employee a mutually agreeable amount each month toward the Employee’s Base Salary, and the balance of Base Salary unpaid, shall be accrued and recorded as an obligation of the Company. It shall become payable to the Employee when the Company is cash flow positive or at a time mutually agreed by the Company and Employee.

 

The Employee shall also be eligible to earn an additional payment (Bonus) of $70,632. The parties consider the Bonus Pay as “at-risk” and therefore not guaranteed. Bonus Pay could include a cash bonus, commission, and other at-risk pay categories. Bonus shall be determined at the sole discretion of the Company. The Employee’s Bonus shall be based on Employee’s annual performance reviews and overall company performance, subject to the terms and conditions of applicable incentive plans and policies.

 

Should this Contract be terminated, payments under Section 2 shall cease; provided, however, that Employee shall be entitled to Base Salary and accrued Base Salary for periods or partial periods that occurred before the date of termination and for which the Employee has not yet been paid and for any commission earned per the Company’s customary procedures, if applicable.

 

After completion of 90-days of Employment, Employee shall be entitled to a pro-rated 15 days paid time per year for utilization by Employee for personal business, illness, care of another person, or vacation. Personal Leave shall be calculated from the effective date of this Contract as of the date first above written through December 31st.

 

Employee shall be permitted to carry over into the following year of employment a maximum of five days of Personal Leave; however, as of December 31, Employee shall forfeit unused Personal Leave benefits above five days. Further, Employee shall not be permitted to carry over or accumulate more than ten days of Personal Leave from one year to the next.

 

Jacob Ellman Employment Agreement

 

Pursuant to the Company’s Compensation Committee approval of July 21, 2022, The Company entered a formal Employment Agreement with Jacob Ellman, the Company’s Chief Business Development Officer and the Company entered into the Agreement with Mr. Ellman as of October 14, 2022. As compensation under the Employment Agreement, beginning March 1, 2022, Employee will earn a Base Salary in the amount of $128,656 per annum, $10,721.33 per month, less statutory and other required deductions, for all work and services Ian James performs for the Company. The Company calculates Annual Base Salary on a January 1 through December 31 basis (i.e., a calendar year). Base Salary payments shall be subject to applicable federal, state, and local withholding. Under the Agreement, the Employee and Company mutually agree that until the Company is cash flow positive, the Company shall pay Employee a mutually agreeable amount each month toward the Employee’s Base Salary, and the balance of Base Salary unpaid, shall be accrued and recorded as an obligation of the Company. It shall become payable to the Employee when the Company is cash flow positive or at a time mutually agreed by the Company and Employee.

 

The Employee shall also be eligible to earn an additional payment (Bonus) of $41,140. The parties consider the Bonus Pay as “at-risk” and therefore not guaranteed. Bonus Pay could include a cash bonus, commission, and other at-risk pay categories. Bonus shall be determined at the sole discretion of the Company. The Employee’s Bonus shall be based on Employee’s annual performance reviews and overall company performance, subject to the terms and conditions of applicable incentive plans and policies.

 

Should this Contract be terminated, payments under Section 2 shall cease; provided, however, that Employee shall be entitled to Base Salary and accrued Base Salary for periods or partial periods that occurred before the date of termination and for which the Employee has not yet been paid and for any commission earned per the Company’s customary procedures, if applicable.

 

After completion of 90-days of Employment, Employee shall be entitled to a pro-rated 15 days paid time per year for utilization by Employee for personal business, illness, care of another person, or vacation. Personal Leave shall be calculated from the effective date of this Contract as of the date first above written through December 31st.

 

Employee shall be permitted to carry over into the following year of employment a maximum of five days of Personal Leave; however, as of December 31, Employee shall forfeit unused Personal Leave benefits above five days. Further, Employee shall not be permitted to carry over or accumulate more than ten days of Personal Leave from one year to the next.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Convertible Note Payable
6 Months Ended
Aug. 31, 2022
Convertible Note Payable Disclosure [Abstract]  
Convertible Note Payable

Note 7 - Convertible Note Payable

 

On June 7, 2022, the Company entered into a second Securities Purchase Agreement with Mast Hill Fund, L.P., a Delaware limited partnership (“Mast Hill”). The first Security Purchase Agreement with Mast Hill Fund, L.P. was entered On April 12, 2022. Pursuant to the June 7, 2022 Security Purchase Agreement, Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on June 7, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on June 7, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.

 

Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.

 

In connection with the Purchase Agreements, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Mast Hill, pursuant to which the Company is obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the Commitment Shares and the shares of the Company’s common stock that may be issued to Mast Hill pursuant to the conversion of the Note.

 

JH Darbie & Co., Inc. (“JH Darbie”) and the Company are parties to a Finder’s Fee Agreement, signed March 15, 2020 (“Finder’s Agreement”) pursuant to which JH Darbie would introduce the Issuer to third-party investors. Pursuant to the Finder’s Agreement, in relation to both the April 12, 2022 and the June 7, 2022 Securities Purchase Agreement with Mast Hill Fund, L.P., J.H. Darbie received approximately $22,320 for each Security Purchase Agreement. In addition, JH Darbie is to receive non-callable warrants of equal to 8% warrant coverage of the amount raised. The warrants shall entitle JH Darbie thereof to purchase common stock of the Company at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of the Issuer’s common stock on the date of the Transaction, whichever is lower (such price, the “Warrant Price”). The warrants shall be exercisable immediately after the date of issuance, shall have anti-dilutive price protection, participating registration rights, and shall expire 5 years after the date of issuance, in accordance with the Finder’s Agreement.

 

On July 11, 2022, Mast Hill Fund agreed to extend the timeframes in section 2(a) of the Registration Rights Agreement dated 4/12/22 to 180 calendar days to file the initial Registration Statement and 270 calendar days to have it declared effective. On October 11, 2022, Mast Hill Fund agreed to extend the timeframes in section 2(a) of the Registration Rights Agreement dated 4/12/22 until February 9, 2023, and to have the Registration Statement become effective on or before February 9, 2037.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.4
Stock Purchase Warrant Liability
6 Months Ended
Aug. 31, 2022
Stock Purchase Warrant Liability [Abstract]  
Stock Purchase Warrant Liability

Note 8 - Stock Purchase Warrant Liability

 

JH Darbie & Co., Inc. (“JH Darbie”) and the Company are parties to a Finder’s Fee Agreement, signed March 15, 2020 (“Finder’s Agreement”) pursuant to which JH Darbie would introduce the Issuer to third-party investors. Pursuant to the Finder’s Agreement, in relation to the April 12, 2022 and the June 7, 2022 Securities Purchase Agreement with Mast Hill Fund, L.P., two equal payments of fees of approximately $22,320 were paid to JH Darbie. In addition, JH Darbie is to receive non-callable warrants of equal to 8% warrant coverage of the amount raised. The warrants shall entitle JH Darbie thereof to purchase common stock of the Company at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of the Issuer’s common stock on the date of the Transaction, whichever is lower (such price, the “Warrant Price”). The warrants shall be exercisable immediately after the date of issuance, shall have anti-dilutive price protection, participating registration rights, and shall expire 5 years after the date of issuance, in accordance with the Finder’s Agreement.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Shareholder Equity
6 Months Ended
Aug. 31, 2022
Shareholder Equity [Abstract]  
Shareholder Equity

Note 9 - Shareholder Equity

 

Preferred Stock

 

The authorized preferred stock of the Company consists of 200,000,000 shares with a par value of $0.0001. There were 700,000 shares issued and outstanding as of August 31, 2022 and February 28, 2022.

 

During the three months ended May 31, 2021, 700,000 shares of Series A Preferred Stock were issued to CRS Consulting, LLC (“CRS”), a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody. CRS is our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock. Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock. On July 19, 2021, these shares were purchased. As of November 30, 2021, our CEO, Ian James, and Director, Stephen Letourneau, each hold 350,000 shares of Series A Preferred Stock (See Note 1).

 

Common Stock

 

The authorized common stock of the Company consists of 500,000,000 shares with a par value of $0.0001. There were 385,198,451 and 370,747,042 shares of common stock issued and outstanding as of August 31, 2022 and February 28, 2022, respectively.

 

At the time of reorganization, former shareholders of Sauer Energy, Inc. became shareholders of Fast Track Solutions, Inc., representing 359,996,332 of the common shares outstanding.

 

On July 19, 2021, 250,000,000 shares of restricted Common Stock were purchased by Ohio Green Ventures, LLC from CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody (See Note 1).

 

On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided.

 

From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau (See Note 1).

 

On August 24, 2021, 50,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $7,000.

 

On October 11, 2021, 2,602,740 shares of Restricted Common Stock were issued to SRAX, Inc as compensation for marketing services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $468,493.

 

On October 11, 2021, 250,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $45,000.

 

On November 17, 2021, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $18,750.

 

On January 3, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $15,000.

 

On January 13, 2022, 549,097 shares of Restricted Common Stock were sold to five shareholders for proceeds totaling $68,000.

 

On April12, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled approximately $15,468.

 

On April 12, 2022, the Company entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., in which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on April 12, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.

 

Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.

 

On May 26, 2022, 11,000,000 share of Restricted Common Stock were issued to the two Sellers of Mango Moi, LLC (See Note 1). The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled approximately $550,000.

 

On July 12, 2022, 100,000 shares of Restricted Common Stock were issued to four Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $3,990.

 

On July 27, 2022 the Company filed its Pre-14-C notice and accompanying Information Statement and furnished this information to the holders of shares of common stock, par value $0.0001 per share, of Better For You Wellness, Inc., a Nevada corporation (the “Company”), pursuant to Section 78.320 of the Nevada General Corporation Law, Section 14 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Regulation 14C and Schedule 14C thereunder, in connection with the approval of the following actions taken by the Company’s Board of Directors (the “Board”) and by written consent of the holders of a majority of the voting power of the issued and outstanding capital stock of the Company, to amend our certificate of incorporation, as amended (the “Certificate”), to increase the number of authorized shares of common stock from 500,000,000 to 1,000,000,000 (the “Authorized Share Increase” or “Corporate Action”).

 

During the period ended August 31, 2022, a total of 30,282 shares of Restricted Common Stock were sold to two shareholders for proceeds totaling approximately $3,75.13.

 

On October 12, 2022, the Board of Directors authorized the issuance of 2,686,667 Common Shares to Mast Hill for consideration of the extension of the 4/12/2022 Registration Rights Agreement.

 

Shares Cancellable

 

On July 11, 2022, the Company entered into a Common Share Option Cancellation and Forfeiture Agreement with former Director Dr. Nicola Finley (the “Option Cancellation and Forfeiture Agreement”). Under the Option Cancellation and Forfeiture Agreement, Dr. Nicola Finley forfeited, and the Company canceled Dr. Nicola Finley’s option to purchase 4,000,000 common shares of the Company that was granted to the optionee pursuant to the Director Agreement dated as of August 29, 2021. Upon such forfeiture and cancellation, Dr. Nicola Finley has no further rights to exercise the option to purchase 4,000,000 common shares of the Company. The cancellation and forfeiture set forth in the Option Cancellation and Forfeiture Agreement shall not affect the restricted common shares granted by the Company to Dr. Nicola Finley pursuant to the Director Agreement dated as of August 29, 2021. As a payment in lieu of whatever benefits, if any, to which Dr. Nicola Finley may have been entitled to under the option to purchase 4,000,000 common shares of the Company, the Company shall pay Dr. Nicola Finley $1.00.

 

Stock Options

 

During the fiscal year ended February 28, 2022, the Company granted options exercisable for up to 20,000,000 shares of Common Stock of which 8,500,000 fully vested on August 31, 2021. The remaining 11,500,000 shares vest over the next 2 years. During the three months ended August 31, 2023, 2,000,000 shares were forfeited. The options have the exercise price of $.25 per share. These options expire 5 years after issue. The aggregate intrinsic value of these outstanding options as of August 31, 2022, was $0. 

 

The Company fair valued the options on the grant dates at $2,127,565 using a Black-Scholes option pricing model with the following assumptions: stock price of $.15 and $.11 per share (based on the quoted trading price on the dates of the grants). The Company is amortizing the expense over the vesting terms of each. The total stock option expense for the period ended August 31, 2022 was approximately $297,414. The total unamortized stock option expense at August 31, 2022 was approximately $1,854,208.

 

Additional Paid-In Capital

 

During the quarterly period ended August 31, 2022, a total of $2,931,841 posted as additional paid-in capital.

 

This includes Common Shares issued for services for the Company including $250,192 for Mast Hill, cash received for shares sold $3,747, $274,025 of share option vestment/expense for the Board of Directors, $17,188 in Warrants issued related to JH Darbie for finder agreement and debt treatment of Mast hill, and negative $223,060 in forfeiture of stock options by former Director Dr. Nicola Finley.

 

Related-Party Transactions

 

Loan to Company

 

During the six-month period ended August 31, 2022, Green Ohio Ventures, LLC, paid expenses on behalf of the Company totaling approximately $82,788 and during the same period, Green Ohio Ventures was reimbursed $176,544, which included the $82,788 expense paid from this period. During the same period of August 31, 2022, Green Ohio Ventures, LLC, loaned the Company $7,000. During the same period, the following Company Officers and Directors made the following financial contributions to the Company:

 

Ian James, the Company’s Chief Executive Officer loaned the Company $18,000 during the period. Additionally, Mr. James paid expenses on behalf of the Company totaling approximately $26,057 and during the same period, Mr. James was reimbursed $19,775, leaving a balance of expense paid from prior reporting periods in the amount of $9,791, which was in addition to the $18,000 loan as referenced above.

 

Stephen Letourneau the Company’s Chief Branding Officer paid expenses on behalf of the Company totaling approximately $48,068, and during the same period, Mr. Letourneau was reimbursed $40,389 leaving a balance of $2,780 to be reimbursed.

 

Director David Deming paid expenses on behalf of the Company totaling approximately $50,000.

 

In addition, the Company acquired $35,000 of a loan to Mango Moi, LLC when it became a wholly-owned subsidiary of the Company. This loan was made to Mango Moi, LLC by a relative of Amanda Cayemitte (i.e., Mr. Gushy Joseph), one of the sellers of the subsidiary. On October 12, 2022, the Board of Directors authorized the issuance of 760,870 Common Shares @ $0.023 per share to retire $17,500 of the $35,000 Loan. The balance of $17,500 was agreed to be paid in the first quarter of the 2023 calendar year.

 

Additionally, during the six-month period ended August 31, 2022, Company Officers Deferred Compensation totaling $190,320. These payments are considered as loans to the Company, which are noninterest-bearing, unsecured, and payable on demand.

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.4
Impairment Expense
6 Months Ended
Aug. 31, 2022
Impairment Expense [Abstract]  
Impairment Expense

Note 10 - Impairment Expense

 

During the period ended August 31, 2022, the Company had no Impairment Expenses.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.4
Subsequent Events
6 Months Ended
Aug. 31, 2022
Subsequent Events [Abstract]  
Subsequent Events

Note 11 - Subsequent Events

 

On September 20, 2022, the Company entered into a Manufacturing Agreement with Ironwood Clay Company (ICCI) to develop commercially scaled Personal Care Products for Mango Moi and other products in the Company’s portfolio. The Company agreed to pay a non-refundable deposit of $10,000 USD for up to 8 Product Formula. This includes three formulation revisions and samples per Product Formula (each iteration of sampling of up to 500gr./ml.). Additional revisions to the Formula(s) will be charges to the Client at a rate of $500 USD per revision.

 

Once the Company has approved the final Formula(s) and places a Purchase Order exceeding $10,000 USD, the non-refundable deposit will be applied to the total amount of the Purchase Order. Upon ordering at least Twenty-Five Thousand US Dollars ($25,000 USD) of each Product Formula, the exclusivity granted to ICCI herein in respect of such Product and Formula shall cease, the Company shall no longer be obligated to purchase Products from ICCI, and the Client shall be free to engage any other manufacturer for such purpose.

 

On September 22, 2022, the Company announced the cancelation of the Letter of Intent (LOI) to acquire Ironwood Clay Company (ICCI) because ICCI was unable to have its Clay Mining Operation adequately meet SEC reporting requirements related to the mining of a natural resource. Additionally, ICCI owners were unwilling to bifurcate the Mining Operation from the Personal Care Manufacturing.

 

On September 22, 2022, the Company announced the Letter of Intent (LOI) to acquire The Ideation Lab and its functional beverage division, The Jordre Well.

 

The Ideation Lab is a brand solutions incubator and accelerator focused on the plant-based wellness and hemp-infused industry. The Ideation Lab has been developing plant-based wellness brands since 2020, including Garrett and Emmett’s Pet Treats, a pet lifestyle brand, E.J. Well Co, a women’s wellness brand, and others.

 

The Jordre Well is a functional beverage company that is 49% owned by Coffee Holding Co., Inc. (NASDAQ: JVA), a leading integrated wholesale coffee roaster and dealer in the United States. Earlier this week, The Jordre Well announced its portfolio of products from Stephen James Curated Coffee Collection (“SJCCC”), the Company’s premium coffee brand, which is now being sold through Amazon.com and is in discussion with major national retailers. The e-commerce giant carries 8 of SJCCC’s premium coffee products and ships to more than 100 countries around the globe. Additionally, the deal contemplates Coffee Holding Company continuing its global purchase of coffee beans, manufacturing, distribution, and licensure of its Cafe Caribe and Harmony Bay to The Jordre Well for Hemp infusion.

 

On October 11, 2022, Mast Hill Fund agreed to extend the timeframes in section 2(a) of the Registration Rights Agreement dated 4/12/22 to 270 calendar days to file the initial Registration Statement and 360 calendar days to have it declared effective. This extension follows the July 11, 2022 extension in which Mast Hill Fund agreed to extend the timeframes in section 2(a) of the Registration Rights Agreement dated 4/12/22 to 180 calendar days to file the initial Registration Statement and 270 calendar days to have it declared effective. In consideration of the extension, on October 12, 2022, the Board of Directors authorized the issuance of 2,686,667 Common Shares to Mast Hill for consideration of the extension of the 4/12/2022 Registration Rights Agreement.

 

On October 12, 2022, the Board of Directors authorized the issuance of 760,870 Common Shares @ $0.023 per share to retire $17,500 of the $35,000 Loan. The balance of $17,500 was agreed to be paid in the first quarter of the 2023 calendar year.

 

On October 12, 2022, our Board of Directors approved to renew an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies.” In exchange for twelve months of access to the Sequire Platform, we paid SRAX $30,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.4
Accounting Policies, by Policy (Policies)
6 Months Ended
Aug. 31, 2022
Organization and Description of Business [Abstract]  
Principles of Consolidation

Principles of Consolidation

 

The accompanying interim unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements on Form 10-K have been condensed or omitted. The condensed consolidated balance sheet as of February 28, 2022 has been derived from the audited consolidated financial statements as of that date, but does not include all disclosures required for audited annual financial statements. For further information, please refer to and read these interim condensed Consolidated Financial Statements in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended February 28, 2022 filed with the SEC.

 

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Glow Markets, LLC and Mango Moi, LLC. All significant intercompany accounts and transactions have been eliminated.

 

Basis of Presentation

Basis of Presentation

 

This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.

 

Use of Estimates

Use of Estimates

 

There were no material changes in the Company’s significant accounting policies for the three and six months ended August 31, 2022 as compared to the year ended February 28, 2022. See Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022, as filed with the SEC, for additional information regarding the Company’s significant accounting policies and use of estimates.

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at August 31, 2022 and February 28, 2022 were $2,130 and $9,642 respectively.

 

Property and Equipment

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets (primarily three to five years).

 

Revenue Recognition

Revenue Recognition

 

The Company has prepared its unaudited condensed consolidated financial statements in accordance with GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.

 

The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

 

Revenue for products is recognized when the products are delivered to the customer and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of August 31, 2022 and February 28, 2022, the Company had no deferred revenues.

 

Income Taxes

Income Taxes

 

The Company accounts for income taxes under ASC 740, “Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at August 31, 2022.

 

Basic Earnings (Loss) Per Share

Basic Earnings (Loss) Per Share

 

The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, Earnings per Share. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

 

The Company did not have any dilutive instruments for the three and six months ended August 31, 2022, and 2021, respectively. Thus, anti-dilution issues are not applicable.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.

 

ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

 

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of August 31, 2022 and February 28, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.

 

Related Parties

Related Parties

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

Share-Based Compensation

Share-Based Compensation

 

ASC 718, “Compensation – Stock Compensation”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

 

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity–Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

 

Except as specified for the Independent Directors’ compensation, the Company had no stock-based compensation plans as of August 31, 2022 and February 28, 2022.

 

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

 

In June 2016, the FASB issued ASU No. 2016-13 “Credit Losses - Measurement of Credit Losses on Financial Instruments.” ASU No. 2016-13 significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables, by replacing today’s “incurred loss” approach with an “expected loss” model under which allowances will be recognized based on expected rather than incurred losses. ASU No. 2016-13 will become effective for us in the first quarter of 2023. We are evaluating the impact that the adoption of this update will have on our financial statements; however, it is not expected to be material.

 

Reclassification of Prior Year Presentation

Reclassification of Prior Year Presentation

 

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combinations (Tables)
6 Months Ended
Aug. 31, 2022
Business Combinations [Abstract]  
Schedule of fair value of such assets and liabilities
Assets acquired:    
Cash  $913 
Inventory   12,995 
Total Assets Acquired   13,908 
Liabilities assumed:     
Clearbanc Debit Card   2,365 
Notes Payable - PayPal Capital   2,454 
Notes Payable Shopify Capital   53 7 
 Sales Tax Payable   138 
Total Liabilities Assumed   5,494 
      
Total identifiable net assets   8,414 
      
Purchase price   592,000 
      
Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date  $583,586 

 

Schedule of condensed consolidated results of operations
   For the Three months ended 
   (unaudited)   (unaudited) 
   August 31,
2022
   August 31,
2021
 
Total revenues  $1,716   $15,991 
           
Net (loss) income  $(767,677)  $(31,364)
           
Loss per share  $
-
   $
-
 

 

   For the Six months ended 
   (unaudited)   (unaudited) 
   August 31,
2022
   August 31,
2021
 
Total revenues  $2,022   $35,447 
           
Net (loss) income  $(1,659,594)  $(112,841)
           
Loss per share  $
-
   $
-
 

 

Schedule of segment reporting information by segment
   (unaudited)   (unaudited) 
   For the
three months ended
August 31,
   For the
six months ended
August 31,
 
   2022   2021 
Mango Moi:        
Total revenues  $1,716   $8,690 
Net income  $(819)  $(9,100)
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Organization and Description of Business (Details) - USD ($)
1 Months Ended
Aug. 25, 2021
Aug. 24, 2021
Jul. 30, 2021
Jul. 18, 2021
Oct. 12, 2022
Aug. 31, 2022
Apr. 29, 2022
Feb. 28, 2022
Organization and Description of Business (Details) [Line Items]                
Common stock, par value (in Dollars per share)           $ 0.0001   $ 0.0001
Shares of common stock           500,000,000   500,000,000
Fair market value (in Dollars)             $ 550,000  
Common stock, shares issued           385,198,451   370,747,042
Common Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Common stock, par value (in Dollars per share)         $ 0.023      
Fast Track Solutions, Inc. [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of common stock           1,000    
Series A Preferred Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of restricted common stock       250,000,000        
Series of Individually Immaterial Business Acquisitions [Member]                
Organization and Description of Business (Details) [Line Items]                
Owning, percentage 5.00%              
Purchase Price [Member]                
Organization and Description of Business (Details) [Line Items]                
Voting percentage     89.62%          
Paid consideration (in Dollars)     $ 335,000          
Predecessor [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of common stock           1,000    
CRS Consulting, LLC [Member] | Common Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of common stock     250,000,000          
CRS Consulting, LLC [Member] | Series A Preferred Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Shareholder owning preferred stock       700,000        
Sale of shares     700,000          
CRS Consulting, LLC [Member] | Series of Individually Immaterial Business Acquisitions [Member]                
Organization and Description of Business (Details) [Line Items]                
Voting percentage     89.62%          
Ian James [Member] | Series A Preferred Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Transfer of shares     350,000          
Stephen Letourneau [Member] | Series A Preferred Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Transfer of shares     350,000          
Green Ohio Ventures, LLC [Member] | Series A Preferred Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of common stock     250,000,000          
MRKTS Group Inc [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of restricted common stock   17,963,817            
MRKTS Group Inc [Member] | Purchase Price [Member]                
Organization and Description of Business (Details) [Line Items]                
Owning, percentage   5.00%            
Better for You Wellness, Inc. [Member]                
Organization and Description of Business (Details) [Line Items]                
Shares of restricted common stock 24,137,499              
Mango Moi, LLC [Member] | Common Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Common stock, par value (in Dollars per share)             $ 0.0001  
Shares of common stock             11,000,000  
Amanda Cayemitte [Member] | Common Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Common stock, shares issued             5,720,000  
Yapo M’be [Member] | Common Stock [Member]                
Organization and Description of Business (Details) [Line Items]                
Common stock, shares issued             5,280,000  
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Significant Accounting Policies (Details) - USD ($)
Aug. 31, 2022
Feb. 28, 2022
Organization and Description of Business [Abstract]    
Cash and cash equivalents $ 2,130 $ 9,642
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combinations (Details) - USD ($)
6 Months Ended
Apr. 12, 2022
Aug. 31, 2022
Business Combinations [Abstract]    
Purchase price of stock $ 279,000 $ 592,000
Goodwill   $ 583,586
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combinations (Details) - Schedule of fair value of such assets and liabilities
Aug. 31, 2022
USD ($)
Schedule of Fair Value of Such Assets and Liabilities [Abstract]  
Cash $ 913
Inventory 12,995
Total Assets Acquired 13,908
Clearbanc Debit Card 2,365
Notes Payable - PayPal Capital 2,454
Notes Payable Shopify Capital 537
Sales Tax Payable 138
Total Liabilities Assumed 5,494
Total identifiable net assets 8,414
Purchase price 592,000
Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date $ 583,586
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combinations (Details) - Schedule of unaudited condensed consolidated results of operations - Mango Moi [Member] - USD ($)
3 Months Ended 6 Months Ended
Aug. 31, 2022
Aug. 31, 2021
Aug. 31, 2022
Aug. 31, 2021
Condensed Income Statements, Captions [Line Items]        
Total revenues $ 1,716 $ 15,991 $ 2,022 $ 35,447
Net (loss) income $ (767,677) $ (31,364) $ (1,659,594) $ (112,841)
Loss per share (in Dollars per share)
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combinations (Details) - Schedule of unaudited segment reporting information by segment - Mango Moi [Member] - USD ($)
3 Months Ended 6 Months Ended
Aug. 31, 2022
Aug. 31, 2022
Segment Reporting Information [Line Items]    
Total revenues $ 1,716 $ 8,690
Net income $ (819) $ (9,100)
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Commitments and Contingencies (Details) - USD ($)
1 Months Ended 6 Months Ended
Apr. 18, 2022
Sep. 17, 2021
Aug. 31, 2022
Commitments and Contingencies (Details) [Line Items]      
Option to sell investment $ 5,000,000    
Common stock, par value (in Dollars per share) $ 0.0001    
Purchase price per share equal to percentage 90.00%    
Common stock purchase warrant for purchase (in Shares) 1,785,714    
Annual salary of payable     $ 65,000
Consulting agreement, description     Pursuant to the Consulting Agreement, the Company engaged Yapo M’be as a consultant to provide manufacturing services for Mango Moi, to begin on May 2, 2022. As compensation under the Consulting Agreement, the Company agreed to pay Yapo M’be at the rate of $30.00 per hour, not to exceed $1,500 per month.
Ian James Employment Agreement [Member]      
Commitments and Contingencies (Details) [Line Items]      
Base salary per annum     $ 199,196
Base salary per month     16,599.67
Additional payment     68,328
Stephen Letourneau Employment Agreement [Member]      
Commitments and Contingencies (Details) [Line Items]      
Base salary per annum     152,787
Base salary per month     12,732.25
Additional payment     70,632
Jacob Ellman Employment Agreement [Member]      
Commitments and Contingencies (Details) [Line Items]      
Base salary per annum     128,656
Base salary per month     10,721.33
Additional payment     $ 41,140
SRAX [Member]      
Commitments and Contingencies (Details) [Line Items]      
Amount paid   $ 20,000  
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.4
Convertible Note Payable (Details) - USD ($)
6 Months Ended
Jun. 07, 2022
Aug. 31, 2022
Convertible Note Payable (Details) [Line Items]    
Discount amount $ 31,000  
Interest rate 12.00%  
Maturity date Jun. 07, 2023  
Common stock conversion price per share (in Dollars per share) $ 0.037  
Security purchase agreement $ 22,320  
Warrant coverage rate 8.00%  
Exercise price percentage 120.00%  
After the issuance expire period 5 years  
Mast Hill Fund, L.P., [Member]    
Convertible Note Payable (Details) [Line Items]    
Principal amount $ 310,000  
Purchase price $ 279,000  
Commitment shares (in Shares)   4,960,000
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Stock Purchase Warrant Liability (Details) - USD ($)
6 Months Ended
Aug. 31, 2022
Jun. 07, 2022
Stock Purchase Warrant Liability [Abstract]    
Purchase agreement fees (in Dollars)   $ 22,320
Non-callable warrants 8.00%  
Purchase common stock percentage 120.00%  
Warrants exercisable date of issuance 5 years  
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Shareholder Equity (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Oct. 12, 2022
Jul. 12, 2022
Jul. 11, 2022
Apr. 12, 2022
Apr. 12, 2022
Jan. 13, 2022
Jan. 03, 2022
Oct. 11, 2021
Aug. 31, 2021
Aug. 25, 2021
May 26, 2022
Nov. 17, 2021
Aug. 24, 2021
Jul. 19, 2021
May 31, 2022
May 31, 2021
Aug. 31, 2022
Aug. 31, 2021
Oct. 11, 2022
Jul. 27, 2022
Apr. 29, 2022
Feb. 28, 2022
Nov. 30, 2021
Jul. 30, 2021
Shareholder Equity (Details) [Line Items]                                                
Preferred stock, shares authorized (in Shares)                                 200,000,000         200,000,000    
Preferred stock, par value (in Dollars per share)                                 $ 0.0001         $ 0.0001    
Preferred stock, shares issued (in Shares)                                 700,000         700,000    
Preferred stock, shares outstanding (in Shares)                                 700,000         700,000    
Preferred stock, voting rights                             Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock.                  
Common stock, shares authorized (in Shares)                                 500,000,000         500,000,000    
Common stock, par value (in Dollars per share)                                 $ 0.0001         $ 0.0001    
Common stock, shares issued (in Shares)                                 385,198,451         370,747,042    
Common stock, shares outstanding (in Shares)                                 385,198,451         370,747,042    
Restricted common stock                                 $ 375.13              
Principal amount       $ 310,000 $ 310,000                                      
Purchase price       279,000                         592,000              
Discount rate       $ 31,000                         $ 49,475            
Bear interest       12.00%                                        
Price per share (in Dollars per share)       $ 0.037 $ 0.037                                      
Shares issued (in Shares)                                 4,960,000              
Issued and outstanding capital (in Shares)                                       78.32        
Share cancellation and forfeiture agreement description     On July 11, 2022, the Company entered into a Common Share Option Cancellation and Forfeiture Agreement with former Director Dr. Nicola Finley (the “Option Cancellation and Forfeiture Agreement”). Under the Option Cancellation and Forfeiture Agreement, Dr. Nicola Finley forfeited, and the Company canceled Dr. Nicola Finley’s option to purchase 4,000,000 common shares of the Company that was granted to the optionee pursuant to the Director Agreement dated as of August 29, 2021. Upon such forfeiture and cancellation, Dr. Nicola Finley has no further rights to exercise the option to purchase 4,000,000 common shares of the Company. The cancellation and forfeiture set forth in the Option Cancellation and Forfeiture Agreement shall not affect the restricted common shares granted by the Company to Dr. Nicola Finley pursuant to the Director Agreement dated as of August 29, 2021. As a payment in lieu of whatever benefits, if any, to which Dr. Nicola Finley may have been entitled to under the option to purchase 4,000,000 common shares of the Company, the Company shall pay Dr. Nicola Finley $1.00.                                           
Grant option exercisable (in Shares)                                           20,000,000    
Number of vested shares (in Shares)                 8,500,000                              
Stock option, description                                 11,500,000              
Forfeited shares (in Shares)                                 2,000,000              
Stock option expire term                                 5 years              
Stock option outstanding intrinsic value                                 $ 0              
Stock option exercise (in Dollars per share)                                 $ 297,414              
Stock options fair value the grant date (in Dollars per share)                                 $ 2,127,565              
Total unamortized stock option expense                                 $ 1,854,208              
Total payments considered contributions                                 2,931,841              
Shares sold                                 3,747              
Stock expanses                                 274,025              
fair value of warrants realized                                 17,188              
Forfeiture stock compensation                                 223,060              
Paid expenses                                 50,000              
Reimbursed amount                                 40,389              
Expenses paid amount                                 26,057              
Loan amount $ 35,000                                              
Retirement amount $ 17,500                                              
Balance                                 17,500              
Deferred compensation amount                                 $ 190,320              
Stock option exercise                                 stock price of $.15 and $.11 per share (based on the quoted trading price on the dates of the grants).              
Common Stock [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Common stock, par value (in Dollars per share) $ 0.023                                              
Common stock, shares outstanding (in Shares)                                 370,747,042              
Mast Hill Fund, L.P., [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Shares issued                                 $ 250,192              
Share-Based Payment Arrangement, Option [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Stock option exercise (in Dollars per share)                                 $ 25              
Minimum [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Common stock, shares authorized (in Shares)                                       500,000,000        
Maximum [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Common stock, shares authorized (in Shares)                                       1,000,000,000        
Series A Preferred Stock [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Preferred stock, shares issued (in Shares)                                             350,000  
Series A preferred stock were issued (in Shares)                             700,000                  
Shares of restricted common stock (in Shares)                             250,000,000                  
Subsequent Event [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Issuance of common stock (in Shares) 2,686,667                                              
Green Ohio Ventures, LLC [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Paid expenses                                 $ 82,788              
Reimbursed amount                                 176,544              
Expenses paid amount                                 82,788              
Loan amount                                 7,000              
Ian James [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Loan amount                                 18,000              
Addition loan amount                                 18,000              
Stephen Letourneau [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Expenses paid amount                                 48,068              
Board of Directors Chairman [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Restricted common stock (in Shares)   100,000     125,000   125,000         125,000                        
Closing share price   $ 3,990   $ 15,468     $ 15,000         $ 18,750                        
Loan amount                                 $ 35,000              
Issuance of common stock shares (in Shares) 760,870                                              
Board of Directors Chairman [Member] | Subsequent Event [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Common stock, par value (in Dollars per share) $ 0.023                                              
Loan amount $ 35,000                                              
Issuance of common stock shares (in Shares) 760,870                                   2,686,667          
Retirement amount $ 17,500                                              
CRS Consulting, LLC [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Restricted common stock (in Shares)               250,000         50,000                      
Closing share price               $ 45,000         $ 7,000                      
CRS Consulting, LLC [Member] | Series A Preferred Stock [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Series A preferred stock were issued (in Shares)                               700,000                
Sauer Energy, Inc. [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Common shares, outstanding (in Shares)                                 359,996,332              
Green Ohio Ventures, LLC [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Restricted common stock (in Shares)                   24,137,499     17,963,817 250,000,000                    
Green Ohio Ventures, LLC [Member] | Series A Preferred Stock [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Issuance of common stock (in Shares)                                               250,000,000
SRAX, Inc [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Restricted common stock (in Shares)               2,602,740                                
Closing share price               $ 468,493                                
Restricted Common Stock [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Restricted common stock (in Shares)           549,097                     30,282              
Restricted common stock           $ 68,000                                    
Mango Moi, LLC [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Restricted common stock (in Shares)                     11,000,000                          
Closing share price                     $ 550,000                          
Mango Moi, LLC [Member] | Common Stock [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Common stock, shares authorized (in Shares)                                         11,000,000      
Common stock, par value (in Dollars per share)                                         $ 0.0001      
Nevada corporation [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Common stock, par value (in Dollars per share)                                       $ 0.0001        
Ian James [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Reimbursed amount                                 $ 19,775              
Expenses paid amount                                 9,791              
Ian James [Member] | Series A Preferred Stock [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Issuance of common stock shares (in Shares)                                               350,000
Stephen Letourneau [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Reimbursed amount                                 $ 2,780              
Stephen Letourneau [Member] | Series A Preferred Stock [Member]                                                
Shareholder Equity (Details) [Line Items]                                                
Issuance of common stock shares (in Shares)                                               350,000
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Subsequent Events (Details) - Subsequent Event [Member] - USD ($)
1 Months Ended
Oct. 12, 2022
Sep. 20, 2022
Oct. 11, 2022
Subsequent Events (Details) [Line Items]      
Principal amount   $ 10,000  
Additional revisions rate   $ 500  
Purchase agreement description   Once the Company has approved the final Formula(s) and places a Purchase Order exceeding $10,000 USD, the non-refundable deposit will be applied to the total amount of the Purchase Order. Upon ordering at least Twenty-Five Thousand US Dollars ($25,000 USD) of each Product Formula, the exclusivity granted to ICCI herein in respect of such Product and Formula shall cease, the Company shall no longer be obligated to purchase Products from ICCI, and the Client shall be free to engage any other manufacturer for such purpose.   
Warrant coverage raised percentage   49.00%  
Board of Directors Chairman [Member]      
Subsequent Events (Details) [Line Items]      
Issuance of common stock shares (in Shares) 760,870   2,686,667
Common share price per share (in Dollars per share) $ 0.023    
Retirement amount $ 17,500    
Loan amount 35,000    
Balance amount 17,500    
Exchange amount $ 30,000    
XML 42 f10q0822a1_betterforyou_htm.xml IDEA: XBRL DOCUMENT 0001852707 2022-03-01 2022-08-31 0001852707 2023-03-17 0001852707 2022-08-31 0001852707 2022-02-28 0001852707 2022-06-01 2022-08-31 0001852707 2021-06-01 2021-08-31 0001852707 2021-03-01 2021-08-31 0001852707 us-gaap:CommonStockMember 2022-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-02-28 0001852707 bfyw:SharesCancelableMember 2022-02-28 0001852707 us-gaap:RetainedEarningsMember 2022-02-28 0001852707 us-gaap:CommonStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-03-01 2022-05-31 0001852707 bfyw:SharesCancelableMember 2022-03-01 2022-05-31 0001852707 us-gaap:RetainedEarningsMember 2022-03-01 2022-05-31 0001852707 2022-03-01 2022-05-31 0001852707 us-gaap:CommonStockMember 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001852707 bfyw:SharesCancelableMember 2022-05-31 0001852707 us-gaap:RetainedEarningsMember 2022-05-31 0001852707 2022-05-31 0001852707 us-gaap:CommonStockMember 2022-06-01 2022-08-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-06-01 2022-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-06-01 2022-08-31 0001852707 bfyw:SharesCancelableMember 2022-06-01 2022-08-31 0001852707 us-gaap:RetainedEarningsMember 2022-06-01 2022-08-31 0001852707 us-gaap:CommonStockMember 2022-08-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2022-08-31 0001852707 bfyw:SharesCancelableMember 2022-08-31 0001852707 us-gaap:RetainedEarningsMember 2022-08-31 0001852707 us-gaap:CommonStockMember 2021-02-28 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-02-28 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-02-28 0001852707 us-gaap:RetainedEarningsMember 2021-02-28 0001852707 2021-02-28 0001852707 us-gaap:CommonStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-03-01 2021-05-31 0001852707 us-gaap:RetainedEarningsMember 2021-03-01 2021-05-31 0001852707 2021-03-01 2021-05-31 0001852707 us-gaap:CommonStockMember 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-05-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001852707 us-gaap:RetainedEarningsMember 2021-05-31 0001852707 2021-05-31 0001852707 us-gaap:CommonStockMember 2021-06-01 2021-08-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-06-01 2021-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-06-01 2021-08-31 0001852707 us-gaap:RetainedEarningsMember 2021-06-01 2021-08-31 0001852707 us-gaap:CommonStockMember 2021-08-31 0001852707 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-08-31 0001852707 us-gaap:AdditionalPaidInCapitalMember 2021-08-31 0001852707 us-gaap:RetainedEarningsMember 2021-08-31 0001852707 2021-08-31 0001852707 bfyw:PredecessorsMember 2022-08-31 0001852707 bfyw:FastTrackSolutionsIncMember 2022-08-31 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-18 0001852707 us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-18 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-07-30 0001852707 bfyw:CRSConsultingsLLCMember us-gaap:CommonStockMember 2021-07-01 2021-07-30 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember bfyw:CRSConsultingsLLCMember 2021-07-30 0001852707 bfyw:IanJamesMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:StephenLetourneauMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:GreenOhioVenturesLLCMember us-gaap:SeriesAPreferredStockMember 2021-07-30 0001852707 bfyw:PurchasePriceMember 2021-07-01 2021-07-30 0001852707 bfyw:PurchasePriceMember 2021-07-30 0001852707 bfyw:MRKTSGroupIncMember 2021-08-01 2021-08-24 0001852707 bfyw:PurchasePriceMember bfyw:MRKTSGroupIncMember 2021-08-24 0001852707 bfyw:BetterForYouWellnessIncMember 2021-08-01 2021-08-25 0001852707 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2021-08-25 0001852707 bfyw:MangoMoiLLCMember us-gaap:CommonStockMember 2022-04-29 0001852707 2022-04-29 0001852707 bfyw:AmandaCayemitteMember us-gaap:CommonStockMember 2022-04-29 0001852707 bfyw:YapoMbeMember us-gaap:CommonStockMember 2022-04-29 0001852707 bfyw:MangoMoiMember 2022-06-01 2022-08-31 0001852707 bfyw:MangoMoiMember 2021-06-01 2021-08-31 0001852707 bfyw:MangoMoiMember 2022-03-01 2022-08-31 0001852707 bfyw:MangoMoiMember 2021-03-01 2021-08-31 0001852707 bfyw:MangoMoiLLCMember 2022-06-01 2022-08-31 0001852707 bfyw:MangoMoiLLCMember 2022-03-01 2022-08-31 0001852707 bfyw:SRAXIncMember 2021-09-02 2021-09-17 0001852707 2022-04-18 0001852707 2022-04-01 2022-04-18 0001852707 bfyw:IanJamesEmploymentAgreementMember 2022-08-31 0001852707 bfyw:IanJamesEmploymentAgreementMember 2022-03-01 2022-08-31 0001852707 bfyw:StephenLetourneauEmploymentAgreementMember 2022-08-31 0001852707 bfyw:StephenLetourneauEmploymentAgreementMember 2022-03-01 2022-08-31 0001852707 bfyw:JacobEllmanEmploymentAgreementMember 2022-08-31 0001852707 bfyw:JacobEllmanEmploymentAgreementMember 2022-03-01 2022-08-31 0001852707 bfyw:MastHillFundLPMember 2022-06-01 2022-06-07 0001852707 bfyw:MastHillFundLPMember 2022-06-07 0001852707 2022-06-07 0001852707 2022-06-01 2022-06-07 0001852707 bfyw:MastHillFundLPMember 2022-03-01 2022-08-31 0001852707 bfyw:CRSConsultingLLCMember us-gaap:SeriesAPreferredStockMember 2021-03-01 2021-05-31 0001852707 us-gaap:SeriesAPreferredStockMember 2022-03-01 2022-05-31 0001852707 us-gaap:SeriesAPreferredStockMember 2021-11-30 0001852707 bfyw:SauerEnergyIncMember 2022-08-31 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-07-01 2021-07-19 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:GreenOhioVenturesLLCMember 2021-08-23 2021-08-25 0001852707 bfyw:CRSConsultingLLCMember 2021-08-01 2021-08-24 0001852707 bfyw:SRAXIncMember 2021-10-01 2021-10-11 0001852707 bfyw:CRSConsultingLLCMember 2021-10-01 2021-10-11 0001852707 srt:BoardOfDirectorsChairmanMember 2021-11-01 2021-11-17 0001852707 srt:BoardOfDirectorsChairmanMember 2021-12-25 2022-01-03 0001852707 us-gaap:MajorityShareholderMember 2022-01-01 2022-01-13 0001852707 srt:BoardOfDirectorsChairmanMember 2022-04-01 2022-04-12 0001852707 srt:BoardOfDirectorsChairmanMember 2022-04-12 2022-04-12 0001852707 2022-04-12 0001852707 2022-04-12 2022-04-12 0001852707 bfyw:MangoMoiLLCMember 2022-05-01 2022-05-26 0001852707 srt:BoardOfDirectorsChairmanMember 2022-07-01 2022-07-12 0001852707 bfyw:NevadaCorporationMember 2022-07-27 0001852707 2022-07-27 0001852707 srt:MinimumMember 2022-07-27 0001852707 srt:MaximumMember 2022-07-27 0001852707 us-gaap:MajorityShareholderMember 2022-03-01 2022-08-31 0001852707 us-gaap:SubsequentEventMember 2022-10-12 0001852707 2022-07-11 2022-07-11 0001852707 2021-08-31 2021-08-31 0001852707 us-gaap:EmployeeStockOptionMember 2022-03-01 2022-08-31 0001852707 bfyw:MastHillFundLPMember 2022-03-01 2022-08-31 0001852707 bfyw:GreenOhioVenturesLLCMember 2022-03-01 2022-08-31 0001852707 bfyw:IanJamesMember 2022-03-01 2022-08-31 0001852707 bfyw:IanJamesMember 2022-03-01 2022-08-31 0001852707 bfyw:StephenLetourneauMember 2022-03-01 2022-08-31 0001852707 bfyw:StephenLetourneauMember 2022-03-01 2022-08-31 0001852707 srt:BoardOfDirectorsChairmanMember 2022-08-31 0001852707 srt:BoardOfDirectorsChairmanMember 2022-10-12 0001852707 us-gaap:CommonStockMember 2022-10-12 0001852707 2022-10-01 2022-10-12 0001852707 2022-10-12 0001852707 us-gaap:SubsequentEventMember 2022-09-20 0001852707 us-gaap:SubsequentEventMember 2022-09-01 2022-09-20 0001852707 srt:BoardOfDirectorsChairmanMember us-gaap:SubsequentEventMember 2022-10-11 0001852707 srt:BoardOfDirectorsChairmanMember us-gaap:SubsequentEventMember 2022-10-12 0001852707 srt:BoardOfDirectorsChairmanMember us-gaap:SubsequentEventMember 2022-10-01 2022-10-12 shares iso4217:USD iso4217:USD shares pure 10-Q/A true 2022-08-31 false 000-56262 BETTER FOR YOU WELLNESS, INC. NV 87-2903933 1349 East Broad Street Columbus OH 43205 (614) 368-9898 None None Yes Yes Non-accelerated Filer false true false false 2023 404014987 Better For You Wellness, Inc. (the “Company”) is filing this Amendment No. 1 on Form 10-Q/A (this “Amendment No. 1”) to amend its Quarterly Report on Form 10-Q for the quarterly period ended August 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on October 21, 2022 (the “Original Form 10-Q”).Background of RestatementThis Amendment No. 1 is being filed for the sole purpose of restating certain of the financial statements included in the Original Form 10-Q (the “Restatement”) due to the Company discovering that it made the following errors in the Original Form 10-Q: (i) not translating correctly the foreign currency balance for a mark-to-market contract; and (ii) not including certain debt issuance costs in the computation of the effective interest rate for a loan note. In the Original Form 10-Q filed October 21, 2022, the negative net loss was reported as $787,106 for the three months ended May 31, 2022, and $1,582,699 for the six months ended August 31, 2022. The Amended and Restated negative net loss is reported as $767,677 a difference of $19,429 in lower net loss for the three month period ended May 31, 2022, and $76,850 greater net loss for the six month period ended August 31, 2022.On March 3, 2023, the Company filed a Current Report on Form 8-K disclosing that the financial statements included in the Original Form 10-Q should not be relied upon.   In connection with the Restatement, management had concluded that the Company had a material weakness in its internal control over financial reporting as of May 31, 2022, as the Company’s internal control over financial reporting did not operate effectively, resulting in material errors in the financial statements included in the Original 10-Q. For a discussion of management’s considerations of the Company’s disclosure controls and procedures, internal control over financial reporting, and material weakness identified, refer to Controls and Procedures in Part I, Item 4.Internal Control ConsiderationsIn connection with the Restatement, management has concluded that the Company had a material weakness in its internal control over financial reporting as of August 31, 2022, as the Company’s review control over the accuracy of its financial statements did not operate effectively, resulting in material errors in the financial statements. For a discussion of management’s considerations of the Company’s disclosure controls and procedures, internal control over financial reporting, and material weakness identified, refer to Controls and Procedures in Part I, Item 4.Items Amended in this Amendment No. 1This Amendment No. 1 sets forth the Original Form 10-Q, as modified and superseded where necessary to reflect the Restatement and the related disclosure controls and procedures and internal control considerations. Accordingly, the following items included in the Original Form 10-Q have been amended: ●Part I, Item 1, Financial Statements     ●Part I, Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations     ●Part I, Item 4, Controls and Procedures     ●Part II, Item 1A, Risk Factors Additionally, in accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended, the Company is including with this Amendment No. 1 currently dated certifications from its Chief Executive Officer, Chief Financial Officer, and President.Except as described above and in Note 9, Restatement, this Amendment No. 1 does not amend, update or change any other disclosures in the Original Form 10-Q. In addition, the information contained in this Amendment No. 1 does not reflect events occurring after the Original Form 10-Q and does not modify or update the disclosures therein, except to reflect the effects of the Restatement. 2130 9642 123 107068 5198 78072 192591 9642 1935 583485 778011 9642 257821 375408 190320 1656 110000 14 559810 375408 2216 201 543176 1105403 375408 0.0001 0.0001 200000000 200000000 700000 700000 700000 700000 70 70 0.0001 0.0001 500000000 500000000 385198451 385198451 370747042 370747042 38521 37075 2931841 1485364 -250000 -3297825 -1638275 -327392 -365766 778011 9642 1716 2022 3489 9558 -1772 -7536 301663 7000 985713 77000 446262 7005 643257 9057 747925 14005 1628970 86057 -749697 -14005 -1636506 -86057 17980 23043 -17980 -23043 -767677 -14005 -1659549 -86057 0 0 0 0 372031446 360000680 372031446 250434405 370747042 37075 700000 70 1485364 -250000 -1638275 -365766 -7048873 -705 -249295 250000 325000 33 -33 5085000 509 272226 272735 11000000 1100 548900 550000 411315 411315 78072 78072 13514 13514 49686 49686 -891872 -891872 380108169 38012 700000 70 2609749 -2530147 117684 5060000 506 250192 250698 30282 3 3747 3750 274025 274025 17188 17188 -223060 -223060 -767677 -767677 385198451 38521 700000 70 2931841 -3297824 -327392 1185 -4935 -3750 359996332 36000 -36000 700000 70 69930 70000 3951 3951 -72051 -72051 359996332 36000 700000 70 39607 -76986 -1850 50000 5 6995 7000 2990 2990 -14005 -14005 360046332 36005 700000 70 49052 -90992 -5865 -1659549 -86057 985713 77000 49475 388 -7899 123 107068 117587 -1750 190320 -7496 -23043 -634985 -7307 2323 2323 56640 558000 75000 365 3750 49686 6942 629796 7307 -7512 9642 2130 30702 78072 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 - Organization and Description of Business</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Better For You Wellness, Inc. (“we,” “us,” “our”, the “Company” or the “Registrant”) was originally incorporated with the name Fast Track Solutions, Inc. in the State of Nevada on December 1, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 26, 2021, the Company entered into an “Agreement and Plan of Merger”, whereas it agreed to, and subsequently participated in, a Nevada holding company reorganization pursuant to NRS 92A.180, NRS 92A.200, NRS 92A.230 and NRS 92A.250 (“Reorganization”). The constituent corporations in the Reorganization were Sauer Energy, Inc. (“SENY” or “Predecessor”), Fast Track Solutions, Inc. (“Successor”), and Fast Track Merger Sub, Inc. (“Merger Sub”). Our former director, Jeffrey DeNunzio, was the sole director/officer of each constituent corporation in the Reorganization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fast Track Solutions, Inc. issued 1,000 common shares of its common stock to Predecessor and Merger Sub issued 1,000 shares of its common stock to Fast Track Solutions, Inc. immediately prior to the Reorganization. As such, immediately prior to the merger, Fast Track Solutions, Inc. became a wholly owned direct subsidiary of Sauer Energy, Inc. and Merger Sub became a wholly owned and direct subsidiary of Fast Track Solutions, Inc.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the above, on April 26, 2021, Sauer Energy, Inc. filed Articles of Merger with the Nevada Secretary of State. The merger became effective on May 5, 2021, at 4:00 PM EST (“Effective Time”). At the Effective Time, Predecessor was merged with and into Merger Sub (the “Merger), and Predecessor became the surviving corporation. Each share of Predecessor common stock issued and outstanding immediately prior to the Effective Time was converted into one validly issued, fully paid and non-assessable share of Fast Track Solutions, Inc.’s (“Successors”) common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fast Track Solutions, Inc., as successor issuer to Sauer Energy, Inc., continued to trade in the OTC MarketPlace under the previous ticker symbol “SENY” until the new ticker symbol “FTRK” for the Company was released into the OTC MarketPlace on May 6, 2021. The Company was given a new CUSIP Number by CUSIP Global Services for its common stock of 31188W108.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company believes that the Reorganization, deemed effective on May 5, 2021, was not a transaction of the type described in subparagraph (a) of Rule 145 under the Securities Act of 1933 and the consummation of the Reorganization will not be deemed to involve an “offer”, “offer to sell”, “offer for sale” or “sale” within the meaning of Section 2(3) of the Securities Act of 1933. The Reorganization was consummated without the vote or consent of the Company’s stockholders. In addition, the provisions of NRS 92A.180 did not provide a stockholder of the Company with appraisal rights in connection with the Reorganization. The Company believes that in the absence of any right of any of the Company’s stockholders to vote with respect to the Reorganization or to insist that their shares be purchased for fair value, the Reorganization could not be deemed to involve an “offer” “offer to sell”; or “sale” within the meaning of Section 2(3) of the Securities Act of 1933.”</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 5, 2021, after the completion of the Holding Company Reorganization, we canceled all of the stock we held in Sauer Energy, Inc., resulting in Sauer Energy, Inc. as a stand-alone company. Pursuant to the holding company merger agreement and effects of merger, all of the assets and liabilities, if any, remain with Sauer Energy, Inc. after the Reorganization. Jeffrey DeNunzio, the Director of Sauer Energy, Inc., did not discover any assets of Sauer Energy, Inc. from the time he was appointed Director until the completion of the Reorganization and subsequent separation of Sauer Energy, Inc. as a stand-alone company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Given that the former business plan and objectives of Sauer Energy, Inc. and the business plan and objectives of Fast Track Solutions, Inc. substantially differed from one another, we conducted the corporate separation with Sauer Energy, Inc. immediately after the effective time of the Reorganization in order to avoid any shareholder confusion. The former business plan of Sauer Energy, Inc. (the development and marketing of wind powered electric generators) under the leadership of its former directors, did not, in any way, represent the blank check business plan of Fast Track Solutions, Inc. at that time, and thus it is the belief of the Company that the corporate separation ameliorated shareholder confusion about our identity and/or corporate objectives. It is our belief that Sauer Energy was a shell company at the time of the Reorganization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The corporate actions taken by the Company, including, but not limited to, the corporate structuring of the transactions, was deemed, in the discretion of our sole director, to be for the benefit of the corporation and its shareholders. Former shareholders of Sauer Energy, Inc. were then the shareholders of Fast Track Solutions, Inc. and had the opportunity to benefit from a business combination with another company. The Company intended to serve as a vehicle to affect an asset acquisition, merger, exchange of capital stock or other business combination with a domestic or foreign business at that time</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After the reorganization and through July 18, 2021, CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody, was our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2021, Better For You Wellness, Inc., FKA “Fast Track Solutions, Inc.”, a Nevada Corporation (the “Company”), entered into a Share Purchase Agreement (the “Agreement”) by and among CRS Consulting, LLC, a Wyoming Limited Liability Company (“CRS”), Green Ohio Ventures, LLC, an Ohio Limited Liability Company (“GOHV”), Ian James, and Stephen Letourneau, pursuant to which, on July 30, 2021 (“Closing Date”), CRS sold 700,000 shares of the Company’s Series A Preferred Stock and 250,000,000 shares of Common Stock, representing approximately 89.62% voting control of the Company; 350,000 shares of Series A Preferred Stock were transferred to Ian James, 350,000 shares of Series A Preferred Stock were transferred to Stephen Letourneau, and 250,000,000 shares of Common Stock were transferred to GOHV. The aforementioned purchasers, collectively, paid consideration of three hundred thirty-five thousand dollars ($335,000) (the “Purchase Price”). The consummation of the transactions contemplated by the Agreement resulted in a change in control of the Company, with GOHV, Ian James, and Stephen Letourneau, becoming the Company’s largest controlling stockholders having approximately 89.62% combined voting control over the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 19, 2021, the Company filed an 8-K with the SEC to disclose an amendment to the Company’s Articles of Incorporation that the Company filed on August 18, 2021, with the Nevada Secretary of State to change its name to Better For You Wellness, Inc. Within the aforementioned 8-K, the Company disclosed that, at the time, it was pending a FINRA corporate action to affect the name change on the OTC to Better For You Wellness, Inc., and also a ticker symbol change. FINRA announced, on their September 29, 2021 daily list, that the market effective date of our name change, and ticker symbol change, will be September 30, 2021. On September 30, 2021, we will begin trading under the symbol BFYW. The new CUSIP number associated with our common stock, as of the market effective date of September 30, 2021, is 08771B105.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided. This transaction did not result in MRKTS Group Inc. owning 5% or more of any class of securities of the issuer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau. The aforementioned transaction(s) did not result in any individual shareholder owning 5% or more of any class of securities of the issuer. The aforementioned transaction was carried out as it was deemed by GOHV to be in the best interests of its members.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 3. 2022, the Company was approved by OTC Markets to up-list its common stock from the OTC Pink Sheets to the OTCQB® Venture Market (the “OTCQB”). The Company began trading of its common shares on the OTCQB as of the market open on February 3, 2022, under its same symbol, “BFYW.”</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s current business plan is to explore and evaluate various opportunities in the plant-based food and beverage and consumer packaged goods sectors, including but not limited to, mergers, acquisitions, or business combination transactions, after which the Company would cease to be a “shell” or “blank check” company. The Company’s principal business objective for the next 12 months and beyond will be to achieve long-term growth potential through a combination with a business rather than immediate, short-term earnings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 15, 2021, the Company’s wholly owned subsidiary, Glow Market, LLC was formed in the State of Ohio. Subsequently, Glow Market, LLC launched its first brand, Better Suds, an online retailer of specialty all-natural, cruelty-free, gluten-free and chemical-free soaps. Better Suds commenced operations in December 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 29, 2022 the Company entered into a Membership Interest Purchase Agreement (the “MIPA”) with Amanda Cayemitte and Yapo M’be (referred to together as the “Sellers”) to acquire the right, title and interest in, including all of the outstanding membership interests (referred to together as the “MM Interests”) of Mango Moi, LLC (“Mango Moi”). Mango Moi is a hair and skincare business located in Chicago, Illinois. Pursuant to the MIPA, in exchange for the MM Interests, the Company agreed to pay the Sellers a purchase price consisting of shares of the Company’s common stock, par value $0.0001 per share which consists of 11,000,000 shares of common stock (the “Company Common Stock”), with a fair market value of approximately $550,000, with 5,720,000 shares of Company Common Stock issued to Amanda Cayemitte and 5,280,000 shares of Company Common Stock issued to Yapo M’be (referred to together herein as the “Purchase Price”). Additionally, pursuant to the terms of the MIPA, the Company agreed to enter into an Employment Agreement with Mango Moi founder Amanda Cayemitte (the “Employment Agreement”), and a Consulting Agreement with Yapo M’be (the “Consulting Agreement”), respectively, as disclosed by the Company on its Current Report on Form 8-K filed with the SEC on May 2, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The MIPA closed (the “Closing”) on May 26, 2022, on which date the Company paid the Sellers the Purchase Price by issuing the Company Common Stock to the Sellers and the Sellers transferred the MM Interests to the Company, and on which date Mango Moi became a wholly owned subsidiary of the Company. At the Closing the Company entered into the Employment Agreement with Amanda Cayemitte and the Consulting Agreement with Yapo M’be.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company intends to optimize Mango Moi’s product formulae and packaging, as well as secure new manufacturing relationships to scale production capacity. Additionally, the Company plans to expand Mango Moi’s product offerings to include additional products and product bundles. Furthermore, the Company intends to grow sales through direct-to-consumer marketing efforts, subscription box sales, and pursuing wholesale sales relationships.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s main office is located at 1349 East Broad Street, Columbus OH 43205.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has elected February 28th as its year end.</p> 1000 1000 700000 250000000 700000 250000000 0.8962 350000 350000 250000000 335000 0.8962 17963817 0.05 24137499 0.05 0.0001 11000000 550000 5720000 5280000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2 - Summary of Significant Accounting Policies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Principles of Consolidation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The accompanying interim unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements on Form 10-K have been condensed or omitted. The condensed consolidated balance sheet as of February 28, 2022 has been derived from the audited consolidated financial statements as of that date, but does not include all disclosures required for audited annual financial statements. For further information, please refer to and read these interim condensed Consolidated Financial Statements in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended February 28, 2022 filed with the SEC.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Glow Markets, LLC and Mango Moi, LLC. All significant intercompany accounts and transactions have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">There were no material changes in the Company’s significant accounting policies for the three and six months ended August 31, 2022 as compared to the year ended February 28, 2022. See Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022, as filed with the SEC, for additional information regarding the Company’s significant accounting policies and use of estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and Cash Equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at August 31, 2022 and February 28, 2022 were $2,130 and $9,642 respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b>Property and Equipment</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets (primarily three to five years).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Revenue Recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has prepared its unaudited condensed consolidated financial statements in accordance with GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue for products is recognized when the products are delivered to the customer and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of August 31, 2022 and February 28, 2022, the Company had no deferred revenues.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes under ASC 740, “<i>Income Taxes</i>.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at August 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basic Earnings (Loss) Per Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, <i>Earnings per Share</i>. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company did not have any dilutive instruments for the three and six months ended August 31, 2022, and 2021, respectively. Thus, anti-dilution issues are not applicable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820, <i>Fair Value Measurements and Disclosures</i>, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of August 31, 2022 and February 28, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Related Parties</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows ASC 850, <i>Related Party Disclosures,</i> for the identification of related parties and disclosure of related party transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Share-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 718, “<i>Compensation – Stock Compensation</i>”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “<i>Equity–Based Payments to Non-Employees.” </i>Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as specified for the Independent Directors’ compensation, the Company had no stock-based compensation plans as of August 31, 2022 and February 28, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"><b>Recently Issued Accounting Pronouncements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In June 2016, the FASB issued ASU No. 2016-13 “Credit Losses - Measurement of Credit Losses on Financial Instruments.” ASU No. 2016-13 significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables, by replacing today’s “incurred loss” approach with an “expected loss” model under which allowances will be recognized based on expected rather than incurred losses. ASU No. 2016-13 will become effective for us in the first quarter of 2023. We are evaluating the impact that the adoption of this update will have on our financial statements; however, it is not expected to be material.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"><b>Reclassification of Prior Year Presentation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Principles of Consolidation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The accompanying interim unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements on Form 10-K have been condensed or omitted. The condensed consolidated balance sheet as of February 28, 2022 has been derived from the audited consolidated financial statements as of that date, but does not include all disclosures required for audited annual financial statements. For further information, please refer to and read these interim condensed Consolidated Financial Statements in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended February 28, 2022 filed with the SEC.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Glow Markets, LLC and Mango Moi, LLC. All significant intercompany accounts and transactions have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">There were no material changes in the Company’s significant accounting policies for the three and six months ended August 31, 2022 as compared to the year ended February 28, 2022. See Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022, as filed with the SEC, for additional information regarding the Company’s significant accounting policies and use of estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the opinion of management, all adjustments necessary in order to make the financial statements not misleading have been included. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and Cash Equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents at August 31, 2022 and February 28, 2022 were $2,130 and $9,642 respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 2130 9642 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><b>Property and Equipment</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the related assets (primarily three to five years).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Revenue Recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has prepared its unaudited condensed consolidated financial statements in accordance with GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company adopted ASC 606 - Revenue from contracts with Customers: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue for products is recognized when the products are delivered to the customer and the customer completes the product inspection. Cash receipts for undelivered products are recorded as deferred revenues. As of August 31, 2022 and February 28, 2022, the Company had no deferred revenues.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes under ASC 740, “<i>Income Taxes</i>.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at August 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basic Earnings (Loss) Per Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes basic and diluted earnings (loss) per share in accordance with ASC Topic 260, <i>Earnings per Share</i>. Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company did not have any dilutive instruments for the three and six months ended August 31, 2022, and 2021, respectively. Thus, anti-dilution issues are not applicable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820, <i>Fair Value Measurements and Disclosures</i>, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">- Level 3 - Inputs that are both significant to the fair value measurement and unobservable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of August 31, 2022 and February 28, 2022. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Related Parties</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows ASC 850, <i>Related Party Disclosures,</i> for the identification of related parties and disclosure of related party transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Share-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 718, “<i>Compensation – Stock Compensation</i>”, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “<i>Equity–Based Payments to Non-Employees.” </i>Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as specified for the Independent Directors’ compensation, the Company had no stock-based compensation plans as of August 31, 2022 and February 28, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"><b>Recently Issued Accounting Pronouncements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In June 2016, the FASB issued ASU No. 2016-13 “Credit Losses - Measurement of Credit Losses on Financial Instruments.” ASU No. 2016-13 significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables, by replacing today’s “incurred loss” approach with an “expected loss” model under which allowances will be recognized based on expected rather than incurred losses. ASU No. 2016-13 will become effective for us in the first quarter of 2023. We are evaluating the impact that the adoption of this update will have on our financial statements; however, it is not expected to be material.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"><b>Reclassification of Prior Year Presentation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3 - Going Concern</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s financial statements are prepared in accordance with generally accepted accounting principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern for one year following the issuance of these financial statements. These adverse conditions are negative financial trends, specifically operating loss, working capital deficiency, and other adverse key financial ratios.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has not established enough sources of revenue to cover its operating costs. Management plans to fund operating expenses with related party capital contributions. There is no assurance that management’s plan will be successful. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4 - Business Combinations</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 29, 2022, we entered into an asset purchase agreement to acquire substantially all of the assets of Mango Moi. The acquisition was accounted for in accordance with GAAP and was made to expand our market share in the personal care category and due to synergies of product lines and services between the Companies. The acquisition closed May 26, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purchase price has been preliminarily allocated to assets acquired and liabilities assumed based on the estimated fair value of such assets and liabilities at the date of acquisitions as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><b>Assets acquired:</b></td><td><b> </b></td> <td colspan="2"><b> </b></td><td><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">913</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Inventory</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,995</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Assets Acquired</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">13,908</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><b>Liabilities assumed:</b></td><td><b> </b></td> <td style="text-align: left"><b> </b></td><td style="text-align: right"><b> </b></td><td style="text-align: left"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Clearbanc Debit Card</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,365</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Notes Payable - PayPal Capital</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,454</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes Payable Shopify Capital</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-size: 10pt">53 7</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"> Sales Tax Payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">138</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Liabilities Assumed</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,494</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total identifiable net assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,414</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Purchase price</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">592,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">583,586</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purchase price of $592,000 was paid in stock and discharge of liability in cash as a combination. Goodwill in the amount of $583,586 was recognized in the acquisition of Mango Moi LLC and is attributable to the cash flows of the business derived from our potential to outperform the market due to its existing relationship and other synergies created within the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As the Company finalizes the fair value of assets acquired and liabilities assumed, additional purchase price adjustments may be recorded. The finalization of the purchase accounting assessment may result in changes in the valuation of assets acquired and liabilities assumed and may have an impact on the Company’s results of operations and financial position.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following unaudited pro forma information presents a summary of the condensed consolidated results of operations for the Company as if the acquisition of Mango Moi had occurred on March 1, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">August 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">August 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 4pt">Total revenues</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">1,716</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">15,991</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Net (loss) income</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(767,677</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(31,364</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Loss per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">August 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">August 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 4pt">Total revenues</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">2,022</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">35,447</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Net (loss) income</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,659,594</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(112,841</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Loss per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited pro forma consolidated results are based on our historical financial statements and those of Mango Moi and do not necessarily indicate the results of operations that would have resulted had the acquisition actually been completed at the beginning of the applicable period presented. The pro forma financial information assumes that the companies were combined as of March 1, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables present the amounts of revenue and earnings of Mango Moi since the acquisition date included in the condensed consolidated income statement for the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><span style="-keep: true"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">(unaudited)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">(unaudited)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the <br/> three months ended <br/> August 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the <br/> six months ended <br/> August 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true">Mango Moi:</span></td><td><span style="-keep: true"> </span></td> <td colspan="2"><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td> <td colspan="2"><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-keep: true">Total revenues</span></td><td style="width: 1%"><span style="-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1,716</span></td><td style="width: 1%; text-align: left"><span style="-keep: true"> </span></td><td style="width: 1%"><span style="-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">8,690</span></td><td style="width: 1%; text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-keep: true">Net income</span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(819</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(9,100</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><b>Assets acquired:</b></td><td><b> </b></td> <td colspan="2"><b> </b></td><td><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Cash</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">913</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Inventory</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,995</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Assets Acquired</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">13,908</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><b>Liabilities assumed:</b></td><td><b> </b></td> <td style="text-align: left"><b> </b></td><td style="text-align: right"><b> </b></td><td style="text-align: left"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Clearbanc Debit Card</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,365</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Notes Payable - PayPal Capital</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,454</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes Payable Shopify Capital</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-size: 10pt">53 7</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"> Sales Tax Payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">138</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Liabilities Assumed</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,494</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total identifiable net assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,414</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Purchase price</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">592,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">583,586</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 913 12995 13908 2365 2454 138 5494 8414 592000 583586 592000 583586 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">August 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">August 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 4pt">Total revenues</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">1,716</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">15,991</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Net (loss) income</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(767,677</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(31,364</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Loss per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Six months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(unaudited)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">August 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">August 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 4pt">Total revenues</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">2,022</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">35,447</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Net (loss) income</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,659,594</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(112,841</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Loss per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 1716 15991 -767677 -31364 2022 35447 -1659594 -112841 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td><span style="-keep: true"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">(unaudited)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">(unaudited)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the <br/> three months ended <br/> August 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the <br/> six months ended <br/> August 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true">Mango Moi:</span></td><td><span style="-keep: true"> </span></td> <td colspan="2"><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td> <td colspan="2"><span style="-keep: true"> </span></td><td><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-keep: true">Total revenues</span></td><td style="width: 1%"><span style="-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1,716</span></td><td style="width: 1%; text-align: left"><span style="-keep: true"> </span></td><td style="width: 1%"><span style="-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">8,690</span></td><td style="width: 1%; text-align: left"><span style="-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-keep: true">Net income</span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(819</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true"> </span></td> <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(9,100</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr> </table> 1716 8690 -819 -9100 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5 - Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company accounts for income taxes under ASC 740, “<i>Income Taxes</i>.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized at August 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 6 - Commitments and Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows ASC 450-20, <i>Los</i>s <i>Contingencies, </i>to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of August 31, 2022 other than the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 17, 2021, our Board of Directors unanimously approved to enter into and consummate an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies”. In exchange for twelve months of access to the Sequire Platform, we paid SRAX $20,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also on September 17, 2021, our Board of Directors unanimously agreed to approve to enter into and consummate another agreement with SRAX, whereas SRAX will provide advertising and marketing services to the Company on a case-by-case basis, as may be requested by the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 18, 2022, Better For You Wellness, Inc., a Nevada corporation (the “Company”), entered into a Standby Equity Commitment Agreement, dated April 11, 2022 (the “SECA”) with MacRab LLC, a Florida limited liability company (the “Investor”). The SECA provides the Company with an option to sell up to $5,000,000 worth of the Company’s common stock, par value $0.0001 (the “Common Stock”), to the Investor, in increments, over the period ending twenty-four (24) months after the date the Registration Statement (as defined below) is deemed effective by the U.S. Securities and Exchange Commission, pursuant to the terms and conditions contained in the SECA. The purchase price per share, for each respective put under the SECA, is equal to 90% of the average of the two (2) lowest volume weighted average prices of the Common Stock during the six (6) trading days following the clearing date associated with the respective put under the SECA. Additionally, we issued a common stock purchase warrant for the purchase of 1,785,714 shares of our common stock (the “Warrant”) to Investor as a commitment fee in connection with the execution of the SECA.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 26, 2022 the Company acquired Mango Moi, LLC as a wholly-owned subsidiary (See Note 1). As part of the purchase agreement, the Company entered into an employment agreement and a consulting agreement as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment Agreement</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Employment Agreement, which is to be effective as of 45 days from the signing of the MIPA, the Company agreed to employ Amanda Cayemitte as the Chief Visionary Officer of Mango Moi to provide duties including normalizing the Company’s strategic-planning processes, forging new working relationships and synergies across the organization, and establishing greater transparency and accountability for those people carrying out the Company’s strategy. As compensation under the Employment Agreement, the Company agreed to pay Amanda Cayemitte an annual salary of $65,000 payable semi-monthly on the first day and the fifteenth day of the month and subject to applicable federal, state, and local withholding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Employment Agreement can be terminated any time by either party by giving 30 days written notice to the other party. If the Employment Agreement is terminated, Amanda Cayemitte will be entitled to receive compensation for:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">one month upon completion of one full calendar year of employment with the Company;</span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">two months upon completion of two full calendar years of employment with the Company, and</span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">three months upon competition of two full calendar years of employment with the Company.</span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, if Amanda Cayemitte breaches any terms of the Employment Agreement, the Company may terminate the Employment Agreement without any notice and with compensation being paid to Amanda Cayemitte only through the date of such termination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Consulting Agreement</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Consulting Agreement, the Company engaged Yapo M’be as a consultant to provide manufacturing services for Mango Moi, to begin on May 2, 2022. As compensation under the Consulting Agreement, the Company agreed to pay Yapo M’be at the rate of $30.00 per hour, not to exceed $1,500 per month. The Consulting Agreement can be terminated by either party upon the failure of the other to perform under the Consulting Agreement by giving ten days written notice to the non-performing party. The Consulting Agreement can also be terminated by the Company by giving ten days written notice to Yapo M’be in the event that there is a reduction of the program budget.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Ian James Employment Agreement<br/> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 21, 2022 the Company’s Compensation Committee approved a formal Employment Agreement with Ian James, the Company’s Chief Executive Officer and the Company entered into the Agreement with Mr. James as of July 21, 2022. As compensation under the Employment Agreement, beginning March 1, 2022, Employee will earn a Base Salary in the amount of $199,196 per annum, $16,599.67 per month, less statutory and other required deductions, for all work and services Ian James performs for the Company. The Company calculates Annual Base Salary on a January 1 through December 31 basis (i.e., a calendar year). Base Salary payments shall be subject to applicable federal, state, and local withholding. Under the Agreement, the Employee and Company mutually agree that until the Company is cash flow positive, the Company shall pay Employee a mutually agreeable amount each month toward the Employee’s Base Salary, and the balance of Base Salary unpaid, shall be accrued and recorded as an obligation of the Company. It shall become payable to the Employee when the Company is cash flow positive or at a time mutually agreed by the Company and Employee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Employee shall also be eligible to earn an additional payment (BONUS) of $68,328. The parties consider the Bonus Pay as “at-risk” and therefore not guaranteed. Bonus Pay could include a cash bonus, commission, and other at-risk pay categories. BONUS shall be determined at the sole discretion of the Company. The Employee’s Bonus shall be based on Employee’s annual performance reviews and overall company performance, subject to the terms and conditions of applicable incentive plans and policies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should this Contract be terminated, payments under Section 2 shall cease; provided, however, that Employee shall be entitled to Base Salary and accrued Base Salary for periods or partial periods that occurred before the date of termination and for which the Employee has not yet been paid and for any commission earned per the Company’s customary procedures, if applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After completion of 90-days of Employment, Employee shall be entitled to a pro-rated 15 days paid time per year for utilization by Employee for personal business, illness, care of another person, or vacation. Personal Leave shall be calculated from the effective date of this Contract as of the date first above written through December 31<sup>st</sup>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Employee shall be permitted to carry over into the following year of employment a maximum of five days of Personal Leave; however, as of December 31, Employee shall forfeit unused Personal Leave benefits above five days. Further, Employee shall not be permitted to carry over or accumulate more than ten days of Personal Leave from one year to the next.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stephen Letourneau Employment Agreement<br/></i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 21, 2022 the Company’s Compensation Committee approved a formal Employment Agreement with Stephen Letourneau, the Company’s Chief Branding Officer and the Company entered into the Agreement with Mr. Letourneau as of July 21, 2022. As compensation under the Employment Agreement, beginning March 1, 2022, Employee will earn a Base Salary in the amount of $152,787 per annum, $12,732.25 per month, less statutory and other required deductions, for all work and services Ian James performs for the Company. The Company calculates Annual Base Salary on a January 1 through December 31 basis (i.e., a calendar year). Base Salary payments shall be subject to applicable federal, state, and local withholding. Under the Agreement, the Employee and Company mutually agree that until the Company is cash flow positive, the Company shall pay Employee a mutually agreeable amount each month toward the Employee’s Base Salary, and the balance of Base Salary unpaid, shall be accrued and recorded as an obligation of the Company. It shall become payable to the Employee when the Company is cash flow positive or at a time mutually agreed by the Company and Employee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Employee shall also be eligible to earn an additional payment (Bonus) of $70,632. The parties consider the Bonus Pay as “at-risk” and therefore not guaranteed. Bonus Pay could include a cash bonus, commission, and other at-risk pay categories. Bonus shall be determined at the sole discretion of the Company. The Employee’s Bonus shall be based on Employee’s annual performance reviews and overall company performance, subject to the terms and conditions of applicable incentive plans and policies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should this Contract be terminated, payments under Section 2 shall cease; provided, however, that Employee shall be entitled to Base Salary and accrued Base Salary for periods or partial periods that occurred before the date of termination and for which the Employee has not yet been paid and for any commission earned per the Company’s customary procedures, if applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After completion of 90-days of Employment, Employee shall be entitled to a pro-rated 15 days paid time per year for utilization by Employee for personal business, illness, care of another person, or vacation. Personal Leave shall be calculated from the effective date of this Contract as of the date first above written through December 31<sup>st</sup>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Employee shall be permitted to carry over into the following year of employment a maximum of five days of Personal Leave; however, as of December 31, Employee shall forfeit unused Personal Leave benefits above five days. Further, Employee shall not be permitted to carry over or accumulate more than ten days of Personal Leave from one year to the next.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Jacob Ellman Employment Agreement<br/></i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Company’s Compensation Committee approval of July 21, 2022, The Company entered a formal Employment Agreement with Jacob Ellman, the Company’s Chief Business Development Officer and the Company entered into the Agreement with Mr. Ellman as of October 14, 2022. As compensation under the Employment Agreement, beginning March 1, 2022, Employee will earn a Base Salary in the amount of $128,656 per annum, $10,721.33 per month, less statutory and other required deductions, for all work and services Ian James performs for the Company. The Company calculates Annual Base Salary on a January 1 through December 31 basis (i.e., a calendar year). Base Salary payments shall be subject to applicable federal, state, and local withholding. Under the Agreement, the Employee and Company mutually agree that until the Company is cash flow positive, the Company shall pay Employee a mutually agreeable amount each month toward the Employee’s Base Salary, and the balance of Base Salary unpaid, shall be accrued and recorded as an obligation of the Company. It shall become payable to the Employee when the Company is cash flow positive or at a time mutually agreed by the Company and Employee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Employee shall also be eligible to earn an additional payment (Bonus) of $41,140. The parties consider the Bonus Pay as “at-risk” and therefore not guaranteed. Bonus Pay could include a cash bonus, commission, and other at-risk pay categories. Bonus shall be determined at the sole discretion of the Company. The Employee’s Bonus shall be based on Employee’s annual performance reviews and overall company performance, subject to the terms and conditions of applicable incentive plans and policies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should this Contract be terminated, payments under Section 2 shall cease; provided, however, that Employee shall be entitled to Base Salary and accrued Base Salary for periods or partial periods that occurred before the date of termination and for which the Employee has not yet been paid and for any commission earned per the Company’s customary procedures, if applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After completion of 90-days of Employment, Employee shall be entitled to a pro-rated 15 days paid time per year for utilization by Employee for personal business, illness, care of another person, or vacation. Personal Leave shall be calculated from the effective date of this Contract as of the date first above written through December 31<sup>st</sup>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Employee shall be permitted to carry over into the following year of employment a maximum of five days of Personal Leave; however, as of December 31, Employee shall forfeit unused Personal Leave benefits above five days. Further, Employee shall not be permitted to carry over or accumulate more than ten days of Personal Leave from one year to the next.</p> 20000 5000000 0.0001 0.90 1785714 65000 Pursuant to the Consulting Agreement, the Company engaged Yapo M’be as a consultant to provide manufacturing services for Mango Moi, to begin on May 2, 2022. As compensation under the Consulting Agreement, the Company agreed to pay Yapo M’be at the rate of $30.00 per hour, not to exceed $1,500 per month. 199196 16599.67 68328 152787 12732.25 70632 128656 10721.33 41140 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 7 - Convertible Note Payable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 7, 2022, the Company entered into a second Securities Purchase Agreement with Mast Hill Fund, L.P., a Delaware limited partnership (“Mast Hill”). The first Security Purchase Agreement with Mast Hill Fund, L.P. was entered On April 12, 2022. Pursuant to the June 7, 2022 Security Purchase Agreement, Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on June 7, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on June 7, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Purchase Agreements, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Mast Hill, pursuant to which the Company is obligated to file a registration statement within 90 days of the date of the Registration Rights Agreement covering the sale of the Commitment Shares and the shares of the Company’s common stock that may be issued to Mast Hill pursuant to the conversion of the Note.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">JH Darbie &amp; Co., Inc. (“JH Darbie”) and the Company are parties to a Finder’s Fee Agreement, signed March 15, 2020 (“Finder’s Agreement”) pursuant to which JH Darbie would introduce the Issuer to third-party investors. Pursuant to the Finder’s Agreement, in relation to both the April 12, 2022 and the June 7, 2022 Securities Purchase Agreement with Mast Hill Fund, L.P., J.H. Darbie received approximately $22,320 for each Security Purchase Agreement. In addition, JH Darbie is to receive non-callable warrants of equal to 8% warrant coverage of the amount raised. The warrants shall entitle JH Darbie thereof to purchase common stock of the Company at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of the Issuer’s common stock on the date of the Transaction, whichever is lower (such price, the “Warrant Price”). The warrants shall be exercisable immediately after the date of issuance, shall have anti-dilutive price protection, participating registration rights, and shall expire 5 years after the date of issuance, in accordance with the Finder’s Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 11, 2022, Mast Hill Fund agreed to extend the timeframes in section 2(a) of the Registration Rights Agreement dated 4/12/22 to 180 calendar days to file the initial Registration Statement and 270 calendar days to have it declared effective. On October 11, 2022, Mast Hill Fund agreed to extend the timeframes in section 2(a) of the Registration Rights Agreement dated 4/12/22 until February 9, 2023, and to have the Registration Statement become effective on or before February 9, 2037.</p> 310000 279000 31000 0.12 2023-06-07 0.037 4960000 22320 0.08 1.20 P5Y <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 8 - Stock Purchase Warrant Liability</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">JH Darbie &amp; Co., Inc. (“JH Darbie”) and the Company are parties to a Finder’s Fee Agreement, signed March 15, 2020 (“Finder’s Agreement”) pursuant to which JH Darbie would introduce the Issuer to third-party investors. Pursuant to the Finder’s Agreement, in relation to the April 12, 2022 and the June 7, 2022 Securities Purchase Agreement with Mast Hill Fund, L.P., two equal payments of fees of approximately $22,320 were paid to JH Darbie. In addition, JH Darbie is to receive non-callable warrants of equal to 8% warrant coverage of the amount raised. The warrants shall entitle JH Darbie thereof to purchase common stock of the Company at a purchase price equal to 120% of the exercise price of the transaction or the public market closing price of the Issuer’s common stock on the date of the Transaction, whichever is lower (such price, the “Warrant Price”). The warrants shall be exercisable immediately after the date of issuance, shall have anti-dilutive price protection, participating registration rights, and shall expire 5 years after the date of issuance, in accordance with the Finder’s Agreement.</p> 22320 0.08 1.20 P5Y <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 9 - Shareholder Equity </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Preferred Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The authorized preferred stock of the Company consists of 200,000,000 shares with a par value of $0.0001. There were 700,000 shares issued and outstanding as of August 31, 2022 and February 28, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended May 31, 2021, 700,000 shares of Series A Preferred Stock were issued to CRS Consulting, LLC (“CRS”), a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody. CRS is our controlling shareholder, owning 700,000 shares of Series A Preferred Stock and 250,000,000 shares of Restricted Common Stock. Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock. On July 19, 2021, these shares were purchased. As of November 30, 2021, our CEO, Ian James, and Director, Stephen Letourneau, each hold 350,000 shares of Series A Preferred Stock (See Note 1).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Common Stock</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The authorized common stock of the Company consists of 500,000,000 shares with a par value of $0.0001. There were 385,198,451 and 370,747,042 shares of common stock issued and outstanding as of August 31, 2022 and February 28, 2022, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the time of reorganization, former shareholders of Sauer Energy, Inc. became shareholders of Fast Track Solutions, Inc., representing 359,996,332 of the common shares outstanding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 19, 2021, 250,000,000 shares of restricted Common Stock were purchased by Ohio Green Ventures, LLC from CRS Consulting, LLC, a Wyoming LLC owned and controlled by Jeffrey DeNunzio, Thomas DeNunzio and Paul Moody (See Note 1).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 24, 2021, Green Ohio Ventures, LLC transferred 17,963,817 shares of restricted Common Stock of Better for You Wellness, Inc. to MRKTS Group Inc. for consulting services provided.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From August 24, 2021 to August 25, 2021, Green Ohio Ventures, LLC distributed, at no cost and in various quantities, a total of 24,137,499 shares of restricted Common Stock of Better for You Wellness, Inc. to 18 of its 20 members. No shares were distributed from GOHV to Ian James and Stephen Letourneau (See Note 1).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 24, 2021, 50,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $7,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 11, 2021, 2,602,740 shares of Restricted Common Stock were issued to SRAX, Inc as compensation for marketing services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $468,493.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 11, 2021, 250,000 shares of Restricted Common Stock were issued to CRS as compensation for consulting services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $45,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17, 2021, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $18,750.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 3, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $15,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 13, 2022, 549,097 shares of Restricted Common Stock were sold to five shareholders for proceeds totaling $68,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April12, 2022, 125,000 shares of Restricted Common Stock were issued to five Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled approximately $15,468.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 12, 2022, the Company entered into a Securities Purchase Agreement with Mast Hill Fund, L.P., in which Mast Hill purchased a promissory note, with a principal amount of $310,000 for a purchase price of $279,000 (the “Note”). The closing of the Purchase Agreements occurred on April 12, 2022. The Note bears an original issue discount of $31,000, each bear interest of 12% per year and mature on April 12, 2023 (the “Maturity Date”). The Note is convertible into shares of the Company’s common stock at conversion price of $0.037 per share, subject to adjustment as provided therein. The Company has the right to prepay the Note in full, including accrued but unpaid interest, without prepayment penalty provided an event of default, as defined therein, has not occurred. In the seven (7) trading days prior to any prepayment Mast Hill shall have the right to convert their Note into Common Stock of the Company in accordance with the terms of such Note. The Note contains events of defaults and certain negative covenants that are typical in the types of transactions contemplated by the Purchase Agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Purchase Agreements, the Company issued to Mast Hill 4,960,000 commitment shares of the Company’s common stock (the “Commitment Shares”) as a condition to closing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 26, 2022, 11,000,000 share of Restricted Common Stock were issued to the two Sellers of Mango Moi, LLC (See Note 1). The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled approximately $550,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 12, 2022, 100,000 shares of Restricted Common Stock were issued to four Directors serving on the Company’s Board of Directors as compensation for services to the Company. The shares were valued at the closing share price on that date, as listed on the OTC Markets, which totaled $3,990.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2022 the Company filed its Pre-14-C notice and accompanying Information Statement and furnished this information to the holders of shares of common stock, par value $0.0001 per share, of Better For You Wellness, Inc., a Nevada corporation (the “Company”), pursuant to Section 78.320 of the Nevada General Corporation Law, Section 14 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Regulation 14C and Schedule 14C thereunder, in connection with the approval of the following actions taken by the Company’s Board of Directors (the “Board”) and by written consent of the holders of a majority of the voting power of the issued and outstanding capital stock of the Company, to amend our certificate of incorporation, as amended (the “Certificate”), to increase the number of authorized shares of common stock from 500,000,000 to 1,000,000,000 (the “Authorized Share Increase” or “Corporate Action”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period ended August 31, 2022, a total of 30,282 shares of Restricted Common Stock were sold to two shareholders for proceeds totaling approximately $<span style="-sec-ix-hidden: hidden-fact-126">3,75.13</span>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 12, 2022, the Board of Directors authorized the issuance of 2,686,667 Common Shares to Mast Hill for consideration of the extension of the 4/12/2022 Registration Rights Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Shares Cancellable</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 11, 2022, the Company entered into a Common Share Option Cancellation and Forfeiture Agreement with former Director Dr. Nicola Finley (the “Option Cancellation and Forfeiture Agreement”). Under the Option Cancellation and Forfeiture Agreement, Dr. Nicola Finley forfeited, and the Company canceled Dr. Nicola Finley’s option to purchase 4,000,000 common shares of the Company that was granted to the optionee pursuant to the Director Agreement dated as of August 29, 2021. Upon such forfeiture and cancellation, Dr. Nicola Finley has no further rights to exercise the option to purchase 4,000,000 common shares of the Company. The cancellation and forfeiture set forth in the Option Cancellation and Forfeiture Agreement shall not affect the restricted common shares granted by the Company to Dr. Nicola Finley pursuant to the Director Agreement dated as of August 29, 2021. As a payment in lieu of whatever benefits, if any, to which Dr. Nicola Finley may have been entitled to under the option to purchase 4,000,000 common shares of the Company, the Company shall pay Dr. Nicola Finley $1.00.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Options</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal year ended February 28, 2022, the Company granted options exercisable for up to 20,000,000 shares of Common Stock of which 8,500,000 fully vested on August 31, 2021. The remaining 11,500,000 shares vest over the next 2 years. During the three months ended August 31, 2023, 2,000,000 shares were forfeited. The options have the exercise price of $.25 per share. These options expire 5 years after issue. The aggregate intrinsic value of these outstanding options as of August 31, 2022, was $0. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company fair valued the options on the grant dates at $2,127,565 using a Black-Scholes option pricing model with the following assumptions: stock price of $.15 and $.11 per share (based on the quoted trading price on the dates of the grants). The Company is amortizing the expense over the vesting terms of each. The total stock option expense for the period ended August 31, 2022 was approximately $297,414. The total unamortized stock option expense at August 31, 2022 was approximately $1,854,208.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Additional Paid-In Capital</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the quarterly period ended August 31, 2022, a total of $2,931,841 posted as additional paid-in capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This includes Common Shares issued for services for the Company including $250,192 for Mast Hill, cash received for shares sold $3,747, $274,025 of share option vestment/expense for the Board of Directors, $17,188 in Warrants issued related to JH Darbie for finder agreement and debt treatment of Mast hill, and negative $223,060 in forfeiture of stock options by former Director Dr. Nicola Finley.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Related-Party Transactions</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Loan to Company</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six-month period ended August 31, 2022, Green Ohio Ventures, LLC, paid expenses on behalf of the Company totaling approximately $82,788 and during the same period, Green Ohio Ventures was reimbursed $176,544, which included the $82,788 expense paid from this period. During the same period of August 31, 2022, Green Ohio Ventures, LLC, loaned the Company $7,000. During the same period, the following Company Officers and Directors made the following financial contributions to the Company:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ian James, the Company’s Chief Executive Officer loaned the Company $18,000 during the period. Additionally, Mr. James paid expenses on behalf of the Company totaling approximately $26,057 and during the same period, Mr. James was reimbursed $19,775, leaving a balance of expense paid from prior reporting periods in the amount of $9,791, which was in addition to the $18,000 loan as referenced above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stephen Letourneau the Company’s Chief Branding Officer paid expenses on behalf of the Company totaling approximately $48,068, and during the same period, Mr. Letourneau was reimbursed $40,389 leaving a balance of $2,780 to be reimbursed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Director David Deming paid expenses on behalf of the Company totaling approximately $50,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company acquired $35,000 of a loan to Mango Moi, LLC when it became a wholly-owned subsidiary of the Company. This loan was made to Mango Moi, LLC by a relative of Amanda Cayemitte (i.e., Mr. Gushy Joseph), one of the sellers of the subsidiary. On October 12, 2022, the Board of Directors authorized the issuance of 760,870 Common Shares @ $0.023 per share to retire $17,500 of the $35,000 Loan. The balance of $17,500 was agreed to be paid in the first quarter of the 2023 calendar year.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, during the six-month period ended August 31, 2022, Company Officers Deferred Compensation totaling $190,320. These payments are considered as loans to the Company, which are noninterest-bearing, unsecured, and payable on demand.</p> 200000000 0.0001 700000 700000 700000 700000 700000 700000 250000000 Series A Preferred Stock has no conversion rights to any other class, and every vote of Series A Preferred Stock has voting rights equal to 1,000 votes of Common Stock. 350000 500000000 0.0001 385198451 370747042 359996332 250000000 17963817 24137499 50000 7000 2602740 468493 250000 45000 125000 18750 125000 15000 549097 68000 125000 15468 310000 279000 31000 0.12 0.037 4960000 11000000 550000 100000 3990 0.0001 78.32 500000000 1000000000 30282 2686667 On July 11, 2022, the Company entered into a Common Share Option Cancellation and Forfeiture Agreement with former Director Dr. Nicola Finley (the “Option Cancellation and Forfeiture Agreement”). Under the Option Cancellation and Forfeiture Agreement, Dr. Nicola Finley forfeited, and the Company canceled Dr. Nicola Finley’s option to purchase 4,000,000 common shares of the Company that was granted to the optionee pursuant to the Director Agreement dated as of August 29, 2021. Upon such forfeiture and cancellation, Dr. Nicola Finley has no further rights to exercise the option to purchase 4,000,000 common shares of the Company. The cancellation and forfeiture set forth in the Option Cancellation and Forfeiture Agreement shall not affect the restricted common shares granted by the Company to Dr. Nicola Finley pursuant to the Director Agreement dated as of August 29, 2021. As a payment in lieu of whatever benefits, if any, to which Dr. Nicola Finley may have been entitled to under the option to purchase 4,000,000 common shares of the Company, the Company shall pay Dr. Nicola Finley $1.00.  20000000 8500000 11,500,000 2000000 25 P5Y 0 2127565 stock price of $.15 and $.11 per share (based on the quoted trading price on the dates of the grants). 297414 1854208 2931841 250192 3747 274025 17188 223060 82788 176544 82788 7000 18000 26057 19775 9791 18000 48068 40389 2780 50000 35000 760870 0.023 17500 35000 17500 190320 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 10 - Impairment Expense</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period ended August 31, 2022, the Company had no Impairment Expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 11 - Subsequent Events</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 20, 2022, the Company entered into a Manufacturing Agreement with Ironwood Clay Company (ICCI) to develop commercially scaled Personal Care Products for Mango Moi and other products in the Company’s portfolio. The Company agreed to pay a non-refundable deposit of $10,000 USD for up to 8 Product Formula. This includes three formulation revisions and samples per Product Formula (each iteration of sampling of up to 500gr./ml.). Additional revisions to the Formula(s) will be charges to the Client at a rate of $500 USD per revision.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once the Company has approved the final Formula(s) and places a Purchase Order exceeding $10,000 USD, the non-refundable deposit will be applied to the total amount of the Purchase Order. Upon ordering at least Twenty-Five Thousand US Dollars ($25,000 USD) of each Product Formula, the exclusivity granted to ICCI herein in respect of such Product and Formula shall cease, the Company shall no longer be obligated to purchase Products from ICCI, and the Client shall be free to engage any other manufacturer for such purpose.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 22, 2022, the Company announced the cancelation of the Letter of Intent (LOI) to acquire Ironwood Clay Company (ICCI) because ICCI was unable to have its Clay Mining Operation adequately meet SEC reporting requirements related to the mining of a natural resource. Additionally, ICCI owners were unwilling to bifurcate the Mining Operation from the Personal Care Manufacturing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 22, 2022, the Company announced the Letter of Intent (LOI) to acquire The Ideation Lab and its functional beverage division, The Jordre Well.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Ideation Lab is a brand solutions incubator and accelerator focused on the plant-based wellness and hemp-infused industry. The Ideation Lab has been developing plant-based wellness brands since 2020, including Garrett and Emmett’s Pet Treats, a pet lifestyle brand, E.J. Well Co, a women’s wellness brand, and others.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Jordre Well is a functional beverage company that is 49% owned by Coffee Holding Co., Inc. (NASDAQ: JVA), a leading integrated wholesale coffee roaster and dealer in the United States. Earlier this week, The Jordre Well announced its portfolio of products from Stephen James Curated Coffee Collection (“SJCCC”), the Company’s premium coffee brand, which is now being sold through Amazon.com and is in discussion with major national retailers. The e-commerce giant carries 8 of SJCCC’s premium coffee products and ships to more than 100 countries around the globe. Additionally, the deal contemplates Coffee Holding Company continuing its global purchase of coffee beans, manufacturing, distribution, and licensure of its Cafe Caribe and Harmony Bay to The Jordre Well for Hemp infusion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 11, 2022, Mast Hill Fund agreed to extend the timeframes in section 2(a) of the Registration Rights Agreement dated 4/12/22 to 270 calendar days to file the initial Registration Statement and 360 calendar days to have it declared effective. This extension follows the July 11, 2022 extension in which Mast Hill Fund agreed to extend the timeframes in section 2(a) of the Registration Rights Agreement dated 4/12/22 to 180 calendar days to file the initial Registration Statement and 270 calendar days to have it declared effective. In consideration of the extension, on October 12, 2022, the Board of Directors authorized the issuance of 2,686,667 Common Shares to Mast Hill for consideration of the extension of the 4/12/2022 Registration Rights Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 12, 2022, the Board of Directors authorized the issuance of 760,870 Common Shares @ $0.023 per share to retire $17,500 of the $35,000 Loan. The balance of $17,500 was agreed to be paid in the first quarter of the 2023 calendar year.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 12, 2022, our Board of Directors approved to renew an agreement with SRAX, Inc., a Delaware Company (“SRAX”). Pursuant to the agreement with SRAX, the Company will be granted access to a platform developed by SRAX, known as the “Sequire Platform” which, amongst other things, will allow the Company to access trading data. According to SRAX, the platform is an investor intelligence and communications management platform that allows users to “unlock stock buyers’ behaviors and trends for issuers of publicly traded companies.” In exchange for twelve months of access to the Sequire Platform, we paid SRAX $30,000. Additional fees may be incurred as a result of this agreement, but we cannot accurately determine what they may be, although we believe any such fees would be nominal.</p> 10000 500 Once the Company has approved the final Formula(s) and places a Purchase Order exceeding $10,000 USD, the non-refundable deposit will be applied to the total amount of the Purchase Order. Upon ordering at least Twenty-Five Thousand US Dollars ($25,000 USD) of each Product Formula, the exclusivity granted to ICCI herein in respect of such Product and Formula shall cease, the Company shall no longer be obligated to purchase Products from ICCI, and the Client shall be free to engage any other manufacturer for such purpose.  0.49 2686667 760870 0.023 17500 35000 17500 30000 NONE 0.00 0.00 0.00 0.00 537 375.13 true --02-28 Q2 0001852707 EXCEL 43 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

UT3)[.G:R1$6+4-%B++0VYXT\1\SZ'+@CWV2Y5765KN1[\KY[&0@'%5= Z[ Z]QUD48W(Q.$,P.1?4LHC M;Y:Z6.;H,T2(VND2%2U"18NQT-K1TNAPQ"S$_:0M6-WK;0+3(-#N YAB58B* MMD1%BX@N+>KC$4_IT[01(XW61LQBV_]A*V;V8,S- 5/["E'1EJAH$2I:C(76 M#K%&#B1F/="X(<.4M!Y0T<(I:/"&#%4$)+HF.B?6 ' 54'&[!S?+=K MK!NAC)B5LHX-6?^X!P,W9+I=-?8H:!$J6HR%UJYK:00L:A:P.BI; M*%C98O?G%V##/-M3\XOJ @[AOL-.R;>.RM=/9N0Q80&4CFD! 16.,37-D3R*L(!B!* VL8U8 M12=4C>G$]N;^C\LL-15A ,>RYQSHVN[01BJA9*,(^P#!W-X90 M74IQ;!_*=]3:,52T"!4MQD)KATJC05&S!M49*L=3OMHFA:@$[.+T5*3K-,GA M=/_QXJ*X9%I+-PYEFA2T43Z459?ES^B(. CZD-4.,H1$)*&2Z]L8# M5RV37&+U%V$!Q;V.MVELE"]F5KY,9^SFIF/HPZQ_"K'<6J*Z%3% F_,#XJLS M?3S L$UFHW8QL]K54?$,GE,QO=Y*.P $;)AO$_5\B@&E2JX=>#Q0TPI)1HN M'N?483;AGCK8NB4AGNMWS7^-<,3,PM& BF=XW#L>G=/&7K>KQM[VB:LJ0F9/ M1S]0X&))!NPWR'$I5?79>A 2,^)VH"(2E!$=#CG-' \RE7$PRT]%C0 ML1K@C?3!AY4#&4K P('G^O8=3## 3@X^"7RN/N,5FCT=FV"H:!$J6HR%UN:\ M44CXI&?>8)X'//,&V$ K0*Y+!? *T.S^B 0#>NQ8 0*6IA4@;W0,_L//O,'C M/O"9-\"N:P5H]G1T?J$^\X:*%F.AM3EO5 _^\Y]Y,W;%<-#5TX MD$M"HA8B+[&\BK" 8MAS-_ [$O?F&4%T9D!<,'!]-Z=&0 M[Z@Z""I:C(76#I5&4>$3ZX=62;&U\7TUXY'ZB[" MXE['VYPV8A(WBTE1EF]$6I[R2^G'^=!_)>_>XE!T?^0C5AT/%E#(@8?!*&5R M": 2BU7K@P44#W"]36VC&7&S9C2T@L,,,X9.)*"0 [*3QVVJ5G!@=1AA <7] MGK<_P[/1I)SIG[%D;CJ"P"E W<>-6&XML8 B!_K$)%?^4Z6/ 89M'AN=R1FL M,_7JBV[!9RG49H[M/? MRG9LL(4N8>B;8#O2:O]:2?N3=/;$Q4^YHE2AYS3)Y'EGI=3ZM-N5T8JF1'[F M:YK!?Q95TJ2+'2?HIH1EG>%9_NU.#,_X1B4LHW<"R4V: M$O%R01/^=-YQ.Z\?[MERI?2'[O!L399T1M6W]9V MVYE)68IS23C&1)T<=X9 MN:=CS],5\A+?&7V26\](2YES_E._3.+SCJ,]H@F-E#9!X.>1CFF2:$O@QS^E MT4[5IJZX_?QJ_3H7#V+F1-(Q3WZP6*W.._T.BNF";!)USY^^T%*0K^U%/)'Y M7_14EG4Z*-I(Q=.R,GB0LJSX)<]E1VQ5 #OF"KBL@)L5>GLJ>&6%O.>ZA6>Y MK$NBR/!,\"A%T2C> MTVB OO),K22Z@B;CW?I=$%"IP*\J+K#5X&BS_(P\]Q/"#L8&?\9OK^Y:W/&J M3O5R>]X>>^/1[ NZOKG],4/7][=?T>W=U?WH83+]"XW&#Y/ODX?)UMZ!&2NI>*2=X1^_N8'SITGRD8SM=$"OZH">S?IP"NO/AX1+ M:1P<1=T@KZN7F"/S(8I6C^@CYL]/1@V4<$RZ@@BF7+ M8AUBBE%Y:M+J'S.D1S*VTVM!U6N!-:2S%1$T7S%C1)_7>J60)L&%%7\K9H.^ M'[I>([3M8F'H.(XYLF'E8VCU<91RH=B_X&%,YPK%3$9\DRE$LO(+DW)#LHBB MB$ME=#]L^=4;]$*_X;W5#7,@D"4&_4I?WZKODH*]B!&= $W.]UO.>_U^PW5K M"^]W?5"Y/K OB2N2+:F$R0-930BJHR(EA2FH@Y,P,F?)_EDT..8L.I*QG6YP MG3K?.M883K)'$,_%BS%M.NUIT1\TET5["^^/H;L%"ZY]@D7YA)+HGD:4/9)Y M0HTRW):,$QIU?.[(RUXMGD&+&_K]L*FE71"*[5FBW1H-7#L;7-(%A05 8V:JT\C> MU:RTL]/^P/&PT_33VMX!TZ$&"=>:<8>W:D4%NJD7+Z,,O]W?86\0-%7\BN3N MUMG=M:=W&#EB T&99(J"?654TD[:V'-ZK7EM;>E0)34#N'8(F-K)[;8BMU%% M;D:Q;1(X";P>P$Q3KJ%@Z#E[(-6M<[W;?]G^@2N2U-MF MM! \19H!Y!O&(&[C@$F=W84#U-4\@-UWC='KR70T';]AC.(CY?ZR WX%2>": M)+"=)"#9ZMVD/A]YXRX#&WC"#X)>,[79&SX@LC5)8#M)W D>41K+8L"..8Q8 MV%H!4J"$D^Q3OC\&O5RP)]T(5;K,*H%);6[N8%_CF3(%K#,%V# &02GF&BAWZ MI!Q\1B_;*.)M$UWIY $D8@U #2'8#B%7Y;D"3)Q,"3;?Z H#NE\S6 9-4IJ M,PFP5;])5X9BP:"']_1\S1KX -98P(3(HMVS(:/K;7 (\"!LD:&AW'Z^P#5? M8/MA@O:]V)7K3;G.4$8GVV<*)Z'OXJ:/1SY6P#4@8#L@Y*F5*#2GL!!ENM=A M60+&8SPVZFD#PR#HM>0\FA<\.R^\RJ%9;!?BM=D NUYS+MM;.T!(C0:> M'0VFM].3 @\J)GBX'TUG&@QNIV8J\(Y*!<>RMML!-15X=BJX?#U]A*59IP_Y MFC_0@@OT1(0@F9D.O#8=P'QWFH/4WOZA^K;N..R$\*-44*3^.#_'H\^*ZBN= M7&)4I"6I>/3S#4Q4-K=]VA_VG;"E^JCW&MVMF[.4BF5^H:CS#P2NN'ZJOE:7 MEJ/\JJ[Q_<(]'1=7C[69XB;T*Q&P,DF4T 68=#Z'$%=17"X6+XJO\_NY.5>* MI_GCBI*8"ET _K_@,'K*%]U =<4[_ ]02P,$% @ 4S)Q5DIL@LZH$@ MZS4 !@ !X;"]W;W)K;&C_OKW.0<7@A*M9+=? M$I,$#@[.]3D'T/-[4WVNETHUXLNJ*.L7!\NF6?]X?%QG2[62]9%9JQ)?YJ9: MR0:/U>*X7E=*YCQI51Q/1J,GQRNIRX.7S_G=3?7RN6F;0I?JIA)UNUK):G.E M"G/_XF!\X%_*_.W6MBH((@8T_'>,Z&6FJ/E? M<6_'GDT.1-;6C5FYR>!@I4O[O_SBY!!-N!@],&'B)DR8;[L0<_E*-O+E\\K< MBXI&@QK]P5OEV6!.EZ24:5/AJ\:\YN6':B%+_9>T(BIS\4K56:77_&SFXJJM M,:.NGQ\W6(WF'&>.\I6E/'F \A/QSI3-LA:ORUSE_?G'X#*P.O&L7DWV$KQL M%T?B9)R*R6@RV4/O)&S]A.F=_,VMBW]=SNJF@OW\>T@*=I'3X47(IWZLUS)3 M+P[@-+6J[M3!RQ^^&S\9/=NSA=.PA=-]U/^6]O93?F\:)<;B4'QEB21(Z4HU MC:H$?$7\85KQ"8Y&[U/QMLR.Q*,?OKN83$;/[E7*?XV?)>Y-6_LWPKTQ;>7> MI*)9*O_ZVJS6LMSXP5@G^GBK%IJ45#;N^V-Q+VL,T@M=RJ+8"%UFIEJ;2C8J MAY,U2YJ>E'*EQ!M9-^(C-/Q93$W1TM8\W[KD5:8-II%$WZL[F4N!O;]2F5K- ML&-KD:,C\:$4E^M*%V+RA%^-+?N.;Z%*R =KZ[(QB2P]YY>+2BF$N8:E>U-( MUMP[52U4)X;[):9B/QJC:'PN&I/RA+J=U>K/%O.QQ[6L&IWI->]1EQCA&5Z: M(M?E0F2.F4J92+')NJWJ%L(#6?'^=BJ>3BZ/QA>C-#P@R$.SR?C8*" M;WN$O3*.Q$=((H-<&]T0L\(K@V3MI)STYXI[[%E,90L9ORXAC\V6+4U?O_\C ML@;W]@8RAFKJVGCQ/4[W:3A0:[.M60GM,9II=2*F[6QK:O>AV^^'MA*4,_$^ MUQ5RD*E2\8N:SRNU@>V\;\N_-%1(1DI&4IM"A8''9C[7&6;"$)3,ELD#@O/6 MV9?;T5Y[KNL6MC%.1Z,1&<,*RJ^7$J&)%M--[5X*9!Y,ASE$\F2E=YOM$]M/ M91]+JY7*-4RVV"1P'_)K,[BMRQK6GBW3>(;HS5@Q;WO5/5,9N;R$2QD*"^:^ MQ!:LY-F9-"A7FP3[&#"]+0$,$Z-!.P1),'O8NHDCP%1EE6H<-QS3K&-:N?GMP$@5@R5:_IW):^G'X/]OPX3/@*P=3YPV?#B_<]ISZ+(_GEU%Y-)=A0@8RD_BN*\ M??W8QKZ(4.)X9U]JJSM]9Z-=\)4C\1J>9*V4=A\ST3-69]1$'R"V;O 'D7K0 MYOJ[2VA#<-<[534NUD.*2MS)0N>4A9AZ*N9MP?%:VY5*4Q[*N@8[/US"7ZC.P>P'$(UH /YND 7WNM&D1ZG3V&>_JS6H&J#L0QUL0+WA."41O MAR?]X6\^WO[JA\\="O YEJ1? ?(#ISOA#S'FS-JYE'6!F,("V@3881:N_SE] M>R/>MY3JD]G&/?]4F)DLX$^P-$B-^=@)>]#?R7A\VDK8N"&9L1 M![P):$&7=Z; +CK8@Q07X9OX)8U'V5;XCTGO(TFZEH7:3?SQ6XHESBI7"LS! M@2GBN5)P\NCDL6>_OV/A=FS5U=^:=VTK 1>P$"*8S!WA90XE94U9VE&/,"L[ M*QL&83%5U4=P*"'S7+/&G9^8.UTS)"*LV0$QY).5 MU!"*J*@R99 %[DHG@Y :MK/LPW;J!"H!.$ORHGG"2)*H$P?T\ W;)O6RM)@# M0(8U)T*&,9?XB%#;JG2(7&;:(O]O MC7.?;3Y@?LG?-C^_]H?M!#QOG*<2D"]4Y(C)SP[B>^5MA13 :9%)*(ZP BHB MSX&-5?BX5 6'BJ&@#VFW1<-Y<&@ Y0^R2,2)0UD@WR6NSM@%-MN%B(,>LE<% MV;#'3N A7<0Q)4I\I(&%EC-=L/P "]D&B5GJ1K%]#:&E3H;;IK\+SVG4*X?* MQ2 D3(-KYKK. -HJ=@3'HY^2]/%:958V3@,Q0.XP !GWYHB_A5D' MUU@QCG$1Y5[CS=K^QIMJSRM@RFG MM"T+AMB=N'-56GN8@=_/(ELJJ&MG$P^K,I$^@',)8&VCY8:&MA4PYYKY=BH+ M=CBH4"#^0KN6SJ#,J8Y"AC8HQI$U84C-AJKZ8\[4GF!GCDC)S ^-=_PP [%R MK+-B.:2!$,4J4; MU_?9DD=3P>Z11:Q-,!\=)*PM5+39+O4YG&)5%>();;?7@, 2!A55@-*'&-]8TXI?/F#DW.0!43Y<>E64%$_H4MT65;B'?&Y!MKAV1JG@Y6 M2"*%I[04K7H^&FUUE%!G,4*BJATI@*+=E$5(2TS.>/C6E%M(#<&07.;:%F53 M6P8#4I$0@+.\$![J7"*K:G6QY#>'GC;!YGTS 00Z!G_"6J7X ML(1*?\>2+22<)I:D>_UU@C]]^/GWCN);3/P%P;NVF6#:J#5%@-]4 _LHE6Q3 M$7>D[^%Q2VZ&L>9.1E9S';>%J65!Q\?3HR>0?5/98Z,OVO\7(,W%R]LUV;Z,F17GW&E**A.HH)?\C MI2%]?)L4AL@EI'L;6B5%,#);. 6^^>*-H$=&@86S<(%0P8TQJJ61M:NHW0!+ M%$M@&J:\U%6S.9PS0D,A7G/?%60DC[T].SHC1QSWG\VZ5W" V1)U*?SJQ MW=R($RGK30&',]QP*;L[O;$EDNVV2.%BOJVY![2=VO*$1/--[C!3F?7=(=/% MCA<(=W%@[9?<2\GMT$&CM#D'!?2V==ZI7F_-GF^UBQ8+=;$SQFJV#8V]7!S^ MFH3^PO3U-=D4(0ZX*5?9V&J9L]!<4;B]H;B5_;:,X4; @_U%3<=:R&TLX+W- M;UK>*PH0AL\"\6K_2>:GKK;?,F=LNR\0O^<\(;;3&"6FA'PI(:Z5[2]+\>;M M^]O+'8@8X0SNBA*/'E!T;=>O<5F6IBTS@HJ6O*X@ MN'5CCSHG3N\BEQH65.BZ23N5V-(DJIMR=VA*23]BW!ZL#7&1VO;A3$5K^FC/ M]K?[FOL:;M:"]%))EF=7^+@5KM[\\FCK)B6W=0F]F4QW!\,6I'2=7.Z/ M._]]<)-#K*&4&%VC,^CL%L- M QP^]K>F,!\V8#IF:/+7K:R>NW9B3X*A.BUK-ONUA MXQY%NAVJ#L^=_8/ Z\K8(PURC*R R.FA[MI?3K[V\ 'F2-A]2US$NG]UUI-@ MLBM!\CX("/43&;.D*@I;K!MWQ"3N9,5'$G\2RG =)/B&(7P.7K#F^.0\/7WZ M]+^1>?*PS,<7ONZ>C% E0_ M'M"8+7-R#1VW5)9$)?3?T=U^5CCL9;("(.$C-F'O-715*N56O^]9.%V:48;3 MC)7K)IPS!T'"N=ZH6=52?#\YXCM"_6#L>FPP:+"#%;I#(6Y)M^M#"F>[ISBA M64<3;G0)Z$^WK6K1'2[]W]4/WXW/3Y]Y W1T>\C##8L!A^,,A3:*M1"XM@[0 MG>V5W5J[P8BNZ-&03@"I$X"-@ER?4_RUH3 R=Z'.!H"AWVC2NR7178U(Z3CUWCF- MC=WDK-R>S'=N8%&D/Z)[ >':T\#\0@+$+)5M3>0=NY+_:3:9LSVH;; MT-4W0<@02)*;_'0B!5&ABI5%<0@)M96$TV15JPHJ.)!P4K% ^:]*?K"FNU0K MG_>!>%TO-$=&2!.[-%H:S+A,I=_W07K\(H G40UI>U5J/HS MN*9NC?<;.%[F[MZ):T02N4!4>DL%F='U[ED8Z8);LJ%'Z+T]YKF?QL+U/\3( MC3M"9+&#,5]/TS6JS!:T2&DNJ>SO?O3A[EJZ8U3Q_>@(1?0898KKYKH(Z6@S MO?%XH"O@[Y9Q#AWH?_4 5->T<8&(#W)==K.,$/KHE:_?G[ENA)USEIY/!CH3 MG&![6,W=[R$H.63X9^GDX@$ZX@$ZW^0K"=W@),C5L\W@K%O]B$MW+8#.O?J] M,"X@$8"#)JT1#9L(APO76"S%ZQ4R]H9[B5UL8.%U!CXW%C+LR"9684=([#0B M;0M#1NU'L;78EKB2OG'LSNHHN\L"KD=$>-$7V%LG* 2&*/)?._QRJPB.,$1" M4J%"W?4-PCU@ZE*X*S83&W=MKB;I"K=&CU';<@Q7K?S<)QYY45)E3^'Z,.:- M>UNQX]+??4.@[9!];35\^@;HC"&X?YDG/:IQ$VXKI&SU7:S.^AQW)C%\R;%_ MLS'N$R7NVI\3T8/YBS\,F=*>M&1I?:-E#1WG\-;-N@%J_"O:9( HB#!TBLS@ MHRVD7=6B4>ZD2RK4D*!D;>L?VTT J^U<^D.X2A4VO2-7\7HU< %?[B'2?!%% M@J1N-MN.'HDJ(;3L@39?.]WFU1,4?#.%L)B]S$)Y5(6+18!\;IP%C7[2#'Y> MT(GGF[:B^$0E7C^,.(%19B44R;>NZH ?[5'A86,. VCOCJ;5'/*CS$56$GXM M,#-?+!%K;QS5:#39E:(/;HF>_(8A,U_PL+>D*2>[M$N'S..3TZ?B-9W37%5& M4JD,$P'LN#9%NT*>%A]^%JW!=YZ=[L+;VO7AT> MNG2I"NF&IE(EWLR-+:3'5[LX=)55,N--17XX&8U.#PNIR[WSU_SLQIZ_-K7/ M=:ENK'!U44B[N5"Y6;_9&^\U#S[JQ=+3@\/SUY5]/QJXMC6L\+?M5J[7J?!9UD9LQG^G*=O=D;D4$J5ZDG"1+_K=2E MRG,2!#.^1)E[K4K:V/_<2'_'9\=99M*I2Y/_IC._?+/W)X3DI>:W/&_8AW6GDSV1%H[;XJX&184N@S_R_OHA]Z&EZ-'-DSBA@G;'12Q ME6^EE^>OK5D+2ZLAC3[P47DWC-,E!>766[S5V.?/;T,PA)F+6[TH]5RGLO1B MFJ:F+KTN%^+&Y#K5RKT^]-!'NP[3*/LBR)X\(OM4?#"E7SIQ568JV]Y_"#M; M8R>-L1>3)P5.Z\50'(T'8C*:3)Z0=]0>_HCE'3TB[^]V(4O]APSY46;BK7*I MU15_ATCLR>.<-P>X?@IZ?]G_)Z6_8OQ2DS$@7A62=(H$3=6EZFN MQQ57]^E2E@L%HXM".T*=Y 6M^],/+R>3T=GMU25_&I_M#V!YFL-DG(%6Z!+9 M4:=!.E037HCQZ. ?+'AJO4YSA0>D^6-KB+@]^.=07"KK@9V0$1"V2<6Y,;ZD M &3:I;EQ-7(G*6E)GF^B?IP8.\F"R^!4,G#\TQD=J*SAK>>="&V-M7_K>;2- M@S!6F$)["!AR !^)T$SF$*Y$Z"22G?Q.S6Q->3-Y&4H6"ER0GR'N*[+)FH(/ MT$N 9RR6,8#2"UHU2&8U/AE$$>YJ'"/@I;[G$/\OM:84@9=;9=%+N]0,R2UB M7EL89_O!&0@D-]H =22\0;1#>LDLP5*GVJ3N7'C9/].[5MEM=R;-'O^]+D.K M6FN_W!W6;_52\ER"3,/1/ZK*6+^=!>0AVC*'^[!DHZ05BA!\1T#G.L?SUE[4 M2)LESX0Q&ICX" HU9^.\;RQ[5N/Q>FDHZLC%,4H;+5%[0CN!\J63L92[>E"Y1O.5 M7 47TFDV]8;@O/0-N.&AZX"RKTYV:%Q%H$RPN@K[<2;*(B".(\N AJ@.>*IL M\>5A\'8G[!VGWPY=% W*7U;3>]U"]2!9J%)91A8L4)7O$N=3R1G'R3:^L04]7$- #$@Y1XQ!U)S%SM-\'D'7FZ,Z,;O'?(F1+#!0FD.!3RL^I, M8?M0>'51Q=Y-747.YQ@9 G]@3Z/7R:(%**Q7/FS-M9SIO*,07<.AA;"=K"+- MC^T)6B@CGJH+WH>726..Z)ECU4J5=31 W5?482L-!;8E#2.?-1@ZL3@4&B4G#H=2C09 M#DA./34@A CS$T%4G9,#Y]14(RLP3O73YE*Z)9^2/UPAOBN9L[J[7L]@'"( MY8,L,90A67*-U516*Q6/E7 Z23J17FC*>F@A.K@)D2!@B(" XLAI"%@OB6K6 M%N#C @K,4-1DB^ILZ9GY\!6%^P&L<,OYNJLRWOTX&8R/1BSIQS\/3H\GY*M* M\12;;X;H/IC,K=^P#/)&Q4F^]5BUCP%<(4 9F9$:ATCSJ5 ^=4&,%&\RA;)$ M+*D8AAB&NF^"VY59:0(6FHI";M%01&/O 8T.HE"(&1CC2@4L:F*7)<" >9TC M#"O5-GFK@M)8&R]0O.B=&M$*WH=_YUC/B.;VAZ JG.CX/S5 G7:B: )/W+(= M!(@U_&]3A2X946S&=):SY.?I]":@U@Z1WP[KHD]UDN^E.L.MP\K,,/A-;R_% MZ>@4,UKC'JH=.B:/JRX5Z$>>IV*T:2=AYM(]<0J\&9PH,KT>K"*53A47'^U2B)B7T MV[F&4D#)=/F(XJ_UDA-?G.PCM3A%_E -.G+M)D_* FO )S?7!$ZM,U'[2/NL M)E=JUPG. AH0*+?OJ<0R13G>(PF-.QL,[QX0G<@5=:% D5@*C9)5N+"*2 *5 M2E<^D!:BAHV"OMZ$#+,95Q/=22E+*YK6 + -S.TAI]D%/H.MM%S*C(C7#I'7 M)0Z@Q)V\5]L W))Y,EB'59Y7,;%-*&5_.AX-FKEZ6Q*1ZU1<25L"8X *[XUS M^^(&_KI=DH.WH;ZH:G+@C#>%#IS75!Y"P 4<=H2@)VU#=9=(=NF(K) M*>QJE5<[M68ZX_[&32T\@$Y"JG -$-K+]U/,0*CQ"=^WD?YN63MZZ_5!T,7Y MZKCI,S'V@7"G=V9US]0RRZW1_@(6J"]\8*B@[;> M.>.T)ZWE"YT>+TEK),PV]6D>;5&@"GE\SVV"_ 7+YV3^BLV?J50&^IBT'8-] M AN) 0="PPU%%[3"0D^+E!.G0 M<^<'#/X@=YV M[T;A@/Q'L61BS$^?2H#@X+0+[7Q7*T M-A=Z Q)$6;62#DM M=P;T8XT0-KRPZ-0%CL@5Q8B,P7R >H)>#\&]-DIDI7/OL+6*KO&N2Y0+EO"5 M!O26V\9U=P94%;"T.4]KHIG1]25E63MOL-J^ULU *,T:,O#OE*9!QH'F6__N M;-LW)-)AS,ZE37:>IO.>B-X[VR&B=9#HY.WV#LG[*@Q<3:SD# YYTF'?Z1CQ M0@T7PT&X?$#@A"5>NQ_:5E352FPNR.)(0R-/PK384.>PULR,#1=OF[[VB8A_5LJ]@C:8SU? #!K(# MHDI)20.(VHE6Q$@"6[Z1EE.WWY'FH(QF[0)DG0"R^HLW20^D!J&?'5S(<"]9 MT+@8_,AM>?RR:\M;;[E)C,_$K3?IYV3KU:.]W]':@Q#?M+9PUANY":&!UE^@ M]:K1.HR7^LG5/5TH4-Y0'F@B@FTQ7Z-A5]2UD5AO&Q/F/+_6H-^3T;CTV#6N^GMA8C.G]Y^ M@A^&@MX>C(\:UUV"Y&DOB'5Q2^MU//X]9^LU74#M8A>-2Q\JZ5\7X03-)=[2 MK 5!-N?U6F-JC]@BTJ N#^HH& 4&UU[-!5COMY0V \E_]/N)"PR:<0DK9QNZ M1F"[&!,T=M&< MLZ8LC@>1XF0&?!FQT1DUW*V[&$R_R!T42*3:,5W5X1A/"ZTL]E<6SCN M"Y()4$.11#8=#9/?%,.](ER2OOTY"]G+%V"1A_"PV1(IC$%UQ72$%3,-IG>U MW3G]GE%\T6@LHN1IAJ(&VQZ4+U&2YEZ7TSNGFW!*DD;E#4B>3?Y%%YM;-^[- M+V<5O0\7GY%_)MV%DVT%QG)N[ZG330L.&O$L(7;RK^2P"T=\R@_'&I)-*4%N ]_>;8?"$% M[9^&G/\74$L#!!0 ( %,R<59$G[4P_@, /<( 9 >&PO=V]R:W-H M965T2#?+WL94,?*?[6WWOL\LF*TAW9H)T5 MGNI5=CV_NCEG^23PNZ9-.%@+9E(Z]\";]VJ5S1@0&:HB6Y#X>Z1;,H8- <:G MG9J(807;=3!H).V_%?/NWB<*!P.7M!H=@I% GWZ"BA_%Y&N5YZMQ&> MI6&-%XEJT@8X;3DI'Z/'K89>7/_DM&W$K;,5>;O,(TSR15[MU&]&]>(%]0MQ MYVQL@_C!*E)?ZN> ,N$I]GANBJ,&KX?F3"SFIZ*8%<41>XN)WR+96_P??N+/ MZS)$CTKXZSFJHZ7SYRUQ=UR%7E:TRE#^@?PC9>O7K^87LW='<)Y/.,^/6?_O M/!Q7_\5%$@OQG?B2[Z\M8=WUTFY?O[HLYF_?!5%K*VVEI1$ARDAHL!B$]'0" M5CW^E=#<+)7S"G*$>HRM:,B2E\9L^8;Z""D6&6QD=[W7L-@;@J&^-[J2I2$1 MG9"B27BJ'9[8RL@;N.T-G ><$'I;&OV/Y"X]<;60(1!#LDH8_6G0*MT(W!@M M2VUTU%#4-NE:;DT#FX,/Q#+E$!";$,X.R:-/.VQ3JD=B:0!1FFV'DP3, M2XW3,*!&)(C!K')#&84L\9HE;U_'G M'!%@U\8%7/*#F7#*7D>F2Y#49*OMZ0F'WP&1GYP^T/; 1MR7T6Y!7?KHB @ M+XW&JZ0$63IO/./C=<*84N].QLI/ M$=B7$<>\,L"5,K:O>A;RBCLN-<:I0#6QLNRX_\(+6H>],O+C^<1$+#$/3&# M3"@X'W$4.BARA- RER.%??;ZD;S12;ZB&ZNSL+8:H'\?LN(FN3Z.M=!&#,BU;?)F09P'&PO=V]R:W-H965T MB M#[1$6^Q*HDI2<=RO[QF2ENVL$VR!/FPL49SAF=N9X5ZLE?YLRZ+REQV M]:IG:BUXYH3*HI?T^^->R675N;IP:_?Z MZD(UMI"5N-?,-&7)]>9:%&I]V8D[VX5?Y"JWM-"[NJCY2CP(^VM]K_'6:[5D MLA25D:IB6BPO._/X_'I(^]V&WZ18F[UG1I8LE/I,+S]EEYT^ 1*%2"UIX/AY M$C>B*$@18/P==';:(TEP_WFK_7MG.VQ9<"-N5/&[S&Q^V9EV6":6O"GL+VK] MHPCVC$A?J@KC_K*UWSL8=%C:&*O*( P$I:S\+W\.?M@3F/9?$4B"0.)P^X,< MRH_<\JL+K=9,TVYHHP=GJI,&.%E14!ZLQE<).7MUW1BL&,-N5+F0%2=7F8N> MA6K:T$N#FFNO)GE%S9C=J*Z3MY4.&]69VP0=UG2 M3Y(W] U:.P=.W^"_V,G^F"^,U:3LH(-V0=VW/Z?*S:OM2Q8,O.>[K*U8**R M0HN,R2)/&./]($DC72UN>8&[ZEJ<'+&0#4XVRWHC%>I0$W8G/TP MG]]'O,K<[I)G@LX7SS4MJ49C27\&BYF< P_DZ?1::*,J7K"4%E-NQ4IIX(-( MUC@%9E,)O9+"0:RURIK4,G*C<;LHKC+%RT+8M1!.:P0?XE3(?&E)6B@#$^[X MAB5C[U._J74?_ V+\ B5T(?<*20*FR,,FPB.4X0R<[[UK@LNSAR>0O*%+' 6 MX3.@4JP3*\$%WF)AK"R=AB67FCWQ G;"--.D>:OQI2+K1#.(86NT9P\=@G@ MU=J<1_-#0.?1#3!#]5#TA)Q"9;VV(!]U9?QK= M?FD&M!6"ZP4"SCZ*A;3LANN,)=W!>!11'AMVSS=\40BD,Y[NH?V&UY).2;K# MT?#%IH=,!FP2/? "6Q[Y<[LM'DP#U'U,\^#:47@7T=I3 MWX9?5?N1\=$Z8:/IH#N:CH_E&/291%1GOV%D8"XEQAP P9QKM;HN9YEPOG. MGJW#=L3M&18V.RS&.!(G/>A?F&)1;$_FS77@Q:NK0F4@'&5.E%,]:^=0)1CH^HM U%6_@*YP) MYF9N1 5R/ZI2IKG&3,[BVZESZY1485"IB#?Q9%0A,Q?BXV"H(>U'&1DNER_3 M^J#%P7;D49HV&HZ*\/&.(PC,SS/Q6?1]T/B8HY>RTL].@F:GZ'UKU"G;>XXP M$2'V;B;:/09JT@+DVR $)SAB$H_I=P06CJ-/2/KWZ$GF%(Y!*1-EO)^,)]WQ M9,).Z05:!N,A.XUNL8L:9NB@)Z L_&NA/LCG_Q4H>"E)\#L QPXGQX'&W?%H MUAW-AAYJC-8R'<:O8G79<2PGCL4X(L&V=1)_Y" $A3H#SEWJ8:JQPE<$\B1& K#B<&!DH M/Q5?N,2U0'PIFFS7:5ZI[)!4;3C;HM:B5MJ1HG?3V:N)O:V$\!O1<.>LC5J@ MYZ\7Y+0[GO5=FN_R>QK/?&;/NC&:].FQBT-O[W)7HB.Y*RR:$GG/W_/:U?:6 M//>7P]UV?\5&B) DAA5B"='^V6348=I?6_V+5;6[*BZ4Q<73/>:XZ0M-&_!] MJ=!BPPL=T/[?P=6_4$L#!!0 ( %,R<5;/=.EE+ ( .4$ 9 >&PO M=V]R:W-H965T=(%HX,!+ MH1-2&%/-@T!G!7*J![)"87=V4G%J;*CV@:X4TMR#>!E$83@-.&6"I+'/K54: MR]J43.!:@:XYI^IEB:5L$C(DQ\0#VQ?&)8(TKN@>-VA^5&MEHZ!GR1E'H9D4 MH'"7D,5POAR[>E_PDV&C3];@G&RE?'+!79Z0T G"$C/C&*C]/.,*R](161E_ M.T[2'^F I^LC^U?OW7K94HTK6?YBN2D2,B.0XX[6I7F0S3?L_$P<7R9+[7^A M:6M'(P)9K8WD'=@JX$RT7WKH_H<3P"Q\!Q!U@,CK;@_R*F^IH6FL9 /*55LV MM_!6/=J*8\)=RL8HN\LLSJ1W(I,4,>!L8PN'V0=>MFBHW?04[B7PA0: MOH@<\__Q@572RXF.#Y@&?TK;A7VVG^%%V[K_RML'X)ZJ/1,:2MQ9 M:#BXGA!0[5"U@9&5;^2M-'8L_+*P[Q J5V#W=]+Z[P)W0/^RI:]02P,$% M @ 4S)Q5F&UL[5MK;QLW%OT^OX)PLPL'&,N2_,X+L)T439 T1KQIMUCL!VJ&DK@9#562 M(T7]]7ON)>W2N:\:5;L#_O]X_V9U.7.BV?\V95] M\OI@_\6SN9RH:^4_SJ\LWNTW M4G(]4Z73IA16C9_OG ^>7!S2>E[PDU9+UWDMR)*1,9_HS>O\^4Z?%%*%RCQ) MD/AKH2Y549 @J/%KE+G3'$D;NZ]KZ=^S[;!E))VZ-,7/.O?3YSNG.R)78UD5 M_H-9_J"B/4S.)F:##39?A;?HY^Z&PX[=^R81@W M#%GO*9-4MA:36DT0LVE7=#.5U24*Z]Q5.-??[%I9G-M(>7O1.R MS,6E*;TN)ZK,M'+/]CV.H(7[611W$<0-;Q%W+-Y!P-2)5V6N\O7]^U"MT6]8 MZW37IB8-!*H;]X? .>0>-O05XI1=J)T7?_UN<-Q_>H<)AXT)AW=)OW_([A;W MH_%*'(L]<;=K_C95M&(NRY48FP+%[,3Y]:4X/.KO#?NI>&O<^HY4O"_%M9I[ M-1LI*P8G'$-$TE167!AI=S:Q8J%]X(Z(/M MNL1+TBHS)0,(E)8HZHE5BE1&V?BIN/YP_O=4O"ZS7BJD>*D*N92VU7OWK]^= M#H?]I[2,7PZ>/NZ)J\JZ2D*$-XF'E5ME^H[Y2UT48J3$Q&(7E)19IIPC7:68 M%](35 (9%D"\.1Z/5E'&I](LH;)C8;4JZM<*+A!7<5]4*UE.=3:%$3-33IP7 M!ELL]L&[<"PK("D&:WJ1 E$5*W,L%3D@H2?.L\Q8?H\5K3F-JIKB#0\O%."& M70V0U!1&E027SV95J3-)..J /B7@FAW4B/!3Z8-&3E1(>/9&-+$J"Y-]$I"- M/T?5"D_IR>#D*9PXE0N-Z'-HO55E[I!=T,&YBJ0@0^;5J-!9L4K(*,7:P%HD M6'15#_$6ZG,VE<@\WNR7JE@H,0M(!!%M@,CN39?#GW"&U#G[1CQ"-O?[?;@M MSS59+ LQ5HKL7D'A1)=992V%'5JC+SG@/QV"X+@V=U)8ZDEP)LO2>%*ALDA: M)'>ND-" _"3TTUF=+.D2HTDDA0:%V538,62U,5>8+L*PUD MR )Z%LX(\^6U1BISI<6J^[VB"[FXM4J6>*+@%W8D9RE)U#FVY0MEO7:4A201 M#."3(K!("!XUXE.'I\YF:MGPGE-[H]4>_4W=5R/[91T*./_7"CD;:JRSMT?0 M(BO2I(:+']5"YCC2V+FQG.MBMU.I M47:-&VGP$:=@P7V,SUGJ*PK%C( MHE+B4;^'O8--I]+::UK;>#:)F5!KG\+%^"^S[$1D )+4!@A35IL/BX1@ Y]G$]N9]??% 33>V=S43D?$CE7>06*!UJDTH,:/:8P#&G MZ.&4\5@QAZRS[6/ONH>J0V$#)U3 L%DDGD[4^AJF74,"P'U)1 M'*1.=1+LD))&_L4E''.9)H+A/.05FPS*VF,R7D<:$]5G9!!_%!T:3 ."O0/*#8\C2'2A46;< MP7*L*"6=T2O@03EU.X>/5'J@&%KAJY'2N<=T2N]?0@ #AP[J@R?7UF MXXA. ^N>N(YUZ+>S>6%6;%JS@[F"#+VB\ ST38^0=>C=$_&JW=L@8Y>$\<'; M%E%_ 2M*-/<*X'];D9+#=7@4L\R:6K;7[!(G$.=@-X MO90KA=AQ5H8-4ZW&XB=-!4W>?#\>HPAL LD,20 M8J*T[^D M.V2A?ZMS?Q,U&8V 2MD>2%7)6D,6\1:BTDC8"4N)UUQZ;4%O&3JF>N[8^6Y5 M*JPC*,JL<4%S[$2S_XV7I@PZ2%$)3N6(38+$*LGPB%S&G044+%OQ*C 64P&2 M8GL))6,(A)29%T1LK%VQ7N$YG);>, 2 MRI*0SX%!=,*$C_6%@B'; G,DS]!F\#Q4_XT M9@SOXB6HI'\AV2)/ B,ET:AK6"*+%.&#K<&]8+NRX/I&)5+L0]?=FO9@AY3( M@1!*!EDB\GK&349IIEI4J"MZ/]$+T>T"-Q[>Z MF7I">VYZP[5)?SXY.SI_"O2H+7JKDI>6&A M:GC#0S&N(!8>0M,&-5BA ]"3#J TR!A3X&DC&_TIB3U]BW#J7C>%N]^1SC%K M3YC".S?.P!%_[I">^ $M%>T3G7A\,XE'EGHX,PA< M;-*("I6VQ'RA7&5%UX(Y4D3*^3J$>-]0U90%D1_+EY2&4D%;OJ'4BD!0CZ8! M=2.X'>>W+6(#D[;U3$ Z7L46(,OE*[&,O.!C#07#(*P M!JS3T$. J@0)W&I#I[T!5TD+5[=J>PM) M,$30CWP:]4=I$N_<5O'< M XB65UF7?B&))E;.<'_/)\H#0J'8&SE#_FPM+/"T-Q5J8CBX2=2:YG[93:=P M,T2O:<=<4O!XO;B]=ELUTNTG,#]Y%;@D #KRDZ:[;1"YA(DL> D78-XGO$&R$1O!@V&OD1' MY:'-P2#A 8?8U3W% XFU%@/.WI4&= F36EQ60IO^4P3E8Q/'-GA)&U:EXD0X M]IS*5W3E"F@72@I1TL5:JL&43+JI&-.<\Z&=&9P,0OX MIAO(A3=+FFIU56QJH>.GM"F $=Z7&<->UX]52:TN;=T(VFOY"HE]8#O&YG'4 M5R8&I'DBNUC1I,%KWTA ?:B:>J[?9A1-_%3Y^TX2=(-$KPY$<-T?>;(!B3QU MB/*[3!.G!95J5%707D>EJ. 20MQVQADS2NQ>O/_QX_7C0*1/TX/A:9!* $Y7 M"VJYNLZ6"U-63EP1C7;UO5CZ/:M=/$)"0@(P& MF_'"I,+H;RI&]#@--^DX3&G+.1[$^9/15<-8* B99$ ;T6;>FM?]UQEX(=P/C=9%E"]8'3 MYLIN[;;ABUG&8;JCY^!3CJE]&QCT2AX[KM]1SOI[3%KPLFV8:7*W$R6=LF>9 M#PWBB",0=(('TI%O460&FG\1[_K$E1JYT<>.*WU4.2E':4 -X'9_%8@HNLY3CMU''+=5/2U^EZ5LWH\W'0.$1HW=ZG;>(' MY3MZI9M:P=]CT&^TEPHPD6QX;J1*-=;T-2L9W![:$]]7EOQ_0QXE[NV6>S6G/O56>=Q*2B6K;TM] M;^IS%P>^0&_AB=LM%#A9FV7>0H$[IG\E'IRL\V!Q#QY\-$Q/3D_6>3 ^.ACV MAD=?S(,31L%OSX,35/E_ 0].-N[WWY ')PT/%M^8!R?,@\4WYL%)G+%\=1Y, MA"_PX)-^>HSR^E_CP>N,]8$'/_#@!Q[\P(,?>/ ?Y,%O9&9&XE51 )3^V+?6 M]R*_<,,FL4S7>%1-5/\ 1>ZJ>BB=D GO,V_X MWY\=WH9%]^')P]/T^.CC7EQ/ST9#GH'!YL\.;G/O/AK\>3D?O/BK\F3 MD_O/B[\.3TZ^8%[\%7AR=M/FO8[OTB;*3OAW]U1+T!;#C].:SYM?MIW'G[1UBX/OPL$$00G M=&!I8VSM]TZ.=H0-O[4+;[R9\^_;1L:CR/CE5$E $RW \[$QOGY#!S0_>'SQ M;U!+ P04 " !3,G%6U%(NW' ' !,$P &0 'AL+W=O=7H#2;*:=*T85V8B>^5#G.N)+49L<5S^X\ M;.T#1+8D3$B X"6]?=[&B I,I:UD]H7B20:C;ZG1U$9[= MV:L+4_M":;JSPM5E*>WV/15FAZ_N[]"M6!/%L9\XYM/^>5HQ@9109EG#1)_ M#W1#1<&*8,:?CAL)'):RKKP7\WF M(S7^O&9]F2E<^!6;*'MR.A)9[;PIF\VPH%0Z_LO')@Z]#6>S9S:DS88TV!T/ M"E9^D%Y>75BS$9:EH8TO@JMA-XQ3FI-R[RU6%?;YJQNC'\AZM2A(_,-X$G=R M*W%S,?70SC+3K-'T/FI*G]'T1GPQVJ^=^$7GE _W3V%59UK:FO8^/:CPNEY- MQ/%\+-)9FA[0=]RY>AST'?^@J^*#=]2>'M/]0H@YK"KM/Q2OQ;$!^U>)S MK2$48S\6?DV0+BNIMX*T)TNY4-J;1 I'F=&YN*>LMLHKR!:;\67Z3SXJ,J"G%;ZWPL_CZYFXR%%!^HD!N)X!>J5!Z:*VF])NO6JA)' M/_]TEJ:S\VYSN)^?OYR(WV#44EGGD^;P[0\=+3;2=<[ X^O*JD+,T^CSA'6Y M6D*#-\'_?D3$@1/'R>ZTJEG-X69E3:F<,W8K-((]CI;QJF9S';,Q8DLW78P0!!;)$> M+,_3%Z(B*[:\(($7\"G7V_#0XX$[7UB$8PQBHV':@UG*B:R'8,:C<&L R;7^ M-I#EO?/3([^[58UD4QQD56U#GG M26:9K:%P47M1ZTJJO(MBQ O::J,G&('6+ M$J+,$2:('BBEI>M.83<4U6*"S M=)RP=8!AE_Z)^*2#N8[WBZ/3EP(\&(S*Y99]58 BAT!O^Q;LL(YHX7WX1D)/,!6X;,%FIG0QS M1 "=I[(J)'/58OM<93UED#U" VI-0EGE++X+Z\GX[9O(!8Q>%<%W$.9B /-^ M1=WL--P'#6U5,40D.Y8K]C'AM$7J"+C @FZFJ"X7^YQ)GNL34/Z55HI;:] 2 M9C_78^F^E0'O6%D@=57(1Y.%M3+U# ! 9E!ZJ]GE-$*_MR"9<4^ MQ%1#V"4]EFO4Q\KY_!',:A<*@9=E=8Y#T8X_Z6S2-=U.HHUZTIK;QI6+AMLU M]_V0YEN%Z<]VAM]2OS,*IU;,0E\DL"/FKP/IS[KCOMO[-.>M9XS/F..=#QM3 M%P%LUN1U%CGH$T?'QC@HF[]B2YE<'L"GQNZIT.F$Q" M+<@+:@7X$$BS *8C"SLJ%3^K,&-T+R[$7[/$(=;V\-M))F MAK%2.6XJS,Z=BM@A8(CRT+P[/C0EWF]VD\X \=]U!\#_R4S4V39/9R^29@,] MDLU4?VX*K+XC<\$]#8^J&N20H:CL-[P'MU/38%?$TOZ*-/H)0?RV.V0<^0AM MR7*D\1J,BZ/0PL()L0Q2$5"@<1UDAN6'2D<>*F/] F =+NBG;8#L&ZNST<[D&QF5BH+'F4W#3__5&2XZ9#EP/V MDE@R^?$C^4GT9&/HP9:(#IXJI>TT*9VK+]+4YB56P@Y,C9K?K Q5PO&2UJFM M"441G"J59L/A:5H)J9/9).PM:#8QC5-2XX+ -E4E:'N%RFRFR2C9;7R1Z]+Y MC70VJ<4:[]']52^(5VF'4L@*M95& ^%JFLQ'%U=C;Q\,_I:XL7O/X#-9&O/@ M%W?%-!EZ0J@P=QY!\-\C7J-2'HAI?&\QDRZD=]Q_WJ'?A-PYEZ6P>&W4-UFX M2-=:9JG9E!)77\%T]M'?8< MSH<_<W@DQ1+J:3;3E+'4;QMFK>(5Q$Q^PGB*7PVVI46_M %%B_] M4V;74LEW]?RSZ" MCU\']V?HPM8BQVG"A\0B/6(R>_=F=#J\/$!]W%$?'T+_I6X=1OS3.(1S.(+_ MK?O1V:6%&T28KPF1C[WK@Y5KC05\%DP*1B=! <,N MW ^^G=\N.M0-V8:3Z'&H32D9XSF'C6E4 5([,D638V!Y9VV#Y(FY4E)QY)EN MV>81^1B2'?CJ!,!H@C^RWV,N_8VE1+AXHG%O7I-4,,JBCF%7FH^-1CAK-^\Q M;TB&\G2=Z%#Y9G E%\,ZN)5*P4VCBSY\&BRX#VYC +\W0G%YM][8@EG!"C'\ MB[HF\R3Y#D.U[?V69?UCKN,&0S=DX1EVE1EP3T$4A?3<^WL5DZ%EA#GR-0K: MZ*-<*"66BHL9Q1)B119L>?YVMP^Y>43B*]Z_]SF+RC3<%A+28C& K^4>A"T9 M%3@#Z1CY.3S[$7I_X_L:2Y.;JN("VR#=%KN3FF-Y=99<>VYRQVV4#=^V#CU\ M0LIE9]/"\/G75L3)82ALUO_2*"NH$\9*?#B8%-V%G M_O4Y2+\7%(I<*%]IGI7\\-XV+-H0H1\<6N7O#N?"O]G)_=4Z+CGIF%]HE*PJ M+&20 8B50WI!25JO;H[5B\ZEX$8SF#PJI&K\]&RS936Y.%7[\3CGLF:MB[0>IMVU]JB6+[@2V*,@>HL GJ"?RW%#AEU'ZAX[2/)"1OP.]7AFO6+GR [K-K]A]02P,$% @ 4S)Q5@?^FWIZ M$ <#, !D !X;"]W;W)K&UL[5M;<]LXLG[G MKT!Y?;:2*EH6*924XNKC@[LZ=.G0>(@BQ,*%(A2#N:7W^^;@"\ MZ&([R3YM[<-D;!)H]+V_;M!/;_/BBUDJ58IOJS0SSXZ69;E^K&2)7XOK4[,NE)SSIE5Z&O?[9ZE:G.U&4A M3+5:R6+S0J7Y[;.CZ,@_^*2OER4].'W^="VOU94J_[&^+/#;:4UEKE%_RNU:UI_2Q(DEF>?Z%?WLR?'?6)(96JI"0*$O^[41^FN6';+,I%$7>?J'GI?+9T>3(S%7"UFEY:?\]C?E MY!D1O21/#?\K;NW:0?]())4I\Y7;# Y6.K/_E]^<'EH;)H%>/6UTN7F MZ6D)NO3V-'$T7E@:\0$:9^)]GI5+(UYEH,'"RG^]WQFR@(^\7_[Y+7DAOO)49P\,6N9J&='" 2C MBAMU]/SO?XO.^K_

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 45 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 46 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 142 252 1 false 38 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.betterforyouwellness.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Unaudited Condensed Consolidated Balance Sheet Sheet http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet Unaudited Condensed Consolidated Balance Sheet Statements 2 false false R3.htm 002 - Statement - Unaudited Condensed Consolidated Balance Sheet (Parentheticals) Sheet http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals Unaudited Condensed Consolidated Balance Sheet (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statement of Operations (Unaudited) Sheet http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statement of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statement of Operations (Unaudited) (Parentheticals) Sheet http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement_Parentheticals Condensed Consolidated Statement of Operations (Unaudited) (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Consolidated and Condensed Statement of Changes in Stockholder (Deficit) (Unaudited) Sheet http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3 Consolidated and Condensed Statement of Changes in Stockholder (Deficit) (Unaudited) Statements 6 false false R7.htm 006 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows Sheet http://www.betterforyouwellness.com/role/ConsolidatedCashFlow Unaudited Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 007 - Disclosure - Organization and Description of Business Sheet http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 8 false false R9.htm 008 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Going Concern Sheet http://www.betterforyouwellness.com/role/GoingConcern Going Concern Notes 10 false false R11.htm 010 - Disclosure - Business Combinations Sheet http://www.betterforyouwellness.com/role/BusinessCombinations Business Combinations Notes 11 false false R12.htm 011 - Disclosure - Income Taxes Sheet http://www.betterforyouwellness.com/role/IncomeTaxes Income Taxes Notes 12 false false R13.htm 012 - Disclosure - Commitments and Contingencies Sheet http://www.betterforyouwellness.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 13 false false R14.htm 013 - Disclosure - Convertible Note Payable Sheet http://www.betterforyouwellness.com/role/ConvertibleNotePayable Convertible Note Payable Notes 14 false false R15.htm 014 - Disclosure - Stock Purchase Warrant Liability Sheet http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiability Stock Purchase Warrant Liability Notes 15 false false R16.htm 015 - Disclosure - Shareholder Equity Sheet http://www.betterforyouwellness.com/role/ShareholderEquity Shareholder Equity Notes 16 false false R17.htm 016 - Disclosure - Impairment Expense Sheet http://www.betterforyouwellness.com/role/ImpairmentExpense Impairment Expense Notes 17 false false R18.htm 017 - Disclosure - Subsequent Events Sheet http://www.betterforyouwellness.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 018 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies 19 false false R20.htm 019 - Disclosure - Business Combinations (Tables) Sheet http://www.betterforyouwellness.com/role/BusinessCombinationsTables Business Combinations (Tables) Tables http://www.betterforyouwellness.com/role/BusinessCombinations 20 false false R21.htm 020 - Disclosure - Organization and Description of Business (Details) Sheet http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails Organization and Description of Business (Details) Details http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness 21 false false R22.htm 021 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details 22 false false R23.htm 022 - Disclosure - Business Combinations (Details) Sheet http://www.betterforyouwellness.com/role/BusinessCombinationsDetails Business Combinations (Details) Details http://www.betterforyouwellness.com/role/BusinessCombinationsTables 23 false false R24.htm 023 - Disclosure - Business Combinations (Details) - Schedule of fair value of such assets and liabilities Sheet http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable Business Combinations (Details) - Schedule of fair value of such assets and liabilities Details http://www.betterforyouwellness.com/role/BusinessCombinationsTables 24 false false R25.htm 024 - Disclosure - Business Combinations (Details) - Schedule of unaudited condensed consolidated results of operations Sheet http://www.betterforyouwellness.com/role/ScheduleofunauditedcondensedconsolidatedresultsofoperationsTable Business Combinations (Details) - Schedule of unaudited condensed consolidated results of operations Details http://www.betterforyouwellness.com/role/BusinessCombinationsTables 25 false false R26.htm 025 - Disclosure - Business Combinations (Details) - Schedule of unaudited segment reporting information by segment Sheet http://www.betterforyouwellness.com/role/ScheduleofunauditedsegmentreportinginformationbysegmentTable Business Combinations (Details) - Schedule of unaudited segment reporting information by segment Details http://www.betterforyouwellness.com/role/BusinessCombinationsTables 26 false false R27.htm 026 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.betterforyouwellness.com/role/CommitmentsandContingencies 27 false false R28.htm 027 - Disclosure - Convertible Note Payable (Details) Sheet http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails Convertible Note Payable (Details) Details http://www.betterforyouwellness.com/role/ConvertibleNotePayable 28 false false R29.htm 028 - Disclosure - Stock Purchase Warrant Liability (Details) Sheet http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiabilityDetails Stock Purchase Warrant Liability (Details) Details http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiability 29 false false R30.htm 029 - Disclosure - Shareholder Equity (Details) Sheet http://www.betterforyouwellness.com/role/ShareholderEquityDetails Shareholder Equity (Details) Details http://www.betterforyouwellness.com/role/ShareholderEquity 30 false false R31.htm 030 - Disclosure - Subsequent Events (Details) Sheet http://www.betterforyouwellness.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.betterforyouwellness.com/role/SubsequentEvents 31 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 7 fact(s) appearing in ix:hidden were eligible for transformation: bfyw:ProceedsFromRestrictedCommonStock, dei:SecurityExchangeName, us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther, us-gaap:EarningsPerShareDiluted - f10q0822a1_betterforyou.htm 4506, 4537, 4538, 4539, 4540, 4627, 4632 f10q0822a1_betterforyou.htm bfyw-20220831.xsd bfyw-20220831_cal.xml bfyw-20220831_def.xml bfyw-20220831_lab.xml bfyw-20220831_pre.xml f10q0822a1ex31-1_better.htm f10q0822a1ex31-2_better.htm f10q0822a1ex32-1_better.htm f10q0822a1ex32-2_better.htm http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 49 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q0822a1_betterforyou.htm": { "axisCustom": 0, "axisStandard": 11, "baseTaxonomies": { "http://fasb.org/srt/2022": 3, "http://fasb.org/us-gaap/2022": 431, "http://xbrl.sec.gov/dei/2022": 31 }, "contextCount": 142, "dts": { "calculationLink": { "local": [ "bfyw-20220831_cal.xml" ] }, "definitionLink": { "local": [ "bfyw-20220831_def.xml" ] }, "inline": { "local": [ "f10q0822a1_betterforyou.htm" ] }, "labelLink": { "local": [ "bfyw-20220831_lab.xml" ] }, "presentationLink": { "local": [ "bfyw-20220831_pre.xml" ] }, "schema": { "local": [ "bfyw-20220831.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd" ] } }, "elementCount": 364, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 96, "http://www.betterforyouwellness.com/20220831": 30, "http://xbrl.sec.gov/dei/2022": 5, "total": 131 }, "keyCustom": 45, "keyStandard": 207, "memberCustom": 22, "memberStandard": 12, "nsprefix": "bfyw", "nsuri": "http://www.betterforyouwellness.com/20220831", "report": { "R1": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Going Concern", "menuCat": "Notes", "order": "10", "role": "http://www.betterforyouwellness.com/role/GoingConcern", "shortName": "Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Business Combinations", "menuCat": "Notes", "order": "11", "role": "http://www.betterforyouwellness.com/role/BusinessCombinations", "shortName": "Business Combinations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "12", "role": "http://www.betterforyouwellness.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "13", "role": "http://www.betterforyouwellness.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Convertible Note Payable", "menuCat": "Notes", "order": "14", "role": "http://www.betterforyouwellness.com/role/ConvertibleNotePayable", "shortName": "Convertible Note Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "bfyw:StockPurchaseWarrantLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Stock Purchase Warrant Liability", "menuCat": "Notes", "order": "15", "role": "http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiability", "shortName": "Stock Purchase Warrant Liability", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "bfyw:StockPurchaseWarrantLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Shareholder Equity", "menuCat": "Notes", "order": "16", "role": "http://www.betterforyouwellness.com/role/ShareholderEquity", "shortName": "Shareholder Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "bfyw:ImpairmentExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Impairment Expense", "menuCat": "Notes", "order": "17", "role": "http://www.betterforyouwellness.com/role/ImpairmentExpense", "shortName": "Impairment Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "bfyw:ImpairmentExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "18", "role": "http://www.betterforyouwellness.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Accounting Policies, by Policy (Policies)", "menuCat": "Policies", "order": "19", "role": "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Unaudited Condensed Consolidated Balance Sheet", "menuCat": "Statements", "order": "2", "role": "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet", "shortName": "Unaudited Condensed Consolidated Balance Sheet", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Business Combinations (Tables)", "menuCat": "Tables", "order": "20", "role": "http://www.betterforyouwellness.com/role/BusinessCombinationsTables", "shortName": "Business Combinations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c2", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Organization and Description of Business (Details)", "menuCat": "Details", "order": "21", "role": "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "shortName": "Organization and Description of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c75", "decimals": "0", "lang": null, "name": "bfyw:FairMarketValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Summary of Significant Accounting Policies (Details)", "menuCat": "Details", "order": "22", "role": "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c114", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SupplementalDeferredPurchasePrice", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Business Combinations (Details)", "menuCat": "Details", "order": "23", "role": "http://www.betterforyouwellness.com/role/BusinessCombinationsDetails", "shortName": "Business Combinations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:GoodwillOtherIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Business Combinations (Details) - Schedule of fair value of such assets and liabilities", "menuCat": "Details", "order": "24", "role": "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable", "shortName": "Business Combinations (Details) - Schedule of fair value of such assets and liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "srt:ScheduleOfCondensedIncomeStatementTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c78", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenuesNetOfInterestExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Business Combinations (Details) - Schedule of unaudited condensed consolidated results of operations", "menuCat": "Details", "order": "25", "role": "http://www.betterforyouwellness.com/role/ScheduleofunauditedcondensedconsolidatedresultsofoperationsTable", "shortName": "Business Combinations (Details) - Schedule of unaudited condensed consolidated results of operations", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "srt:ScheduleOfCondensedIncomeStatementTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c78", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenuesNetOfInterestExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c82", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Business Combinations (Details) - Schedule of unaudited segment reporting information by segment", "menuCat": "Details", "order": "26", "role": "http://www.betterforyouwellness.com/role/ScheduleofunauditedsegmentreportinginformationbysegmentTable", "shortName": "Business Combinations (Details) - Schedule of unaudited segment reporting information by segment", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c82", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c85", "decimals": "0", "first": true, "lang": null, "name": "bfyw:InvestmentOwnedSubjectToOptionPrices", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "27", "role": "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c85", "decimals": "0", "first": true, "lang": null, "name": "bfyw:InvestmentOwnedSubjectToOptionPrices", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c95", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Convertible Note Payable (Details)", "menuCat": "Details", "order": "28", "role": "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails", "shortName": "Convertible Note Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c95", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c95", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFeeAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Stock Purchase Warrant Liability (Details)", "menuCat": "Details", "order": "29", "role": "http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiabilityDetails", "shortName": "Stock Purchase Warrant Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c95", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFeeAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c2", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Unaudited Condensed Consolidated Balance Sheet (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Unaudited Condensed Consolidated Balance Sheet (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Shareholder Equity (Details)", "menuCat": "Details", "order": "30", "role": "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "shortName": "Shareholder Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c17", "decimals": null, "lang": "en-US", "name": "us-gaap:PreferredStockVotingRights", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c137", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Subsequent Events (Details)", "menuCat": "Details", "order": "31", "role": "http://www.betterforyouwellness.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c137", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "bfyw:MerchandiseSalesAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Statement of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement", "shortName": "Condensed Consolidated Statement of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "bfyw:MerchandiseSalesAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Statement of Operations (Unaudited) (Parentheticals)", "menuCat": "Statements", "order": "5", "role": "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement_Parentheticals", "shortName": "Condensed Consolidated Statement of Operations (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c36", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated and Condensed Statement of Changes in Stockholder (Deficit) (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3", "shortName": "Consolidated and Condensed Statement of Changes in Stockholder (Deficit) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c36", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow", "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Organization and Description of Business", "menuCat": "Notes", "order": "8", "role": "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0822a1_betterforyou.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 38, "tag": { "bfyw_AdditionalRevisionsRate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The rate of additional revisions rate.", "label": "Additional Revisions Rate", "terseLabel": "Additional revisions rate" } } }, "localname": "AdditionalRevisionsRate", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_AmandaCayemitteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Amanda Cayemitte Member", "terseLabel": "Amanda Cayemitte [Member]" } } }, "localname": "AmandaCayemitteMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_BalanceAgreedPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The balance amount agreed to pay.", "label": "Balance Agreed Paid", "terseLabel": "Balance" } } }, "localname": "BalanceAgreedPaid", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_BetterForYouWellnessIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Better For You Wellness Inc Member", "terseLabel": "Better for You Wellness, Inc. [Member]" } } }, "localname": "BetterForYouWellnessIncMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_CRSConsultingLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CRSConsulting LLCMember", "terseLabel": "CRS Consulting, LLC [Member]" } } }, "localname": "CRSConsultingLLCMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_CRSConsultingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CRSConsultings LLCMember", "terseLabel": "CRS Consulting, LLC [Member]" } } }, "localname": "CRSConsultingsLLCMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_ClosingSharePrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Closing share price.", "label": "Closing Share Price", "terseLabel": "Closing share price" } } }, "localname": "ClosingSharePrice", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_CommitmentsandContingenciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Line Items]" } } }, "localname": "CommitmentsandContingenciesDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "bfyw_CommitmentsandContingenciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "localname": "CommitmentsandContingenciesDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "bfyw_CommonSharesIssuedForServicesToCompany": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of common shares issued for services to company.", "label": "Common Shares Issued For Services To Company", "terseLabel": "Common shares issued for services to the Company" } } }, "localname": "CommonSharesIssuedForServicesToCompany", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "bfyw_CommonSharesIssuedForServicesToTheCompanyinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The shares amount of common shares issued for services to the company.", "label": "Common Shares Issued For Services To The Companyin Shares", "terseLabel": "Common shares issued for services to the Company (in Shares)" } } }, "localname": "CommonSharesIssuedForServicesToTheCompanyinShares", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "bfyw_CommonStockConversionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock conversion price per share.", "label": "Common Stock Conversion Price Per Share", "terseLabel": "Common stock conversion price per share (in Dollars per share)" } } }, "localname": "CommonStockConversionPricePerShare", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "perShareItemType" }, "bfyw_ConsultingAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting agreement description.", "label": "Consulting Agreement Description", "terseLabel": "Consulting agreement, description" } } }, "localname": "ConsultingAgreementDescription", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "bfyw_ConvertibleNotePayableDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Payable (Details) [Line Items]" } } }, "localname": "ConvertibleNotePayableDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "stringItemType" }, "bfyw_ConvertibleNotePayableDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Payable (Details) [Table]" } } }, "localname": "ConvertibleNotePayableDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "stringItemType" }, "bfyw_ConvertibleNotePayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Payable Disclosure [Abstract]" } } }, "localname": "ConvertibleNotePayableLineItems", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayable" ], "xbrltype": "stringItemType" }, "bfyw_ConvertibleNotePayableTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Payable [Table]" } } }, "localname": "ConvertibleNotePayableTable", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayable" ], "xbrltype": "stringItemType" }, "bfyw_DebtForgiveness": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of debt forgiveness.", "label": "Debt Forgiveness", "terseLabel": "Debt Forgiveness" } } }, "localname": "DebtForgiveness", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "bfyw_DiscountOnNotesPayableForWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of discount on notes payable for warrents.", "label": "Discount On Notes Payable For Warrants", "terseLabel": "Discount on notes payable for warrants" } } }, "localname": "DiscountOnNotesPayableForWarrants", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "bfyw_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.betterforyouwellness.com/20220831", "xbrltype": "stringItemType" }, "bfyw_EmployeeBenefitAndSharebasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of bonus for employee benefit and equity-based compensation.", "label": "Employee Benefit And Sharebased Compensation", "terseLabel": "Additional payment" } } }, "localname": "EmployeeBenefitAndSharebasedCompensation", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_ExchangeAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Exchange Amount the portion of the outstanding Principal to be exchanged with respect to which this determination is being made.", "label": "Exchange Amount", "terseLabel": "Exchange amount" } } }, "localname": "ExchangeAmount", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_ExpensesContributedToCapital": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses contributed to capital.", "label": "Expenses Contributed To Capital", "terseLabel": "Expenses contributed to capital" } } }, "localname": "ExpensesContributedToCapital", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "bfyw_FairMarketValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of fair market value.", "label": "Fair Market Value", "terseLabel": "Fair market value (in Dollars)" } } }, "localname": "FairMarketValue", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_FastTrackSolutionsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fast Track Solutions Inc Member", "terseLabel": "Fast Track Solutions, Inc. [Member]" } } }, "localname": "FastTrackSolutionsIncMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_GoingConcernLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern [Abstract]" } } }, "localname": "GoingConcernLineItems", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/GoingConcern" ], "xbrltype": "stringItemType" }, "bfyw_GoingConcernTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern [Table]" } } }, "localname": "GoingConcernTable", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/GoingConcern" ], "xbrltype": "stringItemType" }, "bfyw_GreenOhioVenturesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Green Ohio Ventures LLCMember", "terseLabel": "Green Ohio Ventures, LLC [Member]" } } }, "localname": "GreenOhioVenturesLLCMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_IanJamesEmploymentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ian James Employment Agreement Member", "terseLabel": "Ian James Employment Agreement [Member]" } } }, "localname": "IanJamesEmploymentAgreementMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "bfyw_IanJamesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ian James Member", "terseLabel": "Ian James [Member]" } } }, "localname": "IanJamesMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_ImpairmentExpenseDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Impairment Expense Disclosure Abstract" } } }, "localname": "ImpairmentExpenseDisclosureAbstract", "nsuri": "http://www.betterforyouwellness.com/20220831", "xbrltype": "stringItemType" }, "bfyw_ImpairmentExpenseDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for impairment expense.", "label": "Impairment Expense Disclosure Text Block", "terseLabel": "Impairment Expense" } } }, "localname": "ImpairmentExpenseDisclosureTextBlock", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ImpairmentExpense" ], "xbrltype": "textBlockItemType" }, "bfyw_ImpairmentExpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Impairment Expense [Abstract]" } } }, "localname": "ImpairmentExpenseLineItems", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ImpairmentExpense" ], "xbrltype": "stringItemType" }, "bfyw_ImpairmentExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Impairment Expense [Table]" } } }, "localname": "ImpairmentExpenseTable", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ImpairmentExpense" ], "xbrltype": "stringItemType" }, "bfyw_IncreaseDecreaseInAccountsPayableNet": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of accounts payable Journal Entries refer to the amount payable in accounting entries to the company's creditors for the purchase of goods or services. They are reported under the current head liabilities on the balance sheet, and this account is debited whenever any payment has been made.", "label": "Increase Decrease In Accounts Payable Net", "negatedLabel": "Accounts Payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableNet", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "bfyw_InvestmentOwnedSubjectToOptionPrices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The option price of the investment that is subject to option.", "label": "Investment Owned Subject To Option Prices", "terseLabel": "Option to sell investment" } } }, "localname": "InvestmentOwnedSubjectToOptionPrices", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_JacobEllmanEmploymentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Jacob Ellman Employment Agreement Member", "terseLabel": "Jacob Ellman Employment Agreement [Member]" } } }, "localname": "JacobEllmanEmploymentAgreementMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "bfyw_LoanAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project, usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee.", "label": "Loan Amount", "terseLabel": "Loan amount" } } }, "localname": "LoanAmount", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_MRKTSGroupIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MRKTSGroup Inc Member", "terseLabel": "MRKTS Group Inc [Member]" } } }, "localname": "MRKTSGroupIncMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_MangoMoiLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mango Moi LLCMember", "terseLabel": "Mango Moi [Member]", "verboseLabel": "Mango Moi, LLC [Member]" } } }, "localname": "MangoMoiLLCMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ScheduleofunauditedsegmentreportinginformationbysegmentTable", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_MangoMoiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mango Moi Member", "terseLabel": "Mango Moi [Member]" } } }, "localname": "MangoMoiMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofunauditedcondensedconsolidatedresultsofoperationsTable" ], "xbrltype": "domainItemType" }, "bfyw_MastHillFundLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Mast Hill Fund LPMember", "terseLabel": "Mast Hill Fund, L.P., [Member]" } } }, "localname": "MastHillFundLPMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_MerchandiseSalesAmount": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Merchandise sales amount.", "label": "Merchandise Sales Amount", "terseLabel": "Merchandise Sales" } } }, "localname": "MerchandiseSalesAmount", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "bfyw_NevadaCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nevada Corporation Member", "terseLabel": "Nevada corporation [Member]" } } }, "localname": "NevadaCorporationMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_NoncancelableWarrantsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The issuer of a noncallable bond subjects itself to interest rate risk because, at issuance, it locks in the interest rate it will pay until the security matures. If interest rates decline, the issuer must continue paying the higher rate until the security matures.", "label": "Noncancelable Warrants Percentage", "terseLabel": "Non-callable warrants" } } }, "localname": "NoncancelableWarrantsPercentage", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiabilityDetails" ], "xbrltype": "percentItemType" }, "bfyw_OrganizationandDescriptionofBusinessDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business (Details) [Line Items]" } } }, "localname": "OrganizationandDescriptionofBusinessDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "bfyw_OrganizationandDescriptionofBusinessDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business (Details) [Table]" } } }, "localname": "OrganizationandDescriptionofBusinessDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "bfyw_OutstandingAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount was agreed to paid.", "label": "Outstanding Amount", "terseLabel": "Balance amount" } } }, "localname": "OutstandingAmount", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_PredecessorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Predecessors Member", "terseLabel": "Predecessor [Member]" } } }, "localname": "PredecessorsMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_ProceedsFromRestrictedCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Restricted Common Stock", "terseLabel": "Restricted common stock" } } }, "localname": "ProceedsFromRestrictedCommonStock", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_PurchasePriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase Price Member", "terseLabel": "Purchase Price [Member]" } } }, "localname": "PurchasePriceMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "bfyw_PurchasePricePerShareEqualToPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage to purchase price per share equal.", "label": "Purchase Price Per Share Equal To Percentage", "terseLabel": "Purchase price per share equal to percentage" } } }, "localname": "PurchasePricePerShareEqualToPercentage", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "bfyw_RelatedPartiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for related parties.", "label": "Related Parties Policy Text Block", "terseLabel": "Related Parties" } } }, "localname": "RelatedPartiesPolicyTextBlock", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "bfyw_RestrictedCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares restricted common stock.", "label": "Restricted Common Stock", "terseLabel": "Shares of restricted common stock (in Shares)" } } }, "localname": "RestrictedCommonStock", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_RestrictedCommonStocks": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Common Stocks.", "label": "Restricted Common Stocks", "terseLabel": "Restricted common stock (in Shares)" } } }, "localname": "RestrictedCommonStocks", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_SRAXIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SRAXInc Member", "terseLabel": "SRAX [Member]", "verboseLabel": "SRAX, Inc [Member]" } } }, "localname": "SRAXIncMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_SauerEnergyIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sauer Energy Inc Member", "terseLabel": "Sauer Energy, Inc. [Member]" } } }, "localname": "SauerEnergyIncMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_ScheduleOfFairValueOfSuchAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value of Such Assets and Liabilities [Abstract]" } } }, "localname": "ScheduleOfFairValueOfSuchAssetsAndLiabilitiesAbstract", "nsuri": "http://www.betterforyouwellness.com/20220831", "xbrltype": "stringItemType" }, "bfyw_ScheduleOfUnauditedCondensedConsolidatedResultsOfOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Unaudited Condensed Consolidated Results of Operations [Abstract]" } } }, "localname": "ScheduleOfUnauditedCondensedConsolidatedResultsOfOperationsAbstract", "nsuri": "http://www.betterforyouwellness.com/20220831", "xbrltype": "stringItemType" }, "bfyw_ScheduleOfUnauditedSegmentReportingInformationBySegmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Unaudited Segment Reporting Information by Segment [Abstract]" } } }, "localname": "ScheduleOfUnauditedSegmentReportingInformationBySegmentAbstract", "nsuri": "http://www.betterforyouwellness.com/20220831", "xbrltype": "stringItemType" }, "bfyw_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresdescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeituresdescription", "terseLabel": "Share cancellation and forfeiture agreement description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresdescription", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderEquityDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity (Details) [Line Items]" } } }, "localname": "ShareholderEquityDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderEquityDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity (Details) [Table]" } } }, "localname": "ShareholderEquityDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity [Abstract]" } } }, "localname": "ShareholderEquityLineItems", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquity" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderEquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Equity [Table]" } } }, "localname": "ShareholderEquityTable", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquity" ], "xbrltype": "stringItemType" }, "bfyw_ShareholderOwningPreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shareholders have priority over a company's income, meaning they are paid dividends before common shareholders. Common stockholders are last in line when it comes to company assets, which means they will be paid out after creditors, bondholders, and preferred shareholders.", "label": "Shareholder Owning Preferred Stock", "terseLabel": "Shareholder owning preferred stock" } } }, "localname": "ShareholderOwningPreferredStock", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "bfyw_SharesCancelable": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of shares cancelable.", "label": "Shares Cancelable", "terseLabel": "Shares cancelable" } } }, "localname": "SharesCancelable", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "bfyw_SharesCancelableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Cancelable Member", "terseLabel": "Shares Cancellable" } } }, "localname": "SharesCancelableMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "bfyw_SharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The security that represents ownership in a corporation. Holders of common stock elect the board of directors and vote on corporate policies. This form of equity ownership typically yields higher rates of return long term.", "label": "Shares Of Common Stock", "terseLabel": "Shares of common stock" } } }, "localname": "SharesOfCommonStock", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "bfyw_SharesOfRestrictedCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock refers to unregistered shares of ownership in a corporation that are issued to corporate affiliates, such as executives and directors. Restricted stock is non-transferable and must be traded in compliance with special Securities and Exchange Commission (SEC) regulations.", "label": "Shares Of Restricted Common Stock", "terseLabel": "Shares of restricted common stock" } } }, "localname": "SharesOfRestrictedCommonStock", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "bfyw_StephenLetourneauEmploymentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stephen Letourneau Employment Agreement Member", "terseLabel": "Stephen Letourneau Employment Agreement [Member]" } } }, "localname": "StephenLetourneauEmploymentAgreementMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "bfyw_StephenLetourneauMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stephen Letourneau Member", "terseLabel": "Stephen Letourneau [Member]" } } }, "localname": "StephenLetourneauMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "bfyw_StockIssuedDuringPeriodShareNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Share New Issues", "terseLabel": "Series A preferred stock were issued (in Shares)" } } }, "localname": "StockIssuedDuringPeriodShareNewIssues", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "bfyw_StockIssuedDuringPeriodSharesCommonSharesCanceledAndReturnedToTheCompanyinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of common shares canceled and returned to the Company.", "label": "Stock Issued During Period Shares Common Shares Canceled And Returned To The Companyin Shares", "terseLabel": "Common shares cancelled and returned to the Company (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesCommonSharesCanceledAndReturnedToTheCompanyinShares", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "bfyw_StockIssuedDuringPeriodSharesCommonSharesIssuedForSharesPayableinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of common shares issued for shares payable.", "label": "Stock Issued During Period Shares Common Shares Issued For Shares Payablein Shares", "terseLabel": "Common shares issued for shares payable (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesCommonSharesIssuedForSharesPayableinShares", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "bfyw_StockIssuedDuringPeriodSharesCommonStockPurchaseWarrantForPurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of common stock purchase warrant for purchase.", "label": "Stock Issued During Period Shares Common Stock Purchase Warrant For Purchase", "terseLabel": "Common stock purchase warrant for purchase (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesCommonStockPurchaseWarrantForPurchase", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "sharesItemType" }, "bfyw_StockIssuedDuringPeriodValueCommonSharesCanceledAndReturnedToTheCompany": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period common shares canceled and returned to the Company.", "label": "Stock Issued During Period Value Common Shares Canceled And Returned To The Company", "terseLabel": "Common shares cancelled and returned to the Company" } } }, "localname": "StockIssuedDuringPeriodValueCommonSharesCanceledAndReturnedToTheCompany", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "bfyw_StockIssuedDuringPeriodValueCommonSharesIssuedForSharesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in common shares issued for shares payable.", "label": "Stock Issued During Period Value Common Shares Issued For Shares Payable", "terseLabel": "Common shares issued for shares payable" } } }, "localname": "StockIssuedDuringPeriodValueCommonSharesIssuedForSharesPayable", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "bfyw_StockOptionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock option description.", "label": "Stock Option Description", "terseLabel": "Stock option, description" } } }, "localname": "StockOptionDescription", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_StockOptionExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.", "label": "Stock Option Exercise", "terseLabel": "Stock option exercise (in Dollars per share)" } } }, "localname": "StockOptionExercise", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "bfyw_StockOptionExpanses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Stock Option Expanses", "terseLabel": "Stock expanses" } } }, "localname": "StockOptionExpanses", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_StockPriceDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock price description.", "label": "Stock Price Description", "terseLabel": "Stock option exercise" } } }, "localname": "StockPriceDescription", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "bfyw_StockPurchaseWarrantLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Purchase Warrant Liability [Abstract]" } } }, "localname": "StockPurchaseWarrantLiabilityAbstract", "nsuri": "http://www.betterforyouwellness.com/20220831", "xbrltype": "stringItemType" }, "bfyw_StockPurchaseWarrantLiabilityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of stock purchase warrant liablility.", "label": "Stock Purchase Warrant Liability Text Block", "terseLabel": "Stock Purchase Warrant Liability" } } }, "localname": "StockPurchaseWarrantLiabilityTextBlock", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiability" ], "xbrltype": "textBlockItemType" }, "bfyw_SubsequentEventsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "localname": "SubsequentEventsDetailsLineItems", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "bfyw_SubsequentEventsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "localname": "SubsequentEventsDetailsTable", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "bfyw_TotalPaymentsConsideredContributions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total payments considered contributions.", "label": "Total Payments Considered Contributions", "terseLabel": "Total payments considered contributions" } } }, "localname": "TotalPaymentsConsideredContributions", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_TotalUnamortizedStockOptionExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total unamortized stock option expense.", "label": "Total Unamortized Stock Option Expense", "terseLabel": "Total unamortized stock option expense" } } }, "localname": "TotalUnamortizedStockOptionExpense", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "bfyw_WarrantCoverageRaisedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of warrant coverage amount raised.", "label": "Warrant Coverage Raised Percentage", "terseLabel": "Warrant coverage raised percentage" } } }, "localname": "WarrantCoverageRaisedPercentage", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "bfyw_WarrantsIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of warrants Issued.", "label": "Warrants Issued", "terseLabel": "Warrants Issued" } } }, "localname": "WarrantsIssued", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "bfyw_YapoMbeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Yapo Mbe Member", "terseLabel": "Yapo M\u2019be [Member]" } } }, "localname": "YapoMbeMember", "nsuri": "http://www.betterforyouwellness.com/20220831", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description", "terseLabel": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.betterforyouwellness.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Leader of board of directors.", "label": "Board of Directors Chairman [Member]", "terseLabel": "Board of Directors [Member]", "verboseLabel": "Board of Directors Chairman [Member]" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_CondensedIncomeStatementTable": { "auth_ref": [ "r142", "r331", "r359" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about condensed income statement including, but not limited to, income statements of consolidated entities and consolidation eliminations.", "label": "Condensed Income Statement [Table]" } } }, "localname": "CondensedIncomeStatementTable", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofunauditedcondensedconsolidatedresultsofoperationsTable" ], "xbrltype": "stringItemType" }, "srt_CondensedIncomeStatementsCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Condensed Income Statements, Captions [Line Items]" } } }, "localname": "CondensedIncomeStatementsCaptionsLineItems", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofunauditedcondensedconsolidatedresultsofoperationsTable" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r142", "r266", "r267", "r270", "r271", "r289", "r325", "r330", "r385", "r388", "r389", "r408", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Information by consolidated entity or group of entities.", "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r142", "r266", "r267", "r270", "r271", "r289", "r325", "r330", "r385", "r388", "r389", "r408", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Entity or group of entities consolidated into reporting entity.", "label": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "srt_FinancingReceivableNonaccrualToOutstandingPercent": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Percentage of nonaccrual to total financing receivable outstanding.", "label": "Financing Receivable, Nonaccrual to Outstanding, Percent", "terseLabel": "Warrant coverage rate" } } }, "localname": "FinancingReceivableNonaccrualToOutstandingPercent", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "percentItemType" }, "srt_InterestBearingLiabilitiesAverageRatePaid": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Average rate paid on interest-bearing liabilities.", "label": "Interest-Bearing Liabilities, Average Rate Paid", "terseLabel": "Bear interest" } } }, "localname": "InterestBearingLiabilitiesAverageRatePaid", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "percentItemType" }, "srt_MaximumMember": { "auth_ref": [ "r197", "r198", "r199", "r200", "r232", "r295", "r316", "r326", "r327", "r343", "r346", "r350", "r390", "r400", "r401", "r402", "r403", "r404", "r405" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r197", "r198", "r199", "r200", "r232", "r295", "r316", "r326", "r327", "r343", "r346", "r350", "r390", "r400", "r401", "r402", "r403", "r404", "r405" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r197", "r198", "r199", "r200", "r230", "r232", "r238", "r239", "r240", "r293", "r295", "r316", "r326", "r327", "r343", "r346", "r350", "r383", "r390", "r401", "r402", "r403", "r404", "r405" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r197", "r198", "r199", "r200", "r230", "r232", "r238", "r239", "r240", "r293", "r295", "r316", "r326", "r327", "r343", "r346", "r350", "r383", "r390", "r401", "r402", "r403", "r404", "r405" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": { "auth_ref": [ "r371", "r407" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.", "label": "Condensed Income Statement [Table Text Block]", "terseLabel": "Schedule of condensed consolidated results of operations" } } }, "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r377", "r396" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and Description of Business [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_OtherLongTermInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.", "label": "Accounts and Other Receivables, Net, Current", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsAndOtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r11" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts Payable" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r5", "r349" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional Paid in Capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r243", "r244", "r245", "r372", "r373", "r374", "r393" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket": { "auth_ref": [ "r62", "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.", "label": "Adjustments to Additional Paid in Capital, Fair Value", "terseLabel": "Fair value of warrants issued" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalMarkToMarket", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Adjustments to Additional Paid in Capital, Other", "terseLabel": "Expenses paid on behalf of the Company and contributed to capital -" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r59", "r62", "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Warrants Issued" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile Net Loss to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock option expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expense, after Tax", "terseLabel": "Share based expense" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r25", "r35", "r95", "r212" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortized debt discount and debt issuance costs", "verboseLabel": "Discount rate" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r100", "r105", "r122", "r140", "r174", "r177", "r181", "r186", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r266", "r270", "r276", "r349", "r386", "r387", "r398" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r263", "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r73", "r74", "r263", "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Voting percentage" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total remaining unamortized or unaccreted amounts of premiums, discounts, and intangible assets, in years subsequent to the year of acquisition, when the total amounts of remaining discounts, premiums, and intangible assets exceed 30 percent of stockholders' equity.", "label": "Business Acquisitions, Purchase Price Allocation, Subsequent Years, Remaining Adjustments", "terseLabel": "Purchase price" } } }, "localname": "BusinessAcquisitionsPurchasePriceAllocationSubsequentYearsRemainingAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r78", "r79", "r80" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Paid consideration (in Dollars)" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r81", "r264" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/BusinessCombinations" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r76" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total Assets Acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r76" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": { "auth_ref": [ "r76" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "terseLabel": "Sales Tax Payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r76" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "terseLabel": "Clearbanc Debit Card" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r76" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt", "terseLabel": "Notes Payable - PayPal Capital" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "auth_ref": [ "r76" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "terseLabel": "Notes Payable Shopify Capital" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r75", "r76" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r76" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "totalLabel": "Total Liabilities Assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r75", "r76" ], "calculation": { "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "terseLabel": "Goodwill - Excess of purchase price over fair value of net assets acquired on acquisition date" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleoffairvalueofsuchassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage", "terseLabel": "Owning, percentage" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CapitalUnitsOutstanding": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Number of capital units or capital shares outstanding. This element is relevant to issuers of face-amount certificates and registered investment companies.", "label": "Capital Units, Outstanding", "terseLabel": "Issued and outstanding capital (in Shares)" } } }, "localname": "CapitalUnitsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r37", "r120", "r332" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_OtherLongTermInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r31", "r37", "r42" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r31", "r94" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net Change in Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r123", "r124", "r125", "r140", "r157", "r158", "r160", "r162", "r165", "r166", "r186", "r201", "r203", "r204", "r205", "r208", "r209", "r213", "r214", "r216", "r220", "r226", "r276", "r328", "r358", "r368", "r375" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r58", "r195", "r196", "r322", "r384" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r372", "r373", "r393" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Shares", "verboseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common Stock, No Par Value", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockOtherSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.", "label": "Common Stock, Other Shares, Outstanding", "terseLabel": "Common shares, outstanding (in Shares)" } } }, "localname": "CommonStockOtherSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)", "verboseLabel": "Common share price per share (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "netLabel": "Common stock, shares authorized (in Shares)", "terseLabel": "Common stock, shares authorized", "verboseLabel": "Shares of common stock" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "verboseLabel": "Common stock, shares issued (in Shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r4", "r62" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "verboseLabel": "Common stock, shares outstanding (in Shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r4", "r349" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock ($.0001 par value, 500,000,000 shares authorized, 385,198,451 and 370,747,042 issued and outstanding as of August 31, 2022 and February 28, 2022 respectively)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r84", "r334" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockDescription": { "auth_ref": [ "r39", "r40", "r41" ], "lang": { "en-us": { "role": { "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Description", "terseLabel": "Purchase agreement description" } } }, "localname": "ConversionOfStockDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Convertible Note Payable" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r16" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Noncurrent", "terseLabel": "Convertible notes payable, net accumulated interest" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r21", "r140", "r186", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r276", "r386" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of Good Sold" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r96", "r98", "r210", "r285", "r341", "r342" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFeeAmount": { "auth_ref": [ "r15" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.", "label": "Debt Instrument, Fee Amount", "terseLabel": "Purchase agreement fees (in Dollars)" } } }, "localname": "DebtInstrumentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r16" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentRepurchaseAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value amount of debt instrument that was repurchased.", "label": "Debt Instrument, Repurchase Amount", "terseLabel": "Purchase price" } } }, "localname": "DebtInstrumentRepurchaseAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r95", "r98", "r391" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Discount amount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesRealizedGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).", "label": "Debt Securities, Realized Gain (Loss)", "terseLabel": "fair value of warrants realized" } } }, "localname": "DebtSecuritiesRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationLiabilityCurrent": { "auth_ref": [ "r66", "r67" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.", "label": "Deferred Compensation Liability, Current", "terseLabel": "Deferred Compensation" } } }, "localname": "DeferredCompensationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFuelCost": { "auth_ref": [ "r114" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_OtherLongTermInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of capitalized fuel costs of a regulated entity that are expected to be recoverable through rate adjustments within one year or the normal operating cycle, if longer.", "label": "Deferred Fuel Cost", "terseLabel": "Prepaids and other assets" } } }, "localname": "DeferredFuelCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r35", "r56" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromOtherRelatedPartiesCurrent": { "auth_ref": [ "r99", "r370" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_OtherLongTermInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount receivable from related parties classified as other, due within one year or the normal operating cycle, if longer.", "label": "Due from Other Related Parties, Current", "terseLabel": "Related Party Receivable" } } }, "localname": "DueFromOtherRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r135", "r148", "r149", "r150", "r151", "r152", "r156", "r157", "r160", "r161", "r162", "r163", "r274", "r275", "r312", "r315", "r337" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net loss per common share (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicDistributed": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Dividends declared in the period and the contractual amount of dividends (or interest on participating income bonds) that must be paid per security.", "label": "Earnings Per Share, Basic, Distributed", "terseLabel": "Loss per share (in Dollars per share)" } } }, "localname": "EarningsPerShareBasicDistributed", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofunauditedcondensedconsolidatedresultsofoperationsTable" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r135", "r148", "r149", "r150", "r151", "r152", "r157", "r160", "r161", "r162", "r163", "r274", "r275", "r312", "r315", "r337" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net loss per common share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r44", "r45" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic Earnings (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r62", "r116", "r130", "r131", "r132", "r143", "r144", "r145", "r147", "r153", "r155", "r164", "r187", "r227", "r243", "r244", "r245", "r256", "r257", "r273", "r277", "r278", "r279", "r280", "r281", "r282", "r286", "r317", "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Excess Stock, Shares Issued", "terseLabel": "Shares of common stock", "verboseLabel": "Issuance of common stock (in Shares)" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r92", "r93" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r191", "r192", "r193", "r194", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r54", "r55" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r121", "r189", "r311", "r340", "r349", "r381", "r382" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillOtherIncreaseDecrease": { "auth_ref": [ "r190" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Other Increase (Decrease)", "terseLabel": "Goodwill" } } }, "localname": "GoodwillOtherIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/BusinessCombinationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r20", "r140", "r174", "r176", "r180", "r182", "r186", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r276", "r339", "r386" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r141", "r250", "r251", "r254", "r258", "r259", "r260", "r261", "r262" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r129", "r248", "r249", "r251", "r252", "r253", "r255" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r34" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts Receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": { "auth_ref": [ "r34" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Accounts Receivable, Related Parties", "negatedLabel": "Related Party Receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "auth_ref": [ "r34" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.", "label": "Increase (Decrease) in Accrued Interest Receivable, Net", "negatedLabel": "Accrued Interest" } } }, "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r34" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Deferred Compensation" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r34" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in current assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r367" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other Liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Expenses, Other", "terseLabel": "Expenses paid amount" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r97", "r104", "r133", "r173", "r284" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r126", "r333", "r349" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_OtherLongTermInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentMaturityDate": { "auth_ref": [ "r378", "r379" ], "lang": { "en-us": { "role": { "documentation": "Maturity date of investment, in YYYY-MM-DD format.", "label": "Investment Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "InvestmentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "dateItemType" }, "us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue": { "auth_ref": [ "r87", "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Nominal or face amount on the investment owned.", "label": "Investment Owned, Face Amount", "terseLabel": "Principal amount" } } }, "localname": "InvestmentOwnedUnderlyingFaceAmountAtMarketValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Warrants issued and extended for common stock issuance costs" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r12", "r140", "r186", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r267", "r270", "r271", "r276", "r338", "r386", "r398", "r399" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r9", "r102", "r108", "r349", "r369", "r380", "r395" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES & EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDER EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r14", "r119", "r140", "r186", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r267", "r270", "r271", "r276", "r349", "r386", "r398", "r399" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.", "label": "Liabilities, Other than Long-Term Debt, Noncurrent", "terseLabel": "Long-Term Liabilities" } } }, "localname": "LiabilitiesOtherThanLongtermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Retirement amount" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoanProcessingFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses paid for obtaining loans which includes expenses such as application and origination fees.", "label": "Loan Processing Fee", "terseLabel": "Paid expenses" } } }, "localname": "LoanProcessingFee", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansAssumed1": { "auth_ref": [ "r39", "r40", "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of loans assumed in noncash investing or financing activities.", "label": "Loans Assumed", "terseLabel": "Loan amount" } } }, "localname": "LoansAssumed1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MajorityShareholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Owner that controls more than 50 percent of the voting interest in the entity through direct or indirect ownership.", "label": "Majority Shareholder [Member]", "terseLabel": "Restricted Common Stock [Member]" } } }, "localname": "MajorityShareholderMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r137" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r31", "r33", "r36" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r19", "r36", "r103", "r111", "r118", "r127", "r128", "r132", "r140", "r146", "r148", "r149", "r150", "r151", "r154", "r155", "r159", "r174", "r176", "r180", "r182", "r186", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r275", "r276", "r339", "r386" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "netLabel": "Net income", "terseLabel": "Net (loss)", "totalLabel": "Net income/(loss)", "verboseLabel": "Net (loss) income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow", "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement", "http://www.betterforyouwellness.com/role/ScheduleofunauditedcondensedconsolidatedresultsofoperationsTable", "http://www.betterforyouwellness.com/role/ScheduleofunauditedsegmentreportinginformationbysegmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "NON-CASH FINANCING TRANSACTIONS:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r24" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total Other Income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableToBankNoncurrent": { "auth_ref": [ "r2", "r101", "r106" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount due within more than 12 month, or the operating cycle if longer, on all notes payable to banks paid on an installment. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.", "label": "Notes Payable to Bank, Noncurrent", "terseLabel": "Notes Payable - PayPal Capital" } } }, "localname": "NotesPayableToBankNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficersCompensation": { "auth_ref": [ "r366" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold", "terseLabel": "Base salary per month" } } }, "localname": "OfficersCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r174", "r176", "r180", "r182", "r339" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating Income/(Loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "auth_ref": [ "r61", "r89", "r90", "r91" ], "lang": { "en-us": { "role": { "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.", "label": "Option Indexed to Issuer's Equity, Type [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.", "label": "Option Indexed to Issuer's Equity, Type [Domain]" } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r86" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Description of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherCashEquivalentsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Other Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "OtherCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDeferredCostsNet": { "auth_ref": [ "r362" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net amount of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs or deferred acquisition costs of insurance companies.", "label": "Other Deferred Costs, Net", "terseLabel": "Deferred compensation amount" } } }, "localname": "OtherDeferredCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r23", "r112" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Expenses", "negatedLabel": "Other expense" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other Income (Expense)" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r13", "r349" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other Current Liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermInvestments": { "auth_ref": [ "r110", "r361" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term investments classified as other.", "label": "Other Long-Term Investments", "totalLabel": "Total Current assets" } } }, "localname": "OtherLongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermNotesPayable": { "auth_ref": [ "r16" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer.", "label": "Other Notes Payable, Noncurrent", "terseLabel": "Notes Payable Shopify Capital" } } }, "localname": "OtherLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNotesPayableCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Other Notes Payable, Current", "terseLabel": "Note Payable- RP" } } }, "localname": "OtherNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OwnshareLendingArrangementDividendsNotReimbursed": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of dividends paid to holders of record of shares of the entity's stock associated with an own-share lending arrangement in contemplation of a convertible debt offering or other financing, which will not be reimbursed by the counterparty (share borrower) to the arrangement.", "label": "Own-share Lending Arrangement, Dividends, Not Reimbursed", "terseLabel": "Reimbursed amount" } } }, "localname": "OwnshareLendingArrangementDividendsNotReimbursed", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForFees": { "auth_ref": [ "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for fees classified as other.", "label": "Payments for Other Fees", "terseLabel": "Amount paid" } } }, "localname": "PaymentsForFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r30" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r26" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_PaymentsToAcquireOtherInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Fixed Asset" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherInvestments": { "auth_ref": [ "r27" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investments classified as other.", "label": "Payments to Acquire Other Investments", "negatedTotalLabel": "Total Cash Flow from Investing Activities" } } }, "localname": "PaymentsToAcquireOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Shares" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r3", "r213" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Preferred stock, shares authorized (in Shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r3", "r213" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "verboseLabel": "Preferred stock, shares issued (in Shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "verboseLabel": "Preferred stock, shares outstanding (in Shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r3", "r349" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock ( $.0001 par value, 200,000,000 shares authorized; 700,000 issued and outstanding as of August 31, 2022 and February 28, 2022)" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r3", "r63" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred Stock, Voting Rights", "terseLabel": "Preferred stock, voting rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassification of Prior Year Presentation" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r29" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from Convertible loan, net of original issue discount" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r28" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Common Share Issuance" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Proceeds from (Repayments of) Related Party Debt", "terseLabel": "Proceed from related party note payable" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r118", "r127", "r128", "r136", "r140", "r146", "r154", "r155", "r174", "r176", "r180", "r182", "r186", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r265", "r268", "r269", "r275", "r276", "r313", "r339", "r347", "r348", "r365", "r386" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r57", "r109", "r314", "r349" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r57", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_PublicUtilitiesApprovedRateIncreaseDecreasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of public utility's approved rate increase (decrease) by regulatory agency.", "label": "Public Utilities, Approved Rate Increase (Decrease), Percentage", "terseLabel": "Exercise price percentage" } } }, "localname": "PublicUtilitiesApprovedRateIncreaseDecreasePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r231", "r287", "r288" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r115", "r287", "r288", "r397" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r231", "r287", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r397" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails", "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ScheduleofunauditedcondensedconsolidatedresultsofoperationsTable", "http://www.betterforyouwellness.com/role/ScheduleofunauditedsegmentreportinginformationbysegmentTable", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r6", "r64", "r107", "r320", "r321", "r349" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r116", "r143", "r144", "r145", "r147", "r153", "r155", "r187", "r243", "r244", "r245", "r256", "r257", "r273", "r317", "r319" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r171", "r172", "r175", "r178", "r179", "r183", "r184", "r185", "r228", "r229", "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofunauditedsegmentreportinginformationbysegmentTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r134", "r140", "r171", "r172", "r175", "r178", "r179", "r183", "r184", "r185", "r186", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r276", "r313", "r386" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesNetOfInterestExpense": { "auth_ref": [ "r171", "r172", "r175", "r178", "r179", "r183", "r184", "r185" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income after deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues, Net of Interest Expense", "terseLabel": "Total revenues" } } }, "localname": "RevenuesNetOfInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofunauditedcondensedconsolidatedresultsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r366" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold", "terseLabel": "Annual salary of payable" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.", "label": "Sale of Stock, Consideration Received Per Transaction", "terseLabel": "Shares sold" } } }, "localname": "SaleOfStockConsiderationReceivedPerTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of shares" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of fair value of such assets and liabilities" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r49", "r50", "r51", "r53" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofunauditedsegmentreportinginformationbysegmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r49", "r50", "r51", "r53" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of segment reporting information by segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuritiesPurchasedUnderAgreementsToResellIncrease": { "auth_ref": [ "r188" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase from purchase of security purchased under agreement to resell.", "label": "Securities Purchased under Agreements to Resell, Increase", "terseLabel": "Security purchase agreement" } } }, "localname": "SecuritiesPurchasedUnderAgreementsToResellIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ScheduleofunauditedsegmentreportinginformationbysegmentTable" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r22" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, General and Administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r363", "r364", "r392" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]", "netLabel": "Series A Preferred Stock [Member]", "terseLabel": "Series A", "verboseLabel": "Par Value Series A" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "terseLabel": "Series of Individually Immaterial Business Acquisitions [Member]" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServicingLiabilityAtAmortizedValueAdditions": { "auth_ref": [ "r294" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of additions from purchases, assumption or transfer to contract to service financial assets under which estimated future revenues from contractually specified servicing fees, late charges, and other ancillary revenue are not expected to adequately compensate the servicer for performing the servicing.", "label": "Servicing Liability at Amortized Cost, Additions", "terseLabel": "Addition loan amount" } } }, "localname": "ServicingLiabilityAtAmortizedValueAdditions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r34" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share based expenses" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Grant option exercisable (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r70" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Stock option outstanding intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r233", "r235", "r236", "r237", "r238", "r241", "r246", "r247" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number", "terseLabel": "Number of vested shares (in Shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Stock option expire term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Stock options fair value the grant date (in Dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase common stock percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiabilityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Transfer of shares", "verboseLabel": "Issuance of common stock shares (in Shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Price per share (in Dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtInterestRateIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage increase in the stated interest rate on a short-term debt instrument.", "label": "Short-Term Debt, Interest Rate Increase", "terseLabel": "Interest rate" } } }, "localname": "ShortTermDebtInterestRateIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShortTermNonBankLoansAndNotesPayable": { "auth_ref": [ "r10" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowings from a creditor other than a bank with a maturity within one year or operating cycle, if longer.", "label": "Short-Term Non-bank Loans and Notes Payable", "terseLabel": "Clearbanc Debit Card" } } }, "localname": "ShortTermNonBankLoansAndNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r43", "r138" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandbyBondPurchaseCommitmentExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expiration period of standby bond purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Standby Bond Purchase Commitment, Expiration Period", "terseLabel": "After the issuance expire period" } } }, "localname": "StandbyBondPurchaseCommitmentExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails" ], "xbrltype": "durationItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r123", "r124", "r125", "r140", "r157", "r158", "r160", "r162", "r165", "r166", "r186", "r201", "r203", "r204", "r205", "r208", "r209", "r213", "r214", "r216", "r220", "r226", "r276", "r328", "r358", "r368", "r375" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r18", "r62", "r116", "r130", "r131", "r132", "r143", "r144", "r145", "r147", "r153", "r155", "r164", "r187", "r227", "r243", "r244", "r245", "r256", "r257", "r273", "r277", "r278", "r279", "r280", "r281", "r282", "r286", "r317", "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r143", "r144", "r145", "r164", "r296" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "auth_ref": [ "r68", "r71" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Forfeiture stock compensation" } } }, "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r39", "r40", "r41" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Shares issued" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r3", "r4", "r64" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Common shares issued after reorganization (in Shares)", "verboseLabel": "Commitment shares (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConvertibleNotePayableDetails", "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r17", "r62", "r63", "r64", "r211" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Common shares issued for cash received (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r3", "r4", "r62", "r64" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Preferred shares issued after reorganization (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Expenses paid on behalf of the Company and contributed to capital - (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Common shares issued for purchase of subsidiary (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r3", "r4", "r62", "r64" ], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "terseLabel": "Forfeited shares (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r62", "r64" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Shares of restricted common stock" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r18", "r62", "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Common shares issued after reorganization" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r18", "r62", "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Preferred shares issued after reorganization" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r3", "r4", "r62", "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Common shares issued for cash received" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Value, Purchase of Assets", "terseLabel": "Common shares issued for purchase of subsidiary" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r62", "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Forfeiture of stock compensation" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r4", "r7", "r8", "r52", "r349", "r369", "r380", "r395" ], "calculation": { "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Stockholders\u2019 Equity (Deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS\u2019 EQUITY (DEFICIT):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r82", "r83", "r85", "r116", "r117", "r131", "r143", "r144", "r145", "r147", "r153", "r187", "r227", "r243", "r244", "r245", "r256", "r257", "r273", "r277", "r278", "r282", "r286", "r318", "r319", "r369", "r380", "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r65", "r139", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r227", "r272" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholder Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOtherShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of increase (decrease) in shares of stock classified as other.", "label": "Stockholders' Equity, Other Shares", "terseLabel": "Shares issued (in Shares)" } } }, "localname": "StockholdersEquityOtherShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r283", "r291" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r283", "r291" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails", "http://www.betterforyouwellness.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r283", "r291" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r290", "r292" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalDeferredPurchasePrice": { "auth_ref": [ "r39", "r40", "r41" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.", "label": "Supplemental Deferred Purchase Price", "terseLabel": "Purchase price of stock", "verboseLabel": "Purchase price" } } }, "localname": "SupplementalDeferredPurchasePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/BusinessCombinationsDetails", "http://www.betterforyouwellness.com/role/ShareholderEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability for agreement to continue an employee's salary after termination of employment (but before retirement) including death, disability, or other event. For example, a company may agree to continue a disabled employee's salary for six months.", "label": "Supplemental Unemployment Benefits, Salary Continuation", "terseLabel": "Base salary per annum" } } }, "localname": "SupplementalUnemploymentBenefitsSalaryContinuation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TableTextBlockSupplementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Table Text Block Supplement [Abstract]" } } }, "localname": "TableTextBlockSupplementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r46", "r47", "r48", "r167", "r168", "r169", "r170" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants exercisable date of issuance" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/StockPurchaseWarrantLiabilityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r156", "r162" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares outstanding (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.betterforyouwellness.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.16(a))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "340", "Topic": "980", "URI": "https://asc.fasb.org/extlink&oid=123417213&loc=d3e43603-110378", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1405", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "a", "Publisher": "SEC", "Section": "12", "Subsection": "04", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r351": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r352": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r353": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r354": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r355": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r356": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r357": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5283-111683", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r384": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r406": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(4)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r407": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "12", "Subsection": "04", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r408": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(i)", "Subsection": "01", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r409": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "01", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "13", "Subparagraph": "(4)(iv)", "Subsection": "02", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL6757479-112611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128088960&loc=d3e3913-113898", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126965701&loc=d3e15009-113911", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "10", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=6431724&loc=d3e32938-113948", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "10", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=6438156&loc=d3e57880-113973", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 50 0001213900-23-020746-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-020746-xbrl.zip M4$L#!!0 ( %,R<59EY+8_VP\ $>E 1 8F9Y=RTR,#(R,#@S,2YX M.GSIJ3^M8TE]5DEN,D;=K<:CN]S9K5A25LDTK@@N38 M^?4'D&3+DD!2DK;,'#]%D6#S;3[8;#87O_IS[KG6#%*&"#ZH-9\W:A;$-G$0 M'A_4;OI;G7[W[*SVYZ%E_?;J/UM;UFN((04^=*SAPNH2;]JWD36@ +,1H9[U MS/=^M[:LB>]/]^OUN[N[YS9/PVQ$(2,!M2$3+ZRM+2XP%MFE4 CR?\F*/X0@$KG]0 M^QX %XT0=&H6UPOSM-3?\A=3R YJ$:818,/GA([KRT]U+K]5LWQ Q]"_!!YD M4V##90:AQ!#Z/J1?9]+?M67JYM[>7EU^C9,&3*5(_"72(TP^'"WN'J;"G.4!XO";]4\7 MYWU9^)D( MHQRMGD@G&[@_72=>IAVXN52M:242#[@>EGBXZ9V5,T&RB"[!C+C($6/!$7!% MO^Y/(.0&!#EA%7RE7Y6)Y'@28XG1K)@XY.:+CTM]WMKDJ,&?;S ('"1&,B[4 M@9B%3TOQ5B3?D@6\JJXRG2W'T#BUVM >75,H(\X1%:*TW2>8HI;CZ+8>K9>X.^YG&]8U[-^QKU' M#RY94#*=3G>H9;:=8E;!YRH)&5E74^&I\OS,>K9L"1M2GX#4LKVY()N>\A=/ M1GFICKUI .D&T)_P6IL0U^&SPY/O ?(70E"+T/8:X9IDAT4&>SO+\8I9@)-V M>XWG[@3@,606POP]L;^%Q5O/^$00VC"7*8?DV>\-BFL4K.@88W4L O/<<0V93-!7_D=%1P)!( MO<9JJ0R%O7B'.-7E#''@>8!_&O71&"-N MX0#V.[9- NPC/+[FW]K[27YDGFM:+,FQ&P! VQ3>H2;XAPZ$2NT9&;0#\" M-AMI7F(A5E+*9G@K1U$XG1B >!)&!11Q4RBK_H.MIWA:27 "B5L MG+PR'H0W!8B*,>1D/A4!B'4_(O-5S\K+C"NQ%&!%$C:LE)K?#AG\'HAZGXGA M/36337TL]/ RX8B5""N4L;%B)9G)A@R.%O)IW9QIDA6RE0DQY,02_BLV&X4" MK6?Q2\5*SH;$,C/;@?#&BN>W4;)"$C/QA]QYKO4LE)?/W(:XAX1SCZ$/D%L] MJAOG*X@ MC(1C+*Q7;$8(XO8L/V44=X\OJOEU(>L6IGX2/F0;P'E&]++V>8\ MBG7IM$YJ*Q-'49AF/74;YC+=U9Y )W A&8VXSS\#;L ?62#FS0S*:)<;39IY MSQADXBP/R%[0<3-!F *B1=>.0(B^+6!8$H?X3R"Q0BC2R"? ;/IVY182Q O? M=KSN;2>6O7GM!*[/R(@L=Z_HVLL#A14&@UJ98%"U!K3$92V!64ED5@1-I%V! MVS@'#VU+#(Y%I('"*:%B&!;[VZDG(0X7T<=2[:B\H (+E(E2/;0!185:2TA6 M I.8"T8)_O5CE3P?\]?'BP_;?__UR9X&\\]X>\^YWYF-/R_PS7%P]WJ'[NV\ M:]W>#!;,W9G9]PWWK5_W^_#M_4[[V[QIG_N-+Z>GK?Z[^FQ^U/W-4[QS>QH]J+= M;2^<;>_]MZ/[+X.7[X(O0VQW/VY??J#-\?G5B7?3?KTW]G=ON1,YO][S+CKT M\XN]R_K13?.TX0S.AO,3A^W0\RFI8^_FYDN'C8?=X_=>YZU[\?W;;=>K]X"_ M,_?.[_=F3NODZHU_-_]^,R. XMO;]YW35F-4?SN9TO<'!W];W7XO/'#T$U:_ M\IRW$LF+K7,FV*A=#]/[<_^B'O)DC.8M>^63J4M9S&,F.JE:*]M0^(2K9KG3 MYC(9BD)?K>P6J8(EM,TL^?&+:;ETJA(5]\E,^#*[O*9E;<-8T9).?M@J/TU! M2+*="4EFUG)E^&KM]+)\S=\B3TR#+)Q[-%UQ(MH*3\F?$UN*TV01 M_VW%^;;$JZUF:ZO=?#YG3GS LR(*H71XPK0:BCC?0U"HCL/G(6#Q6?5DIC$ M4YFG#EV?+<7(<[=*4+"4L%@K."HTNG="EGI0BP,85Z-3 M@.@'$3^]&O4#>]*1P5-NXT9:HII(@X YG/"6ADF#%R73%9B-,R/A1R>QJ(KZ\I":9Q(8B+ M3XR^#X.]7ONJBE@>\UF>\DD>\NF%4<"KT>JLGHG5\G EDOVDL(KZ82"K%P>Z M$L/@T2+Z:'3U5%) VWYTLS&#JJ 43'4;R.PQ6WFRYBA9!F3]4$GE#98WE4#' M'(VRD-049=(V#,3?T':F3/*F@2HTJZG0,E"%5C45V@:JT*ZFP@L#57A1385M M U78KJ;"2P-5>%E-A1T#5=BIIL*N@2KL5E-AST 5]BH.;28.S\U&,EQ0I(&1 MHW-3K4$T2;2_!XB:Y.4I<*E=O>0DE[' ,TD9#395,")+HHE.4[-5I6^8Z#,U MVU4T,-%E:KZHHH&)'E-SNXH&)CI,S9=5-##17VKN5-' 1'>IN:O6X +@,;D@ MR)PA(8-(&946Z]>L*U9TW' +8!*Z1S#T 5WD@1\!E^6B#U>(_/C3,+PY\:!F M\Y$6^8\(J*6AJG2Z@"+HAAW$8!^X?%#TQ/F#)]!LQCB&1_M MH7,@K-JO?;+$'Y MHO^)3:U $V7WS)&F#P&(9_SW!TZ#/N[9?0:/^K%'ZE MH8J6/IG85T_1,/#%6-H%4^0#]T=J[<#A8Y36PM:Q+=9X1>5<8;$+/:XBWE;B M;F RU<7@5>8X>+:N5A:'/-.5QC'BPZFFJ'\7 9Q5010&6[0;8H9P+E_Y/($L7Z.3_?]^.6O M<&^+D:HGE^E#!L8U305"S:ZT= :#&J0&FZHM:O8N&=422^&LL(_,N(:H0%A! M)8,:H@:;JB'VH"NVBEX#^:M+X>U51K5 /4!-M*/"_4+&M%#S9X#(28I)@27P%E M/)^9VI3309Q;N #T&_1E_-;@%:XT4HUE+;XIP#B#6A:R-B"L%V"0[:P"5A]: MF_$^*UYPB\3M4#"\A;8_(%?2#E]3$5?]@4WZD3&F4NAUZLV$]T^E,9BVQ\;RI3]EN]^ MS<*E#J3:Q;PDV%[N2XH7$DP:GHH :K>'Y5R58EQ7U ,M'Z4UKP,60WRH4W$) M[^07$_8-E,.I&3E,G7FK9]SEU3"!( 4PW5CN$L:)E!1*0VKRLG 6K$:S:TIL M"!UV2HE7HMT9Y:458]>:$U$_1VF/KB/&D[%,=[18)>&^@CS4?P>H$T[X&/?S M1Y"CY.W7,>AGG-FL,H@!5M:0QSG,SYX(Q6$]%?Z,_EH5([< /B M _>&/XN[*>ZC<&^<._K]'V.[= GPRG8H\T;M6>P$8HC[&?(*DW!/$)(_;FFV MZD7PM9L1EO4$Q%XH@U7-0ZND]9P _&3''GY0;#"!4=TQC\+"9#R%VUWT0[>! M/E*A+%;-PHH,@@E'PT#SG\&E'L;R;V8T;WJHPZEU>/(SFC0_+$*H;H0=QY%W M&@*W!V=(!#Q8#_A&^^DJR"H;'\4ZNF0&*1C#'D#"?S,H,E,$4*785> +J^R( M8/,//]_V2,.8Q:INDR=S<1)N#(U7*@54?06"QS4'7;" 'O)]> &](:3)=N<0 M#R#\_W5HLWY>=<,?12H ME%NAD\F9F5JP-364.S68/^"POO6)&_KNQC0Q'33E@0'N!^*K"2(?^#L1&3"& M&@TRC0TX _BMN$ U7.B3$9!XF=,,M8H!:O:41GG-TJ2$"7L+;#(\<5UNT8TE MIA1&3C"9.! -(3#.EX80[V/$P%.\-7M]88HD,^*G6D'$XG M$)]#GXBK0D!@K*=1 6EI90W5K+#S? 93&O24B5_P=02P,$% @ 4S)Q5NS\P1KL"@ ''L !4 !B9GEW M+3(P,C(P.#,Q7V-A;"YX;6SM75MWVK@6?I]?X<-Y.6=U47-I2LAJ.HM :&D) MH5QZR:Q97<86H,26J&1SR:\_DK$3#!88(\?0,T^3<9R]M[YO2_MB27WWY]PR ME2D@%&)TFV_JMDE;%M3RY4=3:;O=;9.U2'!%#L$!U0_D#) M9IE 7V25 "[P0JD3J-QH1,F7E%SNHE"X*.:5?J^J%'*%XO)/_GAG0O0PT"A0 MF-V(7F96-,T'Q'R-R4@MY')%U7\QLWSS8LX?!-Z?%=VW\^5R675_^_0JA6$O M,K%Y]?M-LZN/@:5E(:*VAG2N@,(+ZCYL8EVS721WVJ4(W^#_E_5?R_)'V7PA M6\R_GE,CL\1-4=X1;((.&"JNY1?V8@(N,Q1:$Y,;Y#X;$S"\S R&BQD34BCD MSI'6OLD1Y7G M"MRC#<<$>#C4()EJIL-^I(X^UB@%-M6084)M $UH0T![VH +WG\4,;0\CU'7 M3-TQWT&?R68Z)K\[4!L"\S#@T M.]*TR<];>PQ($Z-1#Q"K@:: VMRM:) +;AUEYKE3?ZC1@3O_/1DJ)TD%IDW] M)RYM+F4[U7A3;F^[N6-5D.M?U[\O8CQL^$%QCO3=4ZEB6*RT+V>SW_WY(L!6=4!OO#2(F!B LW&:4 M&8"CLQPY4@P[6T W3 %+/I0UO KCJ$N&ND5-ZBZ3PAWB*"Z/%6 MD,%;S0%U9J^GSN2K3ULC?.U+AK/=^I:K[8DP%@$^CZWB.ENQZ.+F(/;K10O( M9B8@^H0F31 2#^TW4N8&& )&HE%W@%G%5/I46!>OOC\1R#>!\6 _6X,]5B1Q M\S#9H6(I-%6$@P-;Q5.,O2!$Q\&U3? $$'O19KFES2(,SPPF7(W\I62KJM37 M=S$/VR$2A=V82_D'C(T9-$W)V#^)/6*AP2(>MV!IY%.=H MEJ0PF/<)ZX>GDRZIO;&&>)EFLQ6P!@8V6P7UI-/,78I3[M1$)VDG@N(P'X>[ MU<6PAWFP2HRMK:J.:=$*8V@[3DF$R"Y$-A4<,)W;Q*O?7+%) M?)H-TY!N/BZF*-A)#$%&F)W$F\*6A5%BP&^(3W621@-]$Q+)G8.*84!NJ6:V M-6@T4%6;0%N3W<$5:4D]DXC&@A D42ZQ#Q/N5J'N6",LZ>=;9,S-<"787[3Q M1T?LT()1RLP .L#6( +&M4801"-:T77'IJ-#?+MA!]/8?G!]9Q_UY2^)FS*CYU?5$SW]ZQ2Y?GFE4:#7V,]!2W MH.II<]FESG[*T]T@)^(T4/SLB>:N;&3/]A&+PLS Y>DHD^^ ,"R((+6YX5/@ M:9?=4HJFU%\-W,-6?WV[^7KV]U_?]8DS_X'.RL9C:3KZL4#]FC/[4"+ETN?" M?;^WH&9IJC_FS$^V:G?!I\=2\6&>UYMV[JY>+W0_J]/Y5?5';FITR=VY?5[! M+?H1OZU -#VOO=+NQS7S>YY42:E^I]_WZ*LQJ"U:#GJLOX*UT;73:UGMGGJF MESY7N\ZW2O^FN\A]JUQ];*GW5O?^U??OL-CZHG7,6:Z.^M.KZ9MBM;@PSJPO M#U>/=[VWGYV[ =*KW\Y:7TE^U+R]MOK%#^61?7ZO8V?>+ELW%?+C3;FE7O7S M]9S1:PSFUP8MD>8$J\CJ]^\J=#2HUKY8E4_FS:^'^ZJE=C2[-+>:C^6I4;B^ M_6C/2'].^^!^7*WCN)/X 9B&36@=C(6KTM/N^S9R51PF_<:-)M+9S9^.\3][I)4L [( M3CTKV@OU-5PVIVGVH(8J"X1+$YHL4Y,]/P.R#_EH&40K 5/#-*3;# LE)N 8 M8:#L^,!QE /9,AVV;DA(MZ/R=/XVYGK'CY,Q$:PXFD)FT=6B3WF;YHG5BL[" M-@DO?V17'N%*TE]Q#J!$!)SL+YD6 M)C9\=(7?#OE.K!JD[O[Y-@$6="S)5.W6=^)3*0*@@N^?\8X<3 C081*3*B#Z MI*=2$"3A/NBXE9I. )NF-;#\;P.%G6607L!%4GKB4RDJM!+/G&ZJ= L?;U]Q MN&= \-D^DJ 3G)![H.17XKD$5U5^--IOJC][2!+WRNRE_ 2) MC0NSS_+&)XQ8>_&UA7MG2 ]7]%\.),!-LI*[^6VWOD,.%JP+OW(HY-U0]R*L MVZ%[P=GR-T;2X]JF.MV\+C+E@9,)>T$K]ND73<39LMC"\=OV.&$+)1WM7=77 Q)L4?#O84X:T2)B[ MK6J/-!>-P>1V=(5][4-);5#J\+,3;$5[/A:4()OA^HZU%1>#1P&@$KK:;F+L M;S)@$]\F<. P-^GAT -6@K)AJX 3Y2$",E+O]V@_S50^.WW&^4;9I-+',$VG M'<2V0;C9LHZ?\',;UV[X[;#$CT#=VQ]004;PPN;(]P&\_1 ABZ*NQ(:OX_ 8Q0 MK8J.8'B3]^6W7,7XQP)B;LCRJW"66PV82_'!=(".1P@^,C)G&#;@(&QDY39-KB^?Z*MQ\Q<"'&IMN"2LYM5Y>.I/F6 M>1NH3%N?KC8_8I=\MC'M).OT?'&%7ZE]$)DV)K?Y)2DKCP*VS=TM:]_YCAC, MW;;_/D%GQ_5?+^P2QQJ(-DWW+T-+H$?^@H:G^K'YMW'CH"_(O<8S6?&;3%OE;Q:3;=WOXX(K6"?E>G[1 MNST+_0?(_98+\9EY04O[W=._SLPQ_Q]02P,$% @ 4S)Q5G?U<"_M,@ MT?\" !4 !B9GEW+3(P,C(P.#,Q7V1E9BYX;6SM?6USX[:2[O?]%5[?+_=6 MRO&\G)Q)4IF[)V\?69))L;:4@$I(X0Y$*2,K6_/H%^"*1(MX)".3$ M5;MG)AX3#3P/T&@T&MT__=?3,CQ:0Y0$#@9 M/8ROKH[_Z_\?'?W'3_]YKAZ\X&B"0)3,8K0\^K_I M\O\=G1PMTG3UX^GIX^/CMQ[^G<0+$$SB#'DP(3\X.CG!#59-CA$D#?YX=(F" MH_< ';U\<_3BQ8^O7OWX^N71A\GXZ-6+5Z^+3_[CIS"(/D]! H]POZ/D[7%- MTM,4A=_&:'[ZZL6+UZ?5+QX7O_GC$_E!X___?*''WXXS?]U^ZM)0/M% MW.S+T]_>7S]X"[@$)T&4I"#RB( D^#')?W@=>R#-D13VZXCY&^2_3JI?.R$_ M.GGYZN3URV^?$G_;1?P[?KH54V_@N]/B'X\)7D='/Z$XA/=P=I0/\<=TLX)O MCY-@N0I)S_.?+1"SC:/6-JK5R^^+V3]'_*3/]&?XSA*XC#P"4EG("1C M?EA F!X?D:8_W%\U1CN%:0H1G@R;.'N$81C!).?\E/SR*;.M4]N]_?,.(!BE M"Y@&'@@3DYW?;]K*6*[PJES"AQ3_?8F%=>W_?G.DS]8[;9@#0>OFAO2PP"TO MXM#'>O+BKRQ(-Q/N:&_;.2UTMXE^WJ(Y MB((ONPL2P+2&YU^2[5K"NR';+D$N!^SAV >!3,\^:)T MY'EQ%J5X%[W#^'D!U!J&9,L%(68&\R[&+6/:/8@BG2XWOC>W BO2L,4Q#:*< M5RU$J>T8G-"%2IJ )SW"ZY^;TP7+99 2!9G@I8"I(7,'VWB:^U86K9M_>)LTW^-RV>.:V9ZC!--4_(6C6FZ,O6C.W[^,CG9R&,9S,\ MQ=8@S/!?DXPLVP3FVC$L5RV&:Z*KOS2D&-S/=M*S"&1^@.U +XY\LI#(7[;& M(3[>9V&:Q+-X1=P#6[2[C5A3ICD5V>Y) N=$F2"XBA%9#D%$_!ZY].FF_$>3 M(Y>7=V"S_!RF(- [PZDT;]*VE3.G.PQ,38!!PFC:KL,X>,V9M/&8EF2'ODNT M:M(_0[$M.W6>UZ YO<:S,+O,?YEVC6V_^Z9GEXZSVC('^9Z=UTG+T)LRHBK/ M8R\CBV<4^1=XZ:2;J]V&H]-9;GM;70*0)]MEAMN\\GH3?_EW^4C\ ,LEUQHG M/IP!;"D<'Y5BZB/8MA%$Z2G^Y+3\G=/VY^7$M=S7> F"2+NKQ=>[G<5&9Q>X M">1E4WBR%:S67UH#M PU9(;D+BQ&E<@03&'X]CA+3N8 MK/[<>NUO9Y?8Q,#[,PCOXB3O_FB:I AX:1O%I )C!I)ICDC9WBE18J<0'P>J MG^1J+4=5262QR)6',\H/8^,,D1L(2_VGR]AV>$?_"#6[CF=+U95RXJC.^O+K M&8J7>A2FL1"K&.'=]^WQ"_Q)OBQ^],(8G_C>'J>A#W@+AQ;F!:=M[T,I.2.0CJ).$KJ7MIE+KS#%[B7I=R0[)UW %$G%1V M:!/+:ZB0_I(F 5Q)V"NVJM1A["HBQPEL MQ T^0TFA[$TFF"40+^VNP*@3.( M^^%?9C %T\@P"TPQ MNU7:7SK8&)6T?,>A18>4.T1\^>GF+@2%RP ;'"LBTKQ*XHIRNU6(IF:=(CYB MUFSJ=W'L/P;DN&J4E&VSPR%@AX30C-(%NUBO5DZ3@ST^6H3[>G>?BA=4[M-N M1.M9.MY+B]UZ]X;$FCRH8N.V,ZUV_30<0>Y6F^JD9G"GY;7I\&X%1 @I?=7D_:,DM(".R%\M2 MX7C$Q\_:QOBPB%%*3**;.#H#T>?K&$1$FY"KZF0;HFG69R\C$GL__I MGWCKLNRL.*88AR=>-9[80 G]0%U\$;8W-I:4(6UB3*3$?B(S-J-U6W%0='"8 MX+B&.C*1SX') D3DA)YB=7H.IRE6J9YMAD2"73JVV3.5P9<010G+7H?(NEZ= MQ&0;M$8=5U3?EAF-+CY6,G9>9\^X1=N.+<>IAT..&@Y(0@-.*XAA%QEZ &I$ MTOID<5-C%D1HB0VYCIN4O5VH'^!W<2+94UT'<];RW;,#I,>%1_8.E?Z,7+B- M,"R:!(?'4#5*J/!8LLK(JXDXLL9#JWF7UTXJ'+1QL7?+Y_LY#B"\ X%_%8W! M*DB!Z1M6EA2WYK :*4RDS,9%Y2\W\I_)>)8+^!4!1$,V3D>=ERRP/=#O'\'B!Z+\W+Z[@RC?!JV>0YA"71MA>HM'%E$[,05-Z84-,\K218R"+[M5987'EK!! M1F:) +3EJZ')O4J2[""DE8*&%_W(0\U:Y !-Z&V6DORG)%'L ?BJ2_LZ2&O@ M)Q%7T-FOV@):F0[4"PO13AMRI_AZ2;%AX:23P 81X]UF2('RI6P3& MIRXWX?U9L[T[8 W37E*/.,%JJ^R/<95=;]OM3*8ASL# UD']'8J3Y [%,^,7 M,_66W9WJ%)1% PHQWEK1=T4RTVA>YBM.+.TI;#E.3V<*9'"0LA*"-PKS?\>G M>&+TG(&D^1"G[,4-Q&MR IY,W]NK"7>WFH3SMW&3KPBIK=>&#]A8Q%TNBAN% MY&F60$^KX*;P*G;(P6DDXU.JI;87IU!+KHB?MO6.J M)!6]NXX3:R34)#B,W=!AH8Z-W>PVA222%,2R*<$7-AA[0H"9%6?A591"!)/4 MSA:SW[I3*N3F9#,)UQXXEJ)?\Y[9VC8:;?<@KXT2 WO(6-FX;^(H;BI'.XN! M+6&=ULXB/1H%GF &ZC$'X M81CPE&Q\;]8C\Q$&\P4^HX[6>.G-X4U&AG [:UU]V.!(3?90])@BHB6M/_!T M6\\NE&CAEW^K^Z7]%7H>A%EJ_!*<)64PVPD3)DE/EXMISZE?JZEAMU#AKL(K M_%?3Q@9%0)<\2%5K$QL9CYJ-VW)N@%WN3D900(N+YNN&)@3MZ1KCL]M3>A'F MO_7VN"Q59G9GWO9B'((DP1L("4D8/076ID]+CKT=EUIEA4M88S92R6K#9.LY M:4W0>5G1QB@C% $V=7ZK/ ^7"-9L;-S=4A"R=;O1EO7GB\/P89F,JJZ3!38( M0G8N>+<=*_9.))>\L-T1 MS>@U#DZ6'"7M5!-7D1=F?EXN'N40I2D*IEE:Y E^3_C*,4##_,[X"(^POBI MT4BG^O'*4^#&- ._E;@(VR_3&,_1^DT8\[V961N!S(OB">)YALALP+HA+A[[ MED9];4>%_BCRL4K/$%;IDWBR(+^S M%&SJ@P)*L'S^*IU)D%5.:EO"FZRR[) M=R\H?ZT+[_I">ZQO+:%L.-&9TDPM?N4R+NYMZ7F8.ZYXAHC^:FDC $J4EK2Y MQ.G=LK.R!;*&J-'5 16_\->@F]X!B-:!!Y-)K+(_2S;5DZ?\;,)D(1&&-)HF M0W/_5&_5:9+/KOQP]C_#\8X\!7X#'_-_,7]1*2/3Q<[7;0:W#IMB7*W<$ BT M-:F60.ZA;F>UR@D/T,._:J&809E.;RZBD>YBD*/#2TA$Z>@3(SU]BX_'.8(#/90?= M!:2ZXV"'/\S^($>&I>L<7L?N,I+X)8&W,RM5RI5$]]:^TP-2^.Q!]XJ:NP6Y M(90AN\JUL-2"M^S60.RFV#4@(U"RC#M;'W26^!IHZO@M"4%9(+(<5)L:DS#]:0 M/$:20G'_FQYO)O0Q5D@:SR;,LT-&WE]94.0 /:0QUQ#;8Z;4(:Q8-%P0F6MW M')Y$BMR^7E]H(%AQR+ND,+T0>^*5D^S+0,F61;J: +Q$#\97\8&=[?M"AV"W MR^)7\<>Y*K%HM^=9=!S8ZX7/+T 9[$@)[:_6K@%:YK4V_ M=R$9>"TD):HU/ ;M Y#!33_*:3K+"ECD"PNP_CQ6/<6@BYE@*U< MN?]=DJ?ISVAQ7C6SC#0,C7OHQ9$7A+ A>1*[79U6NNC0DC S.>P09RF] _4" MP?3N1!?B,C+8YN)JO0"AX&LK>0.P660+4UK M *$\M^K^4#Q+X"[SA%N+\W.X0M +;*S<1M-_A_7:Q%*F1*EFGD0$L5(XA\6? MM6Z6'@1[J1-E!;MDV\P^K(*RM6*T[4Y<16L\C6-DWB?.E^6V\(#B?.?SV(#0 MUE;:%COR8/T#@[6%;(I2(IVF/#9*(PU/*P'#,J+O84A\/G< 6;BMTNB MZ^S(EIG>A]NX LZ#%-@]*1]VW>Q'AS.B,Z0:&MK*5(#(4JQN6_AYF<["XG%4 M4JCSK,Q&5R =5\-/DCF=)Q M7V47V6GXEFJULXNRA7\]'/,QME5,1?((YNS&YRLXHJJ@+)-+Q"35Y)"5N+SD MXW7@:[CDXP)LY1R$+;HJ<(4$#")XEB4!N?\FT4?E:,I_,1VPKR2Z?U= $HNA M$>N@!+38@V&$[+*>&AE(_@^V&6[)Z^7-;U=FVZC:*3M'[_UE$('(1WX M&I0T%V KA;NK&59<(Y&(-9)@:APGUE8L35(/;2N)N4Y;J50<99S&NL%^'H1^ MI=:GW<+6=035OY<8RE5RQ3C6J>6+Y$!M. ME4GK0*45R$N*;?)[B^32Y?72+NI *P-5X0%6V;U?E?H=DRRW).\M2;U8>EBD MW/KE<;O4VBT-D4_^G^2<7H,0YA=Y58:7_"A+ M4I_6?U#[S>*9Q;Y/\^*I3%R-_[( T1S>8U0N9C-H_-QRX,X/ZLQS:&*M% SH M-(@^3;8^/'T[Q,2129JKM?/$D8$6FYPR%8 4MQ1ESU M_!EE[.QM=!.GVR2\ES&JLG=(&7?B5AQ;>*KS=9=[0XR/M:BXK6U?I':+_$IF M+8?<+1J'(#!>%UE-MMNSL@ZWFAA+U@9S\9KR%LU!5(;%@\@_AXF'@A7YKWA6 M78GHEN$NPY3RXB=AX%E\Y<06I&FRU&'9/3@ELS/R[Q!,L)XN7Q*4DP:$6P6> MD,6/"[ 7:R1=S&)VL+;.431L58V MN'H+U_L9$K@6+/U+'4]IO:6)=.F7]E?6/&<@#)O330S=UARF#*X]G>(HQ3/A M(LPU]=OC!,[)7\R>0!^R*:GTE>)-X3S.INEH&F=IHW>V%(>\8&?YZ(53N.EU-L*12IV?3V(EI3EC92KJ@.%ZN4=NW;L9)"W6ZG,N365X>LFI=1R&13!@2#RR64LWLI@M#U::5UZ[-H<[;5I?46HR=9W-4K)L;5L%(6[ M\^QKS83&78XBS#W>6&J!8L0Q7A5IU#JUT=M2.[^)VM K3T=K4_Y,Q_O^P*<[ M28AK->B-TG1 M';)%V#?>Y>4>WFY78%0#1JDLD4Y\/LL5"!"98E5U*BW-TFI&3;-P/M?1+*WF MY#4+X],#:Q8QG+L\,8RQ'E:ST+LBU"BR)/1(172A1E,U.(Q#F";PKXP,8)U' MB':X?ZNW8RO;.DM,EWO#>H,VKPGIVL'O,VBGPG85&=NC*@V,-ND$ON M[\H3X0,I"'R1I,$2I,8?[>TU[C#QBQI5^Z!8>JM8HLS M@R3[_+P RBZ+8GE#LF$DT+/S+' ;-F*7+::8P>QI;*#$3_RTF+D *,)](R^) MH78)$TMR%<*C1)$2M9(M7_%6/KTL0H+P$;>WQRU6$>YHM=UNJ8=;D9 [' M&I'$L.2070!6V6G:3+C.76H,;RF_A=ZK.1D42MAY!5M-UMFZ795G/*QZ,?O! M&A+KQLY"TNG!4%2B%KK5>=ET'<7'6M]1'.&_>K"VMNUN.QL_WRF*'Q++ZMA6+ N\+WUY!91? MG&K?<7T%CX$>O 7TLQ"2I'_Y:? +]*]\HJ)G ?1'20+3I,J.C-5WK:H!_C=L M)_E6PRQ-]\ZA8:3ZML@X,<;3K"8HK?5R'..E&>7YT,C1=?L07WU^X'9K

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

CAB?O(]&AD)U3KI:>LY!HZ&UIU$H^"QB( MV$@73X$\B/G?0Q%%T$26I4]W81RK9^HH,-D4LU$@%K5; M;:Q]@%JKTY"GYOKP)E/M@.HM9F/DC"INK4ZMHW' LAOT8Y($D*1]!>4&NYDOQXG%0@1 6'3R+B.I-'/"+(PS$& P^[Q3S M';MUU)#DGD :Y+'KFEX$OVQ9_=9LF=1=]Z#]VWE<%%>G(B8T!NH%P!U0+X%@ M#8A<+58I/C[7'YHRPEP^ZE'+LFYLAIHK=8,J7EO9#'I1\3%<8-A[J\L>Y$)4 M^&\)4KSM^4B'^QSQO*.-3D_5-,$#Z7] IZ=#JY:FP+]3N?E&\Y75KM(OQUV^)6=PZ(MX72Z"BE50G<%; MJ,R6UYNNY9;#6FCSF&M -ZM\O87][W9'";F?%$'1M(I&7O2^"%E!$.:<$H?N MTT40K(+*95"]#C4TBY4*1YY3UX86TOP (FVJ6>9J7;Z+I:Q2ZTF>3M^S M^$YD-L@062S?N/JO_R=%W3R58%>.&PKNR^42J+F&6_-"#4\>PW0HY/H+@SZ< M&C&5X@\.%AJ,KIS%MR9 6>W3D]++9J[ 8"%MWK6[&34&ES4V#=6L)[T?5#$@^$.M!QB YT'.K0A;@;ZL#'R*:H2VM'+7SR46:A-,F, MU0%@*R"V1.$S*#^ ]1"[Y\3(VK3&;S#T M%<)!>7#*7QO*T:BR%'YF$_[I^-&'CP:/\#*$7=_XZY(?.K=]-LNIW(N14;WB M-U&WZ<%4:%'+XT5K&BKGH7KB?U237NMU3?P''&PC?+6ZQ?>@(V_*)FOG,32< MH?;$T:[XX_![0;$<#2-A0"A1>6(GY>4M[.ISV!(%*[1O0]]K5Y@ M.4;E#?:3^QB,E?. 0!>NH-0@+E)-P"&2TG+09 ^.H[--5S4/E1)XM9CD-7(Y3D[^J%+!I M"WR.Z;^(]!2A#8Z.? [@O6->B)Q;"G^K0>%OYT3A;Q4H_*V3 MV!A!N#"[<8X9>EVM^ 6%7DNHP#M^3&EI+_6A+W7O-3ZI]W/ZI-XK?%+OG7Q2 MG[Q?:%_=1KM6N:.DG( :,[B^$A>?AA ;WAM>)>*ERMBEE2@2Q9)A_\I[#]78]]('3 M0?UOVK+%W0*V:V!S,+'XY@('9R?.ZJ;N6,KBL-J_:(QDSX#=(%;6<86+I:8;$- ^L><.+9ZIT1&P+W],XOVS,82+P<]@-4 5;WFJ6%(AEL;BTA MNWS@?=TN),&>!7:;X\T#CB]PGD #,F\KUQS%<%2/1YUL#?N-,K@(]*PQ*:)V MTY?"^SA')=O!H4LETZBGS+ M=2=Q6MWD& !,=\=)('3"%D%CK;D'K'0,2E)4K(!@"?>!8U(,F^S2(HK%X+ZB M@?JNU*Z7WEIK*?#K M%S0#*,EL^!#8?!:BSRDIX<@$&4:2:S>HTL;NX<.M_]\HFW.TJX<457463UY: M90+34AE7JR9V\G*PS3(]S3V;M7KHTR6OG _L?% G75^770P[TN.P@.STA.6> MD!.ST7*ETD40D$6SXC\788R%48G%45H,/2A_0# )7<4N5;<0%_ZA*43:YJ/& MIYN_+F\_ILEV0\[P :]!-10,F:[=[Z"$?1_TGM4O1,\2C:DC(XP57#)LD'N7 M3!/8GDNFCXE-E\Q >L*PE5'&GG/S--Q:%M(4#74*6.Q\T6XY4/D_:A#%H8!% M6P:8V?):-9CE4*\,(M;3,HJDL%R@>I-B/Y26$FB.<>UX;\+"D_T^/C8"7IGK MB'YKQU6]85R4+&J/D?X0)U^.;%W5>HG.8JX;<+MLC1T4;+:FUS?KE. MN=AVRIF^K,N9SN8978H73_\J$,)6H:FB\&U6M;#$P3(IX!'IYG(.:DQ"RZ3D MB[M($ADR/2TSC+G]0FRB_,?:$*+#J/>A:+4I3N)5R1QM6(QL>.$EJA9W_.QA M3!2NHV=/$EO.?? B+X5XLCCXT;N7) C#N!U]M89QM#O4U6H5^CAM/DEIWT55NB4GL,14[6'9PJK3F? !TA M-CSZ#Z!NMYS!>A,E.XP;3>,'WMJ'ZMNS1>:2Q2C$C\>8 6+8?Q+I5=?O^]*/ MNKYT!G?3"7,.QW*1*:@J_!!9#HFVC)M M/WE9_N(!F%M-@,JTAF)*-(2UG4OU0P265CZH]#C4F:> MPE?)ZGDWYM.OL\I9==MW3@5+KO]%G3PV->EQ$C_B-*--OZ@$=1IW<*.:JSDT MJ9V]S?%:ESAYDA/CPW^2&\+?KA;EE:=0>"<5E>>8RTOI %K\\TV!$C9#+<[7 M&T@19CT4X#8JJ(+,[85>S2WOY,U*T?SJP]9?2!3PZ[^;*!/%=CTG/UGCI??, M*8LLJ,I.QB,RX:"L"?USKS:TXX!L$4Z\KT>.OT6SH.Q8*.PA4?S=J7HJ@>!1 MLHV 72F^P8\XWF*(2Z!/!IZ?_QCF#\?;+"?6J%R@Q3/1D/-7T%ZB M]@E7+YE MT@X()W@5^J'PD^@7#GS1F(R*V5\Y_@R&\>,K-C6JV'* "IP5U!5;!-0U0I=H MK22" F3T!>?..YO0'!X.PQ=_SGP<;08,'GF9?F2F"&_WB;1ECY9#29LP!1$YZ!J$B]UPS;9):CTB#^( MML6K*"TVFCW4]9/BH&IC>Y[C]7!)*K9 H_84N*OK)L!TD1G%6B@CS%-/FM1R M6\GMM4;9J==S*COUNO?%")%S2V%A0A^'PH=SHO"A H7M)NY5T4U/<0:&V 6F M'NU&L,-)"!7?XB"[3/(;'*[OMFDF#KHDZ[RD"Z%BI7:84;48A.E!\>%R/=?J M21=_GI8RHZ'%<[\1(77ZC%,_S,3Y)]2^*J+"RL$.4R8XH/.-*QYZ;K75-QK: MZILY::MO%+35-_;/@[]X?G)W&D5K+V:A?S3^ZC[%]%.3F[%T+F*343T;5=/[ MR4'6&:&"7X\SZD2QJ&_ZXO).XUMX-Z=OX9W"M_!N#K;1&PT*OYD3A=\H4/C- M'"C\5H/";^=$X;<*%'[KQ/JR6R;\38U1\,<579H%@8WUZ/IU.@>=&H*$+7H4JN;N?1%B(C,L "U:^^J M--'AZ ?0_FK:0=I8QVE?G5'HQWVUG8)%]E*%686\Q;IL#,A/#BYJ_[%A+I.! MF^#V/EH>-C:UX_'-+73%W$;@S[VX.);?VUJC437T&DA/*N>UDOVKV/!(35!#D'0_JA+&JJ>K:2W6$/GW#U:E+BAJ9"NS9NE^3 MU+H.&\2LK\\4B=%FD%9#C"I,B-$!?@;^ND[/E#-+QI;UP]80D@'W;V-+UICGQI&JZT>9%7Y277.7DU7IZ^ MF1=Y%9Z>OG%.7@U'\-MYD5?!$_S6.7DUXFA>SXN\"H$TKVV3]_9F\??6M8?K MA&2#.(^@]GV/37C[+L<^-@XE]3MU2?UN7I+ZW;"D?N=<$6BT1OUV7N15Z(WZ MK7/R:KS)OYL7>14>Y=\Y)Z]&Z^0/\R*O0N_D#\[)J]'D]?V\R*O0Y?6];?(> M>1$DXM# H0"*LXHLA6(@"YP*:&E:ER^5/;C[;F ^9C;?)V6U<\I>*E(EU'UVJASGTXU*>=50<>+:-3AANP- 6(NQ.RD945J@-!&E.< M>NY%>/!X(L?9ELON1P_"K/.!S.9RE,O49@ZX/2W%P\9V'S;6AK3;?%2M= EM M%@OQ#IRNL<.53%S4:%+!EB?]&F2RF9D.@@/G7%%!BA8+9B)UEJ1%R>/L*CV. MO' MU$[E(E5)K:*Z]%/V$M/X^#$RX558'VM53C(/; M[=TOV,^7"8MUHZ^>F;#*5C47T(:5.%I>Y!NKW M0H=11#VHA^^$UE.5>YW"%MO\(4DA=@]@>-I\FK%V$N"?]$/XV MS_>+Q(MIB[ L([>@,RP\ F @JDP?E4_/0BTZ2[5V^N$NV^<<$2J4!%=)X.!"_7@'1)9 ':R"Z""I603_/ MIF2F.L9<%FK2RVX)_&;UH!\2B'6^">\?Q/ZO7HU@-@FQ63,J#]Q$AL>6(=1M M!JI"FA.YJ]Z'CQB"G$4W$QB&&N-<^NT[(/>L7RY*5LLF EL?DBC :09^GGPG M/3Z*D;_W-DGV!\0FH$7.&JS1;)\\0=>>\PCM/EK"8X.#O.WRR:WKYN>8@!/M MP#[T_")]99%_\M)?<2YME=.]D1\@6*"7I^/&$--#D6^2F9#)+BNIJ5&:B/*W MD7*46\:T !8^@K0QLFSO\<['RG;93X%O8L4G[P& M>CG-M8"_*MI\HU>'9/;;R+9,EJJ>^G62TB^Z88TM$Z@L"$78DRAB[=HP@4B8 MW"NT\9KEZHM]>F9?>RM4[N7:"30.Q=3,1W->V!4B+RJ? 2^W$&%,_M&H-WX> M+\FAF!%])6E,!<6A*Q=>@OF#>\\#.%,6HLYO@XU4";RV]MLEGT-UV$>7A/ M#_9;G.<1M6@*JQCZE$&Y:6K+D;Y=3)1P)1DNXD[1:K,9W6BHYN>B6XHEM<&YV&MT,KC9936J=78W>D M/%KI5NY+2;6J W/$@U?[:4ZEDU4X.5!4J4V"Y@>J)5.WN9=3#7"U*NHO>]%U MDH7T+)]&MI2VM!K%.PR/0,ZJJ6 &5)-1.9LO<4XL0G4NM^T]1=)8ON!M[\BM MY'->5A+:;-+D$0!\!LKF%!, 1<*3$)D%H)I#@,8 MQ;CP.2#&VL8;%L!QDOA;4,E+LK*PIE Q!L$@)QJJ"VF7FGTL+#O9L;]-J:XK M1;A&;)_@HG8OZ\;RJ%[?]5UD/^H(O81[TMMF M1, E?BKZIP.L:1*3'WTFO>V',8N&IFWGK15"50%B^LQGJUJJDW(QWN]LA;D@<@'10)'%"3D@-U@$J M 4,%9*@"#35@0P#<#&+G[#*#:[VXD@E[6<0-$.7G;V.@TZAD/M2],U> E\VW M.&[@IF%XZP$J6^H6X;Q.T[RXF D_( $-;#F9EZD'4G"[6]\ED8C\Q2#$1CET MXK>@[=KN'%2L)L5M-BS$QHL^Q[AJY'>$8[P*\XS8MEZZ X46QENYL#=60LVE M4+G6 6*KH>9R3F5>&WGN]V!(0LM][LLVI1NO3!Q0Z,+*!L^E"RN#IGH4YWG!F=Y&OK$1BBJ][1_T1@I[.A AAUPBAO5"R$V!*+ .[]LSG!= 6$? MVG O&?L3VW;#ZPVQ$L$#/9B.5 [LIR2Y2$CJ@LWCA@ W&^8 50$-3K=O^KQ/ MJOF5N/9UB*'OJ3D)CK:]&=6S&&3+JC6Q:SXNTGQ@62\Z5PX."5Y\1\<@(2R8 MPQ* M LGWZA)[@,IM#\0-8UOQZ7.)-AZ#I+PO=E+NV13#XKV-Y8VN0/M (R/PB5RG M>!UNUZ+#KSD1O/U4%Y=ST8MB]E=N786#V/%XJTB2UEFI%(O.2M"M-UZ8@@(J M3)RA7F$PBP:7O_[P]I &F"NO8[&(G0(X@MCR>F9IIC;[@G$JW3FH-:C.L[K4 MH")!+/IH^J6OBF@6.]4[<_1 S M^A)66.^-/$4H]\KJBGN[$EZQ!ZOK3"OA$QJJ%K\IUG=WT]F/+GS/ MSYYDMO@A&UH?BKWG)S$AQ79C6?&W\4>7;HII:3NB+:G%35MA.\1""C 4P4S2 M3-ZEN3ER#EV[^I#WM(0(.:M!WJ=>"D_#6=FT]LC+0E\8DE8,KCOV'B ZP6D\ M#A<%WICA',UDW=;@8]$T8 M":)6BU4,VA&\@]Y1A0GIN\+&[ M6G0<3+@O0%*L:TG6S/[OUO.!'2;+^Y=NYJ"HM! 88;J_J" H3.9E^\^B^A./ MI_*J3CU:6#N7^J;[4'D\SN5I!H7RQ'CT3J@AE/4=JISR#7T>3U_=0[*GY?Q/ M!9!4*GR(O_^Y?/H:_!;4^1B@D/ONBM3Y=(F?Z%^,LG/I"O P]\0&.#:WE/ 4 MZFTU MF[5WA;G)[&.+W?M;IY\POJ;:$L,!V,.$W*K=\H.+#W[Q-"!&W%YK8* M41R3'Z_29?(DC!OMUMZ &=#C#>:X+G[20Z(;E"#%U:8N(E\6.9[;O0%JYO,Z M)K$I:($ZG1'0SVR>VY-"C ]7TPRA;TV_'-_<'B=QMHT@&"Z[N#B6JYCV<%2- M=^I2%>#04S527.TVPUVM0I\8!$I)&2P&G?67O"?G;#'Y )T^EP5U(5D;#"J( M^Z CBVZ,Z)88'DZ#,3F(MUD1NY+,QX$(1G.^T:Q,>@ M=R+*$+44"=.QJ!SL+ B8 SC?VN;@9M?8:':A M;WJ\M1S\D/K9]?&[>Q^1S8W6$,*XS@KDQ[Q#F6H\_ M@.ZDW91G!^078,$COA1AZPU,5F%^D61"N^ 2 [7]9(W1"QCWU2CM*MS4("E0 MY?&D2PA[*9W\Z+:B9_PR63Y _-O&BW=A,4B87R@,&2P6@_;A9#E4K5>,=7D< M:V/?O[N:T<]F#&G'L!MX9NK:UKP ;-MLXF/0XX4,45LFZC*AV=M>6<:LG5,, M<>"B#XC.1(VIJ)M#W2KMX((/P\CU>*)*#\NW7"8J\F_ <>H*A8%W6#1AMTRV MHO@(46S%5T8MN;I_H[AK;C$1CN=B:M%IIC'9I0$UB!GWV%8CA^VRA<4S GWL MO$J);?$8$OQ5WTWH-'@X*2?.Y/&D@X[T!86+NN46X?C?6TC^>:0"HM(1G$U M; :_^[>3VB8"5+CO)W*\YU -F]45A<\U&ZC$.ORRWEQFOF_K32AUG]?[A+)W M-2DKK5^GQ)8N0\!/_PW%T))V.57.1G1Z'0"/Z IP&>'U-G%@5*FAV3.L M=*AC];O[G.&KU6F6AVNB@X5?%QD%#V/5.,5VHRZ^K39"O"^(A[)AI"IS=E1Q M2A,%KXEVL6Q."L 0)0HS/U =J3:?/F<#7.ODF0IQMJ=;?_(VR:>[@6P(&(3( M*-?Q2BU@>XJ0@XK-BFAX\X#C"YR3-6/L;4^KLFU5:Y"!X#"V JJ70/4:=6<5 MUSQ01[3'(%T:62YU0UN[ANQ==).D8L]_U6NHFH#8#.?U;KHH=.]&XFA)U^2KG"8;].]XF ;[\%L=%$.&=X8H*UAO8G;I@I[4DC7Q%>G MNBT?ZD7BQ?)ZPS!B!B7^:T![2J^+@\V:/C]Z4!LXSZ!R(126;I::AA=7T3=4 MSF,E(.G,=HGP3NUO)Y_'$'(\\51W,! MAC:)7#R9@E,,0HN+LL]#42KEVS'U"-( [V(BURGH*AY2B!:/%RJ$L'I5G[8N M%477?:FQ Q:&X/;US@*E>1)GC<&N:URFQ(8OHT#K:HZ2:LGB:I>P5!51VJAZ MV:E_/)?"ET+,!4\3VK2SW1JC/K"H?+%[6.,ZKY89QHZ/LGMU8_IL.N/QL1LX MPV4DL5QVQK0Y&I$X'$$/"!S\0"2.@#_Y5:JQ)2KV[-VD7%VDQB2A\"(U/I\L M:P5(::@;J]]@+X(3[*,7QK+< IK*44\#^X)-1#"SR#=PJQ#DB/$8JD(*>\^C MBS510=ZQM\/K,,\'GIO98%2-[M7>LQYVSH.^YTN4X&A7Y\*30VF.'0JK2,&@ MTB)V:J^TP.6),@KGTGE5L!FX[S6*= ^2MB.&+R%*.!7#FTQ51L:3KUTU](BA?Y!1(:;F3I. !KE72 MR^2!TWG%,W44M5XF.X1QVW HKH:T>&LA%[I* "!H\XBW Y%5O?UP?+-^/J# ML@)AY7NA7S3;Y( ?RST/3YXVH11==88,L&Q"X1R*AM!$G '1[O/&;B3JC:/ M"S\/'Z75HB$ZBY9Q*=> V_P+6(9(P%>H[G%9+^7XY44=9Z[)I4DQFV\U MC. MB$3&_AC3)GA\VH:#MFZ ;?PTNZ%^>7 MWGHH%;0>C&"TPX;W/.#Y@4,\!"U?8#K)CP-A_YV$3T[8@/MD3TFA3#&NMC/Y MJX\,TK"#@!I#7@2M1L[C8V\3YE[TR4M_72;P_\5/?HUU:))ZM1+MR0+69K'8 M 3KSPI0%E3MEEB[F7+^ $?7L:2\HA;L@=]CC)! 7?:2'#!F$8)2[;/4FK%TE MUN=M9LKXBLT^1845LN$7K.'5A0"2+.DU3?5]68.;M^F@W8 MU)Q//3)8RO!:$+T6T")GD2<,#*@&(1CET-9I0=O5'QQ4;&7CL&P]C(]PC%=A MOH@#_J.QR%M7SD?% F@1%WZZN]ZKO;NW/E4L>]I'CSR-^YU66C@$>83LG"8[ M'"5VWK/G+#DFP*9>=!X'^/FO>"C'JAB-Z'!$ MQCNN?-R!GN\NX:)H->R_]&>SB'=9G%;MXF]5@G7KW>"S-UD[30-_63<&CHX(FV6;&K=3,N0D#@Y;!RWOV$O32[ MP6LOA-2K!I*#QV5SFP/4<1O46QV@AJ.3[@:':[%?XV7 6MK,?1:I-##BEZB)&8 M&I$JDC.V\_1!-P 2'#9^J-$TJ)L] D!T@P0:_?-]8^T-"=J4(_W0*PZU?#'A MF5U-7YJZF9XL#I@NG98X=AB.4=/GE]Q)3UYIR(AJ6'2^%":( FBG^$#60[D_ M,%B@VYW&##+X4T\F/?-FD$)QVH4?#_).315\[!)L.-@=UMX$$!/[8]8/[7P5 MS;[-M](ZYXMR)DZ# T%53E,HR)<'DS\CM6 ?3"V8(&K!+*J&H)^;]X6ZB"KG M+]D%5^Q-"+XAG>INWWR?U=*_/:_W_%'<&26!N7B;\RTPUYK@45(64@/ M83>M 59$!)M=&S&VAQ3E&6='EOCM9,YTQ)80BY\*#1;8H1:\[F_4 ?93G7-! MRD]M[N&;[G2^$@4DFNK^*\C521"0=!^FZH7Y,X!KUT/Q8PP710D.S)U3=9I$ MU&B4[VP(SK1,GBR'B ZR>6?PI7EX*FI@V%-?]C/4!,@**)7@P@8Y5= M210P#EW*F-F!$Y$XXM!)TA=K8K:AE=GLD*M/6?R%T@9P2XKXXQOYOI?25,?XP8 M3T=8A960)B5IH2W03[8M$;)RX&K\U.Q+V7:Z5FJ!^WK@D.Y_>E@'\FZ 0?DB MVU^";ACK0C5XS']7'_R@_@;_IH[JQ@1LY:+6_)0*JGLJ5L),19C8"IR-@/E3*_GN" M]%FF='*;YEQO9JRI +C]35.KJ79* OCDX-]]]6TO1X2<,_@$QK'1US*.[H * MK9<5+*H9VAUSMJJYRX,,\($!,0'[1&/:S2.ZWK07BQMA45W0AC-0@%2,.S-8 M2+K$9*;+4H7Q?NQOF69HZQ*\&7X72@X=GIO5Y+^()D.I+Q=8,C[#]'?U7C2_ M-U6X? I;"=4L?^74=,(S.Y22A[U>]N5EC[9'L?\H=U+M*>4D)UY MDH.6.Z6Z?/ S_-S4?]6/,MN M,9V:A/)5$)O+O5*8M$XKI0E!I)A+0K(-=(6*HDK7 ?_\5>;G9XHU37Q:XJ,:D3 M;4-9'=7!)UOD*U3[;P!\!D:!Z[ M1[-G1 $+2^--P'].Y9![59,%]L23EVB+'6!;&Z-W![F'.)P?4ML8X] 00X^Y M%^5TYI3N:>F858S+G>Z4TE]!Q/N4+]4ES=<4E)G7;OC4-EWWM6UVE5?EV$3H M-IE#?\YL*;W.A&%ZE\?ZTML?(]>P]A%'JFAO?[B\RKI+/B@?GQ"NLN/"LEY) M;-+$7=/>2?^A.B2*[)K6'*70?"4)(F;RH:20B7PY+GU>U=J_9_7JVDD$+FQ9 MJ@=#D2/KXMKLM/?EC)C=FH^^3H:\ MM::AJ;J8.6>Y'5"S><\<3A[)N!2;S$U\ UEQ>PR4W,O^T-:R?&@>GJ2ASWUK MFFC[.,1OL@\4#XU0CQ3#,]\-8W2B]N8)/!=9GAP(.TXI^@@2OMG]L]&EM;HF M8 C'+4$$U/B8-]6&D:>"]HHN%C=4+ MY8Z<&+7O/&_$;_A>:J%8L0R@>J'N^O: R)W%5EX_0VZ5WWL*A1M#!P":!C = M[).?AY"2A/:FAJ1F1$1"[X;U[6+U2(#Q5[M"!O\U-L_/Z4N*X/6DTK)RIBU0 M^ /V>YR&&_TWDAFFPS" $X+-FN:?)"1]<4C432X[)1)TB(4;5@'C%#%$,L08 MNK;_SQ_;)UD>(&A[T]0EE$25NH1TJ'!_0)+%6*+"T-NB.(T%___&$3QY"JR+ M\QJ!W65[O<*XKE/F^[UI="'$?5%U&'1WJ+:H'ER#3;T))T MP.MEMD&"A\88A-:,E!UR6T(I?#XUC_6*L-<, M_9W;89>4H)AA59+DII9K@<)X\$$B^-#5PD&MB^+ITVOIN?;8QW.AJ&]@ [9XKH> 6;> MAJ"@K/Y2<*]O=B:9SN^GZ]!-8)IE]I).IDR?6S.9>&V\:=1([=W&4;XP8C9V MG,?-5A Y.Y4K'C^C-<'ZOGOH3OPL,3Y:F-QKX1&$6H2@S,RW'PG$F9O=Y[JL MCE5Y*/;[GY^?G]7>UZK#B,@]ZB+,TS@>[$WNB&(<Y@3566#J7J<+ M\MITEEZ9KU)?VV8K9=D!$8 #K@-[A=>/;;IH5@07G@AZY;7L N*0'NJ8])Q^ M/6<" !BJ+]YQ1X2[ !.W@P=1-8^9$!2--AP2M,'-CB/[*=W:WXCU@##.A$]. M7/=]6WT[]!A%[1N@#LF_)!-9J 4@A&6.N;4F[02]'D'4OZ&I=?*8JHUUA!,( M0>C-R",OB56?5_J=V=$2C8D-[X]K)I>Z #+[ &"DJ5Z@?+OE@>6]J M=V.[:UH3__866-B.8E-/=WQDJ;&]P75S06VOQ).C]RFMT<0\L(9DCGGS4==%S;;!VDJ^ M#*D!!&Q8.(1)_AG@R'*O4)JL\?M26$O(Z87,0+L9/%(]U[+4\-%+M=J#9U4BV7YPM[8P52K\E%UH@Q+PEN$E6/^2MJ M3FJ+@1PI66_5K!9D'3FCX LQ&2WP61$R& MIXEY=$7]&4MF[%.!W>ZE M>GJU[9%N*)W):^SF)?7*8U3[1*)-ZK "F/>##T57J0FYR8P QE&I VM7;8NZ M-XPO8/Z#B:G>G>CNCV."VWR27 KG@#.N& <6=F3Z.,AA*)RA%=(J.%O+UFMG MM/)W]03SHJA?U'^ F0M,T?\#4$L#!!0 ( %,R<5;U%6]C5S, +,F P 5 M 8F9Y=RTR,#(R,#@S,5]P&UL[7UK<]RVDO;W_15:OU]V*^7(EY/C M.)6<@*2D\:]_ 5YF> %) &P,2,=5NR>R M-(,&^FET-QJ-[A__YW'M'=UC&I+ _^G)\V^?/3G"OA.XQ%_^].3=W=/)W?3B MXLG__.OHZ#]^_,^G3X_>8!]3%&'W:+X]F@;KS9U#CF84^>$BH.NC_XK6_WWT M]&@519L?CH\?'AZ^==AG0H=0' 8Q=7#(?W'T]"D;,!]R2C$?\(>CO$R_\A\_>L3_-$9Q_\$GZR1\>^2]*GW]XF7SZ^>O7KX^3O^X^&A+1!]FPSX]_ M>WMYYZSP&CTE?A@AW^$$0O)#F/SR,G!0E'"R MOGS^[6/H/DGY=G3T(PT\?(L71\G,?XBV&_S3DY"L-QZ?4/*[%<6+GY[,%]L' M-LB+%\^^3X?X?_PW?](_IX$?!AYQ.>]/D,>7$ MST9GWE+C0C'[+EZO$9O'XHXL?;)@PN='$\<)8C]BQO&&\<\A6&L9DB.G@, L MYDW 1F:P.YCZ.E,N?1]N!^:@,4=B3OP$5RV."L,R-S#5T&$;] 6S?F7M528:"1 XQ % MSJ<;YK*NF!?V 5'FXD:7!,V)QS2[UJYO'1#,N2B8H=0*];1EV2!PC+U8;Q"A M7-+.'C?8#[7@KP\"B'P\#_%?,1_[GN\'/15?&0-JV]?MQ,DV^4D+YY;1H"8L M4LTSOE?!%'TV&IC=9R!)1O!^+S<$9"?;[-_@BYAZ:8^^G)W'X M=(G0YL]=O/%Z<;3)4);HB33^H"R..R;'?Q_W#=Q4X(7"E,HBG3OUMF^][S(P,PH'(T M\^UM!^)6P2YB*LE *(SU=FGJ189LGM?1"M-;[& V4WZ>O<)1MDCH72M%>8R]:1"";[+J\#;='OG]5&-*AM$_ M;+@XR;:^#/SE#-,U%YTP/> #0]5(9B]:0\:LF4L9=M]I8!=$R"NH/BWX;BB/ MT$;;&P^E!T'F96WXU.!U82LIV]:L2XR+8+;SS.9YXTT0N _$\X"1VPT[)I3V MO(!R'/6/\$;.[",^I/?"I*3V=#"YW%_*L=V;!$9+*5^&(BW29(O:?$30RK,5 MSMW7,WJ%F9H-KK40LKEY53= \K&0FVZN.:!A.QNAJV-_8;&; ZU21N*Q\A0 MMFU$NZ5?%)R1XBF< /0Y+?(7#=@/LQN+[(K+4)A&AN1 MKK"T;*=@S;]J;M5 M0"/N_5T%_@GR/UT&R.=*C%_)AKM41-@;'AF2X\%8CH-0)EH[I%"UI3,U9RZ' U"<0"!?.UU6NM2^-/R-4U^G79?P MEK_G\;%[AJA/_&4X<9QX'2% ML-YCKSU:/@V8R.XY<%:/Y7"GJ60>6)!_/*Z^,OR7O<>'U5IE7]\BU@\:C$77 M-"'G)H[L#::)J39Z.&LD:EM_ZFXR69[:3:LISS+UR"9QM HH^;S??$80KQ$; M:6ID%PMMWSN(YG<1AO%!X,T(C3&;N8UO-C-H1/.ZCB->ZY87!3X J$5J7PJR M)0Y"G4-[!M@.9(AE*(Y4-TLQ$_!0VA=QPP:XC=(XCS*MO.N1K@-Q7UR9F1&; MVT1EK%YS(]&;%;EC;VZ #F')4/&>%K0=4;S&O"\>V6HCOD,<62;AV(%W51B!ER6EU9R;%I*V%]FU<)#0\:NF8[E$ZX";"V\LIHA._&2 MOV,W[03EDOY:8H,M7V,^T[YANSI:5= MR#S^HMA=$Y_P!4;D'N\Z"L#>CZR9SGA49 NO>MRR]$_N9(<88YY)>6S;^TT%K#)3>ER5 M@+S%RY.[\]MS=B E#C!68AHCB:DU,"C#[7L[UY!F:VN9H-_S,1$6_\N"ZSNAN&"8C^(+] M".V1"@C8WL9*HE9^)U8&5#\F[?4O%I%-9>JA,,P6,GDDQN"KT1E*JFQIFKCIW_"U.@Z<)W MO)C?H]P$-.%:%%$RCZ.TQC.O[QSX$2/L)9?9:?X(^#D'9%)#<==J :#<\SAXYPX_M+#1=<#):BV\9%+GWF>QI3+FC) MH,DC_>RT5_!OL#OQ768P8\H,YBR8K?AG-LC?ROEY0+0&H="%,(-QTU9UX(8% M9+.67P')/M9'+O2)#EK9P[/84D,B66%//W(>I%?.XI+]/35& XDA6X2^W+.1 M'"\MNN))FU$*';1&9RS4N0F65:^H ,1SQ/2>.#B10@[EF$@(JRP^P M:BJ 8&F:;O51AQ%IU<&OQ?3"%$_1.[ WV) K_)#\!?[>48:F'.U0W@W M4\'NO0"!STT'[_T3,G9?+PI]@.ZPPSYJH.5.S\E\>:(B#8/5U\,3]V,<1EP9 MLO4VW2@A^FD6\/_%X'V]5 M#IUYYZ("T'$ 7C,< M^&JE2G0)AC#5"(!WY7F\!9@N" MST$J;,NAM1-S2LNH&ZA<5AAX%*YWD1'Y#9*EYI8PR>Q_/AOL>X*!BP(<_W-! MTDY1/_-[EYBL)<[#"\9P^SVUXRSB3 Z91LBJ#MD0BIY-4;@Z]X*')[W+'K$S M1S:6J7+.K:1Z!*>N<,3'8SK^GC"NGFS?A;P:W*YV]L2)R'W:6-S,PC0F,!2K MV8)ZI>"G,HNM9H+]?:J"3ALNX;.9,T/!)^3V5PO^*W<*0D= MWL3OAN(UB=?06J63GFUCN*; MSX8MCF*FBTYQ^M_"M4MP6[6"7F C74@<(XHF3&)N0:3U,[@T4A)8B:;F[!"C>(HY:;] C,\U; M['%2-X@:2'?0F(#]9A2&Y:+*< WEWR@E*D+2/-?LI?E5]?%70^ZAU$#CV^MR M_-%X90/8+:T^Q]-L"@;/\I)$;9_EH'>RF+. Y0*!O'E^,3^-*4TND-"<>";R MV.3ICF_C:_#6Y>]M34^EF+'PS\2])&MJYK%'M [@[H_0Q MUMIUX1=QT%?A,U0S:D!YX ?5T.8UK8/%(;DH,[7WG&C6;7M+*"]."<^\AV+]J)M E^&O6AEL94N#U7A3>\L>6XX M+U8Z#4)CZD!$:9!>H\2^$*D!(2LX477FKQF<(GVC=2^B)@ M;N.DS2O^XL1N\68GC87H]-8PWJUD+6MR>/3;F0R8%=!7&G)=Q!]I[MI^&10# M,;V!.GL]!*"!KU;Z!66U9'BQPO0M"/<9LR"8U)U/ZP#CQJZ=-Y;C_?)+L^:, M#Z7\.K@/#A>^TP2?SY/_/W_6=8\\G%PKYZ4 D_@!;QE0_$7AD^GCS6H4^^PQ M>QO&?E@A?XEO&??.%@L,?IH[\.1'=A(\-+0]U%A9D@\NQT,2RV$\!SV$B/6Y MXFSH5W1PR0%_.MI;=OXN"JKP-%6CL@O88V+^U)E-;!^P]=V=F4_>V9H*9$K3 M'9,^4>"FG78)^9.*:_\JB';]4\X#FA?ZDSKI=(]B_;BC*M9)#;YNYMA^GK0_ M,*=EKGTWGUNAGO8UG7J(K,'SFY1HVPY6Z0B )I?AWBH>62LP<$V7R,]>7R'? M/<6A0\F&_RM8Y+>R3[2M3)8EFM3;\(AC\)%N,R'-H'"1,?LJ#%R0??>F ,CU M(I,OY.VL1L@UBA>$,<4SAL^)!Q\U!)^>Y7W;+2G%C0H/#K""M[*7[^+U&K$_ M+>[(TB<+XC#-5>?K$\TZ<>/=RJWL,+5!)8G:=IC4]ITL)^%VDZV]]";@J;#, MF<#4?Z+OM_525(8V&,R<5 ->18;.I+N?UK^E?/0I#G%9K2(E37S_39OG4E!Q MXAM;@(J^5^M5(J$'9%"C=%4769 @(5J6:-XSLN410R;TR">1Y-Y$$>E^9NR M2/*$[<3C6G=JR0PIL!#0L;-EB_)SV#18S]FV3DN)Z^8SB08S9&A:2?4(A@C& M-7_@DB1JVY^3@;>XE61Y^26VC M1KO'/:P,'5-[3)&XS;.+EBR4KET5&?TEF*Q"GC2_F\JNIGKLR.1PM&/27;S9 M>,GIT- F["2G;,C$')&/*+1]'V@R:E&&KC%L[EE9:>';M!48B*""#7=!0MJ: MUVX_UE!Y9E&&$]P4M=&RU'U::GN6C4PKQZ!LBK4K(GZOG7?+S2ZW\^H=VR>* M(=W6P<0&I4$'RHVDK)Y;AVW8!SHSM'^L48*"R[LL:\9_DY-4'$Z;@*0]0'IX M3_6&(ERO&.NAT$I,_<12XX2\U]3P5?4=61U'S5=J^;K==$$9L4BV70,$(/[1 MX;5.JT )UVO?)Q*#9?ZH+D_7ABAW;\SVQDJ-/!R_ ;E8;Q"A_-B3MYU7-R"U M,;K"7TWU)27&43<,M5'E#4/#5]4K<%;'43,,+5^WL9L4X$[*:S;P?ZRGYG9Y M$J[8GEUHP4KMB" UT""D4:C;Y?CP)015>?H _BOF*[U/GA_IM^2KC&3J)-!$ M1O?5875 DRDG8CJVWZ1V %?--FE@UOB=FWH:Y\DV^6G[M\SZ+R75I7PP&"]M M)F7[>EPM+;B=:Z";1#U9"(4DO%X4LR,GOFLE);S75$;U/J,?TX'?52F+S+L0 M7R_.PHBL401>/*0RN-5JGFJ@5MEBN4Y3]M"Z6O_!K,Z6HFFYE9>:ZI;CHI7* M3/D<;VBPP33:WGA<<_@NG^B&'U3,@BU-=E2J69Z9@.6=M&"_QN+PR"?Z!]6KHEXMJ%M=&,B.ROH.B$ZH)XC0M\C+\:%=V07/EM,O-Y[!\#0RM$"S'QU<4"1F#:\R^7&YRNKGD7JOF GXT5R8]+'M2YF\L#4#1L,.^,DYO[ M'C>D7\!SXSMGA=W8P[Q6?7*4_HS="Y=;B 7![B0,<13FW8J8]2@T0V1_8[Z> M:S3M'GIV5CTWU=?+X- YO=+RUE(H\)"I@';P7Y2=YL?^7?E.]2%B(U;$"#V MK[WP:)&T'.:4E0T]=MKL/[*?[1U>\LG=XDU N:VZ\)FN7B=K/=EF?S2O2-1F M,1*QZ,ULR&93=M*>LI4'BP4B])Y')H)%&/,7(%Q/(M_U]OIQMGMGJI3>OV-N M(?AQQTADJKBL@I5>"&F-#%MDI&YC.),DK$QVR6:N)$U D M+>>W *Z.5\WU&2GH:)*9.5HR/(.4RP)R@-DSMN4Q_H H_IIS_Q3^DD:2\3/R I;-[[D,[[ -I"F/6OUL8;#<*,+O<")V[RH^A*$OBP%8/[&\,0]:4<^*CE/9_Q5K<, #YCA/$#I'I5@ M?Y7I_G"#)7$/0)S'(<=5 ?YZ2*R#!]5(UK9$7N$AN\1\=E_#N"6LP/J^]A*] M9)YADIX?YO6X;BAQ\,1+!F"_WS] _ATC&M[B-2(\>7B?BF)*!P)-SEI5-&C9 M@P(+[-W% 97>FR!P'XCG#5OY=<[R[VF&N\&#>D=B_W8[]E'LD@B[3I[[X>S> MIV.732%F@AWJ+9YY4E6'0 "6,%1] M)[I[R+&=4>2';.Y\'2?;XE\FCP3:2U(@;,?J2&_C\K-1>78>N%376^0O@[8O7\VI@MD%]5KYB-8JD+J@%(J'U30LI6V*?>P$';%ZIL5NFJ+H,0VH"4QQXO@A4>Z5N% M>TSG0=_S;?5I-2]&Y)P2YM20>1SM#QB&WJ37R W/]LNAVLU'V I 0SDVAFGJ M-\WSPLD^+WR^S?[8-SUZYY3+)*'W/2\JT0!Y*"656F\@>TIG!KJ/-IH)*)TS M558G0])*\7 8N>[Q3,- O>2OAU#@DJOZVL'B\53K?'IY.=4XHNZ_91>H?L?4 MPMKA7??QBJV/:;5_26_4V#_ MY\[0HYFCK=(,K'9\4;#^@K.N&J=M/$K^^QQ_^T+:__#[.@7+QU'W+=J/__GT MZ='_?GC[_KO_^]_?G$W\^+O_W6OW\ZO[Y>];_]UI_/#F%7W]ZM<7']_-MJ'W MZM[Y_,S[)3J.[O OGU^]_/3XW+F,GOUQ?O[B[M?C^\>3Z>_/[MT[^L?WT?>3 MX"K\.?CGA/CWWY]^@SZN3KW?GM,I?77^A_-Q%GZSPJ?;J]C_?/X-.5V>Q;.K M][];\_G7S^8_;/7^,_YKXS_?#=U7OZ?'EY?;9^]_+-ZV7T_4'D_-_OO_^KU_//BS?X\=O M/E^&RY]^^K^CZ=WMTZ=YV763Q\MKND0^^9R,C7RW4#(D6.17N:5 -9U^!1L,9L/_DR_>*0R^HHP[UUS/< ,]PNCMV)/>*HBF> M!CQQRR#0&0';;H_>::^-8P5W51&'&X8R=I@L!314.$ +OC9.KHK6;Z,PS?3V MCN>(Q!Y7[Z%:-*/IN^-$I)$34%[;6F+%0356U?-UF M;$D/F#9>P)7Y5PN'W_XZNWM#@WASX3LJ 7'!]T:HN83+!RO7KP+$21*C. _H M[T'\(8M1J$'2/L((P>E@"53U_:_71[VOCS0*X_=*(YJLV0D73=$6KPF3$04D MQ-\<%S]\,1,&:J-@"$"+H MU<@Y6^G*H@FE;\2PD8A7-SW;^[-#N+O0K#"O'/S2S"RCO 3)XL)WR3UQ8^1Y MVXLU;[I("?)$3U%%NA$@VTQS&D,HKR0!ICZ;X2HL*@5'B^^-5:*C@N\-HIA* M"T;"M<)E&VOMRCQY>LK;05PO[J+ ^63 "C;3L53O%,(,MC!//Y[G:3J4^:2* MBC =OYI!\TUU5^3?.15X :R%E6?C*R MVH95D^Y3X?LY"B-V^G<^W05>G'B3:@'8MN];?6#6R=76E=MQI6LZF-?SC[:\ M&6#@\_=Q)OTZ(2TK#CFH9R=FH?[-4\^B$)7I&/'OQ#2LIJ7+"'3IC:>83?HI M/#O?,5BO ]^<8UC5_7X@E++K^G8XR!GUB$ M8'7RQ4968BHNO-4C+T'@)!6M=CI4'JK&$8:N-YN1:F8*;(4&=0<;)0\G^5RN M8F[DV#\*F_["+UR(0OO;*J1'";T>D^WD3V92JKMAOYAM*MJGX![F M!E.'_;TKZ5(?Q&[68[)5A)+]T$*9G=2X3R-*7?K M,26!FPKMWH-,KZ(>$'7?4/A7_YJ3&+6,Z#)>/P763)UX_OJC8+726%=NJ2YV MR5![:V9>JZA/:>P1%!AP:';Q"]IDGPU$VJXN?%!LV%BQLI#C^_IE4L MI)@*ET>LF7.SGV2J_"9QM HH;UY@#O$:I7'[F*T\S &&N$10O. F]"VBGW"4 MB)SDI7;Y.R/=@;6EYR <]'5PHW@8.;,U41F[<6WD7HXI2.#,3JG;>+U&[$^+ M.[+TR8(XR(_J55SVU8CT-/P(ZQ'E(R9=/ZQ>TCQ4+@NI!6-I/ "2]M'; CEZGMTTJJ3Q'H>+/QDDP(Y)UF MV);2^:'#"9WT;.=$,84&U*4 M:K35C\;=7),O@B@[EFI(L'O3A $L>*F[+ ML92H%\WQ:ZG#PY894A/PE MV37-/=F^11\#FCS,,Z#Z5"C;@KF']E-B+$09#&CX]W.\0FLS53%4J=M]VZ"Q M520%0LQJ?:V:%XL\6V^\8)OT&%I2G)RE-8IF-H]B6_MJ(B+!'K '>;W*:_;# M3V&X46XL%7;9J%/["W*"^9GGK9'?#TBI@6R^M],$4(Y!8)G:(W$@E((,,&5# MM%R'&Y3@%9X']!QC:.^P.KJEZQ^-B$_1YM=X!!BQ5G((_'L<)LNX?O"Q>Q?/ M/V(GF@77R=5P$DV7BUA)#61#%6D")<<8*]Z X"K^*F#'21,7L&(:(\*Q@UF M[[_TBY7EZ6=G?\7(FP5-V:$R]JS5-VGFG8]W9\(3[.,%B<)$JK;I M4F-DXK6T^@3&A7X?3H.]V=+3NM>+!?,1*+<0&^R')N 7DA@GP&)N@3VD4H,P MC>Y@G$D7,PJ)L9\S4^XVP]F@C:4'&Q=P\CP"?+)D*3^*';IIQ&.$5T&$;]"6 MA\!ZID8E8;09F]F)QW/6=^K-4#94)SGE&[E6KJBD/G4.HY[UU#)D39;U9W?2T MQ"F>1Q<^,U Q-U5I3(TXV0W4#27, ]T@#UA=2!*U%Y56<5V*VD.6FV 7>OTA MO\6;+#XZ6?.W:D:AKA&S=MJ"0;C./#C=!H#M.Q^M [;,S]CEV?;&X171&_LF M%O(0[&90KY@8F\\,TW4ZT;1.R2TSQ_FC*.CP9B>]\6$LP4,KM1[S^>TS#-ZB M**8DVIZRR0$#VT!D@)Y5*Y9-O++15+MP$9DN*,P30L2U>5J>>'4,8^50I0Z2 M#$-L7?+ME$';U7*QAQVT8I6F:^)."^ M\]F,=I>8L=3.Y1LF ? M.0Y-\HNNXRB,D.^F8LU3C61$HJ/ODSK-<6@$37Y:NG#,%6O4F\/X''%-7H.U4]?L?.6[\^U)X.]*B^RO;\\>-R2M M79M:/7"?087V^&R%&FLA*S+:*RTF2%N\)&C.M\2V5!9).0FU:53Q_79;GFGG M2-J/2#K*Z'0RPN9K?7%*T(1/RRXJDD'8IS[[4?T/!]56*-!J;J"5+ MJ+W-36)FMQ=\OCLFOGM+EJLH+)P >$066*8ZR=D)=VH+1C?[@)^^VO&)]CW4 MTGKL/1/]$G:GXX7I@-PQ-93FUT%,XT%1 S?D$_S:1]#J2"48K>;::\WI'NW?RMU>3E5R/-K^*K=*BMZ MO&WB F!VC)K!0C';Y#ZFRZUBW3C1%X>9>]E5/4[( CM'@3<48_]Z18+W;*DQ MXZ#:1FGYNLUZ-GJXM/'"UOOUK^45^V2/]&L%DR\B*8#$G)*"ER("I+<];Z8S M2C4GP3ZH=!.UY']_&;P-B)JBJW]KC,Z 8.V6TCZN\#URT32@FR"]1U+ HNF[ MXU1VC9R 2KS0*3RI466R ,+($*@NVDJWREHQQ#Z%(D>](1HY8:/5(T^;F9&( M=Z:_\%UR3]P8>;(AFHY4(_&XUJY!96,P+2R!>#W5&YT/)%HE\L5%;44VL^#, MCXA*#$85MPZ*5E1BI^ V0MG%/_V(#"=W$B#J7B]."<4.^T0X72%"UTAH_[70 MZ2!@QVV31J.+/?IAF_I9Z.N3=$MAZI*R[%7Z]>MK]/&_1F\.._WY#" (-WP6 MMS/ 1KI.^40@"8/@(#1\WM=7"EAJ%>#\(\G[MA/0T"%H63ES,=R\JO0W([T&NPZ2!8&+DX M$-.P>0&G#X"IRC3*[TJB)+)21:&::A!5^G M6\C'49^GM[<\N1THSKT?R\H#$I6X=F'9^A>CVMIK-P.P8&AQ-%OZ22A.)897 MI'VG@%1Y]Y;X9!VOP;A7'L^216YE7V7%=IRF9"+H$9;UI?$&R?KRBNV^Y$G; M'5WX+G[$[BQ(*G[DB?*&SNU2) >M\-68IY^.L;,')I UXMU*$K7M\:I(O0K@ MC0ZQ%H)Y8?C$L4M)&_&'F^E8CL;HPM3".%O9ZS4//UT%?Q@:^)B_!308(Q#2 MLA+AUH\2B/FEGW'E:9YQ=C)6GH\1;2JF834\)R.^I:TH9I-^*L@N#K%_%&U$ M*=;''TAH0);S @8!YH#\;:NF2^/06C<=L!_E$+6WQ.-B_9S,WC'>1 MZ- VK +,S8RTVAM9)(MIN=(#[-^,T)!B%,H;-V>6OD$"J=XJFEJA&LH!P"Q2 M&S6B);;I)P#U@K6M;/ 5?DC^(EE91&JD8:7S"B&39 E87V,EO&YQ&%'B1$F) MJORX((6/^)N#WT -"P8K7]Y?![X/>,&%M"Z44?57(C1XX&28!=7!6/=@41 I MPZ>*-DHCT(E2#-.X-^F?PB"8V8&.$C(4QW1:E.*@Y2KA-?DS=FMP"4/NB>AVM,H5Q&&@;Z(T5WR;VY2 ? M..E'Z('+G0D;OCH"AZ=IT3D&AWXT-?6"D E!LH:DRK 4_^O?&@'K!4O-N7[H MHEPW-' P=L-SM@K]DW?W**/05!+,R'$""(KT;>%W_>!G+8^\+9.F<^1D1?LG MT5M$/^$H<6R!;9(R^5$ K\_<7!X NLSIOI)UB$RY>+WBGCKQE[ W%:Q)#U[;OIC?IUWBCW!B$?C\X+]_"D-&QXM,>];=8.(5!2@(QE=GM8H0%9D7P[T8>NA M[=1-(4K1TKVUOY9NI#.F:%T+MW(8^S=JT[6[M1+^A2,M>,YL&ZU!Y^20R&=-IH#(*9=O)JAQ#2R_=SQX='(:F8^=-5$8% M82.K<@@ALF\484PFCWL1Q ML,>.)_P&FAU>F/TT)VJ@\QN7J,%"DXO:0:O\%]X,GJK:-?%71W!'TK3H' &( MC"KMDU]#[F2XOS1(RZ1P8?0=ZN"$Z"BBS=86S MU0?,$PJQFT>T,'^TR'X_#?RD:V",/-ZF\\50K$>/%8PN1G5HA'.IADA1L^)> M%U9]P19'_) X)BXKS MP5(;9HW[U-BMZ+LWO/WT*7.YSQ&AQI3! 68]+N?J4%#F GO@R/ L2.+4*+T" MSKS$?#/Q])X(F#U/7 M0(,/7\BQ(T?*5H1U?RI[;NY@^WP,D0HQ2W)\^B<*:L&#>'N>9$:Y!"5\N\4. M)O=,E6-:J.(/#: :\<%O2%VFYB)@*UC(M#J;C(EK6PY$ M)@ZNV(\V81@59S >Y:K#WEPH>D?"= 3B,D!^\F(@Y(\YSC'T@;4^_HB<(0%S M!=$M)NMYS(A!W]8HDQ]5&$&= MN7EM$8!L/[U7- [%3)^;4\]JC0J[ E!\E2X?<[3.^)4\C@WTZB21ZM2OR B>L203BH MOV>E0'E4 "NQ-(?_P"$E+H3IVSJI@VKAXV,XWQ17ES/84DS(7$IT/0]ZV*"( M69+#HQ&O :H;II< MS<7@X#6[3I"'? =/EA3SR[;J<[\&?5C_U@@VH&"I.=LA CQ:!T0N ODCX&D0 M1N$5CH#WF)C&:&(T#2S*D3MH%":MXL6?!6KEQ-:^.7@0&A:<,Q\@"8>M_\?C MXO+9/#ZESL:/U5^7V((?(W;$WWL5-<;,F=[%=!'0;1 _8,_S<1A^ZP3K=!Z5 MKJEAQH4GFMDIE=$F\S#)GX-V>9K(*->G%:^^5,"^79[;!M!YAB4>KR:4.I/: M#V*Y=46'D"0;KA48_5+CGMXQB;]TGY&(7T%>^"X/J\7( ^IJ*1[7VDE78D?D M;_\;. * 3F]L/I!H=8N]A&/ABFQFP9D?<24OW9='%;4.BE:NAT$+"C_Z31Z&(/8-\>D%[TU=YK M9JS\CLK056,GE_1[+'C]@E#E"9EIIBVD8;5'6;NPMB F:"<,$IH=H,QV^YWZ M'20T?:YB.]L7@#*3S",G82<22/ =4LWC$C (38!7\\LL-Y-WB M>Q)R1X+7@I(ZP31]=V"J7PA'X[KM--7>U8T)?&;]PZ0.6Q+.: S=]*^STT9J M#!#*\0RJ=Y\*FA\03^^(ID%>7(V$2>ZKP[FXE-M<76-8B<8IH-/) WU3!?0^ MZ\N]Z-/81.)[/DO]Q;[V\>BM$N7;>,#I2OPN?ZMX5LPP4K!&A2I^,O@S;'6)^EV$1/D( M5FY63P,G.8A/?#>-G5_X[*/K]/6$FG/9-I3XBK5!+*0&4O1\74QVXQ:&$]RA MEBQKB)UOE\'],?MZ:E39#WM;VCJHAM)J&*\FBU 3O;1\UZHB,7S_M8-8B%Q8 M,I(R0M:RCGH<<[\693E*&7J+EX3ST8^NT+J?H L'M**R9;=)SFHQ*^#BYW'._*X%1+,F ]F(2ZDB4%ZYC0@A MG\4TIGQ!YR1TD/<[1O3,=T]KL7=%+!H'M1715<6FF2M0 4-=6Z+9LE+6L@RR M3:6>J9'J4WG@INE\=A.V##>Y=O-0/\C*(XW#[E16;Z5[>FD>!3M7/_Z*VR*OTLJM,N*P#BA=ZJS*#EM!O<*44BMY MBS?\I2)S)AG[XG[GX]:!QZ'AVGEC)2JXG]8Y\3"=,D]F&5"(+54>;UP.0H47 M<'%$W3-06DD%P@$7CS@2?=? CAZ=Q?L=D?+Y[$\#Y^PW,'' ZICC4'&-'+'4 M&+P^IU1VH'$JCCH*UZZ%*9#]PS6-T=T:>=Y)'!)^&P)@C,KCC2$?PF,0CSN&@%TK7^ :CFONI17V/#B42L.-PRB) M^&"I[7=!6AZ34J-)EF^J?B&V4'W0<2D[$5=Z-/#NK?'R%?P[1C3BK>338QN( MYU =]D!A*DVZ%AV5#-7X)IH]XDV=';+4PDU[%O;C0&: M.A/ &F+KX7'A.P%EPI$F9O)TW"G/H:+;:>!"Y"6TCS^*$Y,4HR![8&M".4./ M%RY;$UD0)YDEV#YK&GDL"K&#/X"]KS6AF[@NXUZ8_8>OHZW4I2QLHE%'M..$ M3.G1Y!IJGV43FK(?K^DL>.AW2=@TYCB--V#MF'N"=A.$$?+^(!L@)T0X[*@\1C%CK/0TYI/B.WU",>J-3VF@ M,43\RBN':VFLBL!EP*/WJ\"'.$W5!AO)WJ@S :QML"H>60.4[?,7\Z1*3R\\ M:H.-!(\Z$\ :WNKBD3\-ZIUF+QQP%-ZTF!60+6"U8P]L)-YRZQZ?H@AE^3$@ M00?AP&-RT9IX ]8^MN5IVX_'?$*\:0__U_\'4$L#!!0 ( %,R<59EK&V@ MLR$! !K_"P ; 9C$P<3 X,C)A,5]B971T97)F;W)Y;W4N:'1M[+UK<^)( MLC_\GD]1QV?GG.X(X>9^:<_T/V@WGO%9-_8:>F;G>;-1H,)H6TB,+G:SG_[) MK)*$ 'B(I"@-F*GC1!25M8OLS*S,K-^_G\_QCIY99:MF<8O_UN\+OPO8<; M5#7CY9?_;75O[^__]_]]ROT\'M[N_[1M_1K MTWKY %]\<*83]J%4*!7RA6*^5+SR?J/]<*)_HQFZ9K!_?GY^^.!8U+"'IC6F M#M#B/:24+Y9"#\G;;##W(/A\_6*^KGU.L9HO-/+E@!BX\WLT-:5"H?P!O^Y3 MF_FWJTP+[N9W^N^$+Y#*&7VV62D5ZVL>[=WA_Z _G+[-W=UGCL,LH'UJNF], MUPUFV]<#<\Q?4VC,AH"/U=:]R+ =:@R",< S)O9@]@OOL\5LT[4&C+]DQN95 M#RZ60WP.2+'G"7DK^V04/_SSZT-W,&)CFE\DR+7S"!4[^.F0VGW^0_^;.=;: MEK-\)UR_.V@?Q98C0%THGD73B%_,4V#NPXL<2 M'KW?%9O-Y@?^K7?KZIM0/*]03!E5/^4(_N]G1W-T]HG\_$'\D-F8VZ; W\FR.J:&("PKI,DL;7O%?(0$?\-^?)_X# MD((\U;47XR,9P#N9=4/&U'K1C+QC3CZ20O"Q;SJ..88K\*P/DX7G_5<^3^XT MIJL?R;.KL_P3?6$DGY^C=>ZQ$V?YP7CM35.=$8ZH\-/5TDCSMO8?!E_BC7W3 M4IDEGO99IX/OI 1,L$U=4X,O_2>+[XO^]U>?_N>_B[7"C4?[T@@^+ WA4(SS MW[O(OLFV\[GPKE7<7"82F&I/J#''U2$=:_KTXZ8WAF< G@Y/ZG_ZUKGOM;_D MNKU6K]W]^4,?N(F/CT!(9H?8;=]^>[[OW;>[N5;G"VG_\_:W5N?7-KE]_/KU MOMN]?^R<3\5"_A\? M6C]_F/OUIS.=>^_GA3_+:*OCK*@/+<>Y- MG%Z5#4R+>\$?7;C'0M?M:IO95:G#\F.X881SFU?I-#]EU,HS(VJVGS@Y;4/] M C^[^M1R7US;(>6B0M!'6IQS$DS/6>GTLUS03>O,9 F4G#]1:=$3V^K<(=7M M2*7;P_B7AE(_IW4K2UJ7')2?O>=6IWN/ZCKGZ?"G;\_=;ZU.C_0>I2:/TN1. M,%.^*A]:YCBV(A<(/NQ_?:WLF"VX6C.%-\A7G'UJ5 HY*NU4NTHMD4*6+T!/P[M _\'3->"@J&@0W!Z:NTXD-E/E_70'3'0O_H_JOB Z$7E=GH=*Y M1R\,=X5-LQU:GMF+9J.:=3KPS8$MB,_M'O@LY X6M#\?OY$_V@\/G7:WJY#[ MSNWUW+*U&,EP5/P/YY;E4_/*+$<;4-T?,8#J:HZ=\?ASN %JG]ZU?]"!PYE* MS"&Q F82:A-[P@;:4&,JT0RB.389C+A? DZ^-AOY;*0?.#P]R&;:&DZ_&*[" MEU6Y26FG^M)-,ADQ7W+[]:#O@'DXL\Q5Q->])"J&]-V"=F'A+11?OOC5= MP[&FMZ9Z0!GV!A-L%W\D[@3,L %N_:)X&^R5JG23'(=9ZNQQK'IWQ.)UC/7I_OKYNGM-VN.);DZ!I8*%\Z C'?,Z@F\(A=S\HK2T*HFE M9>WF:0J4_59"?K7'HLL75]Q;CIS8_J?!!Y/_&2"#:#_?]I$ M+.B55B$<4JN G"T:J3:A.VC_8P'6T5T8>AZ!)F/V> MO .""5("AK+4L1@5HW]6*E?>[R\.#":OET\@T M@F!&N=;(-QO-QMI][T/+PCZ+[\RW_I__;I2*]1N;])C.)C@H+PH$KK QT%U$ M'D'6Q1&F@TR3W #52':$.,EQ@L#XG%U)3K:(!;?L'E/(B4$!WTQ,I+- M077!:+ T1V-V3@3+F 43/'$MV\6HF6/"+X6_5RR]Z[]'DP/W@5H#Y^/A=XP] MB_-R%-M6T=3-ZBXZ>!:04\9XCA_QL;27$8RF>EU!D/E7=3:<74Q<6?8PS1LA MQ>A@1 :@4.Q%Y7E.P:K,38]%N1W4G8[[IO[.?I_=R7D;:0[+HTS##PSSS:*3 M56GO$>'%U,U,Q]O?X'+#?HAUF8"2AG'"E9DF7VF*!ZB%,;]8IFNHJ*!,ZR.Q M7OKO2H6*4BHWE%*U^OYJ;=C,Q_"^W(GKA7CKU;18ZG/M<4C&=L -B!LX/T'X M<+MXYK$GQE,60E?(64EX5@ZG3,)/PLVNO/8C/])4E<'KQ+_P[(&3+RS,1+*[ MI<>W!",KE?[MVHXVG(JGG9C^>T/%_0&6ZT_!$6.P5,&KOH/&9WQO!JWRT';W MN^)[,> 1M<&/T\&HI[KNN6LV_/N7JZ&E#P9^GWDWP(,]8U_\M%C&W1R>^28N M>,9_R&=H^VL/. 2X(&'Z&U'A6S ;\-:)Q0:,&Q'%DG@&S\VUR3MX,GB9Q'9A MO;)')N[#^REESH@ZB^-YH_-$(\7BQ]Z0WBLY]%S?E4+C[C,&O'?[_X91X8_X M_?!+I,=[&*8?VIP23BZZM,V">()*I_9UL!FV5=3XUK4L>+#(9D2MZ%#'M:\^ M_!EF0;J>7U*&.C\ M*;E'10UZ$^/Q7ZA#"<\T6Q"[V3/"#C>64^8JA2K*TS-[<76Q*=C-]\@[Y'/] MIE0N77LW.".-Y[%,,(]EE>21W80NMRAT@MY C)C]_GI;R0CQ!=GB"4JD9/C9 ME5P\2#C7\HA"XJV_FH$[M'#MNE35#"DYNTH.@)42'6AAA X&(#D61?@CF"R% M $E15\%A,_*17]AC$#EXB^4KVARV":#&5,&5"QX'^AW'_4+ QWES1L3[^AJ& MPSAM*AMJ!D]HYMMIN"]0*MRLHI!_7;SQ;UNZP?M>R7DW+-'G$^ _")N.*@ M!&T(K'A,J!WTG:UT#S]V(NPNJ>+6+0S[Q;2FW.&:TWO\Z[7+9,"3Q %PR#V( MU5J2OWGO.B/!7/Z:SZZM88^:E25&"8YS/RCYO_;I6OQ\.#K;JU:BG69CL=)6 M3(;_CE_Y*V[%&U96VRY-RMS@9?SA*(;>,+?:H%+ /A%V()FW [5AE//$7290 M:(;)/1[7%L88C)Q7!D>5F8$]A^_2IVCEO6GP:G@M,8!\$S7'JV;SM<*@QD"C M.BZ@F(&-E&+O(I5:JDTPA5M35^UOEM_1]Y&&U28?)[8&:O^853J*TN/-:BAS M.,D\SK=W:.P1&*B^*)!W '#N5HA"$[3:O7C:*M,=W6C!+W"#YTR='+BZ!UO_ MD,K-FC9S$Y9L7D8PTG7TY[\S-H'%&I>Z3RWN27ZEUF!$BO4M\#_>&^YX8 54V=PKBE> QH$&QH_]R]5]YVX> M,88[SJLFKW3$6R)"F>9XC#4MYN![=T0M9C^Z#M>HH%K!$P-"&??)7/"B^0MM M?M?5ITJAHA2*%:79J/NT^P1^RHF;D$_B^82_@+O#]4)!*10*9'8+S@K\U2)/ M%ALR"X-1XG;-MET,;,.OS!E5$8[PH>R!2&@4R W,9BC.F\=1"\8/EF5R3Y!!& M2K$4 94:)W4Y+3RL?">?9J]>28K%Z/=\GX'^ ')B U8-;OZ3A9\T U=R" M5>9?0;^P+\P>6-H$5X#\H/ OO.M?Q?"*$W7GP#M_[]!6\R*TMW,1V?=H^WF;B7P7)J >Z[<\BP]S0=O]-[WMP/2#%X+C@E%+_*88URT)"*B-W$N2<&&Y?1'9;(0D,CQ=OHY>[3 M_$XN7T0#FW36(0$I9GXXN]N^#8B$KQX'CMD'_I6\QY,PLQXM#68 /+& 6/^G MUT)@%^S.!&4G-.-K\.R!E@865$P$EZZ(IFZ&>7*&=']^05K3N.)SD.PE]A9Y M73.2'"P]?@73 C^.XQ(D,#GE.)-32DK'K/,2>DLJ ]9R#7,64*$(.?6D.P<+ M-<.8Q<2TO;8&.',\4,HLAVJ&[U3.XA_!U-I8GZN[JG!&\:9ER9P3W! L F%7 M798#K81W>4J0J."DF*_,VV^FX D[P!%5!'*&IJZ;;_@5F.NF9:]^]4?R3GLO MXD 8&M&]89E@Y0\<4&?B:18#MI(!WRP>3'-]JF,[:LX?RMUS,"#R^"]S.#K0 MSQ";:^\T[_%:4-;C\TQE?8>[$/Q9 ]-V CK1E7<=ZM8\&W81IAM>P:]%%YM/]2EZ+J5W4G0J_W6 OE+_#@('HIFUCWDM.Q,71 MT;')W^J-NE(LU +-[XPLQOP-?J'UO])I2.4C%_Y65*J-DE)K-H/?V=J/^5\M MK!77I(=Y_F/Q)3PDYP%#C:!2L\D\D;6Z4JO7@3&J!GS#6>/ _5NQJ51*360S MX .&'SPA8CCS2YDWJ%QH4/6:TJAZR3HO8%LZH0>*JTN#7;L\7B\FMVVA"0^K M-A+0A)4XFK"#: M%,+';&^1>N&Y.1UIA]_E%X?FXC]4U02:S G?JIVM%OI4P>7:U?EM0&PP@OF5 M<2V2)M367"'+3]]6QAK+YXN1;S1RM\ M@HEE#I@*E\$MBLT/H: C)LOK<\%4Y,H0P^FFOZWXZ3;\VJ?@M;YD:)\T([CW M"=R=W+U"[H%5I()?7F=63FMQY+1Z$#G=RENX]V?;FQC\-P2D77V&9*(1NS*_ M'H?YM22#$*M=A&4%FENC0/G&ZG$4: YTR%)H(5J'\JU98-#<4_$^.@!SG@ZF MJ(_P_9$*<)U:S>VJ5@^K.',Q%&=\YNZE.',Q%2=95)Q'-'<3$>)&'"&NGT"# M I/MP(?BD P[_>+\A//0H\TX4]!(4H\N!U1R16(S4=WAV9[+K@#76V-3%7TA M48!L%Y2-S7#&WO@6*RA@$$%J33$P"\*G\VJ2>47,?RE2 W3N(\^T0FZ%5N ? MEQ3#O,ZY)JT! O#%FA(SH=6-(ZN&-[.B+ZR'*^%H0**'S,,M&(A#M*:5XGE M$N^PL;HVO6^%]Y1;3FSUB@\^?%KUU?RCL(J0YWG4ZDV1*K>B]5[P3FY5DRW^ MYR\D8 3/UZ[+U]V5F'J*F;H%.G=H:-P-G6 ?32Q5YBGC/,[=([:V( M@,<]3F8^E128>5&(M[M6E )S3(&I*'Y,8#%8(P&\",U8.Y#%D@3P40 <&"PM MA3QK]G=R1P>.:7%;)2HO@+<5?,\F/G=(\T.;>]Z&PW+N^LYL7^,N\HJ]]%P(SAH MNFR+DVPP%'4[TMAPJ9^JI7A?S%;_X NA!)G-PS1'B41O@YX8<$AL&PCIA,ED M$WX"@\K?W6=JCO9-X*QP@8/@5,=T&&DJ\YDIVB=A :HG'YS!M?2D7(!7[R-;DWL LBAZX F&8$I[)S&:1^4O]Z@OP@ 7OE M44P30YT\48(.'0_KRVXZC]X%C^ AB2D.QAL6+U8.#8.G?VM )Q/<78A-B$AI M$+0,:T.0;M=2\;IK?O0(U?\,# M%R]8+U%DQXP:^"TO@ AUY2G56V2I$4]HG2S/KY.H5>9_7VQ'_#YRP*K7&?%0>3!">#8P!VPN-"L)MI92%F*8$6%25Z>:$?P>/,ETT57%OZ 4LC:'KX#:,&?C3P:795LO$M#T%/[',?XLR1)[[ MQ2_@$4'\3YT:PK?<@, /XKE=HNXU:;,U,\DVF5;,\IE-_S KIN^)9J/5U M;:PYO->*$KX?%DO7^7A,$3B=+W(E?)%?KN+X(KNY'4M.QB>T%.8QREOH( @4 M'U]^DG0($-NX'O/@P<2T);2&_-,XPU[P?]=]G+F\I_M?]&$#EPTTW*YG%E?S MH'PPO5?E)+F$ *',L*G*$ M'[,U<$ ;<9\'@)EQW$C$P/_10*)]3=<L0 MW(29WMMPV4_-P2?VO>8JW(P%DP7]9_1[$:&87>OYU%&OY8U0^>@>]BK$S#\@W?;A]0>[351%C,AM\-?#O,Q6Q_KTJ&!A%' M4(6\"IR7?RC90M%._Y/06UP81>YC6"$I(0#BI4?<4,(OR+1^%$:]T7W>S#ZT>,ZLZ(L(FF,EBI;64K,F9A;I%LA&7! MY/;Q]_LO^6*33(!*?.AU"/;KC_C:T7$4_[WVIB*Y* HC;R8V[O'B#GTLU'AE M2VT8#8"5-H$)6/Q&938@S;_JE['Z.FKQ;O3WEJY9# ^\7+QL,_9]\1K[@<&# MQ:NXW($B6K@*H%FD:H E*4OO&45=G< B#F.F^N(7NO8=4V.7QL #'?;B=7]7 M:9&2-TV?/3G4H?(-:0E?M[6QIE-0^C\F>'00%P<,98@QBYZQ7N;J=$VL1"$H M$J;[,L(@2 [[5*\)D7EA-!0 FP6/YSL_B)6U@1<_0LZ7'[$;1# ]65@L*. 3 MT2HZYQO4KQZ!\'>?HGN&J1ZV[8XG0OJ1#?AEJ,NTI=G?Q1>NX=4:8HCMFOP! M"ID:&.=Y<2EV#^(]2$%5O6$Z--I#H#*0^?!IA$#/A:(0G*=>(C+G.+S-TT > M^T7\#(>VAGM(UM1TPQ50\((!PVTX5Y1"\6TZTV=P**25Z_%\2!PN)08_+HUG M;X\Q>1F;(0W%9JH8%,W$K5%A\OA(%1HG:P+#FY%MP 6<6*\-DXK# MA5?P$JW^$HQRX9!;CU/L4^&G9(HX)!#"#01KSH/B%:NK]G,\'O$*,KU8<55&Q+8?LTOD.4XW5TJPC@Z./[1U0;\V<$@.)']D8\<-98 MC:Q]M!+TQJ)VCGH3C,# 2$9H!RT(QOK;8MZQPF_PANMLQ??7MN39ND5+G,VJ MS:?5R.VL QRL=LQF+GPS[+[SI?W/ V]P;.C1MIY[G*)[ BKSOM/J\&WT^\[=X_/7 M5N_^L3/'"QH]M:LF[MBG),6=IQUFX8B"DC5N;H7ZE8FW!VRVVFM_#97 17 X M85TXDZ-9O@DG(4^^=5K?O@"!7PX$@ ^[8/X(<[ 9Y=%S,*?L2H>DZ/:QTWU\ MN/\"$_*%T_+9:_C3'3$LZ!,M'!8JD,F[8,+><]_OCO4M%_V]4D//O LN1] Z![=RHG#KSJ6"S,IS@BY%/=ZEB*=6:3_( M5W-U&R5^$_Q1C-(GJ<)A:<_5.3TH6X.;RD'/SIY?,1[OR.UOK^]7X^G]EH\A1[WQYZ_)[' MI_8SCS1UTZDRBLUST!D<^MI[_WNZ1Y_ONWP5(TJ: RAEP>#@2*JE!0I/;G[WG MQX=N@(*GY\?;]A><^'.:YMUV!PX:E3AJR#P\S<5#'W$RV[C G8O'WF_MYW/? MM=@5/Z?:UTBQ^MMA=V .S0?=AGMH_]IZX$1PO=?&RM64VD+ELPB_" BT]L3 M07^]D/K[4>VMSU\6*W MW?;MMV=PCMK"-_K6;>.7GC(X*RBD4A/LX!7-@>6@\?\O[;L6>L::F^Z"A]Z_WG;:G$^[:H I"/N\Y37,JY;ZZ)Q .&EOG M'HQP:,)>S/E X 037-MS@@\:/&W_\[?[S_>]M(KU3AMBN^8[RJV(@T1:5L"V M<=!\A/M?.ZU>BM>CZ!V]N0K%1//ME[+$-ZTPF,XP&/8^-\O2$=.F:"$1T3AZ?-%6GXO^0#OZ2BDIV+ M*U:UP@L1#UH!NS3Z:>-<;D]!)P_5;L@O7UFG$@7,@Y*]+2M+IV3EYW:O!V8B M,(_\^?B-_-%^>.BTNUT%&'I[G=2)S2MHP3;ES, *43S#"14*+U><2ZLE[UR# MNBKV'WM_9/):D?F\*W)XCT?908JB5E8W+51!Q:5\4U&4@.9Z"SYR:9\[>BK" M),+_;W'_UEM02:$KDMZP&&S5@,'''SDNO4(VMJ(4Y&AVIM .$QC"#K?DWABV MZ$& Z>IVT%D'A:5'QS!"YUX7UA#)D!_#&4A0Z-8P*K*2\,A3$\MT74G07%7& M_'A7E$GN.Y>2H0=FZ.["L=6;6]UN.Q20.=""E.@*F-2*R5NE)4SZD6;5.^Z9 MM&P\J.WCN7 OPZ3'G?C=]@D\B[=>BZC"7TR:+176ZUY>ZX ^ O:1(]@VY97J MXM2Q2/WG6]L_[:C0%Q^SL8_ W(/_MIZJYL+C-DXU'O)@F,:=10?!Z03P^V>, M+ X /BH;:&.JV]P5$2U8?KG2?C@?#7><5TU^8B7><$4,.H:'NW;^A=+)1^1J MRU#QG_:,I2WGEEH6-EGB82] )P""\6>[AB;>ZMH@ZB6E6"[PPP5"Q'W:-"/; ML7+MJGY!LUP^V2PWE5JE=/Q9CJ^;-F]@;:MM\!Q.%\MFGMF _,MO;,6"J#G;3;(:S_R M(TU5&=PB_LUCH[/\8GKCW$OSP?MXX.JPS$O65-A78)^]EFQX1MA42FT,J?WB MLCO+''L2R[F'S-.8O5EB"W6E4&M(J8TKM6M=SY1([>K>6O$D\-[ /G^F-+3:BF>DW5O3Z> M&([9)HZXG[>UN=WR\1'#'5TF+J^19J*9E9V\<2V+"5$66P%S?HH9[IX('J7D1XK0HZU'YD_,$< M(*&-$]/)^/^'*P):#3*2J416Z*ETW(RIV6Q M;BY#3LLN9L!6;HT_L,H&O^:QUWH@D?E+:UZ[Y4MV1"0\E:BFV]=91"+88;:^ M]WWOZ38QN0>Z)O""D9=B;'\H8D+WYOF^^8T25,=VNS:!:BLGZTB0VL6H.Q^; M>_\GG9D3WYN M=WHD!._#9&B?[6Q)AF0J:!OD=#[1Z2E3PU99N>EP@SPF>3QJ&2I<@3>J#QKM M:[H6*S^L5*TKC5)L7RD[8IC\U.WC;!QBZLKUJE(I'"O]Z)0IWG[.!;DUQQ-F MV/S,G^SK]Z135,+<\H$UW9PQVBPHY5+L4I'L:(2D-G46&URE<5/G%(OXKV1 <8$%*9E*\5T5YDEK[L(VZJ5:;2J-8FR;XG+RND\RZ7N$^Q*,ZEU:.C_9V(0KF,:@XT[:$JI*$-O\04S"PT63K&RS4MM=V1.M.%4"NU6 MY7+Q@N6EPAGN=R74CH8.".7='>2,.> ML+#F\Y(C-T95#:+JV4Q'52EDIUF,OZS*\=[+PWM+!@1F*[R5>"!6SOP.O M@PHED\H@4+*1OW7[^,4"QG]BMUF40;\,!/W.(MJWJ>G<)BV3,?-X_R>=F;]P M$H9D;BT-51AU_^>_&Z5B_6:ITDC6:D@A.*H?K.$98P#>?+&P[/)6-GUH7'_9$K4>KZZ"_S!N;/S&K.Z+62L<,OK?Q>WN; M93LY&JX+A0;5RP]9E3C9!R38J4NA/(/1;SU81&P,KY5KLFK=4NV/;J0-ABY ! M-09,S]19=7&S:$[7F3S-W%OYI'>'%LO^BR M4FIB2[)C]J!?]-\D;(ZA\@X*FZ)2P[4^OG-R<-BD*%5EK5:-=]H7]P9'\!YF MV4$>RU^NYDS).V]65DE-C/;F1Q&D)%,C]W[[Z;1T>&;%C,;1RJ6Z4F[N>YCA MGC,B 7-YRL]51 M% <5F2.4"K0,=;W\'/3HD\.(S79%!1)TJ:M7V!)T>QV-DACD?'7]P<%0"H^$ M?J+!7;^A%H.;GHZ(V8SF%?JJAK&4P!5'*\\N#+4#&H,-+C=QD0- M?ASI]9KA+=,C)OA@0YY-^&1Q8O\KGR=W&M/5C^2)OK ;>.I?+C,&[",IWY#' M"6+3_HAO[S(.U!O"-[V -I+/>T_CVD0\+Q1 #1-6+$505L-KFS3 U09&Q1I^ M>)C^ &](;SJ!<;0L$.3!#>F > LF=$P<6C'\HP_^K_B@D8W!<%<-OV\Q^CW? M9Z!3X+D3SMPPL;4(8I%-X0&'9&AN#J-?'J87QS&;H%-(U ;AYO^A1%-_N:+_ M*A2P;/X#_70:.C^W>[WV<^[N\9G\^?B-_-%^>.BTNUV%W'=NKT^OFX#"6Q-3 MX6S>TWVF:7)=7[^@3GJ<,(LW+[=30?*[;[YV?)\*>NY,"]4V_-]BJ-35G*W] M(&-X]\@F#-BK1J:RP!_%T]._I+\]&OAB#7?INF3_=4/>--49X1@*/\5?>ZYB^7?K]S>""4JE>0P,PJN_7-6NUKPQ:EF* ML:RM),A':H\C]2M'Z,]]Z\,GTD:84H*X--D)0LDYYLZH+GBE5+/^W?7N,KLP8CK-:PP:2E M^LHF];[[]]-^VPC!8PZS.> ]KOG3(4/^E1V3#4.LY)QLC?%(PG7YO_7X?6YW M9-S:=3N3YQ(I7D]5[R4SB2_)04;O-*^4E$?O8XY>5PO#Y!CO3&H\)- MF\?2?S5-E73!UI:IKL=?;V>%=K;S./0\FC55=DJET92M9U/?>K:T]IB.4[2> MO>QI.]KZOZ4\-Y5J-7:+3PF,T\GSVC-C+K*5]#IZ?[5,VR9/ECE<67=U&1V$ MUV=.[V$O< X+!LYQH(]MW)RM\>RSNVPE?7:F6 M8T?'I/ =3OCV.)XF7=W4]Z3&2Y8S7DC[QP0SZ[)S*N+^3[J4M@.2(9(A6>A# MOG]'EHU]]K%5!KP',XB94'C9G[RD_(B6KIL#S*_F7/N,3+LUQ\@TGE[M+1@= MYCP.>_3'FL!DH:C4:K'/IKE$^5L[A=733V$]J6XQ%S&!>[@3AYK 9J.JU(M2 M!G>=PMKII[!^3"%,X9YDE^DZW*V07YG!L @1RU):ZE@S--M!)^9U<2V_Y.#U MT:T%;WJ\R6D9ZOS4>#!?#>]*I::4:OL6!,L-CZ-C9@_S9%_,H$8\9NLFB9A3 MVT/[(J96*8,C69>8R1IF]C# ]L5,4RF<&C$GW]'=IQN0V M2%-JI8;2C'^JF 3;.8)M#RMT"[ U:@>P.-.1IG !<6.YF2P9(AF2&H:Z0C&3K@N& XLCM.7F:EJ=2:L9?@B\C,/.'\ M'\*;W&K^MW,LY?2G-AU[Q^E7:N6:4BW(U.R4(. 0?M=6"-C.!3OY@0'29I1& MM&2(9(ATLX2;Y8R8Y;E8Y)T7<#N#X[8EPB5#)$-2PY DCQK?E U[C\T_F>V< M3QE+8B$@GU4;$WV*=:79.,*AN&F>GK@%M)5U;Y4G/Q\MP!$;W*6R4J@D4@!R M?N ^W;'FR9K5"55F"',[>B'R?W")F:YQX;:V([1L");6:5O;VUI.6VKRRK?G ME)R)HPC0'MV+3YUF?_"0E9;SJKW!K9Q$N3%X MX,9->W1LOIRN:=GR'/RKK/=,.\PAFI>VK&^3MKSUFW;T@>&I1#7=OL[V+G]9U89TW_>> MT.=ASG8IT+6Z4JOO7(54.D -D@38T0&V1Z;UM@#;KWA7XBN3^-K'/=P67TJM MVE2JE9W/Q)$0RR3$]L@5WQ9B^Q7J'AY?TO--H1DO&2(9(AF2@L3*Q2W8N,'- MR@U9^WUYP_>E#=^O/3_J,[6U 6]U^D7378>IQ W'-UO,F$6K'SC,2R -K:6 MW7[#-$W[T%M9$[LG VSA7Y>VLAW:U#* P?83L_Q&O]I@53H>W,2GS+[Z5+B. MW]3W +O>JPQ2B8^MW6.)#XF/=>ZMQ(?$QSK?] +P(1W2%%K7DB&2(9(AI]R* MW3+4^P?_,;A^%-Y*7QB!I:(/SI\YG//_;&*ZCNV KPC//N.X\_89RX<,/L?W M'^\[=UNM\/XTM\0L=_@D/P[Y:F\_SJ9V]DDIE(M*I1*[@TT$"D[> MK50B<7K$2T=B+1U(+%4+2J5<42J[ M9[\DA$3?S/W@4)@-OD/R*9?+>3L*DS!,154PZ6ECL#L[[(T\FV-J*.*"0KK, MTH8W9$RM%\W(.R:\M8 T>Q?\<106PPL#AO7L,^(F/A'[TL#?10K1;^N-&*$# ML*6!%5/LSFJ8#CP2SXH%YFEPTPL>.#>AEI,#H]L9,9O!O%)7U= L!Y#Q4!$> M\D>&FD&-@0:W R(<-H97V-?'&L@2V_S7_5<^3^XTIJL?R1.@]P:>^9?+C $# M+-V0WZGNPE]%DL][/^1*0_PTM$T6GLYB*6(^:WAM4T3M*C3ZY4'$ LW5W(C\ ML=R0WG0"XVA9M*\-;D@'!%B,MV/BT$KA'WWP?\4'C1P+AKMJ^'V+T>_Y/@.M M <^=<#Z&B:U%$(ML"@\X-(ESTQ7]\C"].([9!!T*1ZM%C?^'$DW]Y8K^JU# MAA\?Z*<3Z(*?^]$[H^U>K_V.NUN5R'WG5L0N/ZG PK= M3E1_N@WK!=S"A0LJ%C2IN:ZO&]")OQU1XP6(T S2=\//)B/J[0'D'QG6JC>2&]D,<9I[FH_R%=XP\@F;:!>)2WWQ;4= J94KE0H ME?A-\$>!_ MGK>>3RY[[U08Q)&-(9G94,D7HV 'JBU@P]W(*= M?93@DN#::VAXF=E\.*T9C)XL-F26Q52)+(FL!-260)U$7"I(/1O$M8!S&%RD MNH 4U50PK?.AU9).-(?J&9VG#)%Z-I#R=% (00;ZK>C09GUJLD9OUJ'4&@S< ML:MCC&R&)R_RE5$L98C4LX$1[Y^7T4F(2"^+'5,[1MSNQ,&XC12>6$).2U_* MV)4R-7I0"3)IIBM!MSST,CVY!'G9)P8=P157_:G$6_SY#6)MW7]TFZ7\JNWU#B M45#JE;I2J)2VZ01_*.QG!392@O<;UJI.$NNX!&RGF&Y#R2 MYW)U3D+ &\=;G>L%7@HL)?8,)5:NS"<5W'2MS'4IXU+&I8SO+^/-],IX4:DT MJDJY5I&B+D5=BGJ"GSB E_.@+R7:U6E7HO=(RVCTIY ND$".?=S MQY@DF84OZN4Y_5XKV8&HZ/(:UUC,<2T#/C@F;P]S*UIEI3BA9,>,KE.[EEL2 M>&1[I;3+;D%_.'T3ZNO>MEVF?G$M5%I @*F*'02!/N]OCCNFM@SUV0-=S^R- MV*W?G$W(M>H!1Y,/!A)U#MJY\%N"].@@K4F02I">N2U22;TM M4JHTE5)3VB-2BDXH1>N%J)H>(3K _EW:L)#J6KU4<^[8!E-=&DP2I&D':>/2 M09KVRLL,;)9H?,W&==Z_,J'3CI)6"!*D$ M:=:-CQ/O@&RV/E8E9F;*#)%['FF1F[C*O7CAREWN*V0%J:4+1ZH$:09 6KYT MD,H2BRUV#9CUJ@W@FF/*VHJ4"7S:MPZBG0L/4)MJ)Y8V":I*H2&W":3$9$QB MMG#4-\C+QB2J:J$I94/*1L+F8^72S4<)TO2#5);M2)">N96QZW; OE9&J5Y2 M2J4MVS!D?ZJE?!Q=B5]Z69N,^V<%J;*>0(+TS,V-'0Y<.)BY42]GJJI2EC(D MO"DQ<:W!B-J,F$-BNWU;4S5JR7V)RU)(.^U+S#6M6U75\.3!ZW'8LFWFK-^6 M*!9Q3T+N2TB)R9;$[-#D<44.82QQ\3JV%J682#%)W!V[^,I9"=+T@U36U4B0 MGKG!L<,6Q6$-CFJEH32ER2$%)6EM7KWT C2Y5Y$5I%YZ-8T$Z=G;'?L>#KV_ MW7$.[>QDG<0\AS@T./GFA(.._9@PPY:ME,Y-N>2S):8202I)G7B\E% MQ=5_N[8S!C_&[IDM<)'P\51_HIIZ;]S2B>90W7-(A"NRVEVM-Y1"O91Q;U4* M2_HU^J57I,GX>%:0*LO2)$C/W/;8)SXN;0^9(B[CX)>L6PY/80I9*'%W;,.K M=L@*TH712.M+(E5J2(F[DS-M/PUYR,IEJ2$E4M/JG^[:V=WW/C9YGL6R4BU6 M,NYY2C%(O\(^9-5C9A6V#'UG!:Z'+$;++%PE4L_>OMBUE?M%V1QIARYJ=0:\JA2*0=)*^M+KV240>ZL(%76EDF0GKE9L6M\ M^[+,B@RF;OM/$^_[2(K7U4G"4>T.$T%MW=PWFKV"_'1JE[YIJ9K9+D$N02Y!+D$N02Y!+D"<-\KA>?PK[#TBQ MD&)Q:K%(8;,#*192+*1)E-XM"XGT2T+ZN_61YMKNG42>+'.H.0_F?)S9AE' MFK48<&XTBTHC@68AQY?#]W*=D=)W(.G;HX^/E+X,E#CT35W=A8^5I#>%/E.= M&@.X@0_E*YV2XSG! HN+K61*@)()JKI]G5V:B67R#".NY_= M".NY^\[==@=:XT$>]J/KV XU$%:1V]HVO^OJ4[E14(J%AE*L-;=3=_O+:NH1 M(L4R[EC^=E$2N<,!\R-@ ;/L]E^NYDSOC8'N(K*>3 O?U7(<2^N[#H5!]LR. M:>"[+5/7X99[H ($U5F=FP++;*&XI:TBA5<*[X6MJY*)]TGED(LA7A+ M2[6<)AE>Z)=7K"NUQI8-\[*S#F>QTC#)W>-;RJ4J@E&,O. @RD%)V'%&W1%F"##'D"M'IYKQ:V;!5P3A,N MY24!>8D;&SKD@2F'C UE@?,2N"<$[B$/CI# E<#-B(6R0SG)02R44K6@%)L) M)8UE8=*ES)Q0V1_RV)7,*OM]0)):PBX!O16)7JEVTP3_5=MO9-!M0>$8L-F/;*5*F:+E@U[;9;,K?7*S33%]?"'5X@P52%QKHU M#1 ]&U[Y.!1_.UI?9UTV@%L=;ZRX Z M_LV:5LME*2]27D[@UAW[])USXKP$[@F!>^R32,Z)\Q*XF;50]NC$M:^%HM23 M2KK.PJ1+F3FALC_V83ZIY+S<.LDH>H_=E/J<."^!FU53Y82Q%*5>/8O4;5E0 M,L&,_)LRPF50SYZUFUK?A/B<^2AB>T$P[]B$)Y\1Y"5RI/U/ M1PG#T^G/1EH[M&2!\Q*X*=:?B47D6[IN#JC#1-K-9VHS%3,#P:>A^**V<&_6 M9 G6*TJA5#T'5U>*36K$)JZ^EU67,BB?7?3*TDNI=E,%W+0'Y:6Q^H9G%:7W'#AIA#\D8MBQJ.7\D@5=!YJR 9<)(P/(())PNJ)7!3!5RI/R4, M4P##N/JS(O6G!&Z:@)O^@+WZ;]=VQN TV3VS!=X7/I[J3U13[XU;.M$>B?]EZWHAUY5BXRSJ^Z7\I$9^XBI^6?0G(_?91:^L_)-J-U7 37WD7EHM M,K5^/8?N3&O(-,>UF,BO'\)#S<%W@.!LAT>JG_-6/S+J)&%X!/--UO)*X*8* MN%)_2ABF (9Q]:>L)I? 315P#T7FAL-)$^I\\\QLQ](&F->&=[7>J*5VF/,X MG+E$=IQC24ME/#0LB.!+X$O@2^!+X$O@2^!GS[@QPU:I+7QA105 M*2HI$Y6T=MF0HB)%)66BDM9JYC2(RG[1:"DO69*7(Z43-'8/P3]9YE!S'DP[ M3C"]7JLKM7I"!^<<7S8/D2\@)5)*Y$'WQ*1 IJ.L92N0P5R:%D76?X09 A#K MFL&6.5A)>G_K,]6I,1!U+RWWQ;4=4BXJI4*IE @B*D=6=-M1&ZE.@&2BFFY? M9UGQD+8:QG&[#S3W.K6;'[']Z#JV0PV$U?J#N!M5I=AL*)5J\3C:KI)='UJ* MY:JQ_.VB)'*'9)P1L(!9=OLO5W.F]\9 =Q%93Z:%[VHYCJ7U78?"('MFQS3P MW9:IPV+W<@]4@*"NJ;3Q7"_OLT=OGL3;/8R0-^/Q*!1JS MA8LG:LU P6OY9Q\E9B1FHNC'R\P6>4LS=#Q9;,@LBZD2,!(P\96, ),$D@12 M#/IG/>1#<*&:"I9I/K1NB<[RF9V*S!":#L;[G4FI)20R&E M;>K*+6@] M5JO*2#2FB(\2AKNFPAT*@7$SNX]WY+K$;-8Q>Q35&1>XQSMM70(WZ\!-B[(] MWA&S$K,2L\Q[.&*"I9M%I=BH[IH%GPIYBBH$D4)U#D*UH52LGB:I M6E%F4E&:Y9W%Z^1%)E*H+DZH]FB\>\3ZRWHU=JN0U E5$FE)<_'H)..QHMJ! MDR5Z+A&-'W9(Z!"FCUC,M%ZHH?V'XI0LS,@I-RM.MD-Q-!MSO\Z5T<=6BHSR MU@"$V>8IQ?;ZCI;5IM)LUI1R.79=Y;'G26+P:!@\W,&I&P$H5H7:-JW?)/"R M!;Q5>T!R'H\SCW&#>XVC!??DS&=+@C><+[!O>[,MUXY5KD5:%I'W4?"X5 C& M53Y-J7PN<^:+A<*93OW1L[Z.&T\(RIAW"RFL#$^>>L8FWI@%FE0WO M>QR*OQVMK[,N&\"=CK8"D5LVK9=(/"P)!1<#F/ M\57+OCVPDUCDTFMR93J?HOUCP@S;ZQ,XH9I* U]-J+ZD)A#XHP8-IB$ETT) M-52.$YY!PU3BF&0@>GB11;4@Q5.J63F/&UQSS$=9?:TW&D=*,?W:S!%ZV@)>*M4/ZS0<+36-/[HYWF,-)U4U[JT;JIR]\6MD?^.3=#U92 M=JHV,1$=BH_)) D@"2 )( D@"2 )( D@":#M_(W*R9KGG )SL?P&";P4:*X- MU3U[A%B>+'.H.0_@D<6HWZF7E$+\:,KQ(;ZJOX8$=D:!O4>NQAD#^\ Y&?QE MZ>A$+!H1?Z534B[*'L07T3%GO0*H[)4.SW/:'UW'=JB!V#AT?XU4=FR34G+9 M4G+JME+[E'Q+@;^W9LNI*BDG6Q>0\UIUJ>M>=^(5C4IBD M,*5!F%+J8%2O:Q/E>IVA!"S$(?ZWI-:39JF>VY*Z7JXJ0J"XVL MBTKC(AI99[(UU(CJ MZ#O3ZGISV#-[(^95V6K>36MC(=445T-+#!X1@_&6E3@(]."WVL&)?8B(A%NV MX):*.K,+GL?8F7?'.R-43GVV1'CMBE'=H5'4058,\-B;Z5PU9%6K7#KD/,;5 M'R=2'_7T^CA)='Q**(@@Y24!>8G]8JG\Y&3*R923*2=33J:TV2>^;;N83KN"K[)QKLRHB7G4;,NEGAR5IS=?#K'#*7OK'JH60W9! MDHT))8 D@"2 )( D@"2 )( R!:#8+D7C:,'0-&!.]M;-BN9:7^F\3Q1EJQ:D MQ8I2*,2N*#AU"U()[,P#6^(Z#57WG)QT--^U1??=EOOBVHYLP+LOP5GI]+%> M2Y2/V("W5E *%=F 5TI)MJ7DU.UP(AKP[KS^2H'*FD"=3P/>ZA&;O\L&O!Q[J2X\;MLP"N%*5O"E.)NUI6F4JAFVRN2#7C/5:HVQ!E3U==Z19"R65": MS9WEZ^2]0J5479Q49:&M=55IU':./)Q<>="@0MK/Q"S/M U\6G9G908 MKXVB]^I3;\0('0S\=JXOQ# =9N? B28P!QK<]&)1'72.Y7CUGC8#5%! %]9X M#C6#&@,-[@"OW&$\P?SZM"/R.3M9G.'_RN?)G<9T]2-YHB^@ +KL+Y<9 T!+ M]8;\3G47_BJ2?-[[(5=[XJ>AG(@P7<52!&$UO+9IH_ JQ)/=810:D3^6&]*; M3F <+8OVM<$-Z8"F$./MF#BT[[/0#W!< MCV%B:Q'$(IO" Q9?>X,(35?TR\/TXCAF$W0*=&T07?X?2C3UEROZKP)O@OF! M?CH)G4$2SW?&X->.Y;*K3Y_;O5[[.7?W^$S^?/Q&_F@_/'3:W:Y"[CNWUZ?7 M1L#=6Q/W1&W0+? 7EQ6*BJ8;J!=40[?4'I$[W7RSR;MOOC)Z?V#Z.9VDL)+2 M.]/B]>^V]H.,X=DCFS"@75W8<"WEL#!>[+R&Z4N#:O1HX LBW*7KWJ+-C0#\ M#,OGP/\\;U<-P'J@$QN4@/_7#7G35&>$8RC\)!;C...YBK4_O[SW'CDK8U) &7 "K_YR5;I:8[]O1W@7T/65HRL9XB4;MDL4N5@@SK3:10,Q M<3:D$XC+88>HO,"D)R:68;V2(%R,MTM32Q#29\+05>ED"3%T=^'8ZLVWK>YO MY.[A\8\NN7M^_$H>G]K/K=Y]YU?2NNW=_W[?NV]WUU8@[S%OFV)0FS&7Z/UI M(CW9Y$[/FJW7?HJJ_9U/_2P6UHMNASGD'9;RKHKS^J;S3SLJ@,7';(RKS3UX M50S5>USSI\VAT;GGK8]U[M$-!?AX;PS,,8N;K*S4JDVE6FG&C5KNR$ YK5># M/?:%MIW61DTI5&.?7WJ0.=VGQ\"^VB/4O0.[ZED,^#[0P&5'M8(LPZL&_#W MN,C$,E\UC$/TI^2=BY$4S7A/S FSJ /OY,0APUXU1V/VQX,L!BL&NK.YM/]* M.@HUC[!5-B.5 :K&X()1G)+Q\LMA8<\=K<]S6\,A58K5Y1F8]^FZ'O.U!XMA"003UK[<#@@UI5R(7; [!@P3,;X M/!\W??\GG5G=WYO=Q?*4&7N MEH3ZV4<#[K0?V%<'DQ>E$W="H_F)3OTSQ =_N9K%/KLV:#68%QO,F, M-^JZD\3+\=-7#N!X[G/2U;EA)O:V0'GW;8&,QPKBJ:2>Z5!]UHB,#"US3#"O MTMXQ/+ ?\))TKE+KPR^I([XO(2:!?W$@'70LQSSS$(BM72J[:Y?##_-X)M$1 MFJ*P0^U9%J,G;LB)2O1[CVVW MR+75)ERUIM0JB:1Z92>7)+;!5;W(+*\GRQPPIMK".[LU#?YJ;':LF]B'&'LF M@;":P$[- '<.!98%724R@X*53TI,7CV^W@%;0UQ%X5TCK]7&$;N4I'F^8DMM M+0-2>Y*%5N!/B+7E%3]->/$3GE\!?YY)6<8Q!/B938+E-U3Q-%TOS?6J%.;3 M-(?:?^[*\4_Q.>'BOYU*N#7'8V"R: GG6Y!G#J(#*0"?6X]#P41^GM0:]!RQ MN"?->2LF96VWN%HC=L6'S/5."TIVK2#=#24UI5G9^;C.C.TO[Y>+[IVX9[R$ M>CC+Q-\$$W^/G(!^Y\]O=-[O@MB4FDH]?CU=,@F_VVX<2PP>%H.'SSW?"H,I M2#D_FN5[/LZ+W,Y, T/2:7.(OJ'8-A25PWDK]JU.#\]&91M.&OX?CP)_!9W- M6UK98(P/P!;G&;J&.G\A=.<3LS137:SX;?_PSA.'/S@XGJG#VL,A&\0I]ZTK MU>*^QKVLC3LIBF/'NAH'3QN6ML%%+(62(0ELG>P5A^6Y[=0A??:B&09&',PA MF?#U83%M+S/AM=T5Y>'\M?*)EO8U)_THM5-'WRX60[%7UCT.$3EUP'2?+O ^ MS97=%1@SU.U55R41T,%3B6JZ?7W+7.JM,+?J)?NIK5+JU%9)*99C;T1'XBDQ MI77&Z(FKL$I['+J2Q&0=+Q5%6K>2(2E;31,H@.T\=O*BQ">HZ^D]MSI=+.YY M[,C*'HG_S)0)^$2: MUR+\SK3^\%BV)HFPH-0+L7W.[ C;02;KS!K!QA-"'S.B"$?E9]3!(\%YPT1_ MD,.!R/"U,3LU):5UJ13-H&UKD-;+$WK!Q_)9#!+:9=:K-F#VHW6K4VV\;G^_ MH13J4E)/(JD?'%2HW.?ZE,OE/&=I$K;JQ#&0I*>-8=GJL#?R;(ZQM(U?4 C, MLS:\(6-JO6A&WC'AK05TIKP+OH-56'2P!@Q[^\Z(F_A$G("&WH@1.@#Q!P9- M,0[-U^@<)OH#2S6XZ<6B.J__P3B/,V(V Q!35]4P=1CDB)&0ESX'M]L. M7."E$]>G'5X:6+S\]O_*Y\F=QG3U(WFB+^P&7O&7RT"=?"2U&_([U5WXJTCR M>>]W7!+%3T,1@C!!Q5($136\MBER>A5BQC+UL89]-3=P#A:%NUK M@QO2 04JQMLQ<6B5\(\^^+_B@T:&!<-=-?R^Q>CW?)^!UH;G3C@?P\36(HA% M-H4'++[V!A'"2O3+P_3B.&83E Y8[?QV_A92V$Z$^'\HT=1?KNB_"@4LI_Q M/R5*RL_]3Y^9 W\26&7)GZ9+_F"ZCCW2E-R],0!=TS\:6X 6;IAC]<2W0!_> MFF!2&;;X*]",N;M ,W8#S3A/[$FF4)@='7<,3QHLV4;X63/ 7&R!3?2O1^N% M&MZA]K.QP0>P?9XL6!4,QSOP/ACL;*SHS.BF[5JL!V_XK(/)E!\4_H5O^%?Q MBC"PCR:H?W#-7K"T#OW>JT,S^=^N[6C#:8 (5-PD3#6WMK_ &"UMPC^;PYS? MVR\ 04(TA77:W&Q'"',8%M[C M5"K21NZH#2RPT"SHFKJ+G/7IU@S^ M%LY=M/XZ[)6J%",Y7]B C?LPXJ("SF>I<'U$$(>QF4(8EY.&<2DY&#\:I#6Q M-)V4:GQ>BP*#'O@(7T[X:0V.F0/WP(-?Z\5BG&RNZ9YTBBJ.?&76"YMA^6W$ M,-V1:' 7WH]EAPK_@>WV;6[].0!4=#2T@3;A0-5@$-1'W)!/%^%6,P, M<3@W<2UTR1UJ"H+0-X,=T02%TVYT_0R+M705TJ"!? MMFWZ['NOK!/3X&GN8.%7.1QCZ)=B3DC7[2_\=/;%;+R/KL5#(G!=U2PV<$Q+ M(?_'AD.+34$!=%SC/QI,(6H:! D G 4W?C"'0VT OP0@,#H8Y58PSEOS R$F?S&_!@ MS:BF&UYH-"?N0CQKCCT?+P6-$Q)9KE=F\A1OJ,U4#'7]&-=-YWC,5 W@ID]S ML'Z@=6)&R35IV:#N!R,E_ LR]XLQY]Q:?==G S1<**PI)AHWYIL!#!:JAZ\F M&CS9FN9@'!&Z=V%ZHA^&-RT]$!FSFBRILWR54DU:9U62TUE/(3,"X4C[YBM3 MT.1=,(QR$= ::CJVTD<+1A=RY '-M[A]6Z:+M1^.!RD^9F%>"/#[F&2\"$1[ M9?CZKW1*JKY11AU2^5@HD*>ON7:W%ZSB[> './#92MYR^,OGOU;FE!:NXOSM MGGN H!F7EA4WH5<#G'YO;#@0@_*>;1SB\"U7K578;,%*_XU:8,](%0-CCY, MQ-(NE">)INO8#OR!CUJI..9'E\,!#43[-,]B!2XR\@H3KJ)#Q)^ND*&KP;4 D M^"+G89H#SQ157F6\2/O5N0>>L[<\"A&C#1*)A_,['8JV:Z M8'5K@^]PS9Z.^Z9.(EP*%QZN\]\8,%9Q>V[^]KO>\]_]VX=>5,%W]U"$+*9C MD9HG05&$>;K)TXM"CX6?\ (B:<#ZBB3/Y&.BZ'_J??Y5-_L8&O6V M33D=2P8("&&Y6&PT_B@6&E*& HC7DY:A6G(R%$9*G^D:>\5P^H@Z$::CDE,Q MQJ"N6101;(;I -0P%&9[=K;8M"3.= +>*0_"]CF:T:Z;4(N^6'0R(N_H>[SS MV06E7ZQ40](&2[5K\3)]/'<";(EX8MXO\UTW?\R-_)W]^Q,0;L1#L^:'YBZS@@&7O MN*.L1#UN8+JZNBTXUV%S!?QR>\//>Y#4_+YB;B2M^>N)QIGG_9FAXZE;C.[J M+*1-<[]Y<5]? A?6!?(&/\)4+'2]*&A:#T;":H O1TSG^C[*_ +VN#H_4RCR M!K3D4*V LH')T+C8NUBVLR/\P1HAC]#O@2;]0U MVM=T+@0*T;@B06+'5!-J*LKYG/%P47\MQVSQKB]>J)9$ADF40+_RCMVO.!88 MED>C_Y/\UR9'O;<5 M&\8S7_LC* W'.V8B/K."N:Q%"X^&YH(JEFCZ:FHJMTZXI>!924#7T+4#(R>2 MG]$,Y+$@%2PAW9P$^FW,W4)O;7_3X,K$?.-< >T\P!)$\L(,/'O9M.SWN9F1 M#3XF&D(C;>('GQ#$8/I6AK$ZJG,4=^4 MXF$Q@0V7;U5J8F^+6WW#1:,RP&'DA-(Q_,C;<8_D.<86P58V7?!V51B"YDQQ MO^X#MYG]!\[@",8QIP?O]^CA!(0G1VA<>!T89,%2Y!&Y&BAI5(Y)Y>ALDXM9 MOYAK:6'.\1)(%->Q8L-R"&RF6(J[^9C$A6\2*A+NK^$X\VKE68(NBEIW+ M:(!7F+D^"X*D?5C(AEH0U@CG-/"]$UC#0EH?M/>=6-'"%U>LK3QK!!XJZ%K\ M :YCN6B3!%\\HL+(,,'NMAS<^9WB^N^3R\T3.EL=89'H QYF)HAGM@2&\UST M PUY7C/$G7[KE>7X>O/*1KCCQ>T,;IA@X("["C"I?[F:[05T?*>'>9W.<#A> MYW$_R@ON"'_]&@*):H[Q)-@!WHT:!T"5"^X/K^4I7-=.I2:*B2=7%I+3$ZW M[K66W4-G9)GNRXC\GZM/<\6&'U*X?>[R'&SAWRODX>$6D\G^F)ICU KP,;35 MS[OAF[HNVD O^\N]$9!N!Q?$IB=U=?+5--6I4">H,?SGP!MR(;E5\%7XUO6] M9GW.WO3(WP,3""QA#^7H8_GE*5CV?3F&8/)O[A)G)S=EZ>DT_'3C ?^]'@^H 4F[X^ M6%LXHI"[O[>"+=&U>_U\1R!=OL= M7@DS!KP1C_0N;W[@KX^__3Y[XCW\\/\HGSDDNNNP"=HT#\P!56DPZBHDG+3[ M!C;$B&?:\)DK%\3,S:@%'*%>_0+8FKT$F0"0W*2(]FBPU 5=XY7YBHUK^!#* ML[LW>C/+ M566KN?3+;EHSJ_2)6>A>@POY./S=1&+NN:C:CNT=?#]+I91#?D+2O']P> M+?7W'EQNQ\%%Z:[-XE<_;E+O#E(8-=@<:G'A]E'TKG !@D?@(9#>F:_,<6W@,!;_V MW=_6LW*/5'!?YF]GCN1MF-+>;/3%-3U5RM%G,KZ?6_;]!3WW!,9E* '3+QU9 MS!0)!R7$B,<3<>"F%_Z8E=:(K4J1ND+)(&@C'ZUA%+%-B%,9:R'NLX&P&J)6 M()BA%]"'8>]F/G]A1'F6YS9*O)D%)2YB#TS-+6KS5S:7*2?=AIE1GWCY6S'A M^C?W!3Z%'(?PCH](\ 9Q:N3_G@ORA;KM6UPD5$$TSYH!P!HJEULO/V!1IL)) MXO=&.'H8["K-O]2;K"L;D@X:7UY:I_S')U%E8 &/8\ M0_PQJSDD6PGO-2FX?X:!D0D3F=L4N]D]MY8BOJ&P(4]511K]^. L%W83U5RW MY4"=H'LUGQDK'G;MO9X:AND: XS\BL=K%C!NXHAZUI(W[T2E&B@Q7;,=938E M8H,SM/NJ>I6Q&/P)$2X*[Z*H4$0Z8)^%WNF[.M<$\+=\F:>X>+]ZP7FQ*.?G M;/O4>\/GNS__$&M-D&N;,[C+@L%8_;:XM2IL MX"]\6T>J.6^JMEVM&-MX(:N+K2K)651G'Y@*V0M6Q%!PKQ M*T\=#:.5*);.//^]UP7&F>[$2Y#RTF&]G#/;2WC/^6<0HO!BQD$H?=G/PA+F M'QI\2T^-$UNNST5B2_L:T&A"ALPO["CM3'V3Z][P;"XV,\O665_+YV7_A#L[ M8U.4WN R,]!!@>$'>Y8?E=,L/X.S\Q>5#XH2_ZEZIP^ MRBWK(S1)_,-1N3UBF+R/H5?11EZIQ8MG_L*XHY=A"0:#B7N0 *GU4K1/&/'P M&@SX4RS7E4JSN9<&RZW68,6&GX]5*I Q7_OM:](Q_E]$-]@J@"H R*P;D52SN)(\>TW+U7I :CC]XTHSOI#MBWH^\ MR__X##-=K]SXZMQ[[EQ\S;LM'%;S*,N!;T1GOM%""P-/&1JS=RW[.R;XJ7C+ MC &*QP#A:/&,'G3QA+<55&AQKTM6IRRB-/'"Q.)Q*A.#B VH6PL#.G.)Q3F- M0YC]F.@F;YFJ$H;55N@Q^Y;&+!,+E;6G3_''3K[/2VN'IBG24/KLE5F8S.CE MI-C8JXU,Z. [Q<+\%[C/1L4O$J*#C+A<5$*ZR;FH8:!%3C>-ESP,9TQ>+//-&9&) MZ3">MA^D#M&H++/@_1;E&6G."!OB^MGX"B@5F%7Q8$8M-#Q2N0ZF(9&Z<3&) MU#692)W51.K$ZRF+R194=L F$RT9JQ%;%[Z"SFB>!MKH(&SSA0K)/.@F5V+@LTUL%RFXRXR^%0*>='!Z33X![%D MCMB8'[G K]@FG8"WZH7I\&7<'D2!5-':\UKWY;10.TL>AD^A%C^54"1>+%A, ML%IPULU2;.J4UC2S)%^%*XLE:+[['I&?-]\#Z?ZI-6NXBE9#"RC%K$ Z!2 Z MCD#EGW1BDJ^> ()M\BY(.$'GQWQAW+R@=B[TZ"X84VS604C8,SR4(-*@L<, MR+?FZ,QOU21(QI:9@6$8KBX.]U :S\8Z<^D#LG+S9(4;S7[]&C!G1ANVN:+& M"XS1U(3D!UTE_ YSM0)B?ZX+M[ 8B M>0,<6\^U7)^P-[^O-J%>_P6R/L6EOD=:6RA/[XE:CQ87/96;7$_,XB'&59DM M3X@#$4XL7!<*A>)R*''B5ZUX#H''"WMSN+2RQ[&6LR&)$&G+=<#@UOZSJ;-A M,4X.E-_3D<&+F';Q9 M++%\G*U57),!Y8UA/W1X9>DO3%B-OK:K42W&RUGB89RZ$[;6(P^V!*,6[ M?I1[9.?M-LI2(^XHR8I1QEI)/D1S@ MW09Z3JC8: 7*%U,ON=T@[?%$-Z<\GWVV M)+/14 H\67C9 KMR\X*^_*O9D[T>/%YV(X;&_3R7A;I$#!BB>7OK!8>>&<9Z M>!@1X(3Y,E[Z3M!S'9.%O,Y5)6&52'MSUMH\\6K68L+EK"@DQ(/*'-Y$]4+0 M$M*'0,T/,F/@B2^O/-LF##&>7!NV3O#O>7E&5**:6,C@G- M&LX"7K";%K+8A.C-4SR3[.B.NO-M=,/)DSFO/:G'HI5&.O\B2B.LL;W%LV(J M""F(,T%,O%ZTE&"]Z'+),D>P.7&T,5B09,XOX5$1L-VP00LW ER="O"(P#NO MK:*XUPW.%+7%QJM(L0/R7#R06Q2:6TP7$07PJ_C[N#5 O$?SR:/P2,V9+BZ[ M(<3G<&/ WU/@K:H7:?4?2'C[-0P[BXYMZ/.QH'L>GMDF[A/Q&7WBOF..?E,69I"1>B5E*L!(S:I.']S$3)T1@&,#S M]+$-3[%<:9(V%F!^MDR*22.@L!T%GJ"[X[YKD\??2*5?%B! M@I4AVC?!,ASLC9<:Z ECYHB=FS)JP4*M7L=AV/$W$V*?<-:%1VJ 2?!_6@-^ M]C)F:<%\#31F;WUN6;RG)7\:68GD21?KCKRJ@!E99$97SB1;3EMOC+= M>K:W ].&T+IG) J<)[$)K_M!B1 9)P3(X9;J+>>^O!MD2E>;Z(@% M$A^P,1&5'"Y6'K+,$P[#9PCS305M/'].L#@7DQ\$M?;$8*PFQ'Q#9F"G^PFU MF+H4E[)R5<<$%T%/$)(=W\/Z_)+;,<-',T0P06-:]=S= T M'3QCV0\I8>)RSL!;O'/ZT(P/=EP7+2=J&)CTNIF)?@0*J/U[B*/!//!.2]Q/ M5H/RU*@9ZE.='P5O8[J>ES07L@*\?36T$?CS59CW5S\/F!>0Q3TH.DC( RL0 M[U)X5I-J,M'4/?!OP D+<0[F7Y1W\NT>_V4>ER+/H^;E8T/A_(0G1R$3?M(! MX3%5ON'&X45YE,1F :@'D4>\DJ@C7KWZW'^[QD*'\:5IC4^&;;O%GG3>A\T!(K'*^#0]1/9'>?3/U7=E/_Y0CU'U^1)VS< M;Q9'#V@\1$C%HSYH(:_-(U:8%4VR'+E,M:T+_4 M>[NHJ0Q7S,_T&L/41P-'X&T,J6)NUG:FOVXS#LM((/>UBO:9]W M)&H2<\*\\ZH"TB[1&*[M!K;J*FUX(%0EJ"TU/,XI<*##:HH&I)&)1QLFA'M] MC<3.*+7Y41VP7//]SB ')VKQCC98>MS\B'@7;R6-RSO/#II]'7AO2DZTVT;E M##=@^79@.'PSN,7!C14.[!9'%E6\+J(ABQ$'P)/\,,E!UV;/$/:YF$QO:8@< MPN6IY/IN4E+;4B5_L]GCL V.;V*F=F@ZX-/!K1:(JG$6H__*H0 MX=IX=(GS<"OUSE"US!\1KQ JG=_;-MY@Y.66^>DK2.*;TVB*\(%G&X#AT(/%7JBU:N');6(TLM85HLQ\0%VN0]C<3: ;JTR@E7*2Y'QR M2(@+G!S\=%#>"?Z)+S&;F28(R9C34;#U;!%\_L.5\W7>/I:A@J$I7UMG<4G#C' MQH_?83>KL,!G0-+34._6O)AZM[JL=TNVWFU;1[BPV]K4W'9[D]HC<-/Q'VQY M\4IUU#J[[G/&>5BB;@J^FJMO_D>(B$OT5X*S(K;'WJJ(]Y9H.4I>R\!K FOS M]7:DO8QXOS^@#^WV5^:MOCGO5!18>#5X/BR88RQ&1'LH:''K>1Q@?>M8,/Z& M;6Z"8UB]0OD!(HO-1G]- M M?H56R8+?PF/?R]LTW*%:7VNR1\NB1]PC6YBT MEG-++0MW>3=4H)248CFBU@''L9[@'9J6'X3@IE*K+#>!G2L%2)T%E+PNV#5= M9MM\F2<+*W*=Z1/VQ0!=@3/(#Q;<<4V)^[Q3!$-XAHT@C\MU0)M8;1+WJE=3 MYF-P1D)Z5J4=LW"*46DX_$$[0.X$4S*'%.:32+ L8!M7S4\X?-+Z!/AVQ2BZR1Q@[(+V[$HEA;G>3W^F($'J,ZZ7?N> MH)IS;39T=5@M7V=EL#Q]FZF^I_UN8L'-%C;1%8LD+(.\]SM&MNSWQX@>;8OS ME(27BCLF'!3+6^K<9Q&X>&8#\\70]DA4W/B@ P@.JLW(N?1>3D)OOTBK?<0%#5Y%']5O>6 MU HUDB>^AL6@,(J"@\Z1+4!^"P\W0??9'\F[XGOO(.OAU-\HX[?Z?1,&WKTW MY%UIX58P<;B?A\)C]H%N+Z77VT#SGP2_++\'LP;KTL%"XS MAQK/3KM4<=PQ):)86V6_;R.%B3$[D W3FA5<:O8,)ZH(!^'FT:P@$[LF,[2> M0]O0OG0$=Z:1T6?YLM&\=QAPXQXY 5"?<>,CV)]2P,> M#XX9LQ[]L:/=ONKWB<;:Q4L)O/4RTX&*.Z8/%%?F#\2 P5$BZD&:."H@34RS M@],L4A]S:%'4*X6@<_+/V@(8M$]^(V7R+3C M2-H+ ?S4M;QST]\*J ^GZ5WY)M6CENNMW-$+X$*B5Y@%CIVEGR4_)_1;J'HYTDS-%G MRYF(RB?0,C^+FBOGPQK()\7>: M MKP[:UX(L^YS<9+'#J^&8&_]3'-\]?^!;A3,93G>%8W5TR%-^M2X:L)C FI M+2Y@]Y0][P^&4,!MEAK!WL7< \:PH7M;,4M0R1]9$R3#^?TU'= MF@>[:!W\ MNQ7 02EY9!CX(I[*BN?$S7,S*"9IZZ)!#,[:1!7F4-#7: JW6X54!S2E9MW7 MO?(L/Z0EYG.H4V?"^MZ.S8 S2.D\C.)24&EH3\X2T?/41:;YHR#Q^)3""2,L ME:D&2#+S%A>O8I"1A@B" 0@T@=6N&WPDJ.\JZT12\NLI[D_CAV@PE/L .6C\ MGY1MVSXR$L/H56_G#,ZN)Y^LYG7'B+V>X7&S8KJ\V9AFVR^N)GYPV- T:F*D MJ7P F;XQ5?0"IED>L2_U2,)G7L%BD!4Y9$JI(MJV^X)8F MT8K9Z69=/?PZ F14[;)B=Z],9U7Z#)W1RSWC4Y:1 T=):CZ.FOB!:4'D.,GF MHTH(H*2BUN$$9JP6JFJPWN MQ"]L&$ \74&@/$/=NV)2OCD_*;^)W-.TGB5R5XE0R MX'%\,/"ZJH?^ *Y(:Z9KR_RO,WRP5J5AE02BE##3H$8NT5%%)&V873>U]+=^ MZ,09MT(T%(@*N>7KLNY9-ZGRN#LCFHMV;T)N[XB&7YH:WM@Z]E'E?;F-I93R M(&#D9"?-?M/W&(0@&:)':4X?W*]?SA$7+NUX>C)][GY.-CT9/!%IG-QPU*_X/RE.;(J-+U-*H\/ MV^A:.7N,7LT8,76ZBZ7#R'031K$>B"3=HJPS[,/=XY$.D\FQBGZNG=B.TQJ! M35ROS326,89#&T1BJ%<,F\/3@#K'D$B@4H:4HX=B(K5?-.K_#-."\W?H$BW> M,UO4?=UQD>/LG$8'H4]]6'#K(Y[M-5[;O&*C3Y;3X7LK:?X-9LRW?1&LAK_M_S57 MUCTCZU(8FC$42N5Y!$G5X?5QA5C=%^C?Z?1 KMTE#\\T>;"UC8W=9U/<>/12 MW/B@BAN;*T*(FG40HG5TZOY*.G5O\SH59+]G)58; M6P7KF +33=C 5Q$_00CA@3W-N"V[_.4R:58U.VZ91WVRNC*OWF*9L'-^J[E% M:?:4]YMB 46)/W&(<'"0'_*;%\V>L"4GQM]2.U<[0=F1C?/4KW_3;=KX4?:. MAB[3.A3QR&.S&7GG-,M2THVA3F@X3]?&+YO;[1'_4G/G,ZTGOP@=BLD#/-!J4Z%CXKI7%?#". MS_ >QC/Q>=KN' TRS#G9J MK57QY=$/1"&)JI)ICCE3G5@&F7!Q?.J.]Y4#G!9)94.JMFF?&5I*!IA$:K_#F?@"=)]RQ!'(..)Y2A+YDD7^'6&U58/)YM'I#OCNA9 M:JX581>M^6U#UI$H*_5K2>5&TX*'C2.W1, ='W_<:/PF'2V]JHQ%O^OB@8 9 MF#D!D;ODA-+0P8#V&-+',#A."8*!GL57+-=!*$TF*WSS%@6ON NE(CN/'"". MJDAD6GI1[/A?JU=)'2_]=Y@Q>M")3@0<-]&M.^&\ZZ9^):)/0(B! 0 &#@)0 MH_E<@%4^['!CKG*$@AZ\373#=^DOR,@K_@8VK66%X+[R^8[ +JLS(3T)]5US M-[YSE86FOD%_[54@BX$?CB'3!:EI%U5S)IH47&TYA9O&JYK=2$^1%VMOXA8$ M>):[0L,:-'Q35A&Y1C--D=-*! WAI0+ KF]M9WE&40;^MT12E!H42C?)H\)> MJI_L;0WS(=-FXE< 7I; T==W<_H^6%M_U08:\Q%#ZVBQUAUHPGMJP5FNXV\LD\X'8#;=JL*3$AZX(93J IT7>E-E$>ZD1(4\?[N_O9^I5SK'2L< MK83EG+]PU,-G>NX[\UQ3RN5!,SNX#B;1GZ=I>535UXBJ2L -3=$=>4*0#5X@E_.IMA:_YXJLT[>92DZ0WN &(_(9/M]KRLTD%J[NQ3V M=$9\SHMA<+9ZG1M>:OQT' GPW"TA+_'=FI\V&_\:5<&X*Z- 'IH%?P^*945T M5:L.7;6V+MA@ROS==S M<_/A 9W5(!*PA]"9 [!YR]F7-,LU>,9S]4-MN?8T M96+,A"6B;<]0_E;$>+3VEW0A:>Z<^V9I0O_L*"%]4 M1SJ-G,EAYK8HK8SOKJGR'BDK7FO%E'AK*JO&&K+V Q(29XG_YS!17G.W<2 * M[OW)Y1M]2),1\Q?9)#L^OMUNM(PA%AF7&OC(=Y2,:63M^1R_BD=!P9'68Z MR4O',:.)^P\=2X584W0NM7:\OY54INMB;]/;D\[!CE.CS;1'%ME.=MIPP%87 M/YB+FO#=,*MU3W_#^L+Z#'0]./ %U5)XSS0]N=.DSZ,E.6RMF*9O+/#?.0DG9X79F,0U$0$WHL%:LI7<> "'LN-0MGN\9MA%:1EWW MVW38+DY0K_ A)8D\3>EPS)*ES?3%[[C1[ YWP0)XB!_MZV?_P-S.RD?5\BMD MTR:K+.Z]5AS6MR_*P#YG2$XGXW\+-W4J"ZJYZ:1_Q:+0D7]+$@O=OWUF<]6)D0M*6('"\\:]MJ"SLTOSI0-Q'=XT^MA# M9H_TO M;>,W5JA5I(V1 [P^,\JQA>1+4TSV%AD5F;' \I8I$8]V3^#!Q@VFS<154+UA MK#,1=5J_F_($F/RSD/N6;>4$,\X1 ET*SC-@]AZGC28<"H<^5*(2)A?:+R,2 MDU>YFEW>#XEFO(C;VXY'@?6HH4XCVQ[O,D,;["PBT/=?_K)X>W5]LM$;MW65 M?0G^6MIF7.QN=\3++Z;A'IF&YK&^\]R[ RYNQ!I<I_RF-1._PE3D?F?YM:-$VVO^<0HK/9R!^W0^[PL3]?<#'XC S(/$*OQ3I MV)P;VG;P(4B]K]),%)2&7. D2XFR>NP67BB62*53[X) M5I%>X5,X\IL'=YG>6NCL]1YR]6?CV51_'K]4?VZV^G-)#=I:3?%NNHNR4:A" M.@*CDV-Q \!/^C0^=$#R3#,"S@48!UBC!2<9?%$@,\Y<87LOC8%.--YO@>;& MGJ/A.+.OP><_CISAGD[LO=4$9WXWI9DQNP[Y&\-8G?>^V!S8F8;LTVOP@IUH M"3A)NA_+93N1Y?^*((MKJ D-=4?%\0 ]WI,K[F&(O_,!9_KX;Z-\1*MV:(G# M04[ZQ_SK-SJ&N\4U5GCWY]_\15?[%13-/XK,W/\&15OD_)H%%P7V2JNCH@NC M\*0JY[^*&8COY'LC&_I3IG5^VMYNY>T&P=!*-2,9^[[QF].G>6Z^7/F?0EAF%QJO;G*(QFF"( &\$O)[!P?U)3?SQ"#>1;/O+=;]4Z/ M2'+L;$\7F$8S.#[>GRLSM%C_I9]YT\]^M^;@1AT=]/O?UF]_SD$$YC%6;M,.GX;U4[*OS3,+,;>=:^ M7'2+/=+=XQZR.XZV#^0?"?>Z.SPS-TP/WM_&O"U+?IY(. M>%GMFM7^F"977U76ITU1S%KJO?V]>UOJN]GP56&XO$X':'YX3[)0 ;[DJK,= M?=^^CKJT6K_Z\M_M'LWB=@/03CY3"%ZFFRN^MLB'I(H;,QFJAS-%2]WB8!Y19J.4/JOVC5K!_=+#TEMQ;?$/^PJG8 MQ\UFM60R?'^U'/H&*:]KP!>T4W^:*<>[J\OQY7 PB!DP%\:F#7/E1%G^D)!U M!@X./6B\R+19-+Q]US0+RD7/"T+T/WX\%6+MR6[=7.N&R>HQQ:)& M,IKZ$4N]+73;P\SIQDD7I\-"](:!ZMIC0UR8)_D%50Y8/-HQ)U/,@IY"\*T A\'"5Z))&=, M(;EH^WXX,@W1@9\O8?NF-LI(: G1+;DO,)8\9[@N[B,5EZP--+V %JRRG[E3 M:#4/9X;/<5?=N=-4QJ=)76F.IZL]_4JU)]^CK$$8I+)7G[R 'ZXFX!OD[F:I MLI50PR0X*>IQ+BKG#<0:6OH2^(:GWA6&H\>3EYF@UN5F6^Z $(9Z: MY3SC3MB7IDBHBC*<5UR29\6OR][ST2$7ZYW;]6+S%M)X\&K&#>O@[?/A\>_U MYOO*#=K<5LJKAJ%7<]R7G\(Y<]5<;JY>_;YEU=WKY9[]. :YN85839:7?/5% M9+EDFOM'._M%GHGJF[N1Y$<\ XW[W-HSJ5W$5)SP-AW'ET[/%K=!_^B9^ZS*LY[9[KEU#LI19Z1A \.&_,C9+-G M?_',P#-9Q>-[7\7]X/BXL>%E?%I)B 1$2&1\[? 6H'FUC#C'VL"8VMC M.I:F2#P<,$*ZVQ%,C__GU?;XOCP\. P.#@^7SD TZW?CA)GX1%9D#7VY[(J0 M-=4Z6!ZF,WM!7C3C(].,OT-:0"8@[ *KO??$SJBS$YPJ\-E@V^:KW[=U?&FC MJW6WHVZM..IGG#\]7BW@-Y6HXG& M/9XXSM$:B)C5XCC-@/?42S3N+E>Q<=^KV-H/]O;F._TOT;@'.IB7:-S]Q7[6 MT;'+QGX:P<'^<;"_0I76\XK'K:,QEUZ31C,XVIN?NG@)R#V0P3R;@-S>HPS( M[3^J@-RF.A MR\B[NUI,[GBSX,TZR&8=!),[3EN*2 #8KZ.\2#-LRBE-()*N M7URGTD>A1&)RN8$PA1LR[BA&J4$7!-Y*MW"H@WV"I-N[38=Q5[##\BO597#G M./J3)%7Z'S,]IFY>"O2QD%2V%S=KL*K!3I?38]_6<["M M&MZR MZ ?!2MU\-JS4C=T76NJ[IJ5>21$V[H@>^%)=0;E\,3KEK#S"WHSTEX\73+]P MQ[55,P++/.!>4@;3!U3)-=6^]N)IA)=Y?0#SND(*\&7=R@&91#FGUNA?X^4K M,CS^TLG#O>R<3:U /@98> #S_[+#UEI?2=:_;)B[G-#&(]X!UCO^=>PEUEZ# M9:5DH[^__P'^."3'K!<;AW/4RJW3NF*E.9[,:R\SQ)]FCVI:\XOI;=!GIKC6 MX#'2H(#W6=H_I7OB_G]'Q?4I'8MIG^E/XB'V_PDS-:!]R_?EZZ]F+]!R,SM3 M.3^G16\]D$4_"@Z.ZYCB-KSH=\SW/_71@"X8S,(=J.X51C!-K):2I3E)\C4T MR+))\J/&\:+2LLPLC?O(3VIYUMCKRR[/<="H)7Z\XP4:3]$N6-'P\-O=RF23 MQERCR>VL>VPN3V7ZW>[[V[Z, (SSZN[:W"Y?U[)DT^X%YWYS,SC=9'59A'3C M#]U*EB>ZP$333B0/SCNY//4/]W8#']Q439J9Z/?JW8UQQ^>.+6_8J8\AZO.I =[PX(FE"]$/E%G:"8)ZKI1 MCYXAWSF-:>N3]YTPRT;(BY9)4-]PT'G3QL<)?Q5ER,P/5(=;V6-8@ WD._[; MQ=Z1IB>$B'1]I$BN?)60LM-792&:6J#W.3[RT-UR,(A'S+\7?N2!S1A5%;- BJX3TC*S MKH]=(!&[(B5G@M##36-%TGCCT:VCX>8NNQVCO M/LC2FZBK):1#UE<8);4"%O7\J, 8^BF]>QQ]4YA*&B:C,R9ZHC/?([[)5 @6 M._=6Q77&K>Y%&+T2M;'C?TYK'TYC(,1+.7-"SRRB@:8FL#ZI'W7>=9K,? M"4G?2=(]Y>^N2 )I$M8XFI:[Z^8/JP,ZK)PQ\8ZHC.I1G%YWLG*F@_O*"[]1 M!(REII3NO'PB[>WO;C?I4*(3CJQ3'&RY1_^N#)F^I<])30HZQ6&/%+7C_G;' M=[N1X&M@SJN_(?4;L;IG@M1.'$9]>D9)1$E_X/HK7IC Z]EFZP/2C+$]?S0; M:CK,C$HW#)AT M"!)_J.-&1;CD7HN- YFFU#95+$3!9H3C6'X=8GQME%>4 M_]9ZVV>#_;C/$_KU@(R)-JU0XU"@? %C(]^D8<8&WMN(Y*](L]P;DI45D0SE M)"!DM- 9+68&IPE(W&#+) () S5FP=RHX56F! P&.E__\LO)_P1P G9H:Y ] M%8>W$'&SA[>T98J?:4OT]8Y_0=;", 2F+?58=.ON.7'.DT1?96'"D,D.4]=C M@/X@#@NF*>ZJ&Q73,=_UVR-]CV])>@L<)-_,#$4Q&ZQ_H:_3P_+8' NPJ9(K M$G;]/SG9'PTQ)&L(KF2!["]$3HB&'N)"\+$II_E43/G- MJUE=C.ALJ2,HIY4LJ8U[= =-8NR5NAC,L9J-F!4QEM:(YY% PY]MK0 MX'T0*#]$_.5&5._>>JJWM4%>[3A/X7RMJG\A,ZQ]M2:>IXA%/]5JSEN<\"28 MO+E8:-,A-! -%;UFCX>#)@41>;;='V_@O7.>( M[:"2T)O\^[P0O?NHR=U7E*K]]81R@RTBR!XX&611[#>.Q'@+_#>J@% !^/*O M=.C_30K-=R3OR34BT*O%P/S=B5>(IG#NEWIR?F$2+:G\+.E["-=@<8Y/LXS:(N MS.0^5XJ4YG+'6![.F,_T05M:(/ S\ RS,RJD^!X_D [H=,"O3^^5TS3YPP'^ M.>>TVE_^M&KW1K>_RA@Q/>>WB>I>#MO_)C7Q-3WG,7"#C9E=^.CXJCW"Z*S( MZ&VTDS#&9<^&1JK;;@1T)!OV_V5>O37NR"+!(4 MQN6O?M_=H;>;+)@ M;?>@O+>:>Z^-=1/V"OW[KBD.^J*NHKS0F\7R#_E;(9ILP"_$64V6VFL8?EUL M@JX.UR$>J;7F7SN7.[2WR4(H8Y?OC)'%VRC/X6BB/8*QGOE"&!*Y.2#$6A%/ M-N3B'AVX@[3O>#4]8VSU8<"FG K)R'"BI0.R8(8V=HR[!'@+TOG2)V2VH!RX M@M);IR9R=96?.[M&@0&?H<&,*M M@]>.0S#*W:(>5-N@\;EV%MAO3SN1;9!BJLTFYM^SJ^@8I?&(;6DVWKO2$ILMS<\%[BY>_981T*IE/ M:E6"40:-X/!H/SBLZ<L.L.A^NJM /-%H"2L(H"-M;R!Q<9')SIY$T M291,DETH]9TVK-N[A!?HN1@^!^L9/AOL:/;&"^^.V0#,3+@.S_!J1Q'_S4&QKB5S[8IV:B= M[4$<2HTYW0L1.LPDG>E7?!>:8W(6OHWW=,M9-97MW,).AEP)'D17AHGNWA5( M*7*.['Z4(V[J7W'CMPRV4)*3PB0I&/&O=&K&^&QBER //E#I ,5])M>?#HNZ M-_+T&XU8%1+ZOP1V;A[&NC/4YMHKXA'H\)ET M_R9K:K^">Y^)\Z(&5X"'J*)C>, \%ER(JCC7#,%A$=G1#'9V/^'*^G\8XVFT:M M$W]?9P8E]ARR=X,T!CT ;JB*.*@(TV:$OZ^B&VS"UJZHOML,VX*A&' U*T'K[%\;C"QW3R3Y$$/2L!:?$[E=A1T<&6+TZZZ&SN(_[>Y.\ZI M]""%S9*UK"RL2U9.+SNG,TO]*]76&,E4+#;=9)/H\-V=YGZ4O/JE!C@N M7\T%CW-U4B_L1_'HUWF5W__[?QT?'!Y/JRB8C_-;YEEIHAAJO.C_$\T]'*26 M648[I70COS>DG873A#9&8)[9Q1)BVRK^]M5C36A M,+LOV^HQ;:OB-EU^6^5U^PI!P\E]E<_96&PR;7!SK7^BW=_66Q>%MC21_\O6 M^Z%;#_0&:VT^VGOK[;Z=#>Z\1[#AUL2M-38(7/LCO56T;P( P"?\VQPAC9:Q.V8@FVX,?B>!W =!:]9Z/K1FC1=:L[7E^QZ4Z)H(M,8& M(6@R+:=E!NG9YB(::T*R&AO$9,TIS7&2Z.5*VH5\J_).%C$D:#*O4;?R?!IZ M92+RBO9IU_]7.$C]3SJ:WE8FX\V7ZQN:9 .]Y1 DRX)PL#!!A.QMV4\/S$F"4SD.D#]J<6$$*,9J&3G"P)+AA+@5/& M37YJ!/OZ:S8K=\9K<+RO4\8T&3.=")6RA9;Q "GSKQ&NYTVX"O-^/IXZN@T46@B2CK M\S+%"'<_4]UAQT5'D%!=96'?;P^[5ZIX-HF"QII B<8&D1)R:)R1A/P9XF:U MJ6QN_?3L#I$U40>-#<(.SFFYAN1J-!N3 !>;]CUU%:^\1*%46>H32GXRGNX2 M^58N@OHG<.;ZG8"@;I3)7-LDXQ@ QF, #+X8>\RG;$>+GR3;*^^V?(ZWI%)W M.JMK#A>!,'@AK2C@"Y*^-G9* MJ=CT>9E;%*0)"OENT2D-NC.,N1+^1'+_KGAP-<2?9!'ACX9U]-^JCI1\M!H> MET?X6]&.8C1])3[U>J=RMX&N3@)F45*?ZV3='8:'APGB,4$YC6&GDPUUH:PMMH6-FWAI M.]85NV.0^!W_K+!W8,8#C:>HHH:4DJK=N9.$:EJNY.7D>G4^NMZ8Z<58;WW_ MYV,5K8D8:VP0,O;577"1"F- *_III.4")X@'X[JL$M2;VM]Z<_[YK\O7"YPA M1RMBK,WX](%!4\?P:NZ(LI@J/C@*6LVCFJI'+A,@IP)P+[B%D=$L;])DF/L7 MP!'E!DH=%MM9E)N""[-9,PY$L1=V1>H2=;NH/N<;>+A!A]NFZ$X44F1V[;?Q M=2#@:UWN4*I^_2#6-6C,UC68F?J@Q8OI\8065J9M(W>KZ?Y0/(%.A][KSN\ H?&]6*0?*:7URS87 F, 6%751WOP)[\.AQR MJ[M*XYIXO*O?%LQ+^Y)A:LL<$.7B=<'E?%2ASO M;G,XB?Y9.FR!-UN.0RST=L:1JH8&7TO>#085Q(2!3) D5XMY MS@=S6[";45N-3_",?#G[/BW_\@O\^'R%?$YK5W&"C MKDG)'4 C%IJGC>'K?/"7$8^R!+ &?T<.4_@]Z@_[^+PG\B/[I2I]OY4G@8B2 M(R7!^+E TM]3$;RZ(9DNWI@'+0@W@\'Y4 M13JD$SH<3@\1WT>$^.$6J377Y87:+#'4O<2+)Z5E5N#X#;F%7, T)6[L50HG MI\2-'<'<4/#8JP:/_;L*'A\_D.#Q?C,X/)H2CETH>'R\>V_!8QIJJ[G3W+^[ MX+''OLB/#QY[K8;_ (+'WE@R_@<&CST;//9_=XI4B:CWULF'^(M Z:_JWS(<>.!Y$.:1\'!_CI@^N/FO>5#=H/# M9F.GU9J;#_&6 =-O*A_B+0>FWV0^Q%L>3+^9?(BW IA^ _D0;WDP_2;R(=[R M8/K'E@_93$^J-2&!S0U" N\SN+Q">^H["B[O-8+&7ET+H9?@\DMP^4&KCC6! MEJT- BU?@LLOP>5-B_^:$,S6!B&8+\'EE^#R6K*Y04CI2TSX/F+"#ZNK^(. MGRHU9C2H)/=M_&NC/-? M98VVV-57^:+,LT]X&F=TR3X\KG\%M[,>%(X5-6;5@WGJ=$J:7/B\](_3Z@82 M664=UF:"9T2=L^@*3:^EZR&'HA9<_15ZL]9/V5_T94IZYK^J^U8_?M;"UTY: M(-%[O!8W@"<7O/#F-60\7J&AILV17=.0OY+E*N\B3_Q"ANH9FJ&Z+1=KVFDV M)F&S/Y=^H_22+ICZ,/%GG;E8 W?,<-VD61$&"\]V&W?<5LGX\,L&N9_P)%(A M;^G:5[\[XM(:/W8J@FDN\W%=51FR@$4N$Z=L#IXF9":VUN>$I!R?,M@@L/[?5N(<7L.?J[RVEB=\&&7FS>ES63U/FL=6A0M3@_9H69># MWY;"WO*>,Y,X;N6(+F0JC))<)B!W9D 'P&D0]#WYE4C7<3\E^F&(GR(\Z<&& M*$8#="TP67OZ4PL^FK>):$A;8?CL+G]HC3Y_#'&55>S,UE)VY@:#+^,F5LT: M5&Q/3W<(II^74CM;,ZU#;3BK^^\)VJ_FDHZ9V>1W+S@^F&(R=&A8AVZT7 :[A9^ZC2V)Z_(M\5]++%A.'6%#AIMVV*\HD#&.M%[ MCOVC;\_GU!/=-_M+[9L-5N#\^0>9M%D[(KD.^X/?:$UW C)I.CLV!F!_8?N= MCP,+80$8D +OHO<1LJE6+MZK"A(*S6^Y@S8C O?9^MZUCQN[=G)+&<&!=I4M M5+[#K88R%%G:'7;$H.*S1$?'HZR[+;3KD6[8GD^&'*:- :G;6[+K/5I<;D@9 M,79E<'U:QHTJFGO,IV#LW%B$:<'I7"/@<#&D@[#S%_+)D+X3S2/CAAS>*OFO MGE.:EME!B$G1^]G3[ZJ^TSTB-X#&;DSIO?@:JCK@84&S?E.%#4Y5KA)]4W\H MZE8/[AG]M7Q(("8!\I.0ZSB]I7]LL<_&3Q"K7.O)O[5(L-]>C4B,B4#;OI_@ MEOI]U8U$<82,$7"'A*.:$5&>XY?2S:+M;A0+4;N\+:U'(=96(,H?([L[F Q[1$?A]$=&#,#/0<5&1E.U>=7[O##,&=27>![MP>O2&;VVB-TGQY MAT?Q.,2)>/7[_D241WJ_S9@(TOI>G5,][9AX#";+$K;'!LL?#;%4PY8%5$_ MLHF+1YO%S-XN6]=[OS2:OX#+*O4;1[LE.IQ- M:6-ZXV81J1% LMR;>I?6"(=<-P]K;L ;)RJ@ .,0'H:%I.P@[V%K*^:^NS_M MW;UUWUU0YN]5.V,8_;'$037*.RU#4I5[EJ\NZ&ROA-J(FM0HM>IM6XCG^NMBM-I_N/?*W?0DC6H/+G"IV./=0J&96 MQZE06RW[RUIMZ75Z<:T>H&L%XW:C7A6:P(H5:XM_ !U3RL"\2_?*NZ_,("WF MW"QJO0_EWRH6%.DL:A?M?KRF%0C\6 V2B]2!2<7/U3LU7\R87\)'TOE][X'Z M2&NP']87F9S@U:Y8_M^,RI]HK,$)"KW,3F'7X;SGI ,7<$]K_2CCC[[X40_* MCVHN[$:9[7>2=,5H=&(62/O?H^?TL$S$!X%:/7@^J-6]%]3JO7LU*%Q66?[N M/T,RD>$9S.S_,!O!NO --^_>',.]P0$HP_%E./XC!+(NOTH&U+K*^FZ8E.0B M4SW%>#T>W*/M#+K\U+967I0-HD'^D9,%:VZ]_4TI4I*\L;GT.AP6UVD&K"+ M2WK=ZDQ@CZN3<_$;9EJ\*U19VZ2 &0+/H(:$V!'.!(0T=QD.4@\)T6EM PT. M475&Q^U\"%[E7?;6>)>+,#O/.+36Y9-^.2#>[FZCOG:<[$/V#.]S002[,W,Q M[G,XCB&[^IC6@'YO8HKN>#B+3M'AE/VSP@=FRVED")?GEZ/0Q7DGPRO24ER: M9R) G@TK-X\TROL?OT"#;39(.55'FI.E',*4 ^8^SI>]E<^7#0*S!,0G<8!K M$-PP8!LU(%V.5([,^C8";W:<;=5>E[,0A?1J_,UL-.$TP7?P4)@14!7Y8^:- MZ-\2 '7ZY1(E5ODPAH\?^!\_GMKX+'UG A"HT/E[E/8Q=?A)>IOH;8(YR=(X MED:P?ZI>+U,C_ZWZ/$S^&Z5@'*.5RNT'?,U%.(S]3VG:'>WP ( S&V;V5GA( M7AK* 9Z&SV8OQPH=2'[D4%6?D%A^-,0&VV3;(_WR:A=REO MK+'?(ED[,T,_:$ _2_/_,X7\2:SGU>]3I5?@[FYQ@@2B#*)=RO4[<9CKV!2" M;B/O)I50T,S[WJ02YI(;VG I5[S@2WG[RBM/Q*!L"OE8ZQ HFMP"%24L;I!+ M.]X)W_)S>J.+OG?-5=@.I^_. [=I/5[G;92I3I'2GJCK3L2H)6R:V2+5V%V! MMGY-^Z&UO[K*VKI4RF,7NO'Z,: 9UCTW]U<^-S<(S!1GV97^9^0I'ZR\(AN$ MJXSYPS/R0??B##NGS%*>\/Y#\X3=_-/C=(,GEF(1!7VT'S2.CX*]_+V20=BCGRM2A):ZQ[. M]G,7] \S>V?/-1?'G!]4W)Y?1ZG_(0,!X#]I-PES'\(+3"15$YI8) SAUX4A MO-EA"'8Q_&?D8ARO+/L;I+L'_8J\?%:V\*;OBT:1PSU(A>WN>OW.9R6[Y!&KT3>G.F4(^;#^1__Q-5E M,P#,;$V;^.=V/C0:JP,V-DBA7'="S)'R%=#0JTKY_!#GEUFF434I$XZU-IFB MYL=:PPA0U)5YCI=8PG.#;.5?".+38_!J*,4X3#(3TS81^BI<7D?_@$JMVL@B6_J[WJ:2SZQO;JJFNPQ%[=.S@B M$V"RO<^SV*VK@^T:&T3;K;);5R!36C/B\'*DKCWYRVS3_>=[IJX.66IL$+-$ MN]1B!!J'"V[35>%)JT0]FO4BL_PV9=IZ W+(94N";;725\OIQ(,V8:#-MU?4 M[?%I&]M;>F-O\/Q==;F6V-B-H^!P_W%L[ =1YG3X?,J<]E_*G.Z@S.ENSZ+5 M84"-#>* D*#2?2Y;)B$^1[7=*8+QY23:]$FTZG(M.CGPKV8#5U =W/4+/>(46MEA-V!3 MS=D.*[_ZA7X2LD"+8[%Y>QP55E>)K9\&AEHJD6R_#SN:%.JDD+W&+O*]M0IJ--;H%70Y' QB M7J$P?JMK3"KD0W?9+LA?H5W06/RR1_ZI=>[R[Z-KCWU'7 M'F_=KCTEP&KUKCW>773M\>^D:X_WF+OVK& -K8[B;6P0QKOY?CYKE*].3I53 M6O'2PN>!27AS=5QO8X/ 7G(50!31/%@P&'"/&,1&8TZ)QA+A %;"MRG-3!SK MJJA/87)%VS2--%.$"XM='B=A''IOTP[]/0 1]Z= 59[%-ET=+=S<+%I8:JD6 M#=K=(PZQL0S/QNR@';@BGF30;MZNO@?(8BLX/GZF>WIU>'%STTW):4\W#>.Z MZ[B@24:7BT N,K7=V-L^]#4R5<7V4>.$P%\X3X\($2%7B.#U[6I;VO+*E#HCN,R2*C#SC@,$R81"NJ[TC)AM2- M%(SA[UX:Q^FMA$/$XR[";RHQKO;\\\1SA\Y?E[Y,PB[[+4U"H7@XN8Z6C&VK MD'3!OU/NO::_U.1, ^9.UY]-(>OKR%I[=4PH 0=1,,?".(8H6R_J&*;PQ!'? MJ(-E"PZ) MXX#9^C1]XQB!"VUA;\%JV.8])NQ;NT'S:"9ES12 BU\!N, U7P#?,NXI5[A# M<]79CKYO7T?=KJ()EO]N]VA$VXWF >S?P_V=1DL3BCX+B5^]!*"YV1( 6ZA3 MR4_7',#.B6..28[DS]\$:W!.D9%"]N!RG%/-X.#H(#@XJ,D &;&7+5$)#9NR MG8A61M;<=LTDJ\+MV"R-Y> EU+2A\QY5A\2UQ7IU-'%SXZR">I5/N?L2MU]Z MV-R"4TE.<5RZU+)XKS?S.R*]&>^(=#Y@TYN\K9Z*F ^BJ_).%O''KS8@':N# M4IOWVI!S!B+'U1B^3*"5*/Z#V=SLC(ZC=31AF-&B_MMLQ_\<==*8>]S%:E0Q M'Z?_(YI0<9:]$D/,]7U)JZR3ELZ,.$,"[_9 M,V;S."=8-37,D;Q;Q,5=V,:&;@WC!C"N"2%MCT //*<:[PYAK.,[Y>SB!S5>!/$B6= MOUY&1G3^'IB D/N72A:_- .K8S.S7W7*\5J3$S.V(E;"O057Y"1GYDV!/-"K MQ9$:XH>W) KK[QL262.SF:?C@2E$(;O$ZZTUT7:+&.S?(BKUUS6,R%\<&8_GY M]7+<,-KT1I\W"=W?;TK_R!U_=H.0:H2I-2>EO"Y0:4I;BKR,#_'/>-G>&Y-P MCLL]EVN;C&K/VI>R.F876WSA9&/5GW;FB/+^\M#=\576VW*1K%9S?P:JE%\J M5XYRFMNZM+IXLUJ7KKSOM.YQTE-_*UBQ=*QHD++9(ZP)+\+#?KQ)W)O+, MO.N<8H6:5+]C(CQQ(V1U-&ES@VA2%]3="Z/,($X*1RT)E,1CFX.=F1R E-F" MN8YJ7G.'_Y./PK'-_0TG >WK)F6+J:KF@T3P,]@]JE-V0@3BAD$QL7W9H M097U_*&U\74_[:JXS 4[N5_2&'T9[:_+GL@,J:D%8>'P9[ MC;WZ7A7ZW8>)GKZRWR8_QC/S0!ON1[WUUY2A'7: E5G@T"YN[C M*,5\$+0X1\^'%N?@A1;GH='BM%8O"6ANL"1 E@G72G3((6):L+M,X1_&8WT MC*)9K=71X*T-HL$=O_X_PS K4- \[=36 2V'2WV#)Y>V$/-3G=.&69D(3SGL MKQDUR<$QC?5HKZ9ATR#-=4@_+$42%8W;@ &*2#[$ ^[.97%U%'-K@RCFKX(L M1N$I\MX5K(-&-;HH?,\8F66%IJE9G0,O;JZ D:^)0#5F".'^;M XKD$S8 M)$PEN \[GE8\GU*;J*D)]H+=NGB7P:<;E\50.OSB^"Y>/89H R]F5@3L 242 M^HNBO4$V^X7!1>K_^8?_-LS: MD3AJO8B3C*'-?,(+[=* R,U4H=1?TUBRU^8&J6YQ!NK!OL_2 I$S?: MRW9V?;AAACPT6\'N04V -TK1TU@\.Z@Y3/0F>RT!53YJFV0Q6']S(5]=O#+)]?K;G.RYW?)FS( M?%2*OGO M&2V>@G#I@&7.K!3+KZ&Q[%A.N:Z(BQAE&2NY;6=YJZF]N7L@)E%358]SGL]\KUOSIVN+5![+!MZ5;!)5D([.EUI'K^N^_DB+!IKU=^%>%>@;E_ M2>%NU//!NMK:[/ R AF/ O\3V>_2UVZM@VMSCL^Z>K!Y$.SNUY2/S#K+RDE9 M\@1;HP;S#D^PX^#P<-+9)[6LPAM)^;;#V-3[3)X'0B5&DXQD&?*J/"NYIT'+ MEEURD[.Q[JK3%!Q/!CW-&8Y5!869W@E&)6]P&U]RG,XA%AR=%"9!I+98Z8 MC?H0K1^HC/=(@FLXC8.YVMB91]J\WL(J>8UWO3N%O+<;M(YJ^MK6ZN-YJ[=" M%?+=OQ%\B_J2_[9RSLMGH8!61^:W-HG,MP%:DC'R5%2?C_)ZQ>+=A6)98ZLM M$9IXQAQJK=7AEZT-PB_/2D.J6N 1=FALV7RKN;4JF3[$1IC&9V3EZCL?>$PA M$^M([!AGX2U.[JB@S='!.132!^35C[93$)V#;CB/NA$*6R8+ *-<;@H+$S&! MFKNW:68D_P2O$H$5FOANZ)^&(]JD1:'\K6A'[U8 M91Z:EY2+_*<=U8Z_!!. 7S(!>,LQ ;36+;Y9I/S_\& W.#JL.6FJ"?'_9ZZ( M5:IDEB2&NBL.K>9D7]NRX ""DJD"10;SWF4%JDJK:&F;7K$VNE1%(43WFJL? MZ&/5_9JR!-L@S"] M:GBL.STUY$TA%)J(%)L^$KZ;G%^TN]0:U3&\D\W#3].\R#^K&3NG<4QN2@V; MG2F%T@7>.1.Q=RP2C?DZ$:0<"VP'GL1:\&NZG:')WVY+@X6 GIX#XV$("NCV M7/I)$]!5.!%W%DCSWS-2]=[ U;/+*:J&Y!E-=Y1A:;03/I/S^I6O2 &P$EG M*"!Q]-8B-]IH;EQHHG?];;\/YX!#85195.,+C@R M)N<_G[D=?QQR?.%M,NL%R;9!6Z5(-"VJDW=V=0"WG<*B6$CS<$)Y[LN3'BH+,L36Y3VH"G M<3BR=]@Z.ST]>XU3LZMN5)P.F+@$)5DP/>28[OIP(1B:?8J#]")+N\-.D6OH MK/8K/>8W95*;@?E!5$_NC9Q.+XVCM-H+Q]J:3(82XL#>SE1O2,8DSN2N&J1Y MM$C.I[5&'A^PS[,DI[V'J2O;B,TP6:;4J?]U^=:AD#@RTP9>G?XP#K6C;M'5 M4L3?DR_YI3)U$^52UDQ3FX?] 4HCX:SI6_GZ5OX6-ZF*"H=HCG^N6WK)",C& MO\IV?NG'.Z]W/*<"I'R,MIWT7;?RUR0Y<8QH:H>\PRN'9CV.&)5:((B@26GG MK/+D7XQ T47K%G!N2F+@9DS+_M _9*IC&V8OO&(@.F>I7'C;Y>A7INK MV%H+J\ -@DG/X2*["N_:E&K>:/!#CYO,E1++6F@0A^@)$)8M?>K[^ < M97='-BW$0C3J%%UCY)^>22)?=AOA,X1QQ2#'L LD6LCB M^7I+LSC:?H_>4E^OTV&. ?]UZ;]-XQA,"%L_29M4#.TUI\:QM<"%;3O[.0 E[-_.5F5MI&C?6'T)!U4$RK8Z;BFRQ.$VN MF$/+3]LQHC=:49N7+L\$).\Q!,OXYFEM(?>B._2@Z,!XEERA\@_/D7.C;\\O M^H-++S!@>@8MQ@_,(R]N=SR(NM?CYU/W>OA2][KANM>YVG]OX7-BLZS#CJE< MVQ<88+##4-!PCSJT46PY'!? M&:)?#E$C=-68(U#Q-QZH1;66<.\O+-P;+ Q86KCG2S*\KK.NDDGY&+;YJ(:$ MD@'4T6Y!6PGABT\SR29SP)?]28Z(0ZO^+7J#[:CI,<_ MCI(N/3_3#+*5Q\/J9AY4'2-@$$?-33T>8N[G$4YA$M-=MVWMAS#+2#+YR>_Z M??JG#0A._#?[?RYPU)'0H\?W::D$NT-[&O) MK\M8Q&-LL#I7] X7%M(-@@O'E('(:)W^T-VL/.9DIE\M$R=8@G]/%]>>IJ93 M=I1SV32L4/I[5L?LO4E8W,^^X"S:..A[/7)8_DCCKM1@[$@W*7_K\\GEVY/_ M]U?_SW^>H-$1/#S^"=),5TQ,R: -E=.#Z37Y-EE*7J#*=$4O?9&9*!F:/J'- M"S+[^8[W+LS(;\JD,.96J6\3^K=4^ZR[;50-FG]0\<<,$%3@Y*=#&9M^L5/R M/'6WI2U-&W[YY^GIJ6T:Y-7&\*2ANGDMO4MU=1(HKF]) KC''K96RW)1*HPH8W8=TVK %-D MBW?$L8XC$FRD8>,R["F895%;B,C_"+-^2D]^$S+A]KCLP+W^@T;ML_Y_ MN!&QM13ET<**Y:;7G8.N@ MY@;:O8'6CD/DXA4SPTXE>UW(G5ITO&^TC'!^0V]*FL1KW:*_ U/4>-H M[ V]FBGR9TQ1[1S/FJ*S9$Z7& #NO!6@=$LVU6FM42CSPSOI&.SPS$XZ_F/N MI#-7@QTOK.LV",-= O2Y>ONGO74Y4>\3]%D=[.,&?>ZM4?;Q($"?JTC.CP!] MKC33/%"'3'INWGHZ[-,K#]NG#OM<0*_>K[9$O](O];2/5QKNCGY7-GB[&^N[4WM/Q #V3$S4I1T2>(%F5_JDN);OL7^CK3U90MP 9UN0*+1 X/4B>,/T5 M<%+6"V%)CG<5,D/17,QDW87DM74ZY/SMY#01BBV[3!'B)T>I5]QF$"<-(=5>SBB;[5_ MRG5/-U&J>1R*#+5O;.PP/YB450R&;7+UR%3&2TF#)7I;\D]WS%R=@>19.B\+ M =^MBF]L.P@D!^P"X;W'IYSF4V]QS,W&%)-I#CU7BTXIK7*<;Y_\Y)P[-+45 M1T$SC0!&14L^C'5*/LI+60X\\IWQHAW$3 I,"0=!:%Z["D3:4:*X4Q2F:*3O M3?(7DXF"N,4M'/,X(J'F=+4T_L(H;M-AW,4XDK0/*,)#!"@^A*PT;81GDY4^ M>LE*KRNR_#\A']'A_[>[B^C,+^'O&Y;G]N]G7]]]\IO^IY//)Q_>?7KW^:O6 MU)?>V[/+T[\N+\_./_LGG]_2_S_Y^*_+LTO__+W__NSSR>?3LY./_NGYY[=G M7\UOOKR[_.OC5_[)^<6[+R?XXM+"9>]T=N]_[[=_?Y]F,-RW/Z;I-QRN-@R2 M;^8='X;2.U59$2+49-\VL-8)61'()]"90FE,@)R8&<,AF&'@XH M:*;+R:[[MP2NZ(_ROKHZ4\P6&(5MM,K 08[4&Q[;_K?$D'*)"*.BNB.]S#A, MPN !'(>YY,/8N"O[9?A# -0D8$^G7*[<9\-LY-Q>P/_4IDQ/+WFLE[R\P!@C M3W79I?AH^OO[9"[2I,?QR,-\@<: +HS*UI>W=%KE9AZU*9$'QH33GVM)&/]8 M%G;BUV1]1YUHP$(T?H65+OV%I[^ <4M&YOCO.5"FKD83 R))&_^,;*/QCV"0 M3WP&PZCNAQX95C4?VWA7[9=Q] W[2N39_H+3.%$_BM'M[_L@4YQ$TBG?)RB% M[Z?+G]VP2/JS19P4G@B.]EL8).!L?_%9,B[:_C=W]IJF(&$Y*AGQ$0S$W MUG3B^G$2-(=QWQLR-3 K0OQ(RV_$M.2D98%^30H:A'V-'>]]* %R>9<.V^T< MEP_MJ/VP"TBULD]*6/&F!@GJ4,K+40_L"'CR&5A@ P]".!:OWJB^># M'WJ*Q)P\!89W:ZHE4&)=1;F4XO^2J2O@_]-L9"XC%7P3DHSK:4*J4(CQ ]_4 M,S((GWX(YU 549DEM&J)G<"!=M?A@0'X-RHFR= M[@VXN=3M4[:=Z'7?&!OF.;SOWXJU04CRG&,G,1Y40Z3XZ-)M$RQ"YEJ%71U: ME9UUFL;#/ME] 1.< O_$=W0V7#H [ ,A%&S3 E4Z_'D>??>O4MJOX[@O@#RO M4@8X(+ZGP[H9:91NC#("I@WU[,\-*@S:&6Q;A7)P+AK%4-X[3>BC/O=D?;*; M]JN&LN!DZ.)8:@]'O)SM840JDEO5<4Q-KY(PLDY.J FH6ZK6\24K5^K7'S>7 MYGD%"R\:Q _ LY-<<>@.?^>#L&/^7G%,,X,POY&<=HMKW&_W9U(B168>0RJD M@(]EWH+N,N6UO'\477.5OMON3G,_2E[]\ONTKZJWBE6/ RG'!X?'-#]%U[VN M]IEO!(7[AT(0D:^@N2PRC&7%-["K,_WI9ICS?C>QX/CI>J/[0?/[/BJPKUXF M>%,3_'E89&Q1ODSQIJ;X9#!080:3^&6.-S7'E[%2@Y?IW=3T?B*[IC>,QU0Q M_0_LAB=I!YYPVICV;3S:S@L'Z"XI?./8B0=.CK?W4R,X;!Q(',;_:=?GVMP; ME0S+YKS" : SMU.(4AADN-MLF,+>Z$;%(XFD3#S3_ZD9 S'38SQ1&_\B3 Z M5WZ>"1LBZ-)5./J(A J$7=:K =<<_LG!M M#E5Q'-!F_?MX3AQQ^ :U(KB4@YM24@=L>9\!$_AQE &Q8J(G^+GCG3PIH?R[ MS%/73+^%F\/S\ZK3A;6->M SH/U0ZAM),6?#IZ_([!GVWP\S)$8 KP_#ZJY5/*A;!@3'))*H%) TK$ 9;-,ASUJ60Y=S>F;&V?>7Z+U MH -]# MDFA=F98P7.4:B1[IR+9$UZ-.I)).)/!KA0AV@H!/=SB(&?X$ M5)$*4722]\KK3!,<&*)BG,^6>52X]F M0<+YMFGV#;I!*(9TXI6=SA8^=#[U#9<7KXW## MF$:O%U=TGPJ'A81W:D-B0A[HH<"+*Q"D=,E6+-66=DE@GD-G\>C)ALF60PTTE_*-M9^H>TU+T MU*^"_854<16$;[+5)U(H!C:.869(0^BOBU**GG(*;:TM^>@V8O#3 />3\X1,:A-X6:H4UQ;=/T;DN*RP+1.-=E M"S9AHQE#R[&N#&=-E/2R$+R*S.^EZ]^% M7TD*4=\P(? _((CPB:UK:16IE;; 9N*11Y?(X$5BT*4$51DZDC@$Q44:#FS1 MNW8/%7?IHV?U84>2F!BI<0A:+ZG>2LIYU+'.N 7'A@Z%O MHH+T@@[=@+VD0J7&9J\9DTRV%"2!$5@S"(GO7<9X*IK8ZZH!*RB:] 1.++:= MWFONL " J8)?=",E\J+DYR/MM9@J3N!!NI$NMPBL(P1GF08055U2KQ)28-XX M,W"G!K];/40$H:\!9.. 'Z,J@$3!EZQ*^DR(IC0\5 MK;S]/LVV_Y4.#31T:M"R0X:IZ*,1[Z]!QAT1_4$:)3K,I@,-X\\O4D#;N'S- M"[OIP-G1I("N.<\/PA9+7<0&K(&U;F!/;#DD&EN\:?F>RU/0%W2@-G%\>MIZH4;RZIC$@DN50W.V[1!8L\8=Y117Q M(FJP:QB7*%GZRC@,DM^VOJ]S O>%]GK?Z05+7"375>^ = 0$F!7'*X%-/PR:XSMX:Y M)R7S,'S;DYP+4O7Y@+,"7A@K"7.TO?_7WZ: PTBY39:.Q<1U1@A7YW9ZRVTD MR8V1+^ ]\KRZD=A_ V;T3%0LX6R.A+LI)1U3)\U6 -F9D_E+IFC45?HQF1+] M4_ Q+X\E!?5-9;9$E^ZFNK5C5#TZR/6IVQ/;WE>)T$T*/;2P7UG:0=VE)\WS MJ(U:&W:?Q"&""C7\YWX[_6Y&;E,1.XZTD>D,@12:XJGV!RBQT)?T/0A MY9,F4"W:4#?J3LI_M\+(Y42 5TNJ7N8I,@G^8X(CX<')R00_):?F93Z!? MG0%T5,'T2_)&\! MF1D.3!B.S#)BY+'<;T&TAVS@XRS6W\'M3_V4\0B0 KK-Y+YS9TR$E8E4^:CG M+E%Z%NS/:M[.,^SF=C)U-O9)5S:0#B_#E<]/NY]7XHV\J8U-X6?AK0U!D$47 MAVU$=XQCU%:)ZD7%. D@2RHJ!(**L$&/CO,#PMXKM:5(GZX$DG1H-5EK58$' ME[! '(6/%)TI97(F'2?IC<51Y;T,NV,O^D[COZ:?(%'.M0*&@$&;G[&Z8@,, M;==D++K*2+RM&#;P4]\5[V,$-4-#XEONC1\0 _@!FT)$9JSPL.?,2: #$,,8 M^2.O*[9164/'A"QI%U8XG'<,@0-^4.^AIBS)3=P0XFH<%&Z484V.LQX'K)D) MW3"U:XG']94A>4;"3;0@-/7:_-.<.ZCGII(;D!KX+&)H=:1G3: A&V02Y!S] MK8Q*0ZDT!B>Y15BA>5.-)\P>(BL CI0 8FB%Q5K M&W$/4[XW?F/:M&49RM@K^A%'.!"#1SH@45>L-+QJY%1B)38DXLRZ&!C03C>J M8D $!A9B?,]CJ@N5U94^,S0;SR,#*=$>WE?DJ]]["/2>%=&9+K[B4M[ MR&L)/]*Y0TE[>+H.V"E4+FOO=8XKU 74SLENU5 90- 45CO^%]<"X+U)VU(" M'5VIG#;)3>A"1/<]RT-L&^MH]#I4(JL;VD/T5R8RF7/K5P>I(CM= ?NQ'=5="5O9[H9+K1;8BH M29KI]Y=?/?GMM!3VJ?ELL$_-W1?LTP.77#X(3LJ4Y?-RVMQNE M!(#R!0" = MI2$4QE)TTKZY#AT)A,%$L]BXL04/;"6MB"+P9J$(_#$4P<9 !-X\$($_ T1P MAQ@";S:&P+]?#('WT#%'&XGO:SJ6CG_2O8ERK!ALRXA$5SUUR_)K"I:=*#>I M\S(.;* 'GT'BJ>C- M.FLA>!,!J^(QEKU-:)K?VX2N9*V]CY'\3Y%T$\J88X+?7QA_\=]@>_G93TQ^Z1 M+VF<+KJHD&X/O(^J.Z*-%OA\D?\IBMO#+/$_?KR09R3%-3JL?-SYL!/X%Q\_ MGB)Z4 EQ!II"6T>7@'MN\2AX-NF(3*-[-O2* [IEZ53*>\ MLA1VV>TE)CUH^F5+&T<$B^@![]Y^./FB0U^WS)R(5K;HV\$!(UMS-=!SPQT3 M]71( A2II#:9:U7SC).-*,;*KSFVS)K!<*EW.-:(-2+ MH0MX5X"D/?_S^9MSYJ8NJW#!PW^=QEV&#^6ZM7J:7*4\?N?;*AEUX'_ W"9< M Q9[^GTY,^D:5 ;RQRV#[A%S\",4[N4H)\4JV^-4@ASW2TCZ(W7L0A47)# S M:BUJ=V&-O<$8G CZY< 4@-_CRMT&4PM/'C)MK@S$5?/B@,@R6-]'^GI-7E_ M0Y&.?NW8TI4#P@; 3M^=,VP(VZK'%KCSLZINY]I?V[W09,D=$!(0%E"\935B M1W4KJM!L)#<8;6Y$)XT*^QP1B\2O<\Q]TS,[2J79V34T,!TKJ@!3/X,$^PAI MB-3 VPW'=?E&!_[L"5^L"13!(@QY(X( M+)EL@?VU<[ECS"<2PQ-#%>E.K*6*M+84L"6E'?47XTT^IW2"-J7$I/&;?SGL M]T.Q,"X==%]Y7\\L6 #-';P/40@O*M\G''"O;S%;J/_RQ^H_H"3LCO)RU M+D\70^'+IIH9C&=PLF1EV,[(2GEFFT],$$_E.I A\'JG\$HX'C+0 M)C%0;>8)[H,]C Q=I"1_VU/<$L30"S",C)3$!+=-U30B[R&MN?AI+_5RN:K6 M\\E5-5YR50]59-N_?T@%50B2ZN0IFW=UWEBM800EJ U!ABF/VW@SF<#]D@G< M=_P/;NDE,8B.3+4IK'8:'G-!HP(+#!^3B":'Y$5IQN\X^L\0]IP.@,:1+0J8@L,.#!774V),BENV>= P,;:<7J2'JL3.X,?F1RY! T6LRY5HKI M@BK?6)DDBU/XU\@HN+Q(="@+-]%(6ID(F,0\])L:N:52$+:G+3RU"J";T:8?0U_\KOJ+W#T. M\?7Z*'>N1K9-;NR&,]BZ[UI90RU-VF9([I-=7L0USO]Y]G:[I=#,<6I(WL_5W=CMP^6+J,:+*O+,1]44M/?J4!]^I:?C?,YHG%2M^JY!H* MLJM+?_V\DRG%F%L_E#HM=CK D2;[2\6YN@64EO'ZV=#"984+(T:S<&&:H]MI MR(;48\G!'I8UEN($D38D)XA+-;N7'-")GLJ;N@[=]K$N,ZAOO] M.FI'3[NGW-=J@H9.2I787#3)!+.0:O.:%)"N8) -V<96PL&HN4F-;8#:.?>^ MMR$'4/JF4>J-NHXZ8N)K\M6P3!1VTGX[$H57GP^R\#>Z%A@2Q(:X?%1]TY'9 M"N<)R;.P4^H((AK6@L:2SW.^\Y-6!4X*BE[=M&C#C' 3%<$-=LHI1KFO";*_ M^W!J8NR:=!=0"*[08C20*9\J34(DF.C<,AQ+5YP@9DL^D\Z_LKDXFL8HG1X, M='@ NOB!;F4),+T_A_T!&9E9P711MGW/)3X:#G+_I%/X6UCR/\_?7.*OUX9- M"1GXO'*@&H@<:M8@%B5ZX3>-D 2"*=<^93)$4I%_5^:_\\GIMI\B:D^5)$%6:!NNMCSSZU-^M3M M+B?HQ2%/#G/ OB)_SNBR"( BY,UG)-@9S@7GBNX79I4(20T@;KP+ ^"T:;?D MTE#=^VOY]6,IV"8>M%2C,:WI.ICT04XJP?RKTC1L<0[-5]C[,UJOB$YYI35$ M?6<4T:+3NK]@)-NW"A$QW"[N5GYH[TOO0:^;_)]7S5=3KZQ.J7GL>Q&I?[2S M7T#UB5MS5Q'YI[3Z6&Y0+Z-?:?1Y]/W9C9I;%]WW#OK-UYJB//)AZ]SM-"UB M5;U# QV91D$:R -^!/>1 ([(R_4NWX16NM)B*/8$HJ,])XF9&Q&7F1D0W) MR/(J:FQ"%YT?=S*8\'=\95[N6W/?19>'!(L$Z2HC,[L+^R_-Z.Y7[:WF[E[0 M;!T%S?W]UY.GC#8*]YL_U\B)_HA_^JO/C:,Z%@HW<1(:^_+G^LOJ)F>1*^O; M\=5M:'V;XP5NHZ>=^\\M]1Y+C^8Q3 N@2_3L1G)6%RE32JL!974 MJ:Z#^P *F-J3?_%97V>J%YS?5K!W=+SLM_XH0(/:W7.P[V]X^>]BO> MP0INUIA92#?4#?$#4\A=,-\51RCE@T\^*: M8^LPV&]-6*$OJW>/]D+= $JJWG>:-^#AS_7AWF%PW-Q_VONEL1?L[C[U=PP. MFD?!\>$35WU'!\'N_N&3-2L^J\+?^DB6Q&O_+$%#H8>_(EN'!X?!P>&*:_(( MCJ.M==3'HWB_X&"?G)&]%=W)Q_"*ZZB-UU6-\0MGUY\#KH ?7L9NY?$RF+DH MDYH[KM&&\PY!+;4#&V_<=9_H&4O@Q$!_(&)^XB S>Y4_[1I\B\ BN!4/29R](;7=$IW+3[8/62]-NX+<52LJN5$EVSU4E S)# M&,PN%-4&VWQZ\<%@F[U<+< #*B!RU)@XY*K,+ET'7:^2 3U5$!L*QMSHKW]) M)MM31NW]K.5\V*_6441)51/QHYFVMQP.AT7'E=_D\MRI M+N'!\(,?OXQ+;?_L\.3SD.RRTP:?>8?V&"+=R_/AZ0FZ"\E&EY+*$7O8Y$;; M"XFH-^6NMU/>AN-_XV^CEWMG?"S\8SG4[.?.&4F?2=?'*/'H<$!)1Y=+Y?F@ MU#]BQ D7F:+:&'6E^@NIBMR6JDC4NVOB;+>Y8\FY&]T(\W28%TXM9*:NN'1$ MU]9T/:Q'>3#;)BB/7F9Y:]9%"3>Q'S?Y&A6%K4.((H[B*T,F)]]S?5-V[*BP M,2]YMCAYLY_M[$5OJ2<_>N&;KC#I%!PR7=-/AZT6+26KE&ORG&EO3LZDMXRV MU%J"VP!]9R+!>$3'_BZMW$$+C^&Z-&W_6K9=1OQ7+]G;.PB:!TUEKV@S,"Z MFLZ8'NKIAXX5LUKE_OBW%>MTB=7Z7\/O*CM(V%CHT@\6P4L@CM*H0 TQ& M$7[W,E6 [)L- NY8ZQ)(LC"C1YFTJNU)7PU]J6*N/,@8]_$ ;04,#?;@B[ 8 ML@TBC#]HB";7Z1I6OOSQ2]8T9Q7@4'/K[6]*#7XE+WVH7OW^UFS-RC2" \/A M'+1GB)(_2 ')*25EZYC!B&HZH,W'=9>U*-[RP_;JKA52C?_* MT$(>(3IA&8W'UV5A/8TW2I;H[_@F7 M1?DWD\]W^ ><,8"VV*R/\[1J]1I,$DSAV"'%K^Y4 X^=KKC>H00QS0,=_BH] M;+/ ]'RN$!,YH9T"D7+4U8\28+.3QH:S>76F6=PT/68YDU%2V4NF?K&>/*YT M8'3C:+#&'N[M!H:NP#TE=DQOY*]\)-,"@[T;I8N=+&I#ABL'+VRM'.7[W NY M3Z?L4$@(T&N6F]:6A9 UHZO7 PQG,5""D0;1+=D9QV?%PPC['#JL=+ -:7OMXC MFD:GY!)@0Y#CE/K][,5NPX62*;<+DZ](TV^@*K4=B.RRVVE@E8CEQMS(NS[A M4V6IAI[6UN \: TRPTV(/E6]4(VG@EE28HJ"^7!C/AP7 MX+/]]RG1@<]H1PP^FM:NL6#T6;] L"?TK[@U5^:A,S,/I"L]W0L0TNGJ?TY M.M39.6UGTW['4-P/Z)>9T'4:/SYQ?-=:=S\SE)[R'.[R7C,3Y% [0'0:+27#O/] MM+][&!P?[=E7+ -]77BM2S2>.C/Z@0?V@&3&]O),4C>FVC062\[2X M6]@!"=&JZG=(ASEKT>U*PHMU'OS/]S"HOF8(:5VF\5 C+GDXFB&6"9NYK:FZ";LA#-"WI"W9 M618C:O?)GD;GL(H2-[/1",1@$6YY(7?W3Z2E"K='P5G-S=:Z9*YSH^PKMJ,X M3XAI?P?8_[7_)VD%U@=O(V'0I6.)S!RRNLGB_X8_DH*L$9GT0%Z/N09MP)[O MU@\+'3ZX#(?TCW>)RJY&@8<5!/)++YI9?PYMG^)0^\STN[_Z)]O-W>VCYL'1 MWM&V:?<7^'^J7B]3(UKIS\/DOU'*$A4.N/DE&BB;%YQXL)9D1S[)6>CRZ9IF MMIO@$Y:7DT%&9D;SP$B+"_/F@+ T'$B]DBKZY(J\%-N/^"*6:?W$8&B[(MQ8 M@'EV_1"_1XQ$?"XDKCGT"SMR$*)2+!J$TO? $0%D:!Q&;I)@EW?<8Y9P.)AD M/7W^[@?VCN>O^@3 9'FX_(/]IRVHD]\[55MQ(Z]*YA]&Z0FDP MYU[U6NEM72=@IM_WN\__[=A9^PJSM\X5\JB^)?#]MBEY1?E M^]9N(O8O4_BIVB/^)16WVC<)YRE3Y&F?MCI#3W8KS3J8 .7LTN&SN[O+#;-I MS60#C=0E5ZE .X:\5.RE':;U\R7PSX7IIEO87MVZ MLX)>)5(I$BS$XS^%(W]?GHV6-'N_D@1??/+>77ZU>NF=_3W>N]1-)]*1J?IU MX&X4UE;\\*YIZR GERL[[D$O'[^6#>; MP\N[@ZAL0;U5&9T]+#BMSVGX:3NI^G8>7DA'"O4AS,W1;FB]N["2^>Z!WQO& M?)!&\B0T.0<@)L^%0-J,/_UR__5=Y#/RWHZ M\0C:Z@JN1R+?XG#1!]MDJZ$K4JH)E_W<^J=_79Y=:'_2(R=7_O[ S=DP]>AP M)C'L"9N*U&BKT3@Z^KNQ^P2JVZ8[AMQ MGTL<<)-]K ]7H%U?E],O .ZAGY*D8'1/3'V)5S7K3$*X('G@Y%@E0&(?J+=J MW6*/C7W,E_?SLB5@;71G8L&>?*\M1..&9)HUCLU6JM/6)LKBL8$72O86,MRY M1MRK#+:T!3X1DCJB#??E$NVF]1;AQ#)B)W^/I./41YT%_!@9Y++9H;;8_'CT%?%FH X/A'5:3# M+%'A,/#=" ZWZ&(7!3/F:5 3S1C>,P=6]W!W=\SCA4C63:@V9WFEZ).2(DOC:5;V;WYK M?_Q)4P?'$21&X!HX?>I.YAIWPCS7K<-BT^'5W0YK+H=M"-,.8DHO3-\-M/BB MZ D]4,HR7/93$#**NJI4%P)\N";3@.]\'67%:)L;P1779&*P<\^=;')OZZ=6 M:Q\#=2)TPWX_=#65R[3@=@?70>THG[[+W":LH:^;L@EDPUUC;\+F8I_36:EI M4XTY*UO#8;0,FK($L41[V. %(\!,K<"^E^_TZS2"HR M).H$^XT3%@;Z3@ZL*VLV,%FW?_=V&LV?7S,-POD__WBR,VR.H%*A CTS$>@% M/NJ*YUD"OFM!K&Q@2.3=(JZXA-^ )&0@$P. D6!L$2\=&_Q.%1TV9L+<\=!+ MH)BW*% ,HZL1XGI+2Y27O+?5794YN=7()NF.#JWDPS?:2MG9F9<>/W/+1*"$=R[/\= MT6$7]F%KJCR.E/=AQW\S[%^%M'%H8_Z9DD]Q[?^Y\_^W]^U/C2/)G[_KK]!U M]%QTQQK:LC&&WMV.,P9ZZ.$U0.\\OG%Q(=L%:%J6O'H GK_^*C.K2J6'#39^ MR?@B;K[;V"ZE*K.R\OE)\S<["D%G'-H/W'KX&0Y)'\U>.)J'_-"<.USSV^;5 M-AQPE_'S>W98(0L(,& + S?WYI8'#PP$ )%O9OR[/?7G^_Y9H-(E$R MH9CVR%()87YTQ%FX84'?P!(K)?@@[I*[G3BX,X5;88J 02@=%G$>9-6BJ]R+ M;L:]^.T_/R?9 /X/G%YL]L'_V<(^?7:'X^>=!SC(@*T21J@?H0C3=/VNR##C MUOSA!S]( 0/MHCP,%Y0+#"#8E>C70!2MH*)&(,2P0EVJH%J!'!IIP,AKP'% .\WS2+%WZ+]5RI M%+Y!@[ ']A")?&^AY4SUK!@W"$._Z^#6J#IL[<:HD+<)>%%8KLA-9_ZO"H3^ M=&=?M,*&VDAC>3TERTGX@N0MM\WO VQ.AK9!C/,@A,XMC@Z'NM)D$1(H_@:J MQU=:[AB%$/7/4'X+12A"/.#&TU,MDCWOA;>3.<\J#2)G1!,P0Q+]4S$4>=/: M$9<8J_$3Q6'B).+D@A<(+97P6ERDNJQ( @QLJI M<#5=>V&-/==?LI;1QC28@58+1(*X*/3Y5?/ 7.X/H?*E-7YX_J,G74E)A.CJ MN!2_4T8.Q2R+;T@D V$K%:5I(AL& QJSFC3Y'44J6";>,*J06P7?J-Q7N Y M(&C3?C_V1$UGR'FG6O75$M@5@Q2%H-;1X#7$*\:>"Q<<77.=>,@"%47M, ![ M!>N7H &X42R28YA01/4\B#O17+&8.1>>HYS!9/H">/WL2WA1>X7J/"[JU MN"OR+LEN.8H41@YA;\SW-;R_^;9IC2J,A7CG=#0,JDSI*T;^E.Q4L*6%,E3\ MHC(X"7% IH+"-^!,MM$#'XJUP>J#D.3=/?RRP[C7(CI@J.$%J'CT8[<'='@0 MX^.7Y;K>6"\^_G@VBG6 K!-%QN*I01BC'M_4'O;(A1('IX]F$1H&,DF;@27V M,63+3;RMSG +_B\@X#@A9L*%:$"+%C]#K&<(@^N-.G,8:4I[TT8Z4)4*4129 MR04AL#>VB2CH=X@DW:9^[U/6&_)=,GERHPF=D^E]UA3VS,G2Y7 M-!1R70>6>$58WUU*\!'B49%DM0!["L(BW%WLV\W%W@/_(CCF]EB+=Z&]*1 M1-KQ?H *E7SABRB5.3C^XS<* R1U*1[6I>B.N4)\R]06FM6]9M,ZL*J-==[9 M"ZY9DM8=JS(B>F?$'K(WBIZVSP"EDE21)<,85;79'#6Z>(!; RZY&4LDA%-Z@ M=4B)'S)096<%(1(4LY?2G9FK.*FN-N*!WN%!N$;3*NQX(?H0$@SOH:1.A6ZS\=0*23'A[F$5!"D\,2WDBA%X@P=9 MM[ZYM_4+A.5MX39K&PQ=\,*5!@ 'N5_\\+FN=-YE>@%K\^F9I'AME[*L9CS@ M>C?2 IP7-^U?#T"&!680^2,5\[EP*O"F*0E!"/H8DAEQ4,9^,RE9*Y!0V]-1'22C7\:8R7(#4S#:R#/ZS>I4%&&E M6*E8=9QXR'R2'E2$D$\H!P7U!&RE*GT=LQK94@B=C$BXE XT, 9"$9"QLIY^ M$\"S40VS*A8B\30+\I#:<;I.$G"M;H3'WBBBW!ZAHW4Z\"1@12:,,Q)@T/<, M.Y!DG1[63<.2#N/;^<':JT;W'\T>]R6IX%GRS% \0ZQK94M<'[4QY>HCHE0< MT@0,I522WK&\>J%>\B>G'_>ER\19)5\6&I^TS?@ J.V05R39")CC?<3N"#SM M'42B0SM+@K,2"@89=P'S":<50[2$W(7M9=1$CX_B[Q'$+D.$][O8%5%8T8#& M@@$$4NAO7$QMC$/3(Z79)3-S$$,<\1)"NW/AJHR?2D7R<,7I,7>LQDCQ,(CA M'O9QV*3EZ4HCK03;YE&9^:WS!#6=^->/%$V+HQBA&C0D6$Y@Q\]8B7@PB.J4 M2CZ!%"]BP"722<@-NDZFBZOHNZ;ZKF B'0R0 @_!QY(M3++2Z;80^ET,B'RB MS8,%4!C&73@(2'*-#[_F,LAU+D8:":OG>8+0$X-WEY5$)$5B/ S"!2:2+;B* M)X&D@=D!=S3"R!CX84@(85"0\,$A@QM&"$94;0J(8WSGN5+YL%_]:':Y$ %N M,!S 4&LY$#=X3Q0X/?\&8M]3O,EIT+S1D&*\PU4G=USO;"&4!'*?W*7%IH14 M9E+==9V@&_$(F#="_>THC&(EA MTY-!)=FZOT6M^TF_?@7:\!Z%4?O"!A0*EL>.*QJM,?( N8 -@AG&YWHQ1A(E[$ M/59^-P4QQUK(2G!ZCB,>_!"7P/ MBUP[<%GV?6QQM_A/H%@.,KK@I3C=Q$7WNTS@%#*$&83'"Z?N/L!T:,_W;(GL M:5[@UP^XFH)):G\!*H-,]C>JUH?NQP_UCV8*SP7?%TEAH7R\J%W"9Y,Y]0BH MQ8_\?MLV?\M$I)+$"NX[EO9GA0F2O81,+&,#&!108(I&8B@"Y]&&LFJ=K9KN ML\H\-K>AR/*'Q(KGFZ[O85NAV7%M[\<69SW7HV^@QTTI@OV7*P)^Y(6@@HN= MP%%IL9:T:XN&[6 +0C+YMERL*!!)%C_;MARJH).5_!"OQYH8CAJIFYA M,S8DFF0MQEN01&M'%\4$!NP^P)">;4 '# NTI =%[&TLLRDJ_JYH-KN$6%/8 MR##;(D#&0"<+E@[G\@5PY86I6+R1@TC)Q^_?!+,:&K-4C LSW@.(E/0,*.$& M\%,1B!3EU9;J6/Q^?4CM>I>B>OM256_SKVOEO*F(&@9LJ* J!.X :+O+J=- MZ_CIAL&;5#DNOKIZYVBV\^$Y:Y+Q2-I@/X4UKN+D>#F/U=2YK+6NJ0M4?493 MFQE-C>$X11P%E6K&1B>..V9JNQJ2EY,FT(_R.>AK:KC@!F(+LJ P0RQ)549V M^$.6+5" /,!74"!D)". 77E\$L4QAOA]0E! L+--IAW3W\JX"D,"-MG40OP"S7= MVS$W_LTKN\LMQHKYY[TS@%?]$^S#"E^1;QI7^5^9&[MV1=P^_@!R1P.T)_Y),([7Z,*[-;-M#AGM6,?^P![YY)G;V0,B,FM-*4R!"OI8H M^1-^; JG@))1<%W:.IH!#!;'NO-TM3N6E(A&&YJE")&5='<\6$@9&B2""U3R M8>1;A[P!%=;B6!];V?$38\1),$2R0!&4_,*6 _ "D^)^AM ;+O,#&;UYDQ!*MIU48RQM!2;P7%#LB9 MW*B8[H\1XT.4\)UE&^J8R4S=57H'Z!9??V-NL(A C&;UL"OS'>,]_7Z_Q M8UXEA @\8_PIH^\[)ZD#@R^"3=CEIA)6"#SB_)0(!YDYR(Z&F/J=I. E3V%? MP;,U&,2:8*F]G^0"Q$[(&Y_Q4561G'>=;J]8SDKN+_OL%",3CSKZEZ M+UXR4_).>"R1_!0+0C.H&6/*,;$EM4.(*4DI)O_Y+1,5>\U*=6>OLM>LIR]4 M,W^AT@4CD))=P&.1-RNN'A;;MC6;>-6"\=(:&V)IV<@ARQG?WRNY(M*ACE_N68^&BDH1#',HQ$*8_D)8; M%-3(_*%BD/&(,;B",PPAJT"D', OK%:M"EG%"56.F.V,]8L5$V&54"YHBK:H M+*CMR+&N&:LP6QZAH1 5-ELXX,BQ?E$1Z??MZVW=%0+UJJI5<(NQ *J2TS"J M\MW0*M\A'&G+2AA1H]K2(1?X!)EN"SINF!Y6I*0W='(83Q JS;U&I6GM M""UH%&E4X1@J6>'FO8!FS7F$.8 L(7'F&(E#]YTZ"29V$JFJ5L!ST!S8;%O2 M<_Z@)KMRA_0O&IISY^L31N2$6HT#6LWW\Z\MG4,G>(9O("#H1":@WZ)TG3] M>[HL9$^A-N5B"TF./JN_LZY?[BX E/71KE\Z-(Z($MRK%5^V46B4NU-7SLY= M ./?%6B6&/2E]DN+"6@? M40M']U7((I$]$^<(=B![014T[B0K"!KA=T7NBWG4'[C^L, L,3*)M%N?-&X^ M%4CA[ 2I/WMO9-@!E1'8#(5UN^/.P&R+?A9?8P0C1L0@LAJ&C)AJQ$V$WY3" M;TPB_+CG)+>YM*O,=>03&8W]9J59V]UN-$UE#Z:'#61+ ]*6(KD2*+,A%K#= M0EXY#ZJ?^170PPV?6@'V/EY@J9*UQ'O,2AHVQS8JM;T)U\G('V%T3WM@C)$' M)LN&)1R8LE\:WV(/ @^C72IUX1<=EKFG&,WB%*.!::X%91A-/<,(@BJO&>.% M649MCZ?-,1:T^VN6VD*RC'FB5Y;Q&22&5);1F$N6 MT9PLRVC,( 02;@X@1"0(;?;D88TTUX]XCSED"I<:U1A*"UP8-;!N' M@:(0HLG\;G)N'=%-44 7_\<]#MC&(G!/X" _^"Y7S-SD13P+_@EW:$-9*2Q* MM>'FH^0&1/ENN5KV1-P1VBC44,?D,N\1H)*8Q[(_!B4.=EN\Q.L@XHQ5&D2T MC$@'BG&M*L5XI+ :*:$8V8XCZOIEIC'=94+B/+I=HJ<-%M4(T;H;#5V2UX4! MKE[C/\I.-VP5),'A@!>4-6SC_%I7!2$!C @* 2!DG['AJ54C&:::UUAZS&K$ M^D;1^D4@^)/05Z0]14$#6'W2<%<(>F)FKY'[E1+9)*>JC+P=%>V2=EB1-R;J M(F HLP#G%\8ZK3($Q)YL B)Z:9M4M!?DI,H&-(FL%?G*.C42 M"J=X9S&I,LLICY[.N\#KY7?F&RJ6 WG M>Y87+1RG),('_*5I!6" "$A&&.AO<6=^;6.2:O3RL><5,=R)LJU5E)MQ,&U7J<$8Q" MN#WTNPYB[J>!3=/V/41-P;*$Z![@/23@K>N@OWH9^%PV83"'F :)F%E@/#P& MOG?7\^4H $+&Z_NBM"OB1KZ(K=,C.L/D)JV8ZBH4C4,,H]2,Y@?$ YBRBI.I MX1G\('I4D< 2$B$R=@>!PK5E_K]"SF7]:M\*G;\9+96(1LVJ&*-%8T1O8R(> M>#_:[NBTFCX^M_ )Z=F>AAKAF;V_4F$=^" ;;(,AJ#1X-J2X+[T="OXV=[5@ M.[ZTPL32AG?2,& *WJ!B(&Z'!S(JPDCR("6/0\^#V0& %1R CKJV7>A %$I? M"XM;^_L5:W\7(\2VY\5]ZGE#]81>18>9W/2[<>%3%&1D6RGJJ,*BA!S%NDD!*$]=6\GS1\1UO,)6 .;AQPM1(F(:7GB^%IW!5@6-PS#/T< M'!N2!M1(H0SMR?'+"5CQY]EO%_UWN^%X$W,JPCPQ!(L&8"1Y=_]^5WV'_^8F M7U?^>TKRQIY/F/?=B^X_(_((E_XHD(_!.IFN[IV MC>_#NT]?1GV47@KP;^WQ[HI[^N\)GPO65@??!T_C2_Z<'<]4*2CXS M!A.@7HKP!(HLFCT1#;H.F2MJ302\Y$1DR" )SJLL,FOT!(#$28_\HN32OZP/%.J7?Y!4E5;/,90V[6)Z)E4$)\7+ICMBJ=H(CJ4L^*B%0K7 M B=)NXF>?^\92PLY[IG+<1LU&M?U4<"M!]3UFZNGW%FAZHW*]=3S; Z L?D2-LLN]QHD(&5$SBD\:4Y#Z DY->/FEN?HLIV0CCYGI[,-J M8*6_]MV'Q$^!,&QX*\L=;U.F M"K6D8^ZS:\>9RRGR)Z*B;_]@2:&0?+J(JY ,.(%43&BP:>RB/]-4G =DV0=; M3G[AUN=$A& 7<]@-G Z5*YWP[3?KU9T/]LOI,L" M$A7@A"):RF7GZ.G>Z7!%;.UN6]CW,&[6(_VJJ!A_A&L/W8)Y'I6^H.DP?0KZ M?AAA5R_TP^LG HI%GE7K8U5U:B:=N,S%/')D [@-^#]$"Y;4)_J\!/_6*+Q< MB=WP,U$:J5=F,P=#,5V:Q$#7.2$^0[&2L%T@Z8^W M[ETJB@XJ)$96*Y2 #: M ?KYIS68R$B 2'1$DS_I3DH5[>@JK/;Q@P/S3

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end